text,title,id,project_number,terms,administration,organization,mechanism,year,funding,score
"KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION The overall objective of the proposed research is to develop a clinically useful, computer-based methodology to assist in decision-making tasks in medical imaging.  The methodology consists of a novel approach combining well-established mathematical methods and artificial intelligence techniques for simultaneously representing medical knowledge and handling visual information.  The specific aims of the proposed research are to develop, implement, test, and validate a knowledge-based system for interpreting three-dimensional thallium-201 myocardial distributions obtained by tomographic imaging.  These interpretations will assist clinicians in detecting and localizing coronary artery disease.  The research will be carried out in a collaboration between Emory University and the Georgia Institute of Technology, thus providing a unique, interdisciplinary, and interinstitutional approach that directs complementary clinical and scientific resources toward this important medical problem. The five-year research program consists of four projects, dealing with (1) knowledge representation, (2) image understanding, (3) clinical acceptance and validation, and (4) system extension and refinement.  Preliminary studies indicate that the methodology can provide both accurate cardiac image interpretations and graphical, computer-generated representations of arterial structure.  The approach can serve as a clinically useful model with applications to other imaging modalities, and can also be used as a tool for tutoring and training clinicians.  The knowledge-based system is designed to be sufficiently extensible and flexible to accommodate the far-term objectives of eventually providing decision-making support to clinicians in tasks associated with diagnosis, therapy, and prognosis.  n/a",KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION,3474454,R29LM004692,"['artificial intelligence', ' computed axial tomography', ' computer assisted diagnosis', ' computer assisted medical decision making', ' diagnosis quality /standard', ' heart disorder diagnosis', ' information system analysis']",NLM,GEORGIA INSTITUTE OF TECHNOLOGY,R29,1991,104863,0.05205126584817933
"KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION The overall objective of the proposed research is to develop a clinically useful, computer-based methodology to assist in decision-making tasks in medical imaging.  The methodology consists of a novel approach combining well-established mathematical methods and artificial intelligence techniques for simultaneously representing medical knowledge and handling visual information.  The specific aims of the proposed research are to develop, implement, test, and validate a knowledge-based system for interpreting three-dimensional thallium-201 myocardial distributions obtained by tomographic imaging.  These interpretations will assist clinicians in detecting and localizing coronary artery disease.  The research will be carried out in a collaboration between Emory University and the Georgia Institute of Technology, thus providing a unique, interdisciplinary, and interinstitutional approach that directs complementary clinical and scientific resources toward this important medical problem. The five-year research program consists of four projects, dealing with (1) knowledge representation, (2) image understanding, (3) clinical acceptance and validation, and (4) system extension and refinement.  Preliminary studies indicate that the methodology can provide both accurate cardiac image interpretations and graphical, computer-generated representations of arterial structure.  The approach can serve as a clinically useful model with applications to other imaging modalities, and can also be used as a tool for tutoring and training clinicians.  The knowledge-based system is designed to be sufficiently extensible and flexible to accommodate the far-term objectives of eventually providing decision-making support to clinicians in tasks associated with diagnosis, therapy, and prognosis.  n/a",KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION,3474453,R29LM004692,"['artificial intelligence', ' computed axial tomography', ' computer assisted diagnosis', ' computer assisted medical decision making', ' diagnosis quality /standard', ' heart disorder diagnosis', ' information system analysis']",NLM,GEORGIA INSTITUTE OF TECHNOLOGY,R29,1990,104832,0.05205126584817933
"KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION The overall objective of the proposed research is to develop a clinically useful, computer-based methodology to assist in decision-making tasks in medical imaging.  The methodology consists of a novel approach combining well-established mathematical methods and artificial intelligence techniques for simultaneously representing medical knowledge and handling visual information.  The specific aims of the proposed research are to develop, implement, test, and validate a knowledge-based system for interpreting three-dimensional thallium-201 myocardial distributions obtained by tomographic imaging.  These interpretations will assist clinicians in detecting and localizing coronary artery disease.  The research will be carried out in a collaboration between Emory University and the Georgia Institute of Technology, thus providing a unique, interdisciplinary, and interinstitutional approach that directs complementary clinical and scientific resources toward this important medical problem. The five-year research program consists of four projects, dealing with (1) knowledge representation, (2) image understanding, (3) clinical acceptance and validation, and (4) system extension and refinement.  Preliminary studies indicate that the methodology can provide both accurate cardiac image interpretations and graphical, computer-generated representations of arterial structure.  The approach can serve as a clinically useful model with applications to other imaging modalities, and can also be used as a tool for tutoring and training clinicians.  The knowledge-based system is designed to be sufficiently extensible and flexible to accommodate the far-term objectives of eventually providing decision-making support to clinicians in tasks associated with diagnosis, therapy, and prognosis.  n/a",KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION,3474452,R29LM004692,"['artificial intelligence', ' computed axial tomography', ' computer assisted diagnosis', ' computer assisted medical decision making', ' diagnosis quality /standard', ' heart disorder diagnosis', ' information system analysis']",NLM,GEORGIA INSTITUTE OF TECHNOLOGY,R29,1989,107524,0.05205126584817933
"KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION The overall objective of the proposed research is to develop a clinically useful, computer-based methodology to assist in decision-making tasks in medical imaging.  The methodology consists of a novel approach combining well-established mathematical methods and artificial intelligence techniques for simultaneously representing medical knowledge and handling visual information.  The specific aims of the proposed research are to develop, implement, test, and validate a knowledge-based system for interpreting three-dimensional thallium-201 myocardial distributions obtained by tomographic imaging.  These interpretations will assist clinicians in detecting and localizing coronary artery disease.  The research will be carried out in a collaboration between Emory University and the Georgia Institute of Technology, thus providing a unique, interdisciplinary, and interinstitutional approach that directs complementary clinical and scientific resources toward this important medical problem. The five-year research program consists of four projects, dealing with (1) knowledge representation, (2) image understanding, (3) clinical acceptance and validation, and (4) system extension and refinement.  Preliminary studies indicate that the methodology can provide both accurate cardiac image interpretations and graphical, computer-generated representations of arterial structure.  The approach can serve as a clinically useful model with applications to other imaging modalities, and can also be used as a tool for tutoring and training clinicians.  The knowledge-based system is designed to be sufficiently extensible and flexible to accommodate the far-term objectives of eventually providing decision-making support to clinicians in tasks associated with diagnosis, therapy, and prognosis.  n/a",KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION,3474451,R29LM004692,"['artificial intelligence', ' computed axial tomography', ' computer assisted diagnosis', ' computer assisted medical decision making', ' diagnosis quality /standard', ' heart disorder diagnosis', ' information system analysis']",NLM,GEORGIA INSTITUTE OF TECHNOLOGY,R29,1988,94160,0.05205126584817933
"KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION The overall objective of the proposed research is to develop a clinically useful, computer-based methodology to assist in decision-making tasks in medical imaging.  The methodology consists of a novel approach combining well-established mathematical methods and artificial intelligence techniques for simultaneously representing medical knowledge and handling visual information.  The specific aims of the proposed research are to develop, implement, test, and validate a knowledge-based system for interpreting three-dimensional thallium-201 myocardial distributions obtained by tomographic imaging.  These interpretations will assist clinicians in detecting and localizing coronary artery disease.  The research will be carried out in a collaboration between Emory University and the Georgia Institute of Technology, thus providing a unique, interdisciplinary, and interinstitutional approach that directs complementary clinical and scientific resources toward this important medical problem. The five-year research program consists of four projects, dealing with (1) knowledge representation, (2) image understanding, (3) clinical acceptance and validation, and (4) system extension and refinement.  Preliminary studies indicate that the methodology can provide both accurate cardiac image interpretations and graphical, computer-generated representations of arterial structure.  The approach can serve as a clinically useful model with applications to other imaging modalities, and can also be used as a tool for tutoring and training clinicians.  The knowledge-based system is designed to be sufficiently extensible and flexible to accommodate the far-term objectives of eventually providing decision-making support to clinicians in tasks associated with diagnosis, therapy, and prognosis.  n/a",KNOWLEDGE-BASED SYSTEM FOR CARDIAC IMAGE INTERPRETATION,3474450,R29LM004692,"['artificial intelligence', ' computed axial tomography', ' computer assisted diagnosis', ' computer assisted medical decision making', ' diagnosis quality /standard', ' heart disorder diagnosis', ' information system analysis']",NLM,GEORGIA INSTITUTE OF TECHNOLOGY,R29,1987,95762,0.05205126584817933
"KNOWLEDGE-BASED INTERPRETATION OF CARDIAC ARRHYTHMIAS This renewal application for Project Years 4-6 proposes continuation of  the development of new computer algorithms for reasoning about time-  varying data from underlying causal models. The signals consist of two or  more channels of events, each event having several properties including  time of occurrence and event shape class. The models can be represented as  graphs in which the nodes are digital components, some of which give rise  to observable events. The arcs are physical connections associated with  time delays. The application domain is the electrocardiogram, in which the  P waves and QRS complexes represent two event channels, and optional  intracardiac recordings contribute additional channels. The P waves and  QRS complexes are the results of the all-or-nothing depolarization of the  atria and ventricles, respectively. These cardiac structures are connected  anatomically and functionally by a series of other structures, each  associated with a characteristic conduction time.    This application builds on the results of Project Years 1-2, in which an  analytic approach based on a variation of the hypothesize-and-test  paradigm was used with a hierarchy of models to track the events in the  cardiac rhythm on an event-by-event basis. The output of the system is one  or more complete causal explanations of the observed signal, expressed in  the standard clinical ladder diagram format and consisting of an  instantiated model and event-by-event annotation of causality based on the  model. When a signal admits of more than one explanatory model, each is  developed and displayed separately. The initial hypothesis, that a cardiac  arrhythmia monitor constructed using knowledge-based programming methods  can perform substantially better than current clinical arrhythmia  monitors, has largely been confirmed.    The hypothesis to be tested in this proposal is that the programming  techniques being used not only can perform better qualitatively than do  current clinical arrhythmia monitors, but that they can do so at a level  of performance that is likely to become suitable for the clinical use.  This hypothesis will be tested in a trial comparing the program with  physicians at several levels of experience.    This project is attractive for two reasons. First, it offers new  knowledge-based algorithms for model-based reasoning about time-varying  signals. This is an unsolved problem in the expert systems field. Second,  current cardiac arrhythmia monitors do not perform nearly as well as do  expert nurses, technicians, and physicians. The proposed project will  contribute to the development of an improved generation of arrhythmia  interpretation systems that should result in improved care of patients  with disorders of the heart rhythm, particularly in medically underserved  settings.  n/a",KNOWLEDGE-BASED INTERPRETATION OF CARDIAC ARRHYTHMIAS,2237886,R01LM005530,"['arrhythmia', ' artificial intelligence', ' computer assisted diagnosis', ' computer assisted patient care', ' computer network', ' computer program /software', ' diagnosis design /evaluation', ' diagnosis quality /standard', ' electrocardiographic monitor', ' human subject']",NLM,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,R01,1995,166321,0.1553432412416045
"KNOWLEDGE BASED INTERPRETATION OF CARDIAC ARRHYTHMIAS This application proposes development of new computer algorithms for reasoning about time-varying data from underlying causal models.  The signals consist of two or more channels of events, each event having several properties including time of occurrence and event shape class.  The models can be represented as graphs in which the nodes are digital components, some of which give rise to observable events.  The arcs are physical connections associated with time delays.  The application domain is the electrocardiogram, in which the P waves and QRS complexes represent two event channels, and optional intracardiac recordings contribute additional channels.  The P waves and QRS complexes are the results of the all-or-nothing depolarization of the atria and ventricles, respectively. These cardiac structures are connected anatomically and functionally by a series of other structures, each associated with a characteristic conduction time.  The analytic approach will be a variation of the hypothesize-and-test paradigm.  A hierarchy of models will be constructed whose base is the most complex, most comprehensive model, and whose derivatives are all simpler variants.  The control loop will be based on the ""tracking"" concept used in many knowledge-based monitoring systems.  The output of the proposed system will be one or more complete causal explanations of the observed signal. Each explanation will consist of an instantiated model and event-by-event annotation of causality based on the model.  When a signal admits of more than one explanatory model, each will be developed an displayed separately.  The hypothesis to be tested is that a cardiac arrhythmia monitor constructed using knowledge-based programming methods will perform substantially better than current clinical arrhythmia monitors as measured by correct diagnoses of clinically important arrhythmias such as second degree atrioventricular block, wide complex tachycardias, and detection of subtle signs of preexcitation.  This project is attractive for two reasons.  First, it offers new knowledge-based algorithms for model-based reasoning about time-varying signals.  This is an unsolved problem in the expert systems field.  Second, current cardiac arrhythmia monitors do not perform nearly as well as do expert nurses, technicians, and physicians.  The proposed project will contribute to the development of an improved generation of models that should result in improved care of patients in intensive care settings.  n/a",KNOWLEDGE BASED INTERPRETATION OF CARDIAC ARRHYTHMIAS,2237885,R01LM005530,"['arrhythmia', ' artificial intelligence', ' computer assisted diagnosis', ' computer assisted patient care', ' computer program /software', ' electrocardiographic monitor', ' human subject', ' model design /development']",NLM,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,R01,1994,150544,0.14220248357676307
"KNOWLEDGE-BASED INTERPRETATION OF CARDIAC ARRHYTHMIAS This application proposes development of new computer algorithms for reasoning about time-varying data from underlying causal models.  The signals consist of two or more channels of events, each event having several properties including time of occurrence and event shape class.  The models can be represented as graphs in which the nodes are digital components, some of which give rise to observable events.  The arcs are physical connections associated with time delays.  The application domain is the electrocardiogram, in which the P waves and QRS complexes represent two event channels, and optional intracardiac recordings contribute additional channels.  The P waves and QRS complexes are the results of the all-or-nothing depolarization of the atria and ventricles, respectively. These cardiac structures are connected anatomically and functionally by a series of other structures, each associated with a characteristic conduction time.  The analytic approach will be a variation of the hypothesize-and-test paradigm.  A hierarchy of models will be constructed whose base is the most complex, most comprehensive model, and whose derivatives are all simpler variants.  The control loop will be based on the ""tracking"" concept used in many knowledge-based monitoring systems.  The output of the proposed system will be one or more complete causal explanations of the observed signal. Each explanation will consist of an instantiated model and event-by-event annotation of causality based on the model.  When a signal admits of more than one explanatory model, each will be developed an displayed separately.  The hypothesis to be tested is that a cardiac arrhythmia monitor constructed using knowledge-based programming methods will perform substantially better than current clinical arrhythmia monitors as measured by correct diagnoses of clinically important arrhythmias such as second degree atrioventricular block, wide complex tachycardias, and detection of subtle signs of preexcitation.  This project is attractive for two reasons.  First, it offers new knowledge-based algorithms for model-based reasoning about time-varying signals.  This is an unsolved problem in the expert systems field.  Second, current cardiac arrhythmia monitors do not perform nearly as well as do expert nurses, technicians, and physicians.  The proposed project will contribute to the development of an improved generation of models that should result in improved care of patients in intensive care settings.  n/a",KNOWLEDGE-BASED INTERPRETATION OF CARDIAC ARRHYTHMIAS,3374447,R01LM005530,"['arrhythmia', ' artificial intelligence', ' computer assisted diagnosis', ' computer assisted patient care', ' computer program /software', ' electrocardiographic monitor', ' human subject', ' model design /development']",NLM,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,R01,1993,142349,0.14220248357676307
"KNOWLEDGE-BASED INTERPRETATION OF CARDIAC ARRHYTHMIAS This application proposes development of new computer algorithms for reasoning about time-varying data from underlying causal models.  The signals consist of two or more channels of events, each event having several properties including time of occurrence and event shape class.  The models can be represented as graphs in which the nodes are digital components, some of which give rise to observable events.  The arcs are physical connections associated with time delays.  The application domain is the electrocardiogram, in which the P waves and QRS complexes represent two event channels, and optional intracardiac recordings contribute additional channels.  The P waves and QRS complexes are the results of the all-or-nothing depolarization of the atria and ventricles, respectively. These cardiac structures are connected anatomically and functionally by a series of other structures, each associated with a characteristic conduction time.  The analytic approach will be a variation of the hypothesize-and-test paradigm.  A hierarchy of models will be constructed whose base is the most complex, most comprehensive model, and whose derivatives are all simpler variants.  The control loop will be based on the ""tracking"" concept used in many knowledge-based monitoring systems.  The output of the proposed system will be one or more complete causal explanations of the observed signal. Each explanation will consist of an instantiated model and event-by-event annotation of causality based on the model.  When a signal admits of more than one explanatory model, each will be developed an displayed separately.  The hypothesis to be tested is that a cardiac arrhythmia monitor constructed using knowledge-based programming methods will perform substantially better than current clinical arrhythmia monitors as measured by correct diagnoses of clinically important arrhythmias such as second degree atrioventricular block, wide complex tachycardias, and detection of subtle signs of preexcitation.  This project is attractive for two reasons.  First, it offers new knowledge-based algorithms for model-based reasoning about time-varying signals.  This is an unsolved problem in the expert systems field.  Second, current cardiac arrhythmia monitors do not perform nearly as well as do expert nurses, technicians, and physicians.  The proposed project will contribute to the development of an improved generation of models that should result in improved care of patients in intensive care settings.  n/a",KNOWLEDGE-BASED INTERPRETATION OF CARDIAC ARRHYTHMIAS,3374446,R01LM005530,"['arrhythmia', ' artificial intelligence', ' computer assisted diagnosis', ' computer assisted patient care', ' computer program /software', ' electrocardiographic monitor', ' human subject', ' model design /development']",NLM,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,R01,1992,84744,0.14220248357676307
"MODEL BASED INTERPRETATION OF INTRACARDIAC ELECTROGRAMS Catheter ablation is a medical procedure that involves the destruction of        small volumes of heart tissue with radiofrequency energy.  To be                 successful, catheter ablation requires precise localization of the tissue        to be destroyed. To accomplish this in a typical ablation procedure, five        catheters containing a total of 19 electrode pairs are utilized to record        potentials (called electrograms) from spatially distinct locations within        the heart throughout the cardiac cycle. Experienced cardiologists                interpret the electrograms to locate the conduction pathways responsible         for the arrhythmia. The pathways are destroyed by applications of                radiofrequency energy, thus treating the arrhythmia.                                                                                                              Ablation procedures are performed by highly trained and experienced              cardiology sub-specialists yet the massive amount of data produced during        these procedures creates a data overload problem that can impede the             performance of even the best practitioners. This may be evidenced by (1)         overlooking important signal features, (2) misinterpreting the signals,          and (3) misinterpreting catheter locations in the heart, all of which may        lead to increased procedure duration and/or applications of radiofrequency       energy to the wrong part of the heart.                                                                                                                            The purpose of this project is to develop a model-based system for               interpreting intracardiac electrograms in near real-time. The system is          intended to assist physicians in ""making sense"" of the enormous amounts of       data recorded during a cardiac electrophysiology study. New computer             algorithms for reasoning about the time- and space-varying nature of             intracardiac electrograms from underlying causal models of the heart will        be developed. The models can be represented as a graph of nodes connected        by arcs. The nodes represent specific an atomic regions of the heart while       the arcs represent the connections between the regions.                                                                                                           The analytic approach will be a variation of the hypothesize-and-test            paradigm. The control loop will be based on the ""tracking"" concept whereby       models will be tracked as long as the data supports the model. Rule-based        knowledge will be utilized to generate models based on the observed data.        The output of the system will be a series of ladder diagrams describing          the data. In the event that the data admits more than a single explanatory       model, ladder diagrams will be generated for all created models.                                                                                                  This proposal is an extension of the applicant's graduate and post-              doctoral project, which used the same approach to the simpler domain of          the interpretation of the body-surface electrocardiogram. The domain of          this proposal is more complex because it adds reasoning with a more              detailed three dimensional cardiac model to the temporal reasoning               required for previous work. Also, this domain requires the ability to            account for simultaneous activation of the heart at multiple locations,          which was performed at a rudimentary level in the previous work.                                                                                                  This project is important for three reasons: (1) it offers new knowledge-        based algorithms for reasoning about time- and space-varying data, (2) a         comprehensive and extensible model of the cardiac conduction will be             created that incorporates the spatial resolution necessary for                   interpreting intracardiac electrograms, and (3) a software tool such the         one proposed may help clinicians improve the quality of health care.              n/a",MODEL BASED INTERPRETATION OF INTRACARDIAC ELECTROGRAMS,6126011,R29LM006004,"['arrhythmia', ' artificial intelligence', ' computer assisted diagnosis', ' computer system design /evaluation', ' diagnosis design /evaluation', ' electrocardiography', ' heart catheterization', ' heart conduction system', ' human data', ' interactive multimedia', ' mathematical model', ' model design /development']",NLM,SOUTHWEST RESEARCH INSTITUTE,R29,2000,149839,0.06733834481098765
"MODEL BASED INTERPRETATION OF INTRACARDIAC ELECTROGRAMS Catheter ablation is a medical procedure that involves the destruction of        small volumes of heart tissue with radiofrequency energy.  To be                 successful, catheter ablation requires precise localization of the tissue        to be destroyed. To accomplish this in a typical ablation procedure, five        catheters containing a total of 19 electrode pairs are utilized to record        potentials (called electrograms) from spatially distinct locations within        the heart throughout the cardiac cycle. Experienced cardiologists                interpret the electrograms to locate the conduction pathways responsible         for the arrhythmia. The pathways are destroyed by applications of                radiofrequency energy, thus treating the arrhythmia.                                                                                                              Ablation procedures are performed by highly trained and experienced              cardiology sub-specialists yet the massive amount of data produced during        these procedures creates a data overload problem that can impede the             performance of even the best practitioners. This may be evidenced by (1)         overlooking important signal features, (2) misinterpreting the signals,          and (3) misinterpreting catheter locations in the heart, all of which may        lead to increased procedure duration and/or applications of radiofrequency       energy to the wrong part of the heart.                                                                                                                            The purpose of this project is to develop a model-based system for               interpreting intracardiac electrograms in near real-time. The system is          intended to assist physicians in ""making sense"" of the enormous amounts of       data recorded during a cardiac electrophysiology study. New computer             algorithms for reasoning about the time- and space-varying nature of             intracardiac electrograms from underlying causal models of the heart will        be developed. The models can be represented as a graph of nodes connected        by arcs. The nodes represent specific an atomic regions of the heart while       the arcs represent the connections between the regions.                                                                                                           The analytic approach will be a variation of the hypothesize-and-test            paradigm. The control loop will be based on the ""tracking"" concept whereby       models will be tracked as long as the data supports the model. Rule-based        knowledge will be utilized to generate models based on the observed data.        The output of the system will be a series of ladder diagrams describing          the data. In the event that the data admits more than a single explanatory       model, ladder diagrams will be generated for all created models.                                                                                                  This proposal is an extension of the applicant's graduate and post-              doctoral project, which used the same approach to the simpler domain of          the interpretation of the body-surface electrocardiogram. The domain of          this proposal is more complex because it adds reasoning with a more              detailed three dimensional cardiac model to the temporal reasoning               required for previous work. Also, this domain requires the ability to            account for simultaneous activation of the heart at multiple locations,          which was performed at a rudimentary level in the previous work.                                                                                                  This project is important for three reasons: (1) it offers new knowledge-        based algorithms for reasoning about time- and space-varying data, (2) a         comprehensive and extensible model of the cardiac conduction will be             created that incorporates the spatial resolution necessary for                   interpreting intracardiac electrograms, and (3) a software tool such the         one proposed may help clinicians improve the quality of health care.              n/a",MODEL BASED INTERPRETATION OF INTRACARDIAC ELECTROGRAMS,2899560,R29LM006004,"['arrhythmia', ' artificial intelligence', ' computer assisted diagnosis', ' computer system design /evaluation', ' diagnosis design /evaluation', ' electrocardiography', ' heart catheterization', ' heart conduction system', ' human data', ' interactive multimedia', ' mathematical model', ' model design /development']",NLM,SOUTHWEST RESEARCH INSTITUTE,R29,1999,148802,0.06733834481098765
"MODEL BASED INTERPRETATION OF INTRACARDIAC ELECTROGRAMS Catheter ablation is a medical procedure that involves the destruction of        small volumes of heart tissue with radiofrequency energy.  To be                 successful, catheter ablation requires precise localization of the tissue        to be destroyed. To accomplish this in a typical ablation procedure, five        catheters containing a total of 19 electrode pairs are utilized to record        potentials (called electrograms) from spatially distinct locations within        the heart throughout the cardiac cycle. Experienced cardiologists                interpret the electrograms to locate the conduction pathways responsible         for the arrhythmia. The pathways are destroyed by applications of                radiofrequency energy, thus treating the arrhythmia.                                                                                                              Ablation procedures are performed by highly trained and experienced              cardiology sub-specialists yet the massive amount of data produced during        these procedures creates a data overload problem that can impede the             performance of even the best practitioners. This may be evidenced by (1)         overlooking important signal features, (2) misinterpreting the signals,          and (3) misinterpreting catheter locations in the heart, all of which may        lead to increased procedure duration and/or applications of radiofrequency       energy to the wrong part of the heart.                                                                                                                            The purpose of this project is to develop a model-based system for               interpreting intracardiac electrograms in near real-time. The system is          intended to assist physicians in ""making sense"" of the enormous amounts of       data recorded during a cardiac electrophysiology study. New computer             algorithms for reasoning about the time- and space-varying nature of             intracardiac electrograms from underlying causal models of the heart will        be developed. The models can be represented as a graph of nodes connected        by arcs. The nodes represent specific an atomic regions of the heart while       the arcs represent the connections between the regions.                                                                                                           The analytic approach will be a variation of the hypothesize-and-test            paradigm. The control loop will be based on the ""tracking"" concept whereby       models will be tracked as long as the data supports the model. Rule-based        knowledge will be utilized to generate models based on the observed data.        The output of the system will be a series of ladder diagrams describing          the data. In the event that the data admits more than a single explanatory       model, ladder diagrams will be generated for all created models.                                                                                                  This proposal is an extension of the applicant's graduate and post-              doctoral project, which used the same approach to the simpler domain of          the interpretation of the body-surface electrocardiogram. The domain of          this proposal is more complex because it adds reasoning with a more              detailed three dimensional cardiac model to the temporal reasoning               required for previous work. Also, this domain requires the ability to            account for simultaneous activation of the heart at multiple locations,          which was performed at a rudimentary level in the previous work.                                                                                                  This project is important for three reasons: (1) it offers new knowledge-        based algorithms for reasoning about time- and space-varying data, (2) a         comprehensive and extensible model of the cardiac conduction will be             created that incorporates the spatial resolution necessary for                   interpreting intracardiac electrograms, and (3) a software tool such the         one proposed may help clinicians improve the quality of health care.              n/a",MODEL BASED INTERPRETATION OF INTRACARDIAC ELECTROGRAMS,2032386,R29LM006004,"['arrhythmia', ' artificial intelligence', ' computer assisted diagnosis', ' computer system design /evaluation', ' diagnosis design /evaluation', ' electrocardiography', ' heart catheterization', ' heart conduction system', ' human data', ' interactive multimedia', ' mathematical model', ' model design /development']",NLM,UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT,R29,1997,83300,0.06733834481098765
"Predicting Cardiac Arrest in Pediatric Critical Illness    DESCRIPTION (provided by applicant):  The broad purpose of this proposal is to create a framework for bedside decision support to predict life threatening events before they happen. The specific hypothesis is that models predicting cardiac arrest can be generated from physiologic and laboratory data obtained in the 12 hours preceding the event using logistic regression analysis (LR) and data mining techniques such as support vector machines (SVM), neural networks (NN), Bayesian networks (BN) and decision tree classification (DTC). We further hypothesize that a support vector machine technique will yield the model with the best performance. Specific Aim 1 is to acquire and prepare data for eligible patients by merging information from physiologic, laboratory, and clinical databases and selecting data from twelve hours prior to either a cardiac arrest or the maximum severity of illness. Noise will be removed with automated methods that can be used in real time. Missing data elements will be imputed by statistical methods that are regarded as state of the art. Since the optimum time window to investigate before an arrest has not been established, and since there is no standard process of abstracting trend information, we will generate multiple candidate data sets in an effort to determine the optimum combination of parameters. Data dimensionality will be reduced by three separate feature selection methods, each of which will be used in subsequent modeling procedures. Specific Aim 2 is to create cardiac arrest prediction models from the candidate data sets using LR, SVM, NN, BN and DTC. We will assess model performance with sensitivity, specificity, positive predictive value, negative predictive value, and area under the Receiver Operating Characteristics curve (AUROC) using 10- fold cross validation. We will then assess the ability to generalize by testing the model on unseen data. We will determine the impact of training sample size on model performance by varying the percentage of data used during the 10-fold cross validation for each modeling technique's best performing model. We will then perform a false prediction analysis to determine the etiology of the false prediction. Specific Aim 3 is to determine which modeling process and configuration parameters performs the best, and to determine optimum timing windows for: time to analyze pre-arrest and size of feature window. The significance of this proposal is that successful prediction and early intervention could save thousands of lives annually.          n/a",Predicting Cardiac Arrest in Pediatric Critical Illness,7363692,K22LM008389,"['Adverse event', 'Area', 'Arts', 'Attention', 'Biological Neural Networks', 'Caregivers', 'Chicago', 'Childhood', 'Classification', 'Clinical', 'Computer software', 'Critical Care', 'Critical Illness', 'Data', 'Data Analyses', 'Data Element', 'Data Set', 'Databases', 'Decision Trees', 'Detection', 'Disease', 'Early Intervention', 'Ensure', 'Etiology', 'Event', 'Excision', 'Foundations', 'Genomics', 'Heart Arrest', 'Hour', 'Laboratories', 'Length', 'Life', 'Logistic Regressions', 'Logistics', 'Machine Learning', 'Measurement', 'Methods', 'Modeling', 'Noise', 'Numbers', 'Patients', 'Pediatric Intensive Care Units', 'Performance', 'Physiologic Monitoring', 'Physiological', 'Population', 'Predictive Value', 'Procedures', 'Process', 'Purpose', 'Range', 'Receiver Operating Characteristics', 'Regression Analysis', 'Research Personnel', 'Sample Size', 'Sensitivity and Specificity', 'Series', 'Severity of illness', 'Social Sciences', 'Source', 'Standards of Weights and Measures', 'Statistical Methods', 'System', 'Techniques', 'Testing', 'Time', 'Training', 'Validation', 'Work', 'abstracting', 'base', 'computer based statistical methods', 'data mining', 'data modeling', 'inclusion criteria', 'mortality', 'predictive modeling', 'programs', 'prospective', 'size', 'tool', 'trend', 'vector']",NLM,BAYLOR COLLEGE OF MEDICINE,K22,2008,135000,0.122339808857246
"Predicting Cardiac Arrest in Pediatric Critical Illness    DESCRIPTION (provided by applicant):  The broad purpose of this proposal is to create a framework for bedside decision support to predict life threatening events before they happen. The specific hypothesis is that models predicting cardiac arrest can be generated from physiologic and laboratory data obtained in the 12 hours preceding the event using logistic regression analysis (LR) and data mining techniques such as support vector machines (SVM), neural networks (NN), Bayesian networks (BN) and decision tree classification (DTC). We further hypothesize that a support vector machine technique will yield the model with the best performance. Specific Aim 1 is to acquire and prepare data for eligible patients by merging information from physiologic, laboratory, and clinical databases and selecting data from twelve hours prior to either a cardiac arrest or the maximum severity of illness. Noise will be removed with automated methods that can be used in real time. Missing data elements will be imputed by statistical methods that are regarded as state of the art. Since the optimum time window to investigate before an arrest has not been established, and since there is no standard process of abstracting trend information, we will generate multiple candidate data sets in an effort to determine the optimum combination of parameters. Data dimensionality will be reduced by three separate feature selection methods, each of which will be used in subsequent modeling procedures. Specific Aim 2 is to create cardiac arrest prediction models from the candidate data sets using LR, SVM, NN, BN and DTC. We will assess model performance with sensitivity, specificity, positive predictive value, negative predictive value, and area under the Receiver Operating Characteristics curve (AUROC) using 10- fold cross validation. We will then assess the ability to generalize by testing the model on unseen data. We will determine the impact of training sample size on model performance by varying the percentage of data used during the 10-fold cross validation for each modeling technique's best performing model. We will then perform a false prediction analysis to determine the etiology of the false prediction. Specific Aim 3 is to determine which modeling process and configuration parameters performs the best, and to determine optimum timing windows for: time to analyze pre-arrest and size of feature window. The significance of this proposal is that successful prediction and early intervention could save thousands of lives annually.          n/a",Predicting Cardiac Arrest in Pediatric Critical Illness,7222736,K22LM008389,"['Adverse event', 'Area', 'Arts', 'Attention', 'Biological Neural Networks', 'Caregivers', 'Chicago', 'Childhood', 'Classification', 'Clinical', 'Computer software', 'Critical Care', 'Critical Illness', 'Data', 'Data Analyses', 'Data Element', 'Data Set', 'Databases', 'Decision Trees', 'Detection', 'Disease', 'Early Intervention', 'Ensure', 'Etiology', 'Event', 'Excision', 'Foundations', 'Genomics', 'Heart Arrest', 'Hour', 'Laboratories', 'Length', 'Life', 'Logistic Regressions', 'Logistics', 'Machine Learning', 'Measurement', 'Methods', 'Modeling', 'Noise', 'Numbers', 'Patients', 'Pediatric Intensive Care Units', 'Performance', 'Physiologic Monitoring', 'Physiological', 'Population', 'Predictive Value', 'Procedures', 'Process', 'Purpose', 'Range', 'Receiver Operating Characteristics', 'Regression Analysis', 'Research Personnel', 'Sample Size', 'Sensitivity and Specificity', 'Series', 'Severity of illness', 'Social Sciences', 'Source', 'Standards of Weights and Measures', 'Statistical Methods', 'System', 'Techniques', 'Testing', 'Time', 'Training', 'Validation', 'Work', 'abstracting', 'base', 'computer based statistical methods', 'data mining', 'data modeling', 'inclusion criteria', 'mortality', 'predictive modeling', 'programs', 'prospective', 'size', 'tool', 'trend', 'vector']",NLM,BAYLOR COLLEGE OF MEDICINE,K22,2007,135000,0.122339808857246
"Predicting Cardiac Arrest in Pediatric Critical Illness    DESCRIPTION (provided by applicant):  The broad purpose of this proposal is to create a framework for bedside decision support to predict life threatening events before they happen. The specific hypothesis is that models predicting cardiac arrest can be generated from physiologic and laboratory data obtained in the 12 hours preceding the event using logistic regression analysis (LR) and data mining techniques such as support vector machines (SVM), neural networks (NN), Bayesian networks (BN) and decision tree classification (DTC). We further hypothesize that a support vector machine technique will yield the model with the best performance. Specific Aim 1 is to acquire and prepare data for eligible patients by merging information from physiologic, laboratory, and clinical databases and selecting data from twelve hours prior to either a cardiac arrest or the maximum severity of illness. Noise will be removed with automated methods that can be used in real time. Missing data elements will be imputed by statistical methods that are regarded as state of the art. Since the optimum time window to investigate before an arrest has not been established, and since there is no standard process of abstracting trend information, we will generate multiple candidate data sets in an effort to determine the optimum combination of parameters. Data dimensionality will be reduced by three separate feature selection methods, each of which will be used in subsequent modeling procedures. Specific Aim 2 is to create cardiac arrest prediction models from the candidate data sets using LR, SVM, NN, BN and DTC. We will assess model performance with sensitivity, specificity, positive predictive value, negative predictive value, and area under the Receiver Operating Characteristics curve (AUROC) using 10- fold cross validation. We will then assess the ability to generalize by testing the model on unseen data. We will determine the impact of training sample size on model performance by varying the percentage of data used during the 10-fold cross validation for each modeling technique's best performing model. We will then perform a false prediction analysis to determine the etiology of the false prediction. Specific Aim 3 is to determine which modeling process and configuration parameters performs the best, and to determine optimum timing windows for: time to analyze pre-arrest and size of feature window. The significance of this proposal is that successful prediction and early intervention could save thousands of lives annually.          n/a",Predicting Cardiac Arrest in Pediatric Critical Illness,7106109,K22LM008389,"['clinical research', 'heart arrest', 'model']",NLM,BAYLOR COLLEGE OF MEDICINE,K22,2006,135000,0.122339808857246
"QUALITY OF CARDIAC SURGICAL CARE The proposed study is intended to address a number of important methodological and health policy issues in assessing the quality of cardiac surgical care in Ontario, Canada. Using a new, population-based database from Ontario, this study will contain three major components.  First, a longitudinal study will be conducted assessing trends in risk- adjusted cardiac surgery outcomes (mortality, ICU length of stay, overall postoperative length of stay) in the period 1991 to 1993, among the 9 hospitals performing adult cardiac surgery in Ontario. This study will enable us to determine whether most of the variation in outcomes is due to random cancer alone or due to systematic differences in quality of care.  Second, we will compare the volume, case mix, and outcome of coronary artery bypass grafting (CABG) in Ontario with those in New York State for the period 1991 to 1992. This study will enable us to determine whether there are any significant international differences in risk-adjusted outcomes and will enable us to determine in which case mix groups, CABG surgery is being performed at higher rates in the United States.  Third, we will evaluate the potential role of artificial neural networks as a method for risk adjustment in assessing the quality of cardiac surgical care using the Ontario database. We will compare the performance of neural network models with logistic regression-based models developed using the same data base. From this study, we will be able to determine what the advantages and disadvantages are of using neural networks as a risk-adjustment tool.  The results from the proposed project should be of international interest and will have important health policy implications in both Canada and the United States.  n/a",QUALITY OF CARDIAC SURGICAL CARE,2236921,R03HS008464,"['Canada', ' United States', ' artificial intelligence', ' cardiovascular disorder epidemiology', ' coronary bypass', ' coronary intensive care', ' disease /disorder proneness /risk', ' health care facility information system', ' health care quality', ' heart surgery', ' human data', ' human therapy evaluation', ' longitudinal human study', ' postoperative state']",AHRQ,HARVARD UNIVERSITY (MEDICAL SCHOOL),R03,1994,21002,0.030087808535814154
"Exploring the Feasibility of Computational Markers to Predict Atrial Fibrillation    DESCRIPTION (provided by applicant): Postoperative atrial fibrillation (PAF) affects a large fraction of patients undergoing cardiac surgery. It is associated with increased postoperative mortality and morbidity, and also results in longer and more expensive hospital stays. While treatments such as prophylactic administration of beta-adrenergic blockers and amiodarone can reduce the incidence of PAF, existing tools to match patients to treatments that are appropriate for their risk need to be improved. Many high-risk patients may benefit from more aggressive treatment than they receive presently. Conversely, many low-risk patients are currently treated in excess of their actual risk of developing PAF. The aim of our research is to develop novel computational markers that can be used to risk stratify patients undergoing cardiac surgery for PAF. Our research uses sophisticated signal processing and machine learning techniques to discover information in the electrocardiogram (ECG) signal related to autonomic and impulse conduction abnormalities. We describe how this information can be combined with existing metrics to identify high risk patients. In addition, we propose the creation of a large public dataset of ECG signals with detailed patient meta-data and outcomes for research by the broader scientific community on predicting PAF. The specific aims of this proposal are: (1) To develop a public database with ECG signals and detailed patient metadata for research on predictive PAF. We will collect ECG data from over 900 patients undergoing cardiac surgery at the University of Michigan Medical Center during the first 12 months of this project with an expected PAF incidence of around 30%. We will share this data and other clinical information (i.e., demographics, comorbidities, laboratory reports, information related to the procedure, and the outcome of PAF) in a de- identified manner with the broader research community through PhysioNet; and (2) To develop and validate novel ECG-based risk markers for PAF. We will explore metrics based on the sympathovagal modulation of the heart, e.g., heart rate turbulence (HRT) and deceleration capacity (DC), which have shown recent promise in predicting ventricular arrhythmias. We will also develop new metrics based on the shape of the ECG to assess atrial myocardial instability. These approaches will be validated on the data collected in Aim 1, and will be used to develop models based on non-parametric machine learning techniques to accurately assess PAF risk.           Postoperative atrial fibrillation commonly occurs in patients undergoing cardiac surgery (e.g., coronary artery bypass graft or valve repair). It is associated with an increased risk of both mortality and morbidity, and increases the cost of hospitalization significantly. Successful management of patients undergoing cardiac surgery therefore relies on the ability of clinicians to estimate the risk of postoperative atrial fibrillation, and ideally, to anticipate and prevent this event. We propose to develop low-cost, and widely applicable methods that would improve the ability of physicians to identify patients at high risk of postoperative atrial fibrillation. They key concept for this proposal is that ECG signals contain valuable information that can help predict high or low risk cases using sophisticated techniques from signal processing and machine learning. This information can be used to develop clinical tools to improve management of patients undergoing cardiac surgery. In addition to developing these tools, we also propose the creation of a large public database that can help other researchers with an interest in predicting postoperative atrial fibrillation.",Exploring the Feasibility of Computational Markers to Predict Atrial Fibrillation,8242479,R21LM011026,"['Address', 'Adrenergic beta-Antagonists', 'Adverse effects', 'Affect', 'Amiodarone', 'Arrhythmia', 'Atrial Fibrillation', 'Blinded', 'Bradycardia', 'Cardiac Surgery procedures', 'Clinical', 'Coagulation Process', 'Communities', 'Comorbidity', 'Coronary Artery Bypass', 'Data', 'Data Set', 'Databases', 'Deceleration', 'Electrocardiogram', 'Equilibrium', 'Event', 'Heart', 'Heart Atrium', 'Heart Rate', 'Hospitalization', 'Incidence', 'Institutional Review Boards', 'Laboratories', 'Length of Stay', 'Machine Learning', 'Medical center', 'Metadata', 'Methods', 'Metric', 'Michigan', 'Modeling', 'Morbidity - disease rate', 'Myocardial', 'Operative Surgical Procedures', 'Outcome', 'Outcomes Research', 'Patients', 'Performance', 'Physicians', 'Population', 'Postoperative Period', 'Prevention', 'Procedures', 'Prophylactic treatment', 'Reporting', 'Research', 'Research Activity', 'Research Personnel', 'Risk', 'Risk Estimate', 'Risk Marker', 'Shapes', 'Signal Transduction', 'Techniques', 'Universities', 'Ventricular Arrhythmia', 'Work', 'base', 'clinical practice', 'computerized data processing', 'cost', 'data sharing', 'demographics', 'high risk', 'improved', 'interest', 'millisecond', 'mortality', 'novel', 'prevent', 'prophylactic', 'repaired', 'tool', 'valve replacement']",NLM,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R21,2012,213554,0.08901855172591801
"Exploring the Feasibility of Computational Markers to Predict Atrial Fibrillation    DESCRIPTION (provided by applicant): Postoperative atrial fibrillation (PAF) affects a large fraction of patients undergoing cardiac surgery. It is associated with increased postoperative mortality and morbidity, and also results in longer and more expensive hospital stays. While treatments such as prophylactic administration of beta-adrenergic blockers and amiodarone can reduce the incidence of PAF, existing tools to match patients to treatments that are appropriate for their risk need to be improved. Many high-risk patients may benefit from more aggressive treatment than they receive presently. Conversely, many low-risk patients are currently treated in excess of their actual risk of developing PAF. The aim of our research is to develop novel computational markers that can be used to risk stratify patients undergoing cardiac surgery for PAF. Our research uses sophisticated signal processing and machine learning techniques to discover information in the electrocardiogram (ECG) signal related to autonomic and impulse conduction abnormalities. We describe how this information can be combined with existing metrics to identify high risk patients. In addition, we propose the creation of a large public dataset of ECG signals with detailed patient meta-data and outcomes for research by the broader scientific community on predicting PAF. The specific aims of this proposal are: (1) To develop a public database with ECG signals and detailed patient metadata for research on predictive PAF. We will collect ECG data from over 900 patients undergoing cardiac surgery at the University of Michigan Medical Center during the first 12 months of this project with an expected PAF incidence of around 30%. We will share this data and other clinical information (i.e., demographics, comorbidities, laboratory reports, information related to the procedure, and the outcome of PAF) in a de- identified manner with the broader research community through PhysioNet; and (2) To develop and validate novel ECG-based risk markers for PAF. We will explore metrics based on the sympathovagal modulation of the heart, e.g., heart rate turbulence (HRT) and deceleration capacity (DC), which have shown recent promise in predicting ventricular arrhythmias. We will also develop new metrics based on the shape of the ECG to assess atrial myocardial instability. These approaches will be validated on the data collected in Aim 1, and will be used to develop models based on non-parametric machine learning techniques to accurately assess PAF risk.           Postoperative atrial fibrillation commonly occurs in patients undergoing cardiac surgery (e.g., coronary artery bypass graft or valve repair). It is associated with an increased risk of both mortality and morbidity, and increases the cost of hospitalization significantly. Successful management of patients undergoing cardiac surgery therefore relies on the ability of clinicians to estimate the risk of postoperative atrial fibrillation, and ideally, to anticipate and prevent this event. We propose to develop low-cost, and widely applicable methods that would improve the ability of physicians to identify patients at high risk of postoperative atrial fibrillation. They key concept for this proposal is that ECG signals contain valuable information that can help predict high or low risk cases using sophisticated techniques from signal processing and machine learning. This information can be used to develop clinical tools to improve management of patients undergoing cardiac surgery. In addition to developing these tools, we also propose the creation of a large public database that can help other researchers with an interest in predicting postoperative atrial fibrillation.",Exploring the Feasibility of Computational Markers to Predict Atrial Fibrillation,8484439,R21LM011026,"['Address', 'Adrenergic beta-Antagonists', 'Adverse effects', 'Affect', 'Amiodarone', 'Arrhythmia', 'Atrial Fibrillation', 'Blinded', 'Bradycardia', 'Cardiac Surgery procedures', 'Clinical', 'Coagulation Process', 'Communities', 'Comorbidity', 'Coronary Artery Bypass', 'Data', 'Data Set', 'Databases', 'Deceleration', 'Electrocardiogram', 'Equilibrium', 'Event', 'Heart', 'Heart Atrium', 'Heart Rate', 'Hospitalization', 'Incidence', 'Institutional Review Boards', 'Laboratories', 'Length of Stay', 'Machine Learning', 'Medical center', 'Metadata', 'Methods', 'Metric', 'Michigan', 'Modeling', 'Morbidity - disease rate', 'Myocardial', 'Operative Surgical Procedures', 'Outcome', 'Outcomes Research', 'Patients', 'Performance', 'Physicians', 'Population', 'Postoperative Period', 'Prevention', 'Procedures', 'Prophylactic treatment', 'Reporting', 'Research', 'Research Activity', 'Research Personnel', 'Risk', 'Risk Estimate', 'Risk Marker', 'Shapes', 'Signal Transduction', 'Techniques', 'Universities', 'Ventricular Arrhythmia', 'Work', 'base', 'clinical practice', 'computerized data processing', 'cost', 'data sharing', 'demographics', 'high risk', 'improved', 'interest', 'millisecond', 'mortality', 'novel', 'prevent', 'prophylactic', 'repaired', 'tool', 'valve replacement']",NLM,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R21,2013,152303,0.08901855172591801
"ROLE OF Z BAND IN CARDIAC SARCOMERE In heart muscle cells, the contractile units must be linked by Z bands for effective contraction.  The Z band is a complex protein lattice which is an integral part of the contractile apparatus, but its exact role in contraction is not known.  Z bands vary in width in normal and diseased muscles, but the functional significance of this variation remains obscure.  Using optical diffraction methods, we have identified a common structural unit in Z bands of mammalian cardiac and slow skeletal muscle.  Our optical reconstruction studies show a regular arrangement of axial and cross connecting filaments.  However, the Z band is rarely a uniform lattice, because there is variation in the arrangement of cross connecting filaments.  Two different lattice forms, basket weave and small square are observed and suggest that the Z band is a dynamic structure capable of responding to different physiological states of the muscle.  Our purpose in these studies is to examine structural differences in the Z band lattice between cardiac and slow skeletal muscle, between slow and fast skeletal muscle, between adult and developing muscle, between normal and diseased muscle and to correlate them with specific structural states induced experimentally.  We will generate a three dimensional reconstruction of the Z band by computerized image processing of a tilt series of electron micrographs.  Then we can determine the impact of specific rearrangements within the lattice in different muscle types in different physiological states.  Using goniometer tilt and stereo techniques at standard and high voltages, together with optical diffraction and reconstruction methods, we will examine Z bands 1) in normal muscles fixed or frozen before, during, and after tetanic contraction; 2) in normal muscle partially extracted and reconstituted; 3) in isolated myofibrils; and 4) in postnatally developing intact muscle.  A systematic analysis will be used to answer two questions.  Why does the lattice move?  How is the Z band formed?  The emphasis will be on the three dimensional structure of the Z band lattice.  New information about Z bands structure will help us to understand the significance of widened Z bands in developing muscle and in diseased muscle and may suggest a mechanism for the formation and breakdown of the Z bands.  n/a",ROLE OF Z BAND IN CARDIAC SARCOMERE,3335341,R01HL017376,"['artificial intelligence', ' cytoskeleton', ' dogs', ' electron microscopy', ' gel electrophoresis', ' guinea pigs', ' heart contraction', ' image enhancement', ' laboratory rabbit', ' laboratory rat', ' lasers', ' microtubules', ' muscle disorders', ' muscle function', ' myocardium', ' myofibrils', ' myogenesis', ' protein structure function', ' sarcomeres', ' smooth muscle', ' striated muscles']",NHLBI,BAYLOR COLLEGE OF MEDICINE,R01,1990,140471,0.15038768604234318
"ROLE OF Z BAND IN CARDIAC SARCOMERE In heart muscle cells, the contractile units must be linked by Z bands for effective contraction.  The Z band is a complex protein lattice which is an integral part of the contractile apparatus, but its exact role in contraction is not known.  Z bands vary in width in normal and diseased muscles, but the functional significance of this variation remains obscure.  Using optical diffraction methods, we have identified a common structural unit in Z bands of mammalian cardiac and slow skeletal muscle.  Our optical reconstruction studies show a regular arrangement of axial and cross connecting filaments.  However, the Z band is rarely a uniform lattice, because there is variation in the arrangement of cross connecting filaments.  Two different lattice forms, basket weave and small square are observed and suggest that the Z band is a dynamic structure capable of responding to different physiological states of the muscle.  Our purpose in these studies is to examine structural differences in the Z band lattice between cardiac and slow skeletal muscle, between slow and fast skeletal muscle, between adult and developing muscle, between normal and diseased muscle and to correlate them with specific structural states induced experimentally.  We will generate a three dimensional reconstruction of the Z band by computerized image processing of a tilt series of electron micrographs.  Then we can determine the impact of specific rearrangements within the lattice in different muscle types in different physiological states.  Using goniometer tilt and stereo techniques at standard and high voltages, together with optical diffraction and reconstruction methods, we will examine Z bands 1) in normal muscles fixed or frozen before, during, and after tetanic contraction; 2) in normal muscle partially extracted and reconstituted; 3) in isolated myofibrils; and 4) in postnatally developing intact muscle.  A systematic analysis will be used to answer two questions.  Why does the lattice move?  How is the Z band formed?  The emphasis will be on the three dimensional structure of the Z band lattice.  New information about Z bands structure will help us to understand the significance of widened Z bands in developing muscle and in diseased muscle and may suggest a mechanism for the formation and breakdown of the Z bands.  n/a",ROLE OF Z BAND IN CARDIAC SARCOMERE,3335340,R01HL017376,"['artificial intelligence', ' cytoskeleton', ' dogs', ' electron microscopy', ' gel electrophoresis', ' guinea pigs', ' heart contraction', ' image enhancement', ' laboratory rabbit', ' laboratory rat', ' lasers', ' microtubules', ' muscle disorders', ' muscle function', ' myocardium', ' myofibrils', ' myogenesis', ' protein structure function', ' sarcomeres', ' smooth muscle', ' striated muscles']",NHLBI,BAYLOR COLLEGE OF MEDICINE,R01,1989,142127,0.15038768604234318
"ROLE OF Z BAND IN CARDIAC SARCOMERE In heart muscle cells, the contractile units must be linked by Z bands for effective contraction.  The Z band is a complex protein lattice which is an integral part of the contractile apparatus, but its exact role in contraction is not known.  Z bands vary in width in normal and diseased muscles, but the functional significance of this variation remains obscure.  Using optical diffraction methods, we have identified a common structural unit in Z bands of mammalian cardiac and slow skeletal muscle.  Our optical reconstruction studies show a regular arrangement of axial and cross connecting filaments.  However, the Z band is rarely a uniform lattice, because there is variation in the arrangement of cross connecting filaments.  Two different lattice forms, basket weave and small square are observed and suggest that the Z band is a dynamic structure capable of responding to different physiological states of the muscle.  Our purpose in these studies is to examine structural differences in the Z band lattice between cardiac and slow skeletal muscle, between slow and fast skeletal muscle, between adult and developing muscle, between normal and diseased muscle and to correlate them with specific structural states induced experimentally.  We will generate a three dimensional reconstruction of the Z band by computerized image processing of a tilt series of electron micrographs.  Then we can determine the impact of specific rearrangements within the lattice in different muscle types in different physiological states.  Using goniometer tilt and stereo techniques at standard and high voltages, together with optical diffraction and reconstruction methods, we will examine Z bands 1) in normal muscles fixed or frozen before, during, and after tetanic contraction; 2) in normal muscle partially extracted and reconstituted; 3) in isolated myofibrils; and 4) in postnatally developing intact muscle.  A systematic analysis will be used to answer two questions.  Why does the lattice move?  How is the Z band formed?  The emphasis will be on the three dimensional structure of the Z band lattice.  New information about Z bands structure will help us to understand the significance of widened Z bands in developing muscle and in diseased muscle and may suggest a mechanism for the formation and breakdown of the Z bands.  n/a",ROLE OF Z BAND IN CARDIAC SARCOMERE,3335339,R01HL017376,"['artificial intelligence', ' cytoskeleton', ' dogs', ' electron microscopy', ' gel electrophoresis', ' guinea pigs', ' heart contraction', ' image enhancement', ' laboratory rabbit', ' laboratory rat', ' lasers', ' microtubules', ' muscle disorders', ' muscle function', ' myocardium', ' myofibrils', ' myogenesis', ' protein structure function', ' sarcomeres', ' smooth muscle', ' striated muscles']",NHLBI,BAYLOR COLLEGE OF MEDICINE,R01,1988,148467,0.15038768604234318
"ROLE OF Z BAND IN CARDIAC SARCOMERE In heart muscle cells, the contractile units must be linked by Z bands for effective contraction.  The Z band is a complex protein lattice which is an integral part of the contractile apparatus, but its exact role in contraction is not known.  Z bands vary in width in normal and diseased muscles, but the functional significance of this variation remains obscure.  Using optical diffraction methods, we have identified a common structural unit in Z bands of mammalian cardiac and slow skeletal muscle.  Our optical reconstruction studies show a regular arrangement of axial and cross connecting filaments.  However, the Z band is rarely a uniform lattice, because there is variation in the arrangement of cross connecting filaments.  Two different lattice forms, basket weave and small square are observed and suggest that the Z band is a dynamic structure capable of responding to different physiological states of the muscle.  Our purpose in these studies is to examine structural differences in the Z band lattice between cardiac and slow skeletal muscle, between slow and fast skeletal muscle, between adult and developing muscle, between normal and diseased muscle and to correlate them with specific structural states induced experimentally.  We will generate a three dimensional reconstruction of the Z band by computerized image processing of a tilt series of electron micrographs.  Then we can determine the impact of specific rearrangements within the lattice in different muscle types in different physiological states.  Using goniometer tilt and stereo techniques at standard and high voltages, together with optical diffraction and reconstruction methods, we will examine Z bands 1) in normal muscles fixed or frozen before, during, and after tetanic contraction; 2) in normal muscle partially extracted and reconstituted; 3) in isolated myofibrils; and 4) in postnatally developing intact muscle.  A systematic analysis will be used to answer two questions.  Why does the lattice move?  How is the Z band formed?  The emphasis will be on the three dimensional structure of the Z band lattice.  New information about Z bands structure will help us to understand the significance of widened Z bands in developing muscle and in diseased muscle and may suggest a mechanism for the formation and breakdown of the Z bands.  n/a",ROLE OF Z BAND IN CARDIAC SARCOMERE,3335335,R01HL017376,"['artificial intelligence', ' cytoskeleton', ' electron microscopy', ' gel electrophoresis', ' heart contraction', ' image enhancement', ' lasers', ' muscle disorders', ' muscle function', ' myocardium', ' myofibrils', ' myogenesis', ' sarcomeres', ' smooth muscle', ' striated muscles']",NHLBI,BAYLOR COLLEGE OF MEDICINE,R01,1987,151323,0.15038768604234318
"Real-time Monitoring of Zebrafish ECG with Automated Aberrant Pattern Detection Abstract Sensoriis, Inc is a company that, develops evidence-based sensing solutions to support biological investigations and address health care problems. The goal of this NIH STTR grant with University of Washington (UW) is to provide a flexible system to assess cardiac electrical activities in zebrafish models, supporting heart disease studies and drug screening. Unlike humans, zebrafish hearts can fully regenerate following cardiac injury, thereby providing a tractable model system to study endogenous heart regeneration. Zebrafish have also proven to be an ideal vertebrate model system for phenotype-based screening owing to their physiological similarity to mammals. Further, zebrafish model enables a forward genetic approach to reveal the genetic basis and underlying molecular mechanisms of numerous heart diseases. The conventional setup for cardiac phenotype acquisition in zebrafish (i.e. electrocardiogram  ECG) involves sedation causing variation in functionality. To date, there is no system which can offer cardiac phenotype monitoring in freely-swimming zebrafish, not to mention for multiple fish simultaneously. In this context, we propose and develop 1) a wireless flexible jacket to be worn by zebrafish for real-time assessment of electrical cardiac phenotypes, namely ECG; and 2) a simple-yet-novel apparatus to collect ECG of multiple awake fish. Our devices provide pivotal platforms for cardiac phenotype-related investigations. The obtained data will be processed by smart algorithms to detect aberrant ECG patterns in real time. The proposed systems will facilitate related studies using zebrafish models. Further, the success of this platform also paves the avenue for regenerative medicine and developmental biology studies as well as stem cell-based therapies for cardiac repair. In Phase I of this STTR grant, we will develop i) a polymer-based microelectrode array (MEA) jacket that could be comfortably worn by the zebrafish and provide wireless ECG acquisition; and ii) a 4-chamber apparatus for simultaneous recording of ECG in awake fish. Machine learning-based programs with embedded algorithms will be developed to distinguish ECG patterns such as heart rate, ST and QT intervals, thus can identify anomalies, such as arrhythmias or prolonged QTs. For proof of concept, the system will be validated and compared. PROJECT NARRATIVE In this Phase I STTR grant, Sensoriis, Inc and the University of Washington will develop 1) a world-first wireless flexible membrane for zebrafish with a micro-electrode array (MEA) for ECG measurement and electronics for wireless powering and communication with an external unit; 2) a simple-yet-novel 4-chamber apparatus to acquire ECG of 4 awake fish; and 3) Machine learning-based programs to process the data and detect desired patterns. The goal is to facilitate and reduce cost and time of cardiac phenotype-based screening in the zebrafish models, supporting numerous studies. The proposed system also pave the avenue for heart-disease investigations and stem cell-based therapy validation using zebrafish models.",Real-time Monitoring of Zebrafish ECG with Automated Aberrant Pattern Detection,9556073,R41OD024874,"['Address', 'Adult', 'Affect', 'Algorithmic Analysis', 'Algorithms', 'Amiodarone', 'Animals', 'Arrhythmia', 'Behavior', 'Biological', 'Biological Models', 'Cardiac', 'Cardiac development', 'Cell Therapy', 'Characteristics', 'Collaborations', 'Collection', 'Columbidae', 'Communication', 'Coupling', 'Custom', 'Data', 'Detection', 'Development', 'Developmental Biology', 'Devices', 'Discipline', 'Drug Screening', 'EKG P Wave', 'EKG QRS Complex', 'Electrocardiogram', 'Electrodes', 'Electronics', 'Embryo', 'Environment', 'Fishes', 'Generations', 'Genetic', 'Genetic Diseases', 'Goals', 'Grant', 'Healthcare', 'Heart', 'Heart Diseases', 'Heart Injuries', 'Heart Rate', 'Housing', 'Human', 'Human Genetics', 'Investigation', 'Machine Learning', 'Mammals', 'Manuals', 'Measurement', 'Membrane', 'Mental Depression', 'Microelectrodes', 'Modeling', 'Molecular', 'Molecular Biology', 'Monitor', 'Mutagenesis', 'Myocardium', 'Names', 'Natural regeneration', 'Neurobiology', 'Noise', 'Optics', 'Pattern', 'Pharmaceutical Preparations', 'Pharmacology and Toxicology', 'Phase', 'Phenotype', 'Physiological', 'Polymers', 'Process', 'Regenerative Medicine', 'Resources', 'Role', 'Sampling', 'Scientist', 'Sedation procedure', 'Signal Pathway', 'Signal Transduction', 'Sinus', 'Small Business Technology Transfer Research', 'Stem cells', 'Swimming', 'System', 'Systems Biology', 'Testing', 'Time', 'United States National Institutes of Health', 'Universities', 'Validation', 'Variant', 'Washington', 'Wireless Technology', 'Work', 'Zebrafish', 'awake', 'base', 'cardiac regeneration', 'cardiac repair', 'cost', 'drug use screening', 'evidence base', 'flexibility', 'gene function', 'genetic approach', 'heart electrical activity', 'injured', 'new technology', 'novel', 'programs', 'real time monitoring', 'screening', 'success', 'temporal measurement', 'tool']",OD,"SENSORIIS, INC.",R41,2018,224229,0.17707797380918344
"Cloud-based High-throughput Acquisition and Analytics of Zebrafish Electrocardiogram for Cardiac Studies and Drug Development Project Summary Sensoriis, Inc is a company that, develops evidence-based sensing solutions to support biological investigations and address health care problems. The goal of this NIH SBIR Phase II grant with University of California Irvine is to provide novel systems to assess cardiac electrophysiology in zebrafish models, supporting heart disease studies and drug screening. Heart disease plagues the world as the leading cause of mortality. Cardiac arrhythmic diseases alone contributed about 350,000 deaths annually in the U.S. Although causative genes for some of them have been partially discovered, genetic basis for the majority remains poorly understood. The zebrafish (Dario rerio) model system is an important vertebrate experimental model owing to its small size, low-cost for maintenance, short generation time, amenable and conserved genetics, and optical transparency. Zebrafish have long been used as model system for understanding human cardiac development, disease, and regeneration. Further, zebrafish model enables a forward genetic approach to reveal the genetic basis and underlying molecular mechanisms of numerous heart diseases. Owing to the physiological similarities to humans, zebrafish have also proven to be an ideal model system for drug screening. The conventional setup for cardiac phenotype acquisition in zebrafish (i.e. electrocardiogram  ECG) involves anesthesia causing variation in functionality. To date, there is no system which can offer cardiac phenotype monitoring in freely-swimming zebrafish, not to mention for multiple fish simultaneously. Further, data processing and analysis have been done manually, making it impossible to conduct large-scale studies. In this context, we propose to establish a long-term roadmap using multidisciplinary approaches to enable i) novel devices and systems to provide reliable ECG data of multiple fish (both adult fish and larvae) over a long period of time; ii) cloud-based systems to effectively process and interpret as well as study large-scale data; and iii) a host of cardiac studies as well as drug investigations using the zebrafish models and our novel tools. PROJECT NARRATIVE In this Phase II SBIR grant, Sensoriis, Inc and the University of California Irvine will develop novel bioengineering tools to collect and study electrocardiogram of the zebrafish model with high throughput. The goal is to facilitate and reduce cost and time of cardiac phenotype-based acquisition and analytics in the zebrafish models, supporting numerous cardiac studies and drug screening applications. The system also paves the avenue for investigations of therapeutic potential for cardiac disease.",Cloud-based High-throughput Acquisition and Analytics of Zebrafish Electrocardiogram for Cardiac Studies and Drug Development,10080511,R44OD024874,"['Address', 'Adult', 'Amiodarone', 'Anesthesia procedures', 'Animal Model', 'Animals', 'Arrhythmia', 'Attention', 'Behavior assessment', 'Biological', 'Biological Models', 'Biomedical Engineering', 'California', 'Cardiac', 'Cardiac Electrophysiologic Techniques', 'Cardiac development', 'Cardiology', 'Cardiomyopathies', 'Cessation of life', 'Client', 'Clinic', 'Clinical Research', 'Collection', 'Complement', 'Cost Savings', 'Data', 'Data Analyses', 'Data Collection', 'Detection', 'Development', 'Devices', 'Diagnostic', 'Disease', 'Drug Screening', 'Economics', 'Electrocardiogram', 'Electroencephalogram', 'Electrophysiology (science)', 'Embryo', 'Epilepsy', 'Experimental Models', 'Fishes', 'Funding', 'Generations', 'Genes', 'Genetic', 'Goals', 'Grant', 'Guidelines', 'Head', 'Healthcare', 'Heart', 'Heart Diseases', 'Human', 'Immobilization', 'Industry', 'Institution', 'Investigation', 'Investigational Drugs', 'Larva', 'Life', 'Machine Learning', 'Maintenance', 'Manuals', 'Mental disorders', 'Modeling', 'Molecular', 'Molecular Biology', 'Monitor', 'Natural Products', 'Natural regeneration', 'Neurologic', 'Neuropsychology', 'Optics', 'Pain', 'Pattern', 'Pentylenetetrazole', 'Pharmaceutical Preparations', 'Pharmacotherapy', 'Phase', 'Phenotype', 'Physiological', 'Polymers', 'Process', 'Psychological Transfer', 'Research', 'Research Infrastructure', 'Signal Transduction', 'Small Business Innovation Research Grant', 'Small Business Technology Transfer Research', 'Social Behavior', 'Stream', 'Swimming', 'System', 'Systems Analysis', 'Systems Development', 'Technology', 'Therapeutic', 'Time', 'Traction', 'Training', 'Transgenic Organisms', 'United States National Institutes of Health', 'Universities', 'Variant', 'Verapamil', 'Wireless Technology', 'Zebrafish', 'addiction', 'autism spectrum disorder', 'awake', 'base', 'cloud based', 'cloud platform', 'commercialization', 'computerized data processing', 'cost', 'cost effective', 'data exchange', 'data management', 'drug development', 'evidence base', 'genetic approach', 'graphical user interface', 'innovation', 'interdisciplinary approach', 'interest', 'large scale data', 'machine learning algorithm', 'mortality', 'mutant', 'novel', 'product development', 'real time monitoring', 'research and development', 'research study', 'screening', 'tool', 'wireless communication']",OD,"SENSORIIS, INC.",R44,2020,769421,0.21726582623311805
"Gastrointestinal Safety of Antithrombotic Drug Regimens ABSTRACT Patients with atrial fibrillation, post-acute coronary syndrome and venous thromboembolism are prescribed antithrombotic drugs (antiplatelet agents and oral anticoagulants) in dual and triple combinations. These drugs independently cause gastrointestinal bleeding (GIB) from mucosal defects or vascular abnormalities of the gastrointestinal tract. Cardiac patients are the fastest growing at-risk group due to the rapidly aging US population, their high-burden of co-morbidity, frequent antithrombotic polypharmacy and prescription of new antithrombotic drugs with higher incidence of GI adverse events. The real-world GIB risk of antithrombotic agents used in combination in a diverse cardiac population has yet to be characterized. Furthermore, we have previously demonstrated poor performance of existing risk scores (HAS-BLED, CHA2DS2-VASC etc.) for the prediction of non- warfarin antithrombotic drug bleeding; scores frequently used in the clinical setting despite their inaccuracy. Absence of knowledge regarding the real-world risk of antithrombotic-GIB, and the inability to accurately predict which patients will bleed, hampers patient counselling regarding a frequently occurring adverse event which is known to cause morbidity and mortality among cardiac patients. We propose to fill this knowledge gap by quantifying GIB risk in a large, geographically diverse cohort of elderly and non-elderly cardiac patients with atrial fibrillation, venous thromboembolism or post-acute coronary syndrome. GIB associated with antithrombotic drug combinations will be stratified by underlying cardiac conditions; incidence rates (events/100 patient-years) and propensity-matched Cox proportional models (with 95% confidence intervals) will be used to estimate outcome. We will examine heterogeneity of safety effects related to age, chronic co-morbidity, and hepatic or renal dysfunction. Machine learning techniques will then be used to derive and validate a highly sensitive algorithm for the prediction of antithrombotic-related GIB. Discovery of such an algorithm is the first step in the future application of a predictive model in any evidence-based clinical delivery platform, such as a decision rule or risk calculator. NARRATIVE Gastrointestinal bleeding (GIB) in cardiac patients is common, deadly and on the rise due to an older population, antiplatelet and anticoagulant drugs used in combination, and availability of new drugs with higher GIB risk than their predecessors. Lack of data regarding the magnitude of GIB and limited knowledge of which patients are most at risk, prevents accurate counselling regarding cardiac drug safety. We will quantify this risk, study risk factors; and use machine learning techniques to derive and validate a clinical algorithm to better predict at-risk patients.",Gastrointestinal Safety of Antithrombotic Drug Regimens,9916670,R01HS025402,[' '],AHRQ,MAYO CLINIC ARIZONA,R01,2020,394737,0.19062297931707015
"Gastrointestinal Safety of Antithrombotic Drug Regimens ABSTRACT Patients with atrial fibrillation, post-acute coronary syndrome and venous thromboembolism are prescribed antithrombotic drugs (antiplatelet agents and oral anticoagulants) in dual and triple combinations. These drugs independently cause gastrointestinal bleeding (GIB) from mucosal defects or vascular abnormalities of the gastrointestinal tract. Cardiac patients are the fastest growing at-risk group due to the rapidly aging US population, their high-burden of co-morbidity, frequent antithrombotic polypharmacy and prescription of new antithrombotic drugs with higher incidence of GI adverse events. The real-world GIB risk of antithrombotic agents used in combination in a diverse cardiac population has yet to be characterized. Furthermore, we have previously demonstrated poor performance of existing risk scores (HAS-BLED, CHA2DS2-VASC etc.) for the prediction of non- warfarin antithrombotic drug bleeding; scores frequently used in the clinical setting despite their inaccuracy. Absence of knowledge regarding the real-world risk of antithrombotic-GIB, and the inability to accurately predict which patients will bleed, hampers patient counselling regarding a frequently occurring adverse event which is known to cause morbidity and mortality among cardiac patients. We propose to fill this knowledge gap by quantifying GIB risk in a large, geographically diverse cohort of elderly and non-elderly cardiac patients with atrial fibrillation, venous thromboembolism or post-acute coronary syndrome. GIB associated with antithrombotic drug combinations will be stratified by underlying cardiac conditions; incidence rates (events/100 patient-years) and propensity-matched Cox proportional models (with 95% confidence intervals) will be used to estimate outcome. We will examine heterogeneity of safety effects related to age, chronic co-morbidity, and hepatic or renal dysfunction. Machine learning techniques will then be used to derive and validate a highly sensitive algorithm for the prediction of antithrombotic-related GIB. Discovery of such an algorithm is the first step in the future application of a predictive model in any evidence-based clinical delivery platform, such as a decision rule or risk calculator. NARRATIVE Gastrointestinal bleeding (GIB) in cardiac patients is common, deadly and on the rise due to an older population, antiplatelet and anticoagulant drugs used in combination, and availability of new drugs with higher GIB risk than their predecessors. Lack of data regarding the magnitude of GIB and limited knowledge of which patients are most at risk, prevents accurate counselling regarding cardiac drug safety. We will quantify this risk, study risk factors; and use machine learning techniques to derive and validate a clinical algorithm to better predict at-risk patients.",Gastrointestinal Safety of Antithrombotic Drug Regimens,9692475,R01HS025402,[' '],AHRQ,MAYO CLINIC ARIZONA,R01,2019,394737,0.19062297931707015
"Gastrointestinal Safety of Antithrombotic Drug Regimens ABSTRACT Patients with atrial fibrillation, post-acute coronary syndrome and venous thromboembolism are prescribed antithrombotic drugs (antiplatelet agents and oral anticoagulants) in dual and triple combinations. These drugs independently cause gastrointestinal bleeding (GIB) from mucosal defects or vascular abnormalities of the gastrointestinal tract. Cardiac patients are the fastest growing at-risk group due to the rapidly aging US population, their high-burden of co-morbidity, frequent antithrombotic polypharmacy and prescription of new antithrombotic drugs with higher incidence of GI adverse events. The real-world GIB risk of antithrombotic agents used in combination in a diverse cardiac population has yet to be characterized. Furthermore, we have previously demonstrated poor performance of existing risk scores (HAS-BLED, CHA2DS2-VASC etc.) for the prediction of non- warfarin antithrombotic drug bleeding; scores frequently used in the clinical setting despite their inaccuracy. Absence of knowledge regarding the real-world risk of antithrombotic-GIB, and the inability to accurately predict which patients will bleed, hampers patient counselling regarding a frequently occurring adverse event which is known to cause morbidity and mortality among cardiac patients. We propose to fill this knowledge gap by quantifying GIB risk in a large, geographically diverse cohort of elderly and non-elderly cardiac patients with atrial fibrillation, venous thromboembolism or post-acute coronary syndrome. GIB associated with antithrombotic drug combinations will be stratified by underlying cardiac conditions; incidence rates (events/100 patient-years) and propensity-matched Cox proportional models (with 95% confidence intervals) will be used to estimate outcome. We will examine heterogeneity of safety effects related to age, chronic co-morbidity, and hepatic or renal dysfunction. Machine learning techniques will then be used to derive and validate a highly sensitive algorithm for the prediction of antithrombotic-related GIB. Discovery of such an algorithm is the first step in the future application of a predictive model in any evidence-based clinical delivery platform, such as a decision rule or risk calculator. NARRATIVE Gastrointestinal bleeding (GIB) in cardiac patients is common, deadly and on the rise due to an older population, antiplatelet and anticoagulant drugs used in combination, and availability of new drugs with higher GIB risk than their predecessors. Lack of data regarding the magnitude of GIB and limited knowledge of which patients are most at risk, prevents accurate counselling regarding cardiac drug safety. We will quantify this risk, study risk factors; and use machine learning techniques to derive and validate a clinical algorithm to better predict at-risk patients.",Gastrointestinal Safety of Antithrombotic Drug Regimens,9519828,R01HS025402,[' '],AHRQ,MAYO CLINIC ARIZONA,R01,2018,392266,0.19062297931707015
"Gastrointestinal Safety of Antithrombotic Drug Regimens ABSTRACT Patients with atrial fibrillation, post-acute coronary syndrome and venous thromboembolism are prescribed antithrombotic drugs (antiplatelet agents and oral anticoagulants) in dual and triple combinations. These drugs independently cause gastrointestinal bleeding (GIB) from mucosal defects or vascular abnormalities of the gastrointestinal tract. Cardiac patients are the fastest growing at-risk group due to the rapidly aging US population, their high-burden of co-morbidity, frequent antithrombotic polypharmacy and prescription of new antithrombotic drugs with higher incidence of GI adverse events. The real-world GIB risk of antithrombotic agents used in combination in a diverse cardiac population has yet to be characterized. Furthermore, we have previously demonstrated poor performance of existing risk scores (HAS-BLED, CHA2DS2-VASC etc.) for the prediction of non- warfarin antithrombotic drug bleeding; scores frequently used in the clinical setting despite their inaccuracy. Absence of knowledge regarding the real-world risk of antithrombotic-GIB, and the inability to accurately predict which patients will bleed, hampers patient counselling regarding a frequently occurring adverse event which is known to cause morbidity and mortality among cardiac patients. We propose to fill this knowledge gap by quantifying GIB risk in a large, geographically diverse cohort of elderly and non-elderly cardiac patients with atrial fibrillation, venous thromboembolism or post-acute coronary syndrome. GIB associated with antithrombotic drug combinations will be stratified by underlying cardiac conditions; incidence rates (events/100 patient-years) and propensity-matched Cox proportional models (with 95% confidence intervals) will be used to estimate outcome. We will examine heterogeneity of safety effects related to age, chronic co-morbidity, and hepatic or renal dysfunction. Machine learning techniques will then be used to derive and validate a highly sensitive algorithm for the prediction of antithrombotic-related GIB. Discovery of such an algorithm is the first step in the future application of a predictive model in any evidence-based clinical delivery platform, such as a decision rule or risk calculator. NARRATIVE Gastrointestinal bleeding (GIB) in cardiac patients is common, deadly and on the rise due to an older population, antiplatelet and anticoagulant drugs used in combination, and availability of new drugs with higher GIB risk than their predecessors. Lack of data regarding the magnitude of GIB and limited knowledge of which patients are most at risk, prevents accurate counselling regarding cardiac drug safety. We will quantify this risk, study risk factors; and use machine learning techniques to derive and validate a clinical algorithm to better predict at-risk patients.",Gastrointestinal Safety of Antithrombotic Drug Regimens,9365658,R01HS025402,[' '],AHRQ,MAYO CLINIC ARIZONA,R01,2017,400000,0.19062297931707015
"Novel Non-Invasive Coronary Flow Patterning to Predict Early Coronary Microvascular Disease PROJECT SUMMARY  Coronary microvascular disease (CMD) is notoriously difficult to diagnose non-invasively, and current methods of assessing CMD utilize only the peak velocity of the coronary flow pattern. While new imaging techniques such as cardiac magnetic resonance imaging (MRI) have improved the assessment coronary perfusion, there are currently no non-invasive methods that incorporate the coronary flow pattern over a complete cardiac cycle to definitively assess and predict the development of CMD.  Coronary blood flow (CBF) reflects the summation of flow in the coronary microcirculation, and our lab has begun to harness the full CBF pattern under varying flow and disease conditions (e.g. type 2 diabetes) to determine whether it might harbor novel clues leading to the early detection of CMD. Our past and preliminary data indicate an early onset of CMD in both type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) that occurs prior to the onset of macrovascular complications and that are characterized by blood flow impairments and alterations in coronary resistance microvessel (CRM) structure, function, and biomechanics. Our data also uncovered innovative correlations between CRM structure/biomechanics and our newly-defined features of the coronary flow pattern, some of which were unique to normal or diabetic mice. We have initially utilized these CBF features, in the presence and absence of other factors such as cardiac function, to develop a mathematical model in collaboration with Drs. Christopher Bartlett and William Ray that to date demonstrated that 6 simple factors can predict a normal vs. diabetic coronary flow pattern with 85% predictive accuracy. Utilizing a multidisciplinary approach, these preliminary data strongly suggest that the coronary flow pattern and physiological modulators of it (e.g. coronary micovascular structure/function/biomechanics, cardiac function, etc), may be useful in directly diagnosing early CMD. Therefore, we hypothesize that dissecting the elements that influence coronary flow patterning will be critical determinants in the direct assessment of coronary microvascular disease using computational modeling. Using our previous publications and our preliminary data as guides, the hypothesis will be tested by addressing two specific aims: 1) Determine whether unique time-dependent CBF patterning in normal and T2DM is dictated by a combination of CRM remodeling and biomechanics, coronary flow pattern dynamics, and cardiac function, permitting the development of a computational model to accurately predict CMD; 2) Determine the reproducibility and robustness of the machine learning model in predicting CMD in a diet-induced obesity/diabetes mouse model. If successful, these studies will be the first to simultaneously examine the influence of CRMs, CBF, and cardiac structure/function on the distinct pattern of coronary flow, and it will determine whether a mathematical model may be useful in establishing a direct assessment of CMD to eventually enable clinicians to conduct a more direct non-invasive diagnosis of CMD for the prevention and/or treatment of heart disease. PROJECT NARRATIVE Coronary Artery Disease (CAD) is the leading cause of heart disease and is associated with hypertension, diabetes, and metabolic syndrome. Coronary Microvascular Disease (CMD) is comprised of structural and functional deficits of the tiny coronary arteries that may be an earlier indicator of disease prior to the onset of overt CAD. The proposed multidisciplinary research aims to develop a computational artificial intelligence model that will accurately predict CMD based on a non-invasive coronary flow pattern obtained by Doppler echocardiography.",Novel Non-Invasive Coronary Flow Patterning to Predict Early Coronary Microvascular Disease,10163298,R21EB026518,"['Address', 'Age', 'Artificial Intelligence', 'Biomechanics', 'Blood flow', 'Cardiac', 'Collaborations', 'Computer Models', 'Coronary', 'Coronary Arteriosclerosis', 'Coronary artery', 'Data', 'Development', 'Diabetes Mellitus', 'Diabetic mouse', 'Diet', 'Disease', 'Doppler Echocardiography', 'Early Diagnosis', 'Echocardiography', 'Elements', 'Heart Diseases', 'Hyperemia', 'Hypertension', 'Imaging Techniques', 'Impairment', 'Interdisciplinary Study', 'Laboratories', 'Machine Learning', 'Magnetic Resonance Imaging', 'Measures', 'Metabolic syndrome', 'Methods', 'Microcirculation', 'Microvascular Dysfunction', 'Modeling', 'Non-Insulin-Dependent Diabetes Mellitus', 'Obesity', 'Pattern', 'Physiological', 'Publications', 'Reproducibility', 'Resistance', 'Structure', 'Testing', 'Time', 'base', 'coronary perfusion', 'db/db mouse', 'diabetic', 'disorder prevention', 'early onset', 'experimental study', 'heart function', 'improved', 'innovation', 'interdisciplinary approach', 'macrovascular disease', 'mathematical model', 'noninvasive diagnosis', 'novel', 'pressure', 'prevent']",NIBIB,RESEARCH INST NATIONWIDE CHILDREN'S HOSP,R21,2020,75521,0.0817696730414578
"Novel Non-Invasive Coronary Flow Patterning to Predict Early Coronary Microvascular Disease PROJECT SUMMARY  Coronary microvascular disease (CMD) is notoriously difficult to diagnose non-invasively, and current methods of assessing CMD utilize only the peak velocity of the coronary flow pattern. While new imaging techniques such as cardiac magnetic resonance imaging (MRI) have improved the assessment coronary perfusion, there are currently no non-invasive methods that incorporate the coronary flow pattern over a complete cardiac cycle to definitively assess and predict the development of CMD.  Coronary blood flow (CBF) reflects the summation of flow in the coronary microcirculation, and our lab has begun to harness the full CBF pattern under varying flow and disease conditions (e.g. type 2 diabetes) to determine whether it might harbor novel clues leading to the early detection of CMD. Our past and preliminary data indicate an early onset of CMD in both type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) that occurs prior to the onset of macrovascular complications and that are characterized by blood flow impairments and alterations in coronary resistance microvessel (CRM) structure, function, and biomechanics. Our data also uncovered innovative correlations between CRM structure/biomechanics and our newly-defined features of the coronary flow pattern, some of which were unique to normal or diabetic mice. We have initially utilized these CBF features, in the presence and absence of other factors such as cardiac function, to develop a mathematical model in collaboration with Drs. Christopher Bartlett and William Ray that to date demonstrated that 6 simple factors can predict a normal vs. diabetic coronary flow pattern with 85% predictive accuracy. Utilizing a multidisciplinary approach, these preliminary data strongly suggest that the coronary flow pattern and physiological modulators of it (e.g. coronary micovascular structure/function/biomechanics, cardiac function, etc), may be useful in directly diagnosing early CMD. Therefore, we hypothesize that dissecting the elements that influence coronary flow patterning will be critical determinants in the direct assessment of coronary microvascular disease using computational modeling. Using our previous publications and our preliminary data as guides, the hypothesis will be tested by addressing two specific aims: 1) Determine whether unique time-dependent CBF patterning in normal and T2DM is dictated by a combination of CRM remodeling and biomechanics, coronary flow pattern dynamics, and cardiac function, permitting the development of a computational model to accurately predict CMD; 2) Determine the reproducibility and robustness of the machine learning model in predicting CMD in a diet-induced obesity/diabetes mouse model. If successful, these studies will be the first to simultaneously examine the influence of CRMs, CBF, and cardiac structure/function on the distinct pattern of coronary flow, and it will determine whether a mathematical model may be useful in establishing a direct assessment of CMD to eventually enable clinicians to conduct a more direct non-invasive diagnosis of CMD for the prevention and/or treatment of heart disease. PROJECT NARRATIVE Coronary Artery Disease (CAD) is the leading cause of heart disease and is associated with hypertension, diabetes, and metabolic syndrome. Coronary Microvascular Disease (CMD) is comprised of structural and functional deficits of the tiny coronary arteries that may be an earlier indicator of disease prior to the onset of overt CAD. The proposed multidisciplinary research aims to develop a computational artificial intelligence model that will accurately predict CMD based on a non-invasive coronary flow pattern obtained by Doppler echocardiography.",Novel Non-Invasive Coronary Flow Patterning to Predict Early Coronary Microvascular Disease,9999582,R21EB026518,"['Address', 'Age', 'Artificial Intelligence', 'Biomechanics', 'Blood flow', 'Cardiac', 'Collaborations', 'Computer Models', 'Coronary', 'Coronary Arteriosclerosis', 'Coronary artery', 'Data', 'Development', 'Diabetes Mellitus', 'Diabetic mouse', 'Diet', 'Disease', 'Doppler Echocardiography', 'Early Diagnosis', 'Echocardiography', 'Elements', 'Heart Diseases', 'Hyperemia', 'Hypertension', 'Imaging Techniques', 'Impairment', 'Interdisciplinary Study', 'Laboratories', 'Machine Learning', 'Magnetic Resonance Imaging', 'Measures', 'Metabolic syndrome', 'Methods', 'Microcirculation', 'Microvascular Dysfunction', 'Modeling', 'Non-Insulin-Dependent Diabetes Mellitus', 'Obesity', 'Pattern', 'Physiological', 'Publications', 'Reproducibility', 'Resistance', 'Structure', 'Testing', 'Time', 'base', 'coronary perfusion', 'db/db mouse', 'diabetic', 'disorder prevention', 'early onset', 'experimental study', 'heart function', 'improved', 'innovation', 'interdisciplinary approach', 'macrovascular disease', 'mathematical model', 'noninvasive diagnosis', 'novel', 'pressure', 'prevent']",NIBIB,RESEARCH INST NATIONWIDE CHILDREN'S HOSP,R21,2020,190000,0.0817696730414578
"Novel Non-Invasive Coronary Flow Patterning to Predict Early Coronary Microvascular Disease PROJECT SUMMARY  Coronary microvascular disease (CMD) is notoriously difficult to diagnose non-invasively, and current methods of assessing CMD utilize only the peak velocity of the coronary flow pattern. While new imaging techniques such as cardiac magnetic resonance imaging (MRI) have improved the assessment coronary perfusion, there are currently no non-invasive methods that incorporate the coronary flow pattern over a complete cardiac cycle to definitively assess and predict the development of CMD.  Coronary blood flow (CBF) reflects the summation of flow in the coronary microcirculation, and our lab has begun to harness the full CBF pattern under varying flow and disease conditions (e.g. type 2 diabetes) to determine whether it might harbor novel clues leading to the early detection of CMD. Our past and preliminary data indicate an early onset of CMD in both type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) that occurs prior to the onset of macrovascular complications and that are characterized by blood flow impairments and alterations in coronary resistance microvessel (CRM) structure, function, and biomechanics. Our data also uncovered innovative correlations between CRM structure/biomechanics and our newly-defined features of the coronary flow pattern, some of which were unique to normal or diabetic mice. We have initially utilized these CBF features, in the presence and absence of other factors such as cardiac function, to develop a mathematical model in collaboration with Drs. Christopher Bartlett and William Ray that to date demonstrated that 6 simple factors can predict a normal vs. diabetic coronary flow pattern with 85% predictive accuracy. Utilizing a multidisciplinary approach, these preliminary data strongly suggest that the coronary flow pattern and physiological modulators of it (e.g. coronary micovascular structure/function/biomechanics, cardiac function, etc), may be useful in directly diagnosing early CMD. Therefore, we hypothesize that dissecting the elements that influence coronary flow patterning will be critical determinants in the direct assessment of coronary microvascular disease using computational modeling. Using our previous publications and our preliminary data as guides, the hypothesis will be tested by addressing two specific aims: 1) Determine whether unique time-dependent CBF patterning in normal and T2DM is dictated by a combination of CRM remodeling and biomechanics, coronary flow pattern dynamics, and cardiac function, permitting the development of a computational model to accurately predict CMD; 2) Determine the reproducibility and robustness of the machine learning model in predicting CMD in a diet-induced obesity/diabetes mouse model. If successful, these studies will be the first to simultaneously examine the influence of CRMs, CBF, and cardiac structure/function on the distinct pattern of coronary flow, and it will determine whether a mathematical model may be useful in establishing a direct assessment of CMD to eventually enable clinicians to conduct a more direct non-invasive diagnosis of CMD for the prevention and/or treatment of heart disease. PROJECT NARRATIVE Coronary Artery Disease (CAD) is the leading cause of heart disease and is associated with hypertension, diabetes, and metabolic syndrome. Coronary Microvascular Disease (CMD) is comprised of structural and functional deficits of the tiny coronary arteries that may be an earlier indicator of disease prior to the onset of overt CAD. The proposed multidisciplinary research aims to develop a computational artificial intelligence model that will accurately predict CMD based on a non-invasive coronary flow pattern obtained by Doppler echocardiography.",Novel Non-Invasive Coronary Flow Patterning to Predict Early Coronary Microvascular Disease,9769734,R21EB026518,"['Address', 'Age', 'Artificial Intelligence', 'Biomechanics', 'Blood flow', 'Cardiac', 'Collaborations', 'Computer Simulation', 'Coronary', 'Coronary Arteriosclerosis', 'Coronary artery', 'Data', 'Development', 'Diabetes Mellitus', 'Diabetic mouse', 'Diet', 'Disease', 'Doppler Echocardiography', 'Early Diagnosis', 'Echocardiography', 'Elements', 'Heart Diseases', 'Hyperemia', 'Hypertension', 'Imaging Techniques', 'Impairment', 'Interdisciplinary Study', 'Laboratories', 'Machine Learning', 'Magnetic Resonance Imaging', 'Measures', 'Metabolic syndrome', 'Methods', 'Microcirculation', 'Microvascular Dysfunction', 'Modeling', 'Non-Insulin-Dependent Diabetes Mellitus', 'Obesity', 'Pattern', 'Physiological', 'Publications', 'Reproducibility', 'Resistance', 'Structure', 'Testing', 'Time', 'base', 'coronary perfusion', 'db/db mouse', 'diabetic', 'disorder prevention', 'early onset', 'experimental study', 'heart function', 'improved', 'innovation', 'interdisciplinary approach', 'macrovascular disease', 'mathematical model', 'noninvasive diagnosis', 'novel', 'pressure', 'prevent']",NIBIB,RESEARCH INST NATIONWIDE CHILDREN'S HOSP,R21,2019,228000,0.0817696730414578
"Novel Non-Invasive Coronary Flow Patterning to Predict Early Coronary Microvascular Disease PROJECT SUMMARY  Coronary microvascular disease (CMD) is notoriously difficult to diagnose non-invasively, and current methods of assessing CMD utilize only the peak velocity of the coronary flow pattern. While new imaging techniques such as cardiac magnetic resonance imaging (MRI) have improved the assessment coronary perfusion, there are currently no non-invasive methods that incorporate the coronary flow pattern over a complete cardiac cycle to definitively assess and predict the development of CMD.  Coronary blood flow (CBF) reflects the summation of flow in the coronary microcirculation, and our lab has begun to harness the full CBF pattern under varying flow and disease conditions (e.g. type 2 diabetes) to determine whether it might harbor novel clues leading to the early detection of CMD. Our past and preliminary data indicate an early onset of CMD in both type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) that occurs prior to the onset of macrovascular complications and that are characterized by blood flow impairments and alterations in coronary resistance microvessel (CRM) structure, function, and biomechanics. Our data also uncovered innovative correlations between CRM structure/biomechanics and our newly-defined features of the coronary flow pattern, some of which were unique to normal or diabetic mice. We have initially utilized these CBF features, in the presence and absence of other factors such as cardiac function, to develop a mathematical model in collaboration with Drs. Christopher Bartlett and William Ray that to date demonstrated that 6 simple factors can predict a normal vs. diabetic coronary flow pattern with 85% predictive accuracy. Utilizing a multidisciplinary approach, these preliminary data strongly suggest that the coronary flow pattern and physiological modulators of it (e.g. coronary micovascular structure/function/biomechanics, cardiac function, etc), may be useful in directly diagnosing early CMD. Therefore, we hypothesize that dissecting the elements that influence coronary flow patterning will be critical determinants in the direct assessment of coronary microvascular disease using computational modeling. Using our previous publications and our preliminary data as guides, the hypothesis will be tested by addressing two specific aims: 1) Determine whether unique time-dependent CBF patterning in normal and T2DM is dictated by a combination of CRM remodeling and biomechanics, coronary flow pattern dynamics, and cardiac function, permitting the development of a computational model to accurately predict CMD; 2) Determine the reproducibility and robustness of the machine learning model in predicting CMD in a diet-induced obesity/diabetes mouse model. If successful, these studies will be the first to simultaneously examine the influence of CRMs, CBF, and cardiac structure/function on the distinct pattern of coronary flow, and it will determine whether a mathematical model may be useful in establishing a direct assessment of CMD to eventually enable clinicians to conduct a more direct non-invasive diagnosis of CMD for the prevention and/or treatment of heart disease. PROJECT NARRATIVE Coronary Artery Disease (CAD) is the leading cause of heart disease and is associated with hypertension, diabetes, and metabolic syndrome. Coronary Microvascular Disease (CMD) is comprised of structural and functional deficits of the tiny coronary arteries that may be an earlier indicator of disease prior to the onset of overt CAD. The proposed multidisciplinary research aims to develop a computational artificial intelligence model that will accurately predict CMD based on a non-invasive coronary flow pattern obtained by Doppler echocardiography.",Novel Non-Invasive Coronary Flow Patterning to Predict Early Coronary Microvascular Disease,9584176,R21EB026518,"['Address', 'Age', 'Artificial Intelligence', 'Biomechanics', 'Blood flow', 'Cardiac', 'Collaborations', 'Computer Simulation', 'Coronary', 'Coronary Arteriosclerosis', 'Coronary artery', 'Data', 'Development', 'Diabetes Mellitus', 'Diabetic mouse', 'Diet', 'Disease', 'Doppler Echocardiography', 'Early Diagnosis', 'Echocardiography', 'Elements', 'Heart Diseases', 'Hyperemia', 'Hypertension', 'Imaging Techniques', 'Impairment', 'Interdisciplinary Study', 'Laboratories', 'Machine Learning', 'Magnetic Resonance Imaging', 'Measures', 'Metabolic syndrome', 'Methods', 'Microcirculation', 'Microvascular Dysfunction', 'Modeling', 'Non-Insulin-Dependent Diabetes Mellitus', 'Obesity', 'Pattern', 'Physiological', 'Publications', 'Reproducibility', 'Resistance', 'Structure', 'Testing', 'Time', 'base', 'coronary perfusion', 'db/db mouse', 'diabetic', 'disorder prevention', 'early onset', 'experimental study', 'heart function', 'improved', 'innovation', 'interdisciplinary approach', 'macrovascular disease', 'mathematical model', 'noninvasive diagnosis', 'novel', 'pressure', 'prevent']",NIBIB,RESEARCH INST NATIONWIDE CHILDREN'S HOSP,R21,2018,190000,0.0817696730414578
"Prospective Slice Tracking for Cardiac MRI Project Summary/Abstract Cardiac Magnetic Resonance (CMR) provides arguably the most comprehensive evaluation of the cardiovascular system; however, respiratory motion continues to adversely impact CMR, causing artifacts that lead to poor image quality, repeated scans, and decreased throughput, and thus represents a significant obstacle to clinical utility. For single-shot CMR, cardiac and breathing motions are frozen by limiting the acquisition to an end-diastolic window less than 200 ms. For first pass perfusion, breathing motion cannot be eliminated because data from 50 to 60 consecutive heartbeats are required to capture contrast dynamics. For other single-shot applications such as late gadolinium enhancement (LGE) and parameter mapping, respiratory motion is introduced when the acquisition is repeated across several heartbeats to improve spatial and temporal resolution. To eliminate respiratory motion from single-shot images, non-rigid motion correction (MOCO) has been promoted as an attractive option that provides 100% acquisition efficiently. MOCO can be used either after the reconstruction or during the reconstruction. Such techniques, however, cannot account for through-plane motion, which can only be corrected prospectively, and can fail depending on image quality and the extent of motion. Prospective compensation of the respiratory motion has been recognized as an attractive alternative to existing gating and MOCO methods. Proposed methods use one or more navigator echoesincompatible with or inefficient for many CMR protocolsto capture the respiratory motion and rely on simple parametric models that are inadequate to describe complex respiratory-induced cardiac motion. Due to these limitations, prospective methods have found limited applicability even in research settings. We propose a new framework to prospectively compensate respiratory motion. The proposed method, called PROspective Motion compensation using Pilot Tone (PROMPT), employs Pilot Tone technology and leverages machine learning principles to first learn complex respiratory-induced cardiac motion on a patient-specific basis and then prospectively compensate the motion by tracking the imaging plane, in real time, as a function of a Pilot Tone based respiratory signal. If successful, this synergistic combination of Pilot Tone and machine learning will lead to 100% efficiency for single-shot CMR exams performed under free-breathing conditions, will eliminate the need to setup navigator echoes, respiratory bellows, or other inefficient prospective gating measures, will minimize through-plane motion that can render the images non-diagnostic for CMR applications including fast-pass perfusion, parameter mapping, LGE, and coronary angiography, will provide a reliable surrogate measure of respiratory motion, and will facilitate highly accelerated compressive recovery. Project Narrative Magnetic Resonance Imaging (MRI) has many potential advantages over currently used imaging methods to diagnose heart disease, but MRI images can be ruined if the patient breathes during the scan. In this project, we will develop a method that is insensitive to breathing motion and compare it to existing methods. These efforts should lead to significant improvements in diagnosis of heart disease so that patients may benefit from appropriate treatment.",Prospective Slice Tracking for Cardiac MRI,9587091,R21EB026657,"['Anatomy', 'Breathing', 'Cardiac', 'Cardiovascular system', 'Clinical', 'Complex', 'Coronary Angiography', 'Data', 'Dependence', 'Diagnosis', 'Evaluation', 'Financial compensation', 'Freezing', 'Gadolinium', 'Heart Diseases', 'Image', 'Imaging Techniques', 'Lead', 'Learning', 'Location', 'Machine Learning', 'Magnetic Resonance', 'Magnetic Resonance Imaging', 'Measures', 'Methods', 'Modeling', 'Morphologic artifacts', 'Motion', 'Patients', 'Perfusion', 'Positioning Attribute', 'Protocols documentation', 'Recovery', 'Research', 'Resolution', 'Respiration', 'Scanning', 'Signal Transduction', 'Slice', 'Techniques', 'Technology', 'Testing', 'Time', 'Training', 'Validation', 'artificial neural network', 'base', 'computerized data processing', 'data acquisition', 'healthy volunteer', 'heart motion', 'imaging modality', 'improved', 'prospective', 'reconstruction', 'respiratory', 'technology development', 'temporal measurement', 'volunteer']",NIBIB,OHIO STATE UNIVERSITY,R21,2018,185264,0.08488917665853486
"Prospective Slice Tracking for Cardiac MRI Project Summary/Abstract Cardiac Magnetic Resonance (CMR) provides arguably the most comprehensive evaluation of the cardiovascular system; however, respiratory motion continues to adversely impact CMR, causing artifacts that lead to poor image quality, repeated scans, and decreased throughput, and thus represents a significant obstacle to clinical utility. For single-shot CMR, cardiac and breathing motions are frozen by limiting the acquisition to an end-diastolic window less than 200 ms. For first pass perfusion, breathing motion cannot be eliminated because data from 50 to 60 consecutive heartbeats are required to capture contrast dynamics. For other single-shot applications such as late gadolinium enhancement (LGE) and parameter mapping, respiratory motion is introduced when the acquisition is repeated across several heartbeats to improve spatial and temporal resolution. To eliminate respiratory motion from single-shot images, non-rigid motion correction (MOCO) has been promoted as an attractive option that provides 100% acquisition efficiently. MOCO can be used either after the reconstruction or during the reconstruction. Such techniques, however, cannot account for through-plane motion, which can only be corrected prospectively, and can fail depending on image quality and the extent of motion. Prospective compensation of the respiratory motion has been recognized as an attractive alternative to existing gating and MOCO methods. Proposed methods use one or more navigator echoesincompatible with or inefficient for many CMR protocolsto capture the respiratory motion and rely on simple parametric models that are inadequate to describe complex respiratory-induced cardiac motion. Due to these limitations, prospective methods have found limited applicability even in research settings. We propose a new framework to prospectively compensate respiratory motion. The proposed method, called PROspective Motion compensation using Pilot Tone (PROMPT), employs Pilot Tone technology and leverages machine learning principles to first learn complex respiratory-induced cardiac motion on a patient-specific basis and then prospectively compensate the motion by tracking the imaging plane, in real time, as a function of a Pilot Tone based respiratory signal. If successful, this synergistic combination of Pilot Tone and machine learning will lead to 100% efficiency for single-shot CMR exams performed under free-breathing conditions, will eliminate the need to setup navigator echoes, respiratory bellows, or other inefficient prospective gating measures, will minimize through-plane motion that can render the images non-diagnostic for CMR applications including fast-pass perfusion, parameter mapping, LGE, and coronary angiography, will provide a reliable surrogate measure of respiratory motion, and will facilitate highly accelerated compressive recovery. Project Narrative Magnetic Resonance Imaging (MRI) has many potential advantages over currently used imaging methods to diagnose heart disease, but MRI images can be ruined if the patient breathes during the scan. In this project, we will develop a method that is insensitive to breathing motion and compare it to existing methods. These efforts should lead to significant improvements in diagnosis of heart disease so that patients may benefit from appropriate treatment.",Prospective Slice Tracking for Cardiac MRI,9762101,R21EB026657,"['Anatomy', 'Breathing', 'Cardiac', 'Cardiovascular system', 'Clinical', 'Complex', 'Coronary Angiography', 'Data', 'Dependence', 'Diagnosis', 'Evaluation', 'Financial compensation', 'Freezing', 'Gadolinium', 'Heart Diseases', 'Image', 'Imaging Techniques', 'Lead', 'Learning', 'Location', 'Machine Learning', 'Magnetic Resonance', 'Magnetic Resonance Imaging', 'Measures', 'Methods', 'Modeling', 'Morphologic artifacts', 'Motion', 'Patients', 'Perfusion', 'Positioning Attribute', 'Protocols documentation', 'Recovery', 'Research', 'Resolution', 'Respiration', 'Scanning', 'Signal Transduction', 'Slice', 'Techniques', 'Technology', 'Testing', 'Time', 'Training', 'Validation', 'artificial neural network', 'base', 'computerized data processing', 'data acquisition', 'healthy volunteer', 'heart motion', 'imaging modality', 'improved', 'prospective', 'reconstruction', 'respiratory', 'technology development', 'temporal measurement', 'volunteer']",NIBIB,OHIO STATE UNIVERSITY,R21,2019,223680,0.08488917665853486
"Motion-Resolved, Comprehensive Quantitative Tissue Characterization Using MR Multitasking PROJECT SUMMARY  Quantitative magnetic resonance imaging (MRI) measures tissue parameters such as T1, T2, T2*, and diffusion to detect subtle differences in tissue states (such as microstructure, diffuse fibrosis, edema, hemorrhage, and iron content) from neurological, oncological, and cardiovascular diseases. Because each parameter offers complementary tissue information, multiparameter mapping is very promising for risk assessment, early detection, accurate staging, and treatment monitoring of disease. However, quantitative MRI is typically very time consuming and difficult to perform. Each parameter is typically measured from its own series of images, so measuring multiple parameters leads to long, inefficient scanning sessions. Furthermore, cardiac and breathing motion creates misalignment between images, causing additional problems.  The standard approach to motion is to either remove it (e.g., ask the patient to hold their breath) or to synchronize image acquisition with it (e.g., using electrocardiography (ECG) to monitor cardiac motion). This approach makes scan times even longer, limits imaging to patients who can repeatedly perform long breath holds (which is difficult for aging or weak patients) and who have predictable cardiac motion (which is not true of patients with cardiac arrhythmias). Furthermore, these methods are often unreliable and difficult to perform.  This project is to develop and validate a new technology, MR Multitasking, to perform multiple simultaneous measurements in a single, push-button scan that is both comfortable for patients and simple for technologists to perform. MR Multitasking redesigns quantitative MRI around the concept of images as functions of many time dimensions, each corresponding to a different dynamic process (e.g., motion, T1, T2, T2*, and diffusion), and then uses mathematical models called low-rank tensors to perform fast, multidimensional imaging. This allows continuous acquisition of imaging data even while the subject is moving, providing motion-resolved parameter maps without breath holding or motion synchronization. We will scan healthy subjects, liver patients, prostate cancer patients, and cardiovascular patients to develop and validate this technology and use artificial intelligence to quickly reconstruct images from the collected data. The resulting tool will be applicable to any organ system, offering clinicians and investigators a valuable tool to answer a wide range of biomedical questions. PROJECT NARRATIVE  This project is to develop and validate a one-stop, push-button solution for comprehensive, motion- resolved quantitative magnetic resonance imaging (MRI). This will be accomplished by cultivating a new technology, MR Multitasking, which can measure multiple tissue biomarkers in a single scan, even in moving organs. The resulting technology will be applicable to any organ system, offering clinicians and investigators a valuable tool to diagnose, monitor, and study a wide range of diseases.","Motion-Resolved, Comprehensive Quantitative Tissue Characterization Using MR Multitasking",9886248,R01EB028146,"['Address', 'Aging', 'Algorithms', 'Arrhythmia', 'Artificial Intelligence', 'Blood flow', 'Breathing', 'Cancer Patient', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Clinical', 'Collection', 'Consumption', 'Data', 'Development', 'Diagnosis', 'Diffuse', 'Diffusion', 'Dimensions', 'Disease', 'Early Diagnosis', 'Edema', 'Electrocardiogram', 'Fibrosis', 'Hemorrhage', 'Image', 'Iron', 'Joints', 'Lead', 'Lipids', 'Liver', 'Longitudinal Studies', 'Machine Learning', 'Magnetic Resonance Imaging', 'Magnetism', 'Malignant neoplasm of prostate', 'Maps', 'Measurement', 'Measures', 'Methods', 'Modeling', 'Monitor', 'Morphologic artifacts', 'Motion', 'Nature', 'Neurologic', 'Organ', 'Patients', 'Physiological', 'Positioning Attribute', 'Predisposition', 'Process', 'Property', 'Recovery', 'Reproducibility', 'Research', 'Research Personnel', 'Respiration', 'Risk Assessment', 'Scanning', 'Series', 'Signal Transduction', 'Source', 'Staging', 'System', 'Technology', 'Testing', 'Time', 'Tissue imaging', 'Tissues', 'Validation', 'body system', 'deep learning', 'heart motion', 'image reconstruction', 'magnetic field', 'magnetohydrodynamic', 'mathematical model', 'multitask', 'new technology', 'prospective', 'quantitative imaging', 'reconstruction', 'respiratory', 'time use', 'tissue biomarkers', 'tool']",NIBIB,CEDARS-SINAI MEDICAL CENTER,R01,2020,628575,0.0974443361486156
"Motion-Resolved, Comprehensive Quantitative Tissue Characterization Using MR Multitasking PROJECT SUMMARY  Quantitative magnetic resonance imaging (MRI) measures tissue parameters such as T1, T2, T2*, and diffusion to detect subtle differences in tissue states (such as microstructure, diffuse fibrosis, edema, hemorrhage, and iron content) from neurological, oncological, and cardiovascular diseases. Because each parameter offers complementary tissue information, multiparameter mapping is very promising for risk assessment, early detection, accurate staging, and treatment monitoring of disease. However, quantitative MRI is typically very time consuming and difficult to perform. Each parameter is typically measured from its own series of images, so measuring multiple parameters leads to long, inefficient scanning sessions. Furthermore, cardiac and breathing motion creates misalignment between images, causing additional problems.  The standard approach to motion is to either remove it (e.g., ask the patient to hold their breath) or to synchronize image acquisition with it (e.g., using electrocardiography (ECG) to monitor cardiac motion). This approach makes scan times even longer, limits imaging to patients who can repeatedly perform long breath holds (which is difficult for aging or weak patients) and who have predictable cardiac motion (which is not true of patients with cardiac arrhythmias). Furthermore, these methods are often unreliable and difficult to perform.  This project is to develop and validate a new technology, MR Multitasking, to perform multiple simultaneous measurements in a single, push-button scan that is both comfortable for patients and simple for technologists to perform. MR Multitasking redesigns quantitative MRI around the concept of images as functions of many time dimensions, each corresponding to a different dynamic process (e.g., motion, T1, T2, T2*, and diffusion), and then uses mathematical models called low-rank tensors to perform fast, multidimensional imaging. This allows continuous acquisition of imaging data even while the subject is moving, providing motion-resolved parameter maps without breath holding or motion synchronization. We will scan healthy subjects, liver patients, prostate cancer patients, and cardiovascular patients to develop and validate this technology and use artificial intelligence to quickly reconstruct images from the collected data. The resulting tool will be applicable to any organ system, offering clinicians and investigators a valuable tool to answer a wide range of biomedical questions. PROJECT NARRATIVE  This project is to develop and validate a one-stop, push-button solution for comprehensive, motion- resolved quantitative magnetic resonance imaging (MRI). This will be accomplished by cultivating a new technology, MR Multitasking, which can measure multiple tissue biomarkers in a single scan, even in moving organs. The resulting technology will be applicable to any organ system, offering clinicians and investigators a valuable tool to diagnose, monitor, and study a wide range of diseases.","Motion-Resolved, Comprehensive Quantitative Tissue Characterization Using MR Multitasking",9766063,R01EB028146,"['Address', 'Aging', 'Algorithms', 'Arrhythmia', 'Artificial Intelligence', 'Blood flow', 'Breathing', 'Cancer Patient', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Clinical', 'Collection', 'Consumption', 'Data', 'Development', 'Diagnosis', 'Diffuse', 'Diffusion', 'Dimensions', 'Disease', 'Early Diagnosis', 'Edema', 'Electrocardiogram', 'Fibrosis', 'Hemorrhage', 'Image', 'Iron', 'Joints', 'Lead', 'Lipids', 'Liver', 'Longitudinal Studies', 'Machine Learning', 'Magnetic Resonance Imaging', 'Magnetism', 'Malignant neoplasm of prostate', 'Maps', 'Measurement', 'Measures', 'Methods', 'Modeling', 'Monitor', 'Morphologic artifacts', 'Motion', 'Nature', 'Neurologic', 'Organ', 'Patients', 'Physiological', 'Positioning Attribute', 'Predisposition', 'Process', 'Property', 'Recovery', 'Reproducibility', 'Research', 'Research Personnel', 'Respiration', 'Risk Assessment', 'Scanning', 'Series', 'Signal Transduction', 'Source', 'Staging', 'System', 'Technology', 'Testing', 'Time', 'Tissue imaging', 'Tissues', 'Validation', 'body system', 'deep learning', 'heart motion', 'image reconstruction', 'magnetic field', 'magnetohydrodynamic', 'mathematical model', 'multitask', 'new technology', 'prospective', 'quantitative imaging', 'reconstruction', 'respiratory', 'time use', 'tissue biomarkers', 'tool']",NIBIB,CEDARS-SINAI MEDICAL CENTER,R01,2019,676760,0.0974443361486156
"Robot-Assisted 3D ICE Catheter for Cardiac Ablation ABSTRACT  Although the cardiac ablation procedure for atrial fibrillation has a wide adoption rate, it also has a high recurrence of arrhythmia primarily due to the creation of suboptimal lesions. The procedure is also associated with complications including cardiac perforation, tamponade, atrio-esophageal fistulas and thrombus. Repeated and prolonged X-ray exposure for the clinician can also lead to enhanced risk of cancer. A fluoroless approach using intracardiac echocardiography (ICE) is becoming a more widely adopted imaging option due to the absence of ionizing radiation and the possibility of real-time monitoring of the created lesions. However, the ICE- guided approach suffers from significant shortcomings, which include poor dexterity of the ICE catheter, difficulty in simultaneously manipulating the ICE and ablation catheters, unintuitive image orientation and noisy image quality. There is therefore an unmet need to overcome these shortcomings of the ICE-guided approach to enable better lesion creation and reduced complications associated with the cardiac ablation procedure. The long-term goal of this research is to develop robotic technologies, control and machine learning algorithms to enable ICE- guided cardiac ablation procedures. The objective is to develop a novel robotic manipulator, a steerable ICE catheter, and machine learning and control algorithms to manipulate the ICE catheter and monitor the created lesions in real-time. The rationale that underlies the proposed research is that the robot-assisted steerable ICE catheter with the catheter tracking algorithms will enable simultaneous manipulation of the ICE and ablation catheters. Further, the machine learning algorithms to monitor therapy will reduce the risk of complications, while ensuring the creation of necrotic lesions, thereby reducing the recurrence of AF. In this proposal, we plan to pursue the following specific aims: 1) Design, develop, and model a steerable 3D ICE catheter with enhanced dexterity. 2) Design and develop a robotic manipulator and associated control algorithms to allow for precise manipulation of the ICE catheter. 3) Develop machine-learning and vision-based algorithms integrated with a navigation system for tracking the ablation catheter, and monitoring therapy. 4) Validate the robotic ICE system in heart phantom and porcine models. The proposed research is significant since it will allow for better therapeutic outcomes by reducing recurrence rates and complications associated with cardiac ablation, and avoiding exposure of the patient and clinical care team to X-ray radiation. The proposed research is innovative in that it builds on state-of-the-art robotics technology, machine learning and vision algorithms to enable fluoroless ICE- guided cardiac ablation procedures. PROJECT NARRATIVE  The proposed study addresses an important and under-investigated area of treating atrial fibrillation using a completely fluoroless approach with ICE imaging. The proposed research is significant since it will allow for better therapeutic outcomes by reducing recurrence rates and complications associated with cardiac ablation, and avoiding exposure of the patient and clinical care team to X-ray radiation.",Robot-Assisted 3D ICE Catheter for Cardiac Ablation,9973517,R01EB028278,"['3-Dimensional', 'Address', 'Adopted', 'Adoption', 'Algorithms', 'Anatomy', 'Area', 'Arrhythmia', 'Atrial Fibrillation', 'Canada', 'Cardiac', 'Cardiac ablation', 'Catheters', 'Computer Vision Systems', 'Computer software', 'Coupling', 'Diagnosis', 'Early Diagnosis', 'Echocardiography', 'Ensure', 'Esophageal Fistula', 'Family suidae', 'Fluoroscopy', 'Goals', 'Grant', 'Heart', 'Heart Atrium', 'Hospitals', 'Image', 'Intuition', 'Ionizing radiation', 'Lead', 'Lesion', 'Machine Learning', 'Manuals', 'Maps', 'Medical', 'Microbubbles', 'Modeling', 'Monitor', 'Myocardium', 'Navigation System', 'Necrotic Lesion', 'Ontario', 'Operative Surgical Procedures', 'Patient Care', 'Patients', 'Perforation', 'Performance', 'Positioning Attribute', 'Procedures', 'Pulmonary veins', 'Radial', 'Recurrence', 'Research', 'Research Personnel', 'Risk', 'Robot', 'Robotics', 'Roentgen Rays', 'Surgical Instruments', 'System', 'Technology', 'Thrombus', 'Time', 'Ultrasonography', 'United States', 'Universities', 'Vision', 'Woman', 'Work', 'base', 'cancer risk', 'clinical care', 'convolutional neural network', 'deep learning algorithm', 'design', 'dexterity', 'image guided', 'innovation', 'instrument', 'kinematics', 'light weight', 'machine learning algorithm', 'machine vision', 'novel', 'radio frequency', 'real time monitoring', 'robot assistance', 'therapy outcome', 'time use']",NIBIB,BRIGHAM AND WOMEN'S HOSPITAL,R01,2020,437331,0.1667334276877489
"Estimating Trajectory of Recovery in Cardiac Rehabilitation using Mobile Health Technology and Personalized Machine Learning Project Summary/Abstract The objective of our work leverages mobile health technology to develop machine learning models for longitudinal trajectories of recovery like those needed in cardiac rehabilitation. The investigation uses mobile health technology to quantify trajectories of recovery measures, personalizing understanding of exercise capacity and cardiac function. Exercise-based cardiac rehabilitation programs reduce cardiovascular mortality risks and improve patient outcomes in such longitudinal fashion, through increased exercise capacity as measured by peak V02 improvements over the course of care. These programs have recently been extended to include heart failure with reduced ejection fraction (HFrEF) patients. Despite the reduction in mortality and readmissions, participation and adherence in cardiac rehabilitation programs remains a challenge, especially in underserved communities because of limited program availability, the distance and transportation access to a program, its hours of operation, as well as a lack of diversity and gender-dominated programs. Home-based programs using smartphones have shown to increase adherence and achieve similar outcomes. While home-based programs also improved resting heart rate, systolic blood pressure, and levels of physical activity achieved through metabolic equivalent of tasks and peak V02 at the end of the study, users expressed a desire to have individualized education and treatment. Home-based systems still do not achieve real-time interaction, feedback, and monitoring that center-based rehabilitation does through a lack of feedback and necessity of self-reported exertion values. A system is needed that quantify measures of exercise capacity, which can lead to recovery, dynamically throughout the course of treatment. This proposal develops an unobtrusive system, with new mobile health technology sensors, and trains analytic models that allow for personalized quantification of rehabilitation trajectories in HFrEF patients, which can monitor patient adherence and improvement in measures during exercise as well as while at rest. This system investigates the improvement over the course of a 12-week cardiac rehabilitation study and designs trajectories of recovery to understand improvements in peak V02 and exercise capacity in HFrEF patients by also measuring improvements of measurements of heart rate and blood pressure while at rest. This allows for an investigation of additional measures, over time, that may better quantify recovery in HFrEF patients that can be used for center-based rehabilitation or home-based rehabilitation. This can provide a significant enhancement of metrics that define recovery for HFrEF patients with estimations to metrics that are difficult to collect and evaluate. Project Narrative Quantification of trajectories of recovery for patients through wearable mobile health technologies can provide personal understanding of improvements and challenges faced in recovery by patients with heart failure with reduced ejection fraction. Such a system will indicate to each patient the improvement in exercise capacity needed to continue preventing any recurrent events, allowing participants to have the understanding and individualized feeling they get from clinic visits and center-based cardiac rehabilitation at home or any other location they wish to participate in recovery activities. The exploration of additional markers of recovery can continue to provide quantification of heart failure conditions useful for clinicians and patients alike.",Estimating Trajectory of Recovery in Cardiac Rehabilitation using Mobile Health Technology and Personalized Machine Learning,10018016,R21EB028486,"['Achievement', 'Adherence', 'Behavior', 'Biological Markers', 'Blood Pressure', 'Cardiac rehabilitation', 'Cardiovascular Diseases', 'Cardiovascular system', 'Caregivers', 'Caring', 'Cellular Phone', 'Characteristics', 'Chest', 'Clinic Visits', 'Clinical', 'Communities', 'Data', 'Data Collection', 'Development', 'Devices', 'EFRAC', 'Education', 'Event', 'Exercise', 'Exertion', 'Failure', 'Feedback', 'Feeling', 'Gender', 'Health Technology', 'Heart Rate', 'Heart failure', 'Home environment', 'Hour', 'Individual', 'Intervention', 'Investigation', 'Lead', 'Location', 'Machine Learning', 'Measurement', 'Measures', 'Metabolic', 'Modeling', 'Monitor', 'Outcome', 'Participant', 'Patient Care', 'Patient Monitoring', 'Patient Self-Report', 'Patient-Focused Outcomes', 'Patients', 'Pattern', 'Performance', 'Physical activity', 'Physiologic pulse', 'Positioning Attribute', 'Proxy', 'Pulse Pressure', 'Recovery', 'Recurrence', 'Rehabilitation therapy', 'Research', 'Rest', 'System', 'Techniques', 'Time', 'Training', 'Transportation', 'Update', 'Visit', 'Work', 'Wrist', 'advanced analytics', 'analytical method', 'base', 'compliance behavior', 'design', 'exercise capacity', 'heart function', 'heart rate monitor', 'hospital readmission', 'improved', 'longitudinal analysis', 'mHealth', 'mortality', 'mortality risk', 'novel', 'operation', 'prevent', 'programs', 'rate of change', 'sensor technology', 'smart watch', 'wearable device', 'wearable sensor technology']",NIBIB,TEXAS ENGINEERING EXPERIMENT STATION,R21,2020,177045,0.07080097593491663
"Estimating Trajectory of Recovery in Cardiac Rehabilitation using Mobile Health Technology and Personalized Machine Learning Project Summary/Abstract The objective of our work leverages mobile health technology to develop machine learning models for longitudinal trajectories of recovery like those needed in cardiac rehabilitation. The investigation uses mobile health technology to quantify trajectories of recovery measures, personalizing understanding of exercise capacity and cardiac function. Exercise-based cardiac rehabilitation programs reduce cardiovascular mortality risks and improve patient outcomes in such longitudinal fashion, through increased exercise capacity as measured by peak V02 improvements over the course of care. These programs have recently been extended to include heart failure with reduced ejection fraction (HFrEF) patients. Despite the reduction in mortality and readmissions, participation and adherence in cardiac rehabilitation programs remains a challenge, especially in underserved communities because of limited program availability, the distance and transportation access to a program, its hours of operation, as well as a lack of diversity and gender-dominated programs. Home-based programs using smartphones have shown to increase adherence and achieve similar outcomes. While home-based programs also improved resting heart rate, systolic blood pressure, and levels of physical activity achieved through metabolic equivalent of tasks and peak V02 at the end of the study, users expressed a desire to have individualized education and treatment. Home-based systems still do not achieve real-time interaction, feedback, and monitoring that center-based rehabilitation does through a lack of feedback and necessity of self-reported exertion values. A system is needed that quantify measures of exercise capacity, which can lead to recovery, dynamically throughout the course of treatment. This proposal develops an unobtrusive system, with new mobile health technology sensors, and trains analytic models that allow for personalized quantification of rehabilitation trajectories in HFrEF patients, which can monitor patient adherence and improvement in measures during exercise as well as while at rest. This system investigates the improvement over the course of a 12-week cardiac rehabilitation study and designs trajectories of recovery to understand improvements in peak V02 and exercise capacity in HFrEF patients by also measuring improvements of measurements of heart rate and blood pressure while at rest. This allows for an investigation of additional measures, over time, that may better quantify recovery in HFrEF patients that can be used for center-based rehabilitation or home-based rehabilitation. This can provide a significant enhancement of metrics that define recovery for HFrEF patients with estimations to metrics that are difficult to collect and evaluate. Project Narrative Quantification of trajectories of recovery for patients through wearable mobile health technologies can provide personal understanding of improvements and challenges faced in recovery by patients with heart failure with reduced ejection fraction. Such a system will indicate to each patient the improvement in exercise capacity needed to continue preventing any recurrent events, allowing participants to have the understanding and individualized feeling they get from clinic visits and center-based cardiac rehabilitation at home or any other location they wish to participate in recovery activities. The exploration of additional markers of recovery can continue to provide quantification of heart failure conditions useful for clinicians and patients alike.",Estimating Trajectory of Recovery in Cardiac Rehabilitation using Mobile Health Technology and Personalized Machine Learning,9809933,R21EB028486,"['Achievement', 'Adherence', 'Behavior', 'Biological Markers', 'Blood Pressure', 'Cardiac rehabilitation', 'Cardiovascular Diseases', 'Cardiovascular system', 'Caregivers', 'Caring', 'Cellular Phone', 'Characteristics', 'Chest', 'Clinic Visits', 'Clinical', 'Communities', 'Data', 'Data Collection', 'Development', 'Devices', 'EFRAC', 'Education', 'Event', 'Exercise', 'Exertion', 'Failure', 'Feedback', 'Feeling', 'Gender', 'Health Technology', 'Heart Rate', 'Heart failure', 'Home environment', 'Hour', 'Individual', 'Intervention', 'Investigation', 'Lead', 'Location', 'Machine Learning', 'Measurement', 'Measures', 'Metabolic', 'Modeling', 'Monitor', 'Outcome', 'Participant', 'Patient Care', 'Patient Monitoring', 'Patient Self-Report', 'Patient-Focused Outcomes', 'Patients', 'Pattern', 'Performance', 'Physical activity', 'Physiologic pulse', 'Positioning Attribute', 'Proxy', 'Pulse Pressure', 'Recovery', 'Recurrence', 'Rehabilitation therapy', 'Research', 'Rest', 'System', 'Techniques', 'Time', 'Training', 'Transportation', 'Update', 'Visit', 'Work', 'Wrist', 'analytical method', 'base', 'compliance behavior', 'design', 'exercise capacity', 'heart function', 'heart rate monitor', 'hospital readmission', 'improved', 'longitudinal analysis', 'mHealth', 'mortality', 'mortality risk', 'novel', 'operation', 'prevent', 'programs', 'rate of change', 'sensor technology', 'smart watch', 'wearable device']",NIBIB,TEXAS ENGINEERING EXPERIMENT STATION,R21,2019,208632,0.07080097593491663
"SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING Mapping of cardiac potentials and activation sequences by recording simultaneously from many electrodes applied directly to the heart promises to be a powerful tool for the study and treatment of arrhythmias.  Several major improvements in mapping must be made if it is to fulfill this promise.  The goal of this application is to perform the research and development necessary to bring about these improvements.  1. A computer- assisted mapping system will be constructed capable of recording from 512 channels simultaneously at an effective sampling rate of 15,000 Hz.  Such a system is needed to map the complex activation sequences and high-frequency Purkinje spikes that can occur during some arrhythmias.  2. Improved methods will be developed to construct electrodes reliably, accurately, quickly, inexpensively, and in large numbers using microelectronic techniques.  3. Fast, accurate methods will be developed to specify the three-dimensional location of epicardial, intracavitary, and plunge electrodes for animal mapping. Computer graphics will be developed to display activation sequences as lines for the endocardium and epicardium or as surfaces in a three-dimensional representation of the thickness of the ventricular wall within seconds of recording the potentials. The lines or surfaces will be animated to move through the heart with time as in a movie.  4.  Robust, quantitative algorithms for detection of the presence and timing of activation from electrode recordings will be developed and will be implemented in software to perform rapidly and with a minimum of human intervention. The data to develop these algorithms will be obtained from experiments in which the presence or absence of activation is known by means independent of the electrode recordings.  5. Experiments will be performed to determine the anatomic and electrical causes of fractionated potentials in cardiac electrode recordings, i.e., cases in which a single, discrete activation complex is not recorded.  6. Methods will be developed to estimate potentials away from the recording electrode sites in those regions in which it is not possible to place electrodes. Examples include estimating endocardial potentials from intracavitary recordings, epicardial potentials from recording from the overlying epicardial fat, and potentials through the ventricular wall from intracavitary and epicardial recordings. The accomplishment of these goals will greatly improve cardiac mapping and should lead to new advances in both the basic understanding and the clinical treatment of cardiac arrhythmias.  n/a",SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING,3345739,R01HL033637,"['artificial intelligence', ' computer graphics /printing', ' diagnosis quality /standard', ' electrocardiography', ' electrophysiology', ' epicardial mapping', ' heart dimension /size', ' heart disorder diagnosis', ' heart rhythm', ' heart surgery', ' human subject', ' microelectrodes', ' myocardial infarction', ' tachycardia']",NHLBI,DUKE UNIVERSITY,R01,1992,162362,0.07781201663865617
"SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING Mapping of cardiac potentials and activation sequences by recording simultaneously from many electrodes applied directly to the heart promises to be a powerful tool for the study and treatment of arrhythmias.  Several major improvements in mapping must be made if it is to fulfill this promise.  The goal of this application is to perform the research and development necessary to bring about these improvements.  1. A computer- assisted mapping system will be constructed capable of recording from 512 channels simultaneously at an effective sampling rate of 15,000 Hz.  Such a system is needed to map the complex activation sequences and high-frequency Purkinje spikes that can occur during some arrhythmias.  2. Improved methods will be developed to construct electrodes reliably, accurately, quickly, inexpensively, and in large numbers using microelectronic techniques.  3. Fast, accurate methods will be developed to specify the three-dimensional location of epicardial, intracavitary, and plunge electrodes for animal mapping. Computer graphics will be developed to display activation sequences as lines for the endocardium and epicardium or as surfaces in a three-dimensional representation of the thickness of the ventricular wall within seconds of recording the potentials. The lines or surfaces will be animated to move through the heart with time as in a movie.  4.  Robust, quantitative algorithms for detection of the presence and timing of activation from electrode recordings will be developed and will be implemented in software to perform rapidly and with a minimum of human intervention. The data to develop these algorithms will be obtained from experiments in which the presence or absence of activation is known by means independent of the electrode recordings.  5. Experiments will be performed to determine the anatomic and electrical causes of fractionated potentials in cardiac electrode recordings, i.e., cases in which a single, discrete activation complex is not recorded.  6. Methods will be developed to estimate potentials away from the recording electrode sites in those regions in which it is not possible to place electrodes. Examples include estimating endocardial potentials from intracavitary recordings, epicardial potentials from recording from the overlying epicardial fat, and potentials through the ventricular wall from intracavitary and epicardial recordings. The accomplishment of these goals will greatly improve cardiac mapping and should lead to new advances in both the basic understanding and the clinical treatment of cardiac arrhythmias.  n/a",SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING,3345738,R01HL033637,"['artificial intelligence', ' computer graphics /printing', ' diagnosis quality /standard', ' electrocardiography', ' electrophysiology', ' epicardial mapping', ' heart dimension /size', ' heart disorder diagnosis', ' heart rhythm', ' heart surgery', ' human subject', ' microelectrodes', ' myocardial infarction', ' tachycardia']",NHLBI,DUKE UNIVERSITY,R01,1991,154062,0.07781201663865617
"SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING Mapping of cardiac potentials and activation sequences by recording simultaneously from many electrodes applied directly to the heart promises to be a powerful tool for the study and treatment of arrhythmias.  Several major improvements in mapping must be made if it is to fulfill this promise.  The goal of this application is to perform the research and development necessary to bring about these improvements.  1. A computer- assisted mapping system will be constructed capable of recording from 512 channels simultaneously at an effective sampling rate of 15,000 Hz.  Such a system is needed to map the complex activation sequences and high-frequency Purkinje spikes that can occur during some arrhythmias.  2. Improved methods will be developed to construct electrodes reliably, accurately, quickly, inexpensively, and in large numbers using microelectronic techniques.  3. Fast, accurate methods will be developed to specify the three-dimensional location of epicardial, intracavitary, and plunge electrodes for animal mapping. Computer graphics will be developed to display activation sequences as lines for the endocardium and epicardium or as surfaces in a three-dimensional representation of the thickness of the ventricular wall within seconds of recording the potentials. The lines or surfaces will be animated to move through the heart with time as in a movie.  4.  Robust, quantitative algorithms for detection of the presence and timing of activation from electrode recordings will be developed and will be implemented in software to perform rapidly and with a minimum of human intervention. The data to develop these algorithms will be obtained from experiments in which the presence or absence of activation is known by means independent of the electrode recordings.  5. Experiments will be performed to determine the anatomic and electrical causes of fractionated potentials in cardiac electrode recordings, i.e., cases in which a single, discrete activation complex is not recorded.  6. Methods will be developed to estimate potentials away from the recording electrode sites in those regions in which it is not possible to place electrodes. Examples include estimating endocardial potentials from intracavitary recordings, epicardial potentials from recording from the overlying epicardial fat, and potentials through the ventricular wall from intracavitary and epicardial recordings. The accomplishment of these goals will greatly improve cardiac mapping and should lead to new advances in both the basic understanding and the clinical treatment of cardiac arrhythmias.  n/a",SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING,3345737,R01HL033637,"['artificial intelligence', ' computer graphics /printing', ' diagnosis quality /standard', ' electrocardiography', ' electrophysiology', ' epicardial mapping', ' heart dimension /size', ' heart disorder diagnosis', ' heart rhythm', ' heart surgery', ' human subject', ' microelectrodes', ' myocardial infarction', ' tachycardia']",NHLBI,DUKE UNIVERSITY,R01,1990,148137,0.07781201663865617
"SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING Mapping of cardiac potentials and activation sequences by recording simultaneously from many electrodes applied directly to the heart promises to be a powerful tool for the study and treatment of arrhythmias.  Several major improvements in mapping must be made if it is to fulfill this promise.  The goal of this application is to perform the research and development necessary to bring about these improvements.  1. A computer- assisted mapping system will be constructed capable of recording from 512 channels simultaneously at an effective sampling rate of 15,000 Hz.  Such a system is needed to map the complex activation sequences and high-frequency Purkinje spikes that can occur during some arrhythmias.  2. Improved methods will be developed to construct electrodes reliably, accurately, quickly, inexpensively, and in large numbers using microelectronic techniques.  3. Fast, accurate methods will be developed to specify the three-dimensional location of epicardial, intracavitary, and plunge electrodes for animal mapping. Computer graphics will be developed to display activation sequences as lines for the endocardium and epicardium or as surfaces in a three-dimensional representation of the thickness of the ventricular wall within seconds of recording the potentials. The lines or surfaces will be animated to move through the heart with time as in a movie.  4.  Robust, quantitative algorithms for detection of the presence and timing of activation from electrode recordings will be developed and will be implemented in software to perform rapidly and with a minimum of human intervention. The data to develop these algorithms will be obtained from experiments in which the presence or absence of activation is known by means independent of the electrode recordings.  5. Experiments will be performed to determine the anatomic and electrical causes of fractionated potentials in cardiac electrode recordings, i.e., cases in which a single, discrete activation complex is not recorded.  6. Methods will be developed to estimate potentials away from the recording electrode sites in those regions in which it is not possible to place electrodes. Examples include estimating endocardial potentials from intracavitary recordings, epicardial potentials from recording from the overlying epicardial fat, and potentials through the ventricular wall from intracavitary and epicardial recordings. The accomplishment of these goals will greatly improve cardiac mapping and should lead to new advances in both the basic understanding and the clinical treatment of cardiac arrhythmias.  n/a",SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING,3345736,R01HL033637,"['artificial intelligence', ' computer graphics /printing', ' diagnosis quality /standard', ' electrocardiography', ' electrophysiology', ' epicardial mapping', ' heart dimension /size', ' heart disorder diagnosis', ' heart rhythm', ' heart surgery', ' human subject', ' microelectrodes', ' myocardial infarction', ' tachycardia']",NHLBI,DUKE UNIVERSITY,R01,1989,152720,0.07781201663865617
"SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING Mapping of cardiac potentials and activation sequences by recording simultaneously from many electrodes applied directly to the heart promises to be a powerful tool for the study and treatment of arrhythmias.  Several major improvements in mapping must be made if it is to fulfill this promise.  The goal of this application is to perform the research and development necessary to bring about these improvements.  1. A computer- assisted mapping system will be constructed capable of recording from 512 channels simultaneously at an effective sampling rate of 15,000 Hz.  Such a system is needed to map the complex activation sequences and high-frequency Purkinje spikes that can occur during some arrhythmias.  2. Improved methods will be developed to construct electrodes reliably, accurately, quickly, inexpensively, and in large numbers using microelectronic techniques.  3. Fast, accurate methods will be developed to specify the three-dimensional location of epicardial, intracavitary, and plunge electrodes for animal mapping. Computer graphics will be developed to display activation sequences as lines for the endocardium and epicardium or as surfaces in a three-dimensional representation of the thickness of the ventricular wall within seconds of recording the potentials. The lines or surfaces will be animated to move through the heart with time as in a movie.  4.  Robust, quantitative algorithms for detection of the presence and timing of activation from electrode recordings will be developed and will be implemented in software to perform rapidly and with a minimum of human intervention. The data to develop these algorithms will be obtained from experiments in which the presence or absence of activation is known by means independent of the electrode recordings.  5. Experiments will be performed to determine the anatomic and electrical causes of fractionated potentials in cardiac electrode recordings, i.e., cases in which a single, discrete activation complex is not recorded.  6. Methods will be developed to estimate potentials away from the recording electrode sites in those regions in which it is not possible to place electrodes. Examples include estimating endocardial potentials from intracavitary recordings, epicardial potentials from recording from the overlying epicardial fat, and potentials through the ventricular wall from intracavitary and epicardial recordings. The accomplishment of these goals will greatly improve cardiac mapping and should lead to new advances in both the basic understanding and the clinical treatment of cardiac arrhythmias.  n/a",SIGNAL ACQUISITION AND ANALYSIS IN CARDIAC MAPPING,3345730,R01HL033637,"['artificial intelligence', ' computer graphics /printing', ' diagnosis quality /standard', ' electrocardiography', ' electrophysiology', ' epicardial mapping', ' heart dimension /size', ' heart disorder diagnosis', ' heart rhythm', ' heart surgery', ' human subject', ' microelectrodes', ' myocardial infarction', ' tachycardia']",NHLBI,DUKE UNIVERSITY,R01,1988,151731,0.07781201663865617
"MULTIMODALITY CARDIAC IMAGE UNDERSTANDING An image understanding system is proposed to analyze cardiac dysfunction found by combining information from multiple, noninvasive imaging modality studies.  The system is a model for intelligent multimodality image understanding in general, but is applied to a very specific problem:  detection and rating of left ventricular (LV) aneurysms.  Key features of the system are:  1) its ability to handle and quantify uncertain or partial image- derived information in a concise way using probabilistic evidential reasoning, 2) its ability to fuse pertinent relative information from independent diagnostic images of the same patient to achieve an algorithm-assembled, consensus, quantitative opinion of cardiac shape and motion, and finally 3) to arrive at a decision- level set of numbers that quantify and localize left ventricular aneurysm formation for each patient.  The availability of data such as described in 3) will enable more precise prognostic or diagnostic risk classification for patients, making therapy alternatives more rational.  Because of the subjective probabilistic reasoning strategy (based on the principle of maximum entropy) the final quantitative results will carry not only the system's assessment of a particular patients' heart, but also the degree of confidence that the automated analysis system has in the result it presents.  This confidence is increased when similar LV motion and shape is perceived by the multiple imaging modalities.  The proposed system design is influenced by current artificial intelligence and image understanding technologies, but remains firmly grounded in more classical mathematical and statistical methodology.  The system will be initially tested using radionuclide angiographic (RNA) and two-dimensional echocardiographic (2DE) semi- quantified (manual tracing of LV borders) and then fully quantified (by the system's own border-finding algorithm) studies and compared with qualitative readings, quantified contrast ventriculograms, and then with surgeon's and pathologist's measurements and reports.  Preliminary studies show that 1) RNA left lateral view qualitative studies correlate well with pathology, 2) that complementary 2DE views help resolve RNA problems with finding the anterior LV wall and 3) quantification of LV motion and shape better defines the spectrum between normal and grossly abnormal.  Subsequent incorporation of magnetic resonance images (which have improved LV boundary definition) into the evaluation system will test its ability to adapt to and profit from new types of data.  n/a",MULTIMODALITY CARDIAC IMAGE UNDERSTANDING,3471118,R29HL038333,"['aneurysm', ' angiocardiography', ' cardiography', ' computer assisted patient care', ' computer simulation', ' diagnosis design /evaluation', ' echocardiography', ' heart function', ' heart ventricle', ' human subject', ' image processing', ' magnetic resonance imaging', ' mathematical model', ' noninvasive diagnosis', ' radiocardiography']",NHLBI,YALE UNIVERSITY,R29,1992,95490,0.05364453756787771
"MULTIMODALITY CARDIAC IMAGE UNDERSTANDING An image understanding system is proposed to analyze cardiac dysfunction found by combining information from multiple, noninvasive imaging modality studies.  The system is a model for intelligent multimodality image understanding in general, but is applied to a very specific problem:  detection and rating of left ventricular (LV) aneurysms.  Key features of the system are:  1) its ability to handle and quantify uncertain or partial image- derived information in a concise way using probabilistic evidential reasoning, 2) its ability to fuse pertinent relative information from independent diagnostic images of the same patient to achieve an algorithm-assembled, consensus, quantitative opinion of cardiac shape and motion, and finally 3) to arrive at a decision- level set of numbers that quantify and localize left ventricular aneurysm formation for each patient.  The availability of data such as described in 3) will enable more precise prognostic or diagnostic risk classification for patients, making therapy alternatives more rational.  Because of the subjective probabilistic reasoning strategy (based on the principle of maximum entropy) the final quantitative results will carry not only the system's assessment of a particular patients' heart, but also the degree of confidence that the automated analysis system has in the result it presents.  This confidence is increased when similar LV motion and shape is perceived by the multiple imaging modalities.  The proposed system design is influenced by current artificial intelligence and image understanding technologies, but remains firmly grounded in more classical mathematical and statistical methodology.  The system will be initially tested using radionuclide angiographic (RNA) and two-dimensional echocardiographic (2DE) semi- quantified (manual tracing of LV borders) and then fully quantified (by the system's own border-finding algorithm) studies and compared with qualitative readings, quantified contrast ventriculograms, and then with surgeon's and pathologist's measurements and reports.  Preliminary studies show that 1) RNA left lateral view qualitative studies correlate well with pathology, 2) that complementary 2DE views help resolve RNA problems with finding the anterior LV wall and 3) quantification of LV motion and shape better defines the spectrum between normal and grossly abnormal.  Subsequent incorporation of magnetic resonance images (which have improved LV boundary definition) into the evaluation system will test its ability to adapt to and profit from new types of data.  n/a",MULTIMODALITY CARDIAC IMAGE UNDERSTANDING,3471117,R29HL038333,"['aneurysm', ' angiocardiography', ' cardiography', ' computer assisted patient care', ' computer simulation', ' diagnosis design /evaluation', ' echocardiography', ' heart function', ' heart ventricle', ' human subject', ' image processing', ' magnetic resonance imaging', ' mathematical model', ' noninvasive diagnosis', ' radiocardiography']",NHLBI,YALE UNIVERSITY,R29,1991,118987,0.05364453756787771
"MULTIMODALITY CARDIAC IMAGE UNDERSTANDING An image understanding system is proposed to analyze cardiac dysfunction found by combining information from multiple, noninvasive imaging modality studies.  The system is a model for intelligent multimodality image understanding in general, but is applied to a very specific problem:  detection and rating of left ventricular (LV) aneurysms.  Key features of the system are:  1) its ability to handle and quantify uncertain or partial image- derived information in a concise way using probabilistic evidential reasoning, 2) its ability to fuse pertinent relative information from independent diagnostic images of the same patient to achieve an algorithm-assembled, consensus, quantitative opinion of cardiac shape and motion, and finally 3) to arrive at a decision- level set of numbers that quantify and localize left ventricular aneurysm formation for each patient.  The availability of data such as described in 3) will enable more precise prognostic or diagnostic risk classification for patients, making therapy alternatives more rational.  Because of the subjective probabilistic reasoning strategy (based on the principle of maximum entropy) the final quantitative results will carry not only the system's assessment of a particular patients' heart, but also the degree of confidence that the automated analysis system has in the result it presents.  This confidence is increased when similar LV motion and shape is perceived by the multiple imaging modalities.  The proposed system design is influenced by current artificial intelligence and image understanding technologies, but remains firmly grounded in more classical mathematical and statistical methodology.  The system will be initially tested using radionuclide angiographic (RNA) and two-dimensional echocardiographic (2DE) semi- quantified (manual tracing of LV borders) and then fully quantified (by the system's own border-finding algorithm) studies and compared with qualitative readings, quantified contrast ventriculograms, and then with surgeon's and pathologist's measurements and reports.  Preliminary studies show that 1) RNA left lateral view qualitative studies correlate well with pathology, 2) that complementary 2DE views help resolve RNA problems with finding the anterior LV wall and 3) quantification of LV motion and shape better defines the spectrum between normal and grossly abnormal.  Subsequent incorporation of magnetic resonance images (which have improved LV boundary definition) into the evaluation system will test its ability to adapt to and profit from new types of data.  n/a",MULTIMODALITY CARDIAC IMAGE UNDERSTANDING,3471116,R29HL038333,"['aneurysm', ' angiocardiography', ' cardiography', ' computer assisted patient care', ' computer simulation', ' diagnosis design /evaluation', ' echocardiography', ' heart function', ' heart ventricle', ' human subject', ' image processing', ' magnetic resonance imaging', ' mathematical model', ' noninvasive diagnosis', ' radiocardiography']",NHLBI,YALE UNIVERSITY,R29,1990,119078,0.05364453756787771
"MULTIMODALITY CARDIAC IMAGE UNDERSTANDING An image understanding system is proposed to analyze cardiac dysfunction found by combining information from multiple, noninvasive imaging modality studies.  The system is a model for intelligent multimodality image understanding in general, but is applied to a very specific problem:  detection and rating of left ventricular (LV) aneurysms.  Key features of the system are:  1) its ability to handle and quantify uncertain or partial image- derived information in a concise way using probabilistic evidential reasoning, 2) its ability to fuse pertinent relative information from independent diagnostic images of the same patient to achieve an algorithm-assembled, consensus, quantitative opinion of cardiac shape and motion, and finally 3) to arrive at a decision- level set of numbers that quantify and localize left ventricular aneurysm formation for each patient.  The availability of data such as described in 3) will enable more precise prognostic or diagnostic risk classification for patients, making therapy alternatives more rational.  Because of the subjective probabilistic reasoning strategy (based on the principle of maximum entropy) the final quantitative results will carry not only the system's assessment of a particular patients' heart, but also the degree of confidence that the automated analysis system has in the result it presents.  This confidence is increased when similar LV motion and shape is perceived by the multiple imaging modalities.  The proposed system design is influenced by current artificial intelligence and image understanding technologies, but remains firmly grounded in more classical mathematical and statistical methodology.  The system will be initially tested using radionuclide angiographic (RNA) and two-dimensional echocardiographic (2DE) semi- quantified (manual tracing of LV borders) and then fully quantified (by the system's own border-finding algorithm) studies and compared with qualitative readings, quantified contrast ventriculograms, and then with surgeon's and pathologist's measurements and reports.  Preliminary studies show that 1) RNA left lateral view qualitative studies correlate well with pathology, 2) that complementary 2DE views help resolve RNA problems with finding the anterior LV wall and 3) quantification of LV motion and shape better defines the spectrum between normal and grossly abnormal.  Subsequent incorporation of magnetic resonance images (which have improved LV boundary definition) into the evaluation system will test its ability to adapt to and profit from new types of data.  n/a",MULTIMODALITY CARDIAC IMAGE UNDERSTANDING,3471115,R29HL038333,"['aneurysm', ' angiocardiography', ' cardiography', ' computer assisted patient care', ' computer simulation', ' diagnosis design /evaluation', ' echocardiography', ' heart function', ' heart ventricle', ' human subject', ' image processing', ' magnetic resonance imaging', ' mathematical model', ' noninvasive diagnosis', ' radiocardiography']",NHLBI,YALE UNIVERSITY,R29,1989,116419,0.05364453756787771
"MULTIMODALITY CARDIAC IMAGE UNDERSTANDING An image understanding system is proposed to analyze cardiac dysfunction found by combining information from multiple, noninvasive imaging modality studies.  The system is a model for intelligent multimodality image understanding in general, but is applied to a very specific problem:  detection and rating of left ventricular (LV) aneurysms.  Key features of the system are:  1) its ability to handle and quantify uncertain or partial image- derived information in a concise way using probabilistic evidential reasoning, 2) its ability to fuse pertinent relative information from independent diagnostic images of the same patient to achieve an algorithm-assembled, consensus, quantitative opinion of cardiac shape and motion, and finally 3) to arrive at a decision- level set of numbers that quantify and localize left ventricular aneurysm formation for each patient.  The availability of data such as described in 3) will enable more precise prognostic or diagnostic risk classification for patients, making therapy alternatives more rational.  Because of the subjective probabilistic reasoning strategy (based on the principle of maximum entropy) the final quantitative results will carry not only the system's assessment of a particular patients' heart, but also the degree of confidence that the automated analysis system has in the result it presents.  This confidence is increased when similar LV motion and shape is perceived by the multiple imaging modalities.  The proposed system design is influenced by current artificial intelligence and image understanding technologies, but remains firmly grounded in more classical mathematical and statistical methodology.  The system will be initially tested using radionuclide angiographic (RNA) and two-dimensional echocardiographic (2DE) semi- quantified (manual tracing of LV borders) and then fully quantified (by the system's own border-finding algorithm) studies and compared with qualitative readings, quantified contrast ventriculograms, and then with surgeon's and pathologist's measurements and reports.  Preliminary studies show that 1) RNA left lateral view qualitative studies correlate well with pathology, 2) that complementary 2DE views help resolve RNA problems with finding the anterior LV wall and 3) quantification of LV motion and shape better defines the spectrum between normal and grossly abnormal.  Subsequent incorporation of magnetic resonance images (which have improved LV boundary definition) into the evaluation system will test its ability to adapt to and profit from new types of data.  n/a",MULTIMODALITY CARDIAC IMAGE UNDERSTANDING,3471114,R29HL038333,"['aneurysm', ' angiocardiography', ' cardiography', ' computer assisted patient care', ' computer simulation', ' diagnosis design /evaluation', ' echocardiography', ' heart function', ' heart ventricle', ' human subject', ' image processing', ' magnetic resonance imaging', ' mathematical model', ' noninvasive diagnosis', ' radiocardiography']",NHLBI,YALE UNIVERSITY,R29,1988,97551,0.05364453756787771
"SIGNAL PROCESSING/AUTOMATION FOR CARDIAC OUTPUT MONITOR Thermal dilution is by far the most common method of measuring cardiac output. Over one million thermodilution pulmonary artery catheters are used each year in the U.S. We have applied artificial neural networks to improve the accuracy of the thermal dilution cardiac output measurement and allow using small injectate volumes (2 ml). We propose to build an automated system using a modified syringe pump and a solid state injectate cooler to automatically measure cardiac output once every minute. Recently introduced devices automate this measurement and provide continuous measurement, however, these devices require special catheters costing $195.00 per patient and require long averaging periods (10 min.). Our system would achieve the same accuracy and real-time data using a standard catheter costing $40.00 per patient. We have tested the technique in five animals and have found the system capable of making cardiac output measurements using only 2 ml injectate volumes. The small volume technique gave measurements with accuracy similar to those obtained using the standard of 10 ml iced injectate over wide range of cardiac outputs. We plan to build a proto-type automated system and test it in 10 animals. Less than 12% errors in animal tests using the automated system will be considered success.  n/a",SIGNAL PROCESSING/AUTOMATION FOR CARDIAC OUTPUT MONITOR,2230990,R43HL053195,"['artificial intelligence', ' biological information processing', ' biomedical automation', ' biomedical equipment development', ' cardiac output', ' clinical biomedical equipment', ' computer system design /evaluation', ' drug delivery systems', ' indicator dilution test', ' injection /infusion', ' patient monitoring device', ' personal computers', ' swine', ' thermal blood flow measurement']",NHLBI,"AXON MEDICAL, INC.",R43,1994,75000,0.20626906234513956
"Automated Quantitation of 3D Echocardiograms In Phase I we developed a method for automated border detection (ABD) of echocardiographic scans that is feasible for clinical application. The accuracy of our processes provides exceeds Phase I goals and is comparable to interobserver variability in measuring volume and ejection fraction, and in border location. For a diverse set of patients, we have achieved an accuracy of 10 ml for endocardial volume, 4% for ejection fraction, and ,2.0 mm for border position. Our processes operates in 4 min. In Phase II we propose to continue research and development to move our ABD technology closer to clinical user. Our first specific aim is to reduce the amount of manual input required even further. Our second aim is to develop a prototype system suitable for clinical evaluation. Our third aim is to perform a pilot trial to evaluate the performance of our ABD process, as a preparation for a more formal, multi-center clinical trial planned for Phase III. The proposed research is important because quantitative 3D echo provides greater accuracy and reproducibility and more comprehensive information on cardiac status than currently available imaging techniques. The significant advantages of 3D echo are not currently available for clinical practice because it is impractical without automation. PROPOSED COMMERCIAL APPLICATIONS: Automation of echocardiogram border detection enables physicians to obtain accurate, reproducible and comprehensive measurements of the heart's size, shape and function. This technology can be included in ultrasound systems or provided in workstations. The core technology can be applied to other organs and other imaging modalities. n/a",Automated Quantitation of 3D Echocardiograms,6622226,R44HL059054,"['artificial intelligence', ' bioimaging /biomedical imaging', ' biomedical automation', ' biomedical equipment development', ' clinical research', ' computer program /software', ' computer system design /evaluation', ' diagnosis design /evaluation', ' echocardiography', ' heart disorder diagnosis', ' heart ventricle', ' human subject', ' image processing', ' papillary muscles', ' pericardium']",NHLBI,"QUANTIGRAPHICS, INC.",R44,2003,244092,0.048943046858998425
"Automated Quantitation of 3D Echocardiograms In Phase I we developed a method for automated border detection (ABD) of echocardiographic scans that is feasible for clinical application. The accuracy of our processes provides exceeds Phase I goals and is comparable to interobserver variability in measuring volume and ejection fraction, and in border location. For a diverse set of patients, we have achieved an accuracy of 10 ml for endocardial volume, 4% for ejection fraction, and ,2.0 mm for border position. Our processes operates in 4 min. In Phase II we propose to continue research and development to move our ABD technology closer to clinical user. Our first specific aim is to reduce the amount of manual input required even further. Our second aim is to develop a prototype system suitable for clinical evaluation. Our third aim is to perform a pilot trial to evaluate the performance of our ABD process, as a preparation for a more formal, multi-center clinical trial planned for Phase III. The proposed research is important because quantitative 3D echo provides greater accuracy and reproducibility and more comprehensive information on cardiac status than currently available imaging techniques. The significant advantages of 3D echo are not currently available for clinical practice because it is impractical without automation. PROPOSED COMMERCIAL APPLICATIONS: Automation of echocardiogram border detection enables physicians to obtain accurate, reproducible and comprehensive measurements of the heart's size, shape and function. This technology can be included in ultrasound systems or provided in workstations. The core technology can be applied to other organs and other imaging modalities. n/a",Automated Quantitation of 3D Echocardiograms,6443269,R44HL059054,"['artificial intelligence', ' bioimaging /biomedical imaging', ' biomedical automation', ' biomedical equipment development', ' clinical research', ' computer program /software', ' computer system design /evaluation', ' diagnosis design /evaluation', ' echocardiography', ' heart disorder diagnosis', ' heart ventricle', ' human subject', ' image processing', ' papillary muscles', ' pericardium']",NHLBI,"QUANTIGRAPHICS, INC.",R44,2002,255191,0.048943046858998425
"A Novel, Low-Cost Device to Guide Peripherally Inserted Central Catheter (PICC) Line Placement Abstract In the United States alone, more than three million peripherally inserted central catheters (PICCs) are placed each year to provide IV therapies, where navigation through the venous system is typically performed blind, or without navigation guidance. Improper PICC placement is relatively common, is costly, and has serious complications for critically-ill patients. Unfortunately, under blind placement 30-55% of PICC tips are not optimally placed on the first attempt and require repositioning, which has an average direct cost of $223 per patient and often necessitates the removal and reinsertion of the catheter line that carries a 4-6% risk of pneumothorax. Moreover, approximately 17% of these improperly positioned PICCs are placed into the right atrium, which is associated with a multitude of life-threatening complications. Improper placement of PICCs also often requires referral to an interventional radiologist for fluoroscopic-guided central line placement, which is expensive ($1,000) and requires more radiation exposure for the patient. Not surprisingly, over half of all PICCs are administered to patients over the age of 60. Therefore, safe and accurate PICC placement is critical for providing high-quality care to older Americans. Despite serious adverse events associated with blind placement of PICC lines, current vascular access systems have not been widely adopted. The Teleflex ARROW G4 VPS and the Bard Sherlock 3CG TCS are PICC guidance systems that employ ECG for positioning the PICC tip into the correct location: the region that includes the lower superior vena cava (SVC) and cavoatrial junction (CAJ). While these procedures often limit the need for a confirmatory X-ray, they have poor and variable successful placement rates (44-84%), are 30-70% more expensive than standard PICCs, require skilled staff, and have significantly longer procedure times as compared to standard, blind PICC placement. Additionally, these guidance systems rely on the use of ECG, which is ineffective for patients with cardiac arrhythmias, a condition that affects approximately 16% of all patients requiring a PICC line. To address the need for accurate, safe, and cost- effective PICC placement, Piccolo Medical has developed the Smart PICC system, a point-of-care catheter system that uses unique hemodynamic signatures of different vascular regions for real-time vascular access guidance into the SVC/CAJ. The goals of this Phase II proposal are to validate the accuracy of the Piccolo Smart PICC for navigation and placement of a PICC tip into the SVC or CAJ for adult patients with and without cardiac arrhythmias. First, we will verify the sensitivity of the Smart PICC system algorithm to identify correct PICC placement in adult patients with both normal and altered cardiac rhythms (Aim 1). Second, we will compare the accuracy of the Smart PICC system to the most widely used catheter navigation system (BDs Sherlock 3CG TCS) in a head-to-head superiority study (Aim 2).The data obtained will support FDA 510(k) clearance and will allow us to commercialize the system within ~2.5 years of the funding of this proposal. Narrative Peripherally inserted central catheters (PICCs) are widely used to provide life-sustaining intravenous therapies, where navigation through the venous system is typically performed blind, or without navigation guidance. Commercially available PICC navigation systems can be effective, but have limitations that have impeded adoption into the clinic. We propose an inexpensive, easily operated catheter system for real-time vascular access guidance that addresses the limitations of current systems.","A Novel, Low-Cost Device to Guide Peripherally Inserted Central Catheter (PICC) Line Placement",10019319,R44AG060793,"['Address', 'Adopted', 'Adoption', 'Adult', 'Adverse event', 'Affect', 'Age', 'Algorithms', 'American', 'Anatomy', 'Area Under Curve', 'Arrhythmia', 'Automobile Driving', 'Blinded', 'Blood Vessels', 'Blood flow', 'Cardiac', 'Catheters', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Research', 'Critical Illness', 'Data', 'Detection', 'Devices', 'Direct Costs', 'Distal', 'EKG P Wave', 'Electrocardiogram', 'Excision', 'Family suidae', 'Funding', 'Future', 'Goals', 'Head', 'Heart Atrium', 'Heart Valves', 'Infusion procedures', 'Intervention', 'Intravenous', 'Lead', 'Life', 'Location', 'Measures', 'Medical', 'Modeling', 'Multi-site clinical study', 'Myocardial', 'Navigation System', 'Nurses', 'Patients', 'Perforation', 'Performance', 'Peripheral', 'Phase', 'Pneumothorax', 'Positioning Attribute', 'Procedures', 'Quality of Care', 'ROC Curve', 'Radiation exposure', 'Randomized', 'Real-Time Systems', 'Research', 'Resolution', 'Right atrial structure', 'Risk', 'Roentgen Rays', 'Savings', 'Serious Adverse Event', 'Signal Transduction', 'Superior vena cava structure', 'System', 'Technology', 'Thermodilution', 'Thoracic Radiography', 'Thrombus', 'Time', 'Training', 'United States', 'Venous system', 'Work', 'base', 'blind', 'cohort', 'cost', 'cost effective', 'follow-up', 'heart rhythm', 'hemodynamics', 'improved', 'in vivo', 'innovation', 'machine learning algorithm', 'novel', 'point of care', 'pre-clinical', 'radiologist', 'sensor']",NIA,"PICCOLO MEDICAL, INC.",R44,2020,561565,0.10511800263327935
"A Novel, Low-Cost Device to Guide Peripherally Inserted Central Catheter (PICC) Line Placement Abstract In the United States alone, more than three million peripherally inserted central catheters (PICCs) are placed each year to provide IV therapies, where navigation through the venous system is typically performed blind, or without navigation guidance. Improper PICC placement is relatively common, is costly, and has serious complications for critically-ill patients. Unfortunately, under blind placement 30-55% of PICC tips are not optimally placed on the first attempt and require repositioning, which has an average direct cost of $223 per patient and often necessitates the removal and reinsertion of the catheter line that carries a 4-6% risk of pneumothorax. Moreover, approximately 17% of these improperly positioned PICCs are placed into the right atrium, which is associated with a multitude of life-threatening complications. Improper placement of PICCs also often requires referral to an interventional radiologist for fluoroscopic-guided central line placement, which is expensive ($1,000) and requires more radiation exposure for the patient. Not surprisingly, over half of all PICCs are administered to patients over the age of 60. Therefore, safe and accurate PICC placement is critical for providing high-quality care to older Americans. Despite serious adverse events associated with blind placement of PICC lines, current vascular access systems have not been widely adopted. The Teleflex ARROW G4 VPS and the Bard Sherlock 3CG TCS are PICC guidance systems that employ ECG for positioning the PICC tip into the correct location: the region that includes the lower superior vena cava (SVC) and cavoatrial junction (CAJ). While these procedures often limit the need for a confirmatory X-ray, they have poor and variable successful placement rates (44-84%), are 30-70% more expensive than standard PICCs, require skilled staff, and have significantly longer procedure times as compared to standard, blind PICC placement. Additionally, these guidance systems rely on the use of ECG, which is ineffective for patients with cardiac arrhythmias, a condition that affects approximately 16% of all patients requiring a PICC line. To address the need for accurate, safe, and cost- effective PICC placement, Piccolo Medical has developed the Smart PICC system, a point-of-care catheter system that uses unique hemodynamic signatures of different vascular regions for real-time vascular access guidance into the SVC/CAJ. The goals of this Phase II proposal are to validate the accuracy of the Piccolo Smart PICC for navigation and placement of a PICC tip into the SVC or CAJ for adult patients with and without cardiac arrhythmias. First, we will verify the sensitivity of the Smart PICC system algorithm to identify correct PICC placement in adult patients with both normal and altered cardiac rhythms (Aim 1). Second, we will compare the accuracy of the Smart PICC system to the most widely used catheter navigation system (BDs Sherlock 3CG TCS) in a head-to-head superiority study (Aim 2).The data obtained will support FDA 510(k) clearance and will allow us to commercialize the system within ~2.5 years of the funding of this proposal. Narrative Peripherally inserted central catheters (PICCs) are widely used to provide life-sustaining intravenous therapies, where navigation through the venous system is typically performed blind, or without navigation guidance. Commercially available PICC navigation systems can be effective, but have limitations that have impeded adoption into the clinic. We propose an inexpensive, easily operated catheter system for real-time vascular access guidance that addresses the limitations of current systems.","A Novel, Low-Cost Device to Guide Peripherally Inserted Central Catheter (PICC) Line Placement",9919215,R44AG060793,"['Address', 'Adopted', 'Adoption', 'Adult', 'Adverse event', 'Affect', 'Age', 'Algorithms', 'American', 'Anatomy', 'Area Under Curve', 'Arrhythmia', 'Automobile Driving', 'Blinded', 'Blood Vessels', 'Blood flow', 'Cardiac', 'Catheters', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Research', 'Critical Illness', 'Data', 'Detection', 'Devices', 'Direct Costs', 'Distal', 'EKG P Wave', 'Electrocardiogram', 'Excision', 'Family suidae', 'Funding', 'Future', 'Goals', 'Head', 'Heart Atrium', 'Heart Valves', 'Infusion procedures', 'Intervention', 'Intravenous', 'Lead', 'Life', 'Location', 'Measures', 'Medical', 'Modeling', 'Multi-Institutional Clinical Trial', 'Myocardial', 'Navigation System', 'Nurses', 'Patients', 'Perforation', 'Performance', 'Peripheral', 'Phase', 'Pneumothorax', 'Positioning Attribute', 'Procedures', 'Quality of Care', 'Radiation exposure', 'Randomized', 'Real-Time Systems', 'Receiver Operating Characteristics', 'Research', 'Resolution', 'Right atrial structure', 'Risk', 'Roentgen Rays', 'Savings', 'Serious Adverse Event', 'Signal Transduction', 'Superior vena cava structure', 'System', 'Technology', 'Thermodilution', 'Thoracic Radiography', 'Thrombus', 'Time', 'Training', 'United States', 'Venous system', 'Work', 'base', 'blind', 'cohort', 'cost', 'cost effective', 'follow-up', 'heart rhythm', 'hemodynamics', 'improved', 'in vivo', 'innovation', 'machine learning algorithm', 'novel', 'point of care', 'pre-clinical', 'radiologist', 'sensor']",NIA,"PICCOLO MEDICAL, INC.",R44,2019,915143,0.10511800263327935
"Reliable and Robust ECG Gating Signal for MR Imaging The focus of this project is to develop and evaluate a noel and reliable system for ECG triggering during cardiac MR imaging. Understanding the mechanism of heart failure and cardiomyopathy using MRI requires reliable and robust ECG gating (or triggering). To provide effective ECG gating, the first specific aim of this Phase I project is to design and develop an ECG lead system and concomitant signal processing methodology to allow for improved ECG detection with the magnetic. Our preliminary data describing our optimal vector signal set approach , coupled with a dual derivative ECG detections scheme, appear to be effective in reliably detecting the ECG during MR imaging. An improved ECG trigger will provide cardiac MRI imaging without the artifacts of cardiac and respiratory motion. Our second specific aim is to design and develop a wireless (telemetry) infrared (IR) system for ECG trigger transmission to eliminate the need for either wiring or a fiber optic cable during MRI examinations. Additionally preliminary data demonstrates the capability of our IR telemetry system to transmit the ECG in laboratory tests. Our optimal telemetry system will also mitigate against many of the artifacts involved in the development of an effective MRI ECG trigger. During Phase I we will demonstrate the feasibility of our system by evaluating system performance in 20 human subjects undergoing cardiac MR imaging. We believe our approach should provide a reliable and robust ECG gated trigger with minimal delay from the onset of the R-wave. Such a trigger would minimize blurring artifacts from cardiac and respiratory motion and improve MR tagging studies. Should our phase I project be successful, we would develop a real-time implementation of the entire system in an expanded Phase II biomedical engineering and extended clinical study. A successful Phase I and II project would likely receive commercial backing from a major MRI instrument manufacturer. PROPOSED COMMERCIAL APPLICATIONS: Potential Commercial applications: Cardiac magnetic resonance imaging (MRI) is one of the most promising areas of MRI technology. There is a large potential commercial opportunity to develop a reliable and effective method to provide a real-time ECG gating and an infrared (IR) ECG telemetry link. n/a",Reliable and Robust ECG Gating Signal for MR Imaging,6486301,R43HL066791,"['artificial intelligence', ' bioengineering /biomedical engineering', ' bioimaging /biomedical imaging', ' biomedical equipment development', ' bronchomotion', ' clinical research', ' electrocardiography', ' heart imaging /visualization /scanning', ' human subject', ' magnetic resonance imaging', ' optics', ' telemetry']",NHLBI,"PERINATRONICS MEDICAL SYSTEMS, INC.",R43,2002,335218,0.15291633754424502
"A Cardiac Screening Device DESCRIPTION (provided by applicant):    The broad, long-term objectives and aims of this project are to provide a reliable and easily-used device for qualified health care professionals to screen for and detect heart murmurs produced from congenital and acquired cardiac defects in children and adults. The device will be designed to distinguish between innocent and pathological heart murmurs with a high degree of accuracy.    The applicant organization, Cardiac Screening Partners, is a joint venture between Cardiac Access, Denver, Colorado and Cardionics, Inc., Webster, Texas. Cardiac Access is comprised of physicians and scientists with a past record of research in cardiac screening (specifically in heart murmurs) and artificial neural networks. Cardionics is a developer and manufacturer of medical devices specifically related to heart and lung sound instrumentation and software.       The proposed research is designed to gather heart sound data from approximately 1600 in children (phase I) and later in adults (phase II). The data will be analyzed using state of the art digital signal analysis processing techniques and custom artificial neural network algorithms. The goal of Phase I research is to build on the success of the preliminary work done by our consultants by further refining and training of artificial neural network algorithms for accuracy in differentiating between innocent and pathologic heart murmurs. n/a",A Cardiac Screening Device,6644431,R43HL073616,"['arrhythmia', ' artificial intelligence', ' child (0-11)', ' clinical research', ' computer data analysis', ' diagnosis design /evaluation', ' electronic recording system', ' heart disorder diagnosis', ' heart function', ' heart sonography', ' human subject', ' sound', ' sound frequency']",NHLBI,CARDIAC SCREENING PARTNERS,R43,2003,99723,0.12248610419651888
"Tailored Exercise Support for Cardiac Patients    DESCRIPTION (provided by applicant): Cardiovascular disease accounts for 50% of all deaths in the United States. While participation in Cardiac Rehabilitation (CR) significantly reduces re-hospitalization and mortality among cardiac patients, the impact of CR on public health is substantially weakened due to poor maintenance of health behaviors, particularly physical activity, after CR is ended. The goal of the proposed project is to test the efficacy of a tailored, motivation-matched intervention to enhance the maintenance of physical activity following CR. The overall scientific question posed by this project is: Can a low-cost, motivationally-tailored intervention delivered via computer expert system significantly improve patients' physical activity participation in the year following phase II cardiac rehabilitation? A two-group design will compare: 1) CR with Tailored Support (Tailored), versus 2) Care as usual following CR (Standard Care). This project utilizes a repeated measures design consisting of baseline (at completion of phase II CR), and follow-up at one, three, six, nine and twelve months. Exercise tolerance tests will be used to validate the primary outcome of self-reported exercise participation. Analyses of important cognitive-behavioral mediators of the intervention efficacy and cost efficacy analyses will be performed. This proposal responds to recommendations of the NHLBI calling for additional research into cost effective behavioral interventions for use in large populations and which target the identification of factors which enhance adherence to preventive behaviors (USDHHS, 1995; 2001), and an NIH joint initiative to investigate innovative approaches to disease prevention through behavior change (1997).         n/a",Tailored Exercise Support for Cardiac Patients,7256209,R01HL075561,"['Accounting', 'Adherence', 'Behavior', 'Behavior Therapy', 'Behavioral', 'Cardiac', 'Cardiovascular Diseases', 'Caring', 'Cessation of life', 'Cognitive', 'Computers', 'Condition', 'Controlled Clinical Trials', 'Effectiveness', 'Effectiveness of Interventions', 'Equilibrium', 'Exercise', 'Exercise Tolerance', 'Experimental Designs', 'Expert Systems', 'Gender', 'Goals', 'Health behavior', 'Hospitalization', 'Human Resources', 'Individual', 'Intervention', 'Interviewer', 'Joints', 'Maintenance', 'Measures', 'Mediation', 'Mediator of activation protein', 'Motivation', 'Outcome', 'Participant', 'Patient Self-Report', 'Patients', 'Persons', 'Phase', 'Physical activity', 'Population', 'Preventive', 'Process', 'Public Health', 'Randomized', 'Readiness', 'Recommendation', 'Rehabilitation therapy', 'Relative (related person)', 'Reporting', 'Research', 'Resources', 'Self Efficacy', 'Standards of Weights and Measures', 'Testing', 'Time', 'Treatment Cost', 'Treatment Efficacy', 'Treatment outcome', 'United States', 'United States National Institutes of Health', 'Week', 'base', 'behavior change', 'cost', 'cost effective', 'cost effectiveness', 'design', 'disorder prevention', 'follow-up', 'health care service utilization', 'improved', 'innovation', 'interest', 'mortality', 'programs', 'theories', 'trial comparing']",NHLBI,MIRIAM HOSPITAL,R01,2007,344891,0.061331467761468986
"Tailored Exercise Support for Cardiac Patients    DESCRIPTION (provided by applicant): Cardiovascular disease accounts for 50% of all deaths in the United States. While participation in Cardiac Rehabilitation (CR) significantly reduces re-hospitalization and mortality among cardiac patients, the impact of CR on public health is substantially weakened due to poor maintenance of health behaviors, particularly physical activity, after CR is ended. The goal of the proposed project is to test the efficacy of a tailored, motivation-matched intervention to enhance the maintenance of physical activity following CR. The overall scientific question posed by this project is: Can a low-cost, motivationally-tailored intervention delivered via computer expert system significantly improve patients' physical activity participation in the year following phase II cardiac rehabilitation? A two-group design will compare: 1) CR with Tailored Support (Tailored), versus 2) Care as usual following CR (Standard Care). This project utilizes a repeated measures design consisting of baseline (at completion of phase II CR), and follow-up at one, three, six, nine and twelve months. Exercise tolerance tests will be used to validate the primary outcome of self-reported exercise participation. Analyses of important cognitive-behavioral mediators of the intervention efficacy and cost efficacy analyses will be performed. This proposal responds to recommendations of the NHLBI calling for additional research into cost effective behavioral interventions for use in large populations and which target the identification of factors which enhance adherence to preventive behaviors (USDHHS, 1995; 2001), and an NIH joint initiative to investigate innovative approaches to disease prevention through behavior change (1997).         n/a",Tailored Exercise Support for Cardiac Patients,7106408,R01HL075561,"['behavioral /social science research tag', 'cardiovascular disorder', 'cardiovascular disorder therapy', 'clinical research', 'cognitive behavior therapy', 'computer assisted instruction', 'exercise', 'health behavior', 'human subject', 'human therapy evaluation', 'interactive multimedia', 'longitudinal human study', 'mathematical model', 'motivation', 'patient oriented research', 'quality of life', 'questionnaires']",NHLBI,MIRIAM HOSPITAL,R01,2006,355651,0.061331467761468986
"Tailored Exercise Support for Cardiac Patients    DESCRIPTION (provided by applicant): Cardiovascular disease accounts for 50% of all deaths in the United States. While participation in Cardiac Rehabilitation (CR) significantly reduces re-hospitalization and mortality among cardiac patients, the impact of CR on public health is substantially weakened due to poor maintenance of health behaviors, particularly physical activity, after CR is ended. The goal of the proposed project is to test the efficacy of a tailored, motivation-matched intervention to enhance the maintenance of physical activity following CR. The overall scientific question posed by this project is: Can a low-cost, motivationally-tailored intervention delivered via computer expert system significantly improve patients' physical activity participation in the year following phase II cardiac rehabilitation? A two-group design will compare: 1) CR with Tailored Support (Tailored), versus 2) Care as usual following CR (Standard Care). This project utilizes a repeated measures design consisting of baseline (at completion of phase II CR), and follow-up at one, three, six, nine and twelve months. Exercise tolerance tests will be used to validate the primary outcome of self-reported exercise participation. Analyses of important cognitive-behavioral mediators of the intervention efficacy and cost efficacy analyses will be performed. This proposal responds to recommendations of the NHLBI calling for additional research into cost effective behavioral interventions for use in large populations and which target the identification of factors which enhance adherence to preventive behaviors (USDHHS, 1995; 2001), and an NIH joint initiative to investigate innovative approaches to disease prevention through behavior change (1997).         n/a",Tailored Exercise Support for Cardiac Patients,6912607,R01HL075561,"['behavioral /social science research tag', 'cardiovascular disorder', 'cardiovascular disorder therapy', 'clinical research', 'cognitive behavior therapy', 'computer assisted instruction', 'exercise', 'health behavior', 'human subject', 'human therapy evaluation', 'interactive multimedia', 'longitudinal human study', 'mathematical model', 'motivation', 'patient oriented research', 'quality of life', 'questionnaires']",NHLBI,MIRIAM HOSPITAL,R01,2005,364210,0.061331467761468986
"Tailored Exercise Support for Cardiac Patients    DESCRIPTION (provided by applicant): Cardiovascular disease accounts for 50% of all deaths in the United States. While participation in Cardiac Rehabilitation (CR) significantly reduces re-hospitalization and mortality among cardiac patients, the impact of CR on public health is substantially weakened due to poor maintenance of health behaviors, particularly physical activity, after CR is ended. The goal of the proposed project is to test the efficacy of a tailored, motivation-matched intervention to enhance the maintenance of physical activity following CR. The overall scientific question posed by this project is: Can a low-cost, motivationally-tailored intervention delivered via computer expert system significantly improve patients' physical activity participation in the year following phase II cardiac rehabilitation? A two-group design will compare: 1) CR with Tailored Support (Tailored), versus 2) Care as usual following CR (Standard Care). This project utilizes a repeated measures design consisting of baseline (at completion of phase II CR), and follow-up at one, three, six, nine and twelve months. Exercise tolerance tests will be used to validate the primary outcome of self-reported exercise participation. Analyses of important cognitive-behavioral mediators of the intervention efficacy and cost efficacy analyses will be performed. This proposal responds to recommendations of the NHLBI calling for additional research into cost effective behavioral interventions for use in large populations and which target the identification of factors which enhance adherence to preventive behaviors (USDHHS, 1995; 2001), and an NIH joint initiative to investigate innovative approaches to disease prevention through behavior change (1997).         n/a",Tailored Exercise Support for Cardiac Patients,6719200,R01HL075561,"['behavioral /social science research tag', 'cardiovascular disorder', 'cardiovascular disorder therapy', 'clinical research', 'cognitive behavior therapy', 'computer assisted instruction', 'exercise', 'health behavior', 'human subject', 'human therapy evaluation', 'interactive multimedia', 'longitudinal human study', 'mathematical model', 'motivation', 'patient oriented research', 'quality of life', 'questionnaires']",NHLBI,MIRIAM HOSPITAL,R01,2004,363975,0.061331467761468986
"21 PINHOLE, NONROTATIONAL CARDIAC SPECT SYSTEM We propose building a 21 pinhole non-rotating SPECT camera, which will acquire views simultaneously, that will be able to do studies either cannot be done or cannot be performed consistently and reliably on current rotational SPECT cameras, which acquires views sequentially.  These studies include tomographic first pass, stress studies, and gated cardiac studies. Tomographic first pass studies allow more accurate quantitative measurements (EFs), and allow wall and valve abnormalities to be located more precisely. Gated cardiac studies can be done more reliably when a posteriori beat selection is done, which the list mode acquisition of the 21 pinhole camera allows.  Multiple studies can then be made from a single acquisition to study different beta types. The high precision necessary in moving heavy heads adds to the cost of SPECT cameras.  Eliminating the movement should substantially reduce the cost, making nuclear cardiac procedures more cost effective. Cost effectiveness can also be increased using a simultaneous dual isotope (Tc-99m & T1-201) protocol.  This has the benefit of requiring only a single session to get both stress and rest images.  This also makes the procedure more comfortable and convenient to the patient and repositioning artifacts are eliminated.  Our 21 pinhole system corrects the downscatter from Tc-99m into the T1-201 window by retaining the entire energy spectrum and using it to estimate the downscatter component. PROPOSED COMMERCIAL APPLICATION:  The 21 pinhole SPECT system will be used by cardiologists to perform the following studies:  First pass studies; Gated studies (both blood pool and perfusion); stress gated studies; and Perfusion studies.  All these studies can be done tomographically, which current systems cannot do for first pass and stress studies.  This will be a dedicated cardiac system.  n/a","21 PINHOLE, NONROTATIONAL CARDIAC SPECT SYSTEM",2867150,R43CA081759,"['artificial intelligence', ' bioimaging /biomedical imaging', ' biomedical equipment development', ' diagnosis design /evaluation', ' heart disorder diagnosis', ' heart imaging /visualization /scanning', ' nuclear medicine', ' phantom model', ' radiation detector', ' radionuclide imaging /scanning', ' single photon emission computed tomography', ' technetium']",NCI,NUCLEAR CARDIOLOGY RESEARCH,R43,1999,145241,0.12333537164200467
"""Connexin-Dependent Transcriptomic Networks in Controlling the Heart Rhythm""    DESCRIPTION (provided by applicant): Extensive literature has reported altered expression and/or mutation of the primary gap junction proteins (connexins, Cx) that couple myocytes in ventricles (Cx43) and atria (Cx40) among major causes of cardiac arrhythmias. We have found that numerous genes controlling a vast number of functional pathways are regulated in Cx43 null tissues and these regulations are accurately predicted from coordination with Cx43 gene (Gja1) in wildtypes. These findings suggest an additional etiology of the disease that is related to connexins but not necessarily to the intercellular coupling they provide. Our working hypothesis is that the genes encoding the heart rhythm determinants (HRD) are interconnected in connexin-dependent and connexin-independent transcriptomic networks whose topologies may change during development and exhibit slight differences between the two genders. Such regulatory networks, where linkage partners are rearranged and strength modified in disease, may explain downstream and parallel ""ripples"" of phenotypic change. We plan to verify this hypothesis, and build and characterize the atrial and ventricular webs of genes encoding hear rhythm determinants. In addition, we shall identify and quantify the connexin-dependent regulatory networks within these webs. Of particular interest will be to identify the gene pairs with strikingly similar or opposite coordination profiles because up-regulation of a similar one or down-regulation of an opposed are expected to compensate for the deficient expression of the counterpart (as ""transcriptomic see-saws""). For these, we shall profile the atrial and ventricular transcriptomes of wildtype, Cx40 null and Cx43 conditional knockdown male and female mice at E19, 1, 2 and 4 weeks of their early life. The expression data will be also used to determine the expression variability and intercoordination of all quantifiable unigenes and study the age and gender dependence of the HRD gene webs. We have developed the Principal Gene Analysis by which to identify the heart rhythm determinants (HRD), build and characterize the webs of their encoding genes. The ""see-saw"" model will be tested by comparing the transcriptomes of cultured cardiomyocytes in which expression of either Cx43 or of certain positive ""see-saw"" partners are knocked-down through siRNA treatment. Thus, this study is expected to reveal new organizational principles of the heart transcriptome and the role of gap junction genes in this organization, with the long-term goal to open novel therapeutic horizons in the treatment of arrhythmia. PUBLIC HEALTH RELEVANCE: Gap junctions between cardiac muscle cells provide the channels for intercellular current flow that assures propagation of contraction throughout the heart. Increasing evidence attributes numerous cardiac arrhythmias to altered gap junctions and the proteins of which they are composed. We hypothesize that this role of gap junction gene expression is due in part to linkage to expression of other genes that affect the cardiac rhythm, and we propose to use gene expression profiling from microarrays to achieve a comprehensive understanding of arrhythmia and to generate hypotheses testable by more focused methods. We plan to profile the gene expressions in atria and ventricles of male and female wildtype mice and mice lacking the main cardiac gap junction proteins at four time- points during evolution to the adult state to identify and quantify on a genome-wide scale the connexin- related transcriptomic determinants of arrhythmia, analyzing their gender dependence and maturation. A major contribution will consist in identifying candidate genes whose manipulation might restore the normal cardiac rhythm based on their similar or opposed expression coordination with cardiac connexins in the sampled transcriptome and to that of other genes whose alteration generates arrhythmia. The study will reveal new organizational principles of the heart transcriptome, with the long- term goal to open novel therapeutic horizons in the treatment of arrhythmia. Our project has the unique feature of describing and quantifying the Cx40- and Cx43-dependent Gene Regulatory Networks of the heart rhythm, with the long term goal to open novel therapeutic horizons in cardiology.           NARRATIVE:  Gap junctions between cardiac muscle cells provide the channels for intercellular current flow that assures propagation of contraction throughout the heart. Increasing evidence attributes numerous cardiac arrhythmias to altered gap junctions and the proteins of which they are composed. We hypothesize that this role of gap junction gene expression is due in part to linkage to expression of other genes that affect the cardiac rhythm, and we propose to use gene expression profiling from microarrays to achieve a comprehensive understanding of arrhythmia and to generate hypotheses testable by more focused methods. We plan to profile the gene expressions in atria and ventricles of male and female wildtype mice and mice lacking the main cardiac gap junction proteins at four time- points during evolution to the adult state to identify and quantify on a genome-wide scale the connexin- related transcriptomic determinants of arrhythmia, analyzing their gender dependence and maturation. A major contribution will consist in identifying candidate genes whose manipulation might restore the normal cardiac rhythm based on their similar or opposed expression coordination with cardiac connexins in the sampled transcriptome and to that of other genes whose alteration generates arrhythmia. The study will reveal new organizational principles of the heart transcriptome, with the long- term goal to open novel therapeutic horizons in the treatment of arrhythmia. Our project has the unique feature of describing and quantifying the Cx40- and Cx43-dependent Gene Regulatory Networks of the heart rhythm, with the long term goal to open novel therapeutic horizons in cardiology.","""Connexin-Dependent Transcriptomic Networks in Controlling the Heart Rhythm""",7851345,R01HL092001,"['Acute', 'Address', 'Adult', 'Affect', 'Age', 'Algorithms', 'Anti-Arrhythmia Agents', 'Arrhythmia', 'Biological', 'Candidate Disease Gene', 'Cardiac', 'Cardiac Myocytes', 'Cardiology', 'Cause of Death', 'Cell Line', 'Cells', 'Chronic', 'Connexin 43', 'Connexins', 'Coupling', 'Data', 'Defect', 'Dependence', 'Development', 'Disease', 'Down-Regulation', 'Etiology', 'Evolution', 'Exhibits', 'Female', 'Gap Junctions', 'Gender', 'Gene Expression', 'Gene Expression Profile', 'Gene Expression Profiling', 'Genes', 'Goals', 'Hearing', 'Heart', 'Heart Atrium', 'Heart Diseases', 'Internet', 'Ions', 'Life', 'Link', 'Literature', 'Methods', 'Mission', 'Modeling', 'Mus', 'Muscle Cells', 'Mutation', 'Pathway interactions', 'Phenotype', 'Principal Component Analysis', 'Recovery', 'Regulation', 'Regulator Genes', 'Reporting', 'Resistance', 'Role', 'Sampling', 'Signaling Molecule', 'Small Interfering RNA', 'Testing', 'Time', 'Tissues', 'Up-Regulation', 'Ventricular', 'Work', 'analytical tool', 'base', 'gap junction channel', 'genome-wide', 'heart rhythm', 'insight', 'interest', 'knock-down', 'male', 'novel therapeutics', 'overexpression', 'public health relevance', 'research study', 'transcriptomics', 'virtual']",NHLBI,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2010,415000,0.14438578175429284
"""Connexin-Dependent Transcriptomic Networks in Controlling the Heart Rhythm""    DESCRIPTION (provided by applicant): Extensive literature has reported altered expression and/or mutation of the primary gap junction proteins (connexins, Cx) that couple myocytes in ventricles (Cx43) and atria (Cx40) among major causes of cardiac arrhythmias. We have found that numerous genes controlling a vast number of functional pathways are regulated in Cx43 null tissues and these regulations are accurately predicted from coordination with Cx43 gene (Gja1) in wildtypes. These findings suggest an additional etiology of the disease that is related to connexins but not necessarily to the intercellular coupling they provide. Our working hypothesis is that the genes encoding the heart rhythm determinants (HRD) are interconnected in connexin-dependent and connexin-independent transcriptomic networks whose topologies may change during development and exhibit slight differences between the two genders. Such regulatory networks, where linkage partners are rearranged and strength modified in disease, may explain downstream and parallel ""ripples"" of phenotypic change. We plan to verify this hypothesis, and build and characterize the atrial and ventricular webs of genes encoding hear rhythm determinants. In addition, we shall identify and quantify the connexin-dependent regulatory networks within these webs. Of particular interest will be to identify the gene pairs with strikingly similar or opposite coordination profiles because up-regulation of a similar one or down-regulation of an opposed are expected to compensate for the deficient expression of the counterpart (as ""transcriptomic see-saws""). For these, we shall profile the atrial and ventricular transcriptomes of wildtype, Cx40 null and Cx43 conditional knockdown male and female mice at E19, 1, 2 and 4 weeks of their early life. The expression data will be also used to determine the expression variability and intercoordination of all quantifiable unigenes and study the age and gender dependence of the HRD gene webs. We have developed the Principal Gene Analysis by which to identify the heart rhythm determinants (HRD), build and characterize the webs of their encoding genes. The ""see-saw"" model will be tested by comparing the transcriptomes of cultured cardiomyocytes in which expression of either Cx43 or of certain positive ""see-saw"" partners are knocked-down through siRNA treatment. Thus, this study is expected to reveal new organizational principles of the heart transcriptome and the role of gap junction genes in this organization, with the long-term goal to open novel therapeutic horizons in the treatment of arrhythmia. PUBLIC HEALTH RELEVANCE: Gap junctions between cardiac muscle cells provide the channels for intercellular current flow that assures propagation of contraction throughout the heart. Increasing evidence attributes numerous cardiac arrhythmias to altered gap junctions and the proteins of which they are composed. We hypothesize that this role of gap junction gene expression is due in part to linkage to expression of other genes that affect the cardiac rhythm, and we propose to use gene expression profiling from microarrays to achieve a comprehensive understanding of arrhythmia and to generate hypotheses testable by more focused methods. We plan to profile the gene expressions in atria and ventricles of male and female wildtype mice and mice lacking the main cardiac gap junction proteins at four time- points during evolution to the adult state to identify and quantify on a genome-wide scale the connexin- related transcriptomic determinants of arrhythmia, analyzing their gender dependence and maturation. A major contribution will consist in identifying candidate genes whose manipulation might restore the normal cardiac rhythm based on their similar or opposed expression coordination with cardiac connexins in the sampled transcriptome and to that of other genes whose alteration generates arrhythmia. The study will reveal new organizational principles of the heart transcriptome, with the long- term goal to open novel therapeutic horizons in the treatment of arrhythmia. Our project has the unique feature of describing and quantifying the Cx40- and Cx43-dependent Gene Regulatory Networks of the heart rhythm, with the long term goal to open novel therapeutic horizons in cardiology.           NARRATIVE:  Gap junctions between cardiac muscle cells provide the channels for intercellular current flow that assures propagation of contraction throughout the heart. Increasing evidence attributes numerous cardiac arrhythmias to altered gap junctions and the proteins of which they are composed. We hypothesize that this role of gap junction gene expression is due in part to linkage to expression of other genes that affect the cardiac rhythm, and we propose to use gene expression profiling from microarrays to achieve a comprehensive understanding of arrhythmia and to generate hypotheses testable by more focused methods. We plan to profile the gene expressions in atria and ventricles of male and female wildtype mice and mice lacking the main cardiac gap junction proteins at four time- points during evolution to the adult state to identify and quantify on a genome-wide scale the connexin- related transcriptomic determinants of arrhythmia, analyzing their gender dependence and maturation. A major contribution will consist in identifying candidate genes whose manipulation might restore the normal cardiac rhythm based on their similar or opposed expression coordination with cardiac connexins in the sampled transcriptome and to that of other genes whose alteration generates arrhythmia. The study will reveal new organizational principles of the heart transcriptome, with the long- term goal to open novel therapeutic horizons in the treatment of arrhythmia. Our project has the unique feature of describing and quantifying the Cx40- and Cx43-dependent Gene Regulatory Networks of the heart rhythm, with the long term goal to open novel therapeutic horizons in cardiology.","""Connexin-Dependent Transcriptomic Networks in Controlling the Heart Rhythm""",7584374,R01HL092001,"['Acute', 'Address', 'Adult', 'Affect', 'Age', 'Algorithms', 'Anti-Arrhythmia Agents', 'Arrhythmia', 'Biological', 'Candidate Disease Gene', 'Cardiac', 'Cardiac Myocytes', 'Cardiology', 'Cause of Death', 'Cell Line', 'Cells', 'Chronic', 'Connexin 43', 'Connexins', 'Coupling', 'Data', 'Defect', 'Dependence', 'Development', 'Disease', 'Down-Regulation', 'Etiology', 'Evolution', 'Exhibits', 'Female', 'Gap Junctions', 'Gender', 'Gene Expression', 'Gene Expression Profile', 'Gene Expression Profiling', 'Genes', 'Goals', 'Hearing', 'Heart', 'Heart Atrium', 'Heart Diseases', 'Internet', 'Ions', 'Life', 'Link', 'Literature', 'Methods', 'Mission', 'Modeling', 'Mus', 'Muscle Cells', 'Mutation', 'Pathway interactions', 'Phenotype', 'Principal Component Analysis', 'Recovery', 'Regulation', 'Regulator Genes', 'Reporting', 'Resistance', 'Role', 'Sampling', 'Signaling Molecule', 'Small Interfering RNA', 'Testing', 'Time', 'Tissues', 'Up-Regulation', 'Ventricular', 'Work', 'analytical tool', 'base', 'gap junction channel', 'genome-wide', 'heart rhythm', 'insight', 'interest', 'knock-down', 'male', 'novel therapeutics', 'overexpression', 'public health relevance', 'research study', 'transcriptomics', 'virtual']",NHLBI,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2009,415000,0.14438578175429284
"Combined Cardiopulmonary Failure in COPD: SPIROMICS HF The death rate and hospitalizations from chronic obstructive pulmonary disease (COPD) have doubled in the last 50 years. A third of COPD hospitalizations overlap with heart failure, mostly with preserved ejection fraction (HFpEF), yet no large COPD study has ascertained cardiac function. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study was funded to test the endothelial hypothesis of emphysema and examine reduced RV dimensions (cor pulmonale parvus) in COPD. In the MESA COPD Study II, we found that associations of reduced pulmonary microvascular blood flow with emphysema do not appear to be confounded by hypoxic pulmonary vasoconstriction and that emphysema on CT predicted RV regression over 5 years. We also developed methods to further subtype emphysema and COPD and scaled them up to the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS). We used unsupervised machine learning to discover new emphysema subtypes that are common and have molecular origins. Separately, we found that 26% of adults have segmental airway variants, which are associated with COPD and the developmental genes FGF10 and RARA. Both genes affect right heart development. In pilot work, we found one dramatically altered RV strain and the other associated with cor pulmonale parvus. Finally, we found that bronchitic symptomatic smokers, who have hyperinflation from gas trapping, may have increased LV diastolic dysfunction. Hence, cardiac alterations in COPD are complex but recent advances in COPD subtyping may allow their personalized diagnosis and treatment. SPIROMICS is an NHLBI-funded prospective study that recruited smokers with COPD and controls and is re-examining 2,000 participants with gold- standard lung phenotyping including full-lung CT. We propose to add comprehensive echocardiography (echo) with speckle-tracking for cardiac mechanics for 1,000 SPIROMICS participants, with exercise in 700 and cardiopulmonary MRI in 600, to test the following hypotheses: 1) machine-learned subtypes of emphysema on CT are associated with specific alterations in cardiac structure and function, which vary from cor pulmonale to LV diastolic dysfunction; 2) participants with segmental airway variants have abnormal RV structure and function; 3) symptomatic smokers have signs of increased LV afterload and LV diastolic dysfunction. Innovative aspects of the application include the use of novel echo and MRI measures in a large, well- characterized cohort of COPD patients. Confirmation of the hypotheses would define the mechanisms of HFpEF in COPD and identify subsets of patients for targeted treatment of cardiopulmonary dysfunction. The death rate and hospitalizations from chronic obstructive pulmonary disease (COPD) have doubled in the last 50 years. A third of COPD hospitalizations overlap with heart failure, mostly with preserved ejection fraction. The proposed study would be the first large study with gold-standard phenotyping of the heart and lungs and would test highly specific hypothesized based upon recent advances in lung subphenotyping to yield personalized approaches to combined cardiopulmonary disease in COPD.",Combined Cardiopulmonary Failure in COPD: SPIROMICS HF,10020427,R01HL093081,"['Adult', 'Affect', 'Apical', 'Blood flow', 'Cardiac', 'Cardiac Output', 'Cardiopulmonary', 'Chronic Obstructive Airway Disease', 'Code', 'Complex', 'DRD1 gene', 'Death Rate', 'Developmental Gene', 'Diffuse', 'Dimensions', 'Drops', 'EFRAC', 'Echocardiography', 'Endothelium', 'Exercise', 'FGF10 gene', 'Failure', 'Fibrosis', 'Functional disorder', 'Funding', 'Gases', 'Genes', 'Gold', 'Heart', 'Heart Atrium', 'Heart failure', 'Hospitalization', 'Impairment', 'Kinetics', 'Lung', 'Lung CAT Scan', 'Machine Learning', 'Magnetic Resonance Imaging', 'Measures', 'Mechanics', 'Methods', 'Molecular', 'Multi-Ethnic Study of Atherosclerosis', 'Myocardial', 'National Heart, Lung, and Blood Institute', 'Outcome Measure', 'Participant', 'Pathology', 'Patients', 'Phenotype', 'Prospective Studies', 'Pulmonary Emphysema', 'Pulmonary Fibrosis', 'Pulmonary Heart Disease', 'Pulmonary artery structure', 'RARA gene', 'Respiratory Failure', 'Right Ventricular Hypertrophy', 'Right ventricular structure', 'Sampling', 'Smoker', 'Structure', 'Suggestion', 'Technology', 'Testing', 'Variant', 'Ventricular', 'Work', 'base', 'cardiogenesis', 'cohort', 'disorder control', 'disorder subtype', 'genetic variant', 'heart function', 'heart preservation', 'indexing', 'innovation', 'interstitial', 'lung hypoxia', 'novel', 'novel diagnostics', 'novel therapeutic intervention', 'patient subsets', 'personalized approach', 'personalized diagnostics', 'personalized medicine', 'preservation', 'pressure', 'receptor', 'recruit', 'targeted treatment', 'unsupervised learning', 'vasoconstriction']",NHLBI,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2020,2331272,0.06492542638502787
"Combined Cardiopulmonary Failure in COPD: SPIROMICS HF The death rate and hospitalizations from chronic obstructive pulmonary disease (COPD) have doubled in the last 50 years. A third of COPD hospitalizations overlap with heart failure, mostly with preserved ejection fraction (HFpEF), yet no large COPD study has ascertained cardiac function. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study was funded to test the endothelial hypothesis of emphysema and examine reduced RV dimensions (cor pulmonale parvus) in COPD. In the MESA COPD Study II, we found that associations of reduced pulmonary microvascular blood flow with emphysema do not appear to be confounded by hypoxic pulmonary vasoconstriction and that emphysema on CT predicted RV regression over 5 years. We also developed methods to further subtype emphysema and COPD and scaled them up to the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS). We used unsupervised machine learning to discover new emphysema subtypes that are common and have molecular origins. Separately, we found that 26% of adults have segmental airway variants, which are associated with COPD and the developmental genes FGF10 and RARA. Both genes affect right heart development. In pilot work, we found one dramatically altered RV strain and the other associated with cor pulmonale parvus. Finally, we found that bronchitic symptomatic smokers, who have hyperinflation from gas trapping, may have increased LV diastolic dysfunction. Hence, cardiac alterations in COPD are complex but recent advances in COPD subtyping may allow their personalized diagnosis and treatment. SPIROMICS is an NHLBI-funded prospective study that recruited smokers with COPD and controls and is re-examining 2,000 participants with gold- standard lung phenotyping including full-lung CT. We propose to add comprehensive echocardiography (echo) with speckle-tracking for cardiac mechanics for 1,000 SPIROMICS participants, with exercise in 700 and cardiopulmonary MRI in 600, to test the following hypotheses: 1) machine-learned subtypes of emphysema on CT are associated with specific alterations in cardiac structure and function, which vary from cor pulmonale to LV diastolic dysfunction; 2) participants with segmental airway variants have abnormal RV structure and function; 3) symptomatic smokers have signs of increased LV afterload and LV diastolic dysfunction. Innovative aspects of the application include the use of novel echo and MRI measures in a large, well- characterized cohort of COPD patients. Confirmation of the hypotheses would define the mechanisms of HFpEF in COPD and identify subsets of patients for targeted treatment of cardiopulmonary dysfunction. The death rate and hospitalizations from chronic obstructive pulmonary disease (COPD) have doubled in the last 50 years. A third of COPD hospitalizations overlap with heart failure, mostly with preserved ejection fraction. The proposed study would be the first large study with gold-standard phenotyping of the heart and lungs and would test highly specific hypothesized based upon recent advances in lung subphenotyping to yield personalized approaches to combined cardiopulmonary disease in COPD.",Combined Cardiopulmonary Failure in COPD: SPIROMICS HF,9819260,R01HL093081,"['Adult', 'Affect', 'Apical', 'Blood flow', 'Cardiac', 'Cardiac Output', 'Cardiopulmonary', 'Chronic Obstructive Airway Disease', 'Code', 'Complex', 'DRD1 gene', 'Death Rate', 'Developmental Gene', 'Diffuse', 'Dimensions', 'Drops', 'EFRAC', 'Echocardiography', 'Endothelium', 'Exercise', 'FGF10 gene', 'Failure', 'Fibrosis', 'Functional disorder', 'Funding', 'Gases', 'Genes', 'Gold', 'Heart', 'Heart Atrium', 'Heart failure', 'Hospitalization', 'Hypoxia', 'Impairment', 'Kinetics', 'Lung', 'Lung CAT Scan', 'Magnetic Resonance Imaging', 'Measures', 'Mechanics', 'Methods', 'Molecular', 'Multi-Ethnic Study of Atherosclerosis', 'Myocardial', 'National Heart, Lung, and Blood Institute', 'Outcome Measure', 'Participant', 'Pathology', 'Patients', 'Phenotype', 'Prospective Studies', 'Pulmonary Emphysema', 'Pulmonary Fibrosis', 'Pulmonary Heart Disease', 'Pulmonary artery structure', 'RARA gene', 'Respiratory Failure', 'Right Ventricular Hypertrophy', 'Right ventricular structure', 'Sampling', 'Smoker', 'Structure', 'Suggestion', 'Technology', 'Testing', 'Variant', 'Ventricular', 'Work', 'base', 'cardiogenesis', 'cohort', 'disorder control', 'disorder subtype', 'genetic variant', 'heart function', 'heart preservation', 'indexing', 'innovation', 'interstitial', 'novel', 'novel diagnostics', 'novel therapeutic intervention', 'patient subsets', 'personalized approach', 'personalized diagnostics', 'personalized medicine', 'preservation', 'pressure', 'receptor', 'recruit', 'targeted treatment', 'unsupervised learning', 'vasoconstriction']",NHLBI,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2019,2391491,0.06492542638502787
"Phosphoprotein Signaling In Experimental Cardiac Remodeling    DESCRIPTION (provided by applicant): Heart failure affects 2-4 million individuals in America and over 15 million people worldwide. Hypertension is the greatest risk factor with over two-thirds of heart failure patients having a history of high blood pressure. Cardiac remodeling in hypertension or pressure overload is defined by concentric cardiac hypertrophy followed by dilatation with systolic failure. Many individual signaling elements and pathways that can regulate cardiovascular remodeling have been identified, however there is a great need to integrate this data and to discover novel mechanisms which will lead to the development of new therapeutic targets and approaches to heart failure. A commonality of the findings to date is the importance of kinases and regulation of proteins by phosphorylations in cardiac hypertrophy and function. The development of proteomics technology has made it possible to simultaneously analyze the abundance of several hundred phosphoproteins in a tissue or cell without apriori knowledge of function or distribution. Advances in analytic approaches use changes in phosphoprotein expression patterns to discover new phosphorylation signaling pathways and networks. This proposal focuses solely on serine and threonine phosphorylations in hypertensive heart failure since several serine-threonine kinases, including MAPKs, are implicated in myocyte hypertrophy, fibrosis, and apoptosis. We will apply phosphoprotein profiling to three defined cardiac phenotypes; 1) normal; 2) compensated hypertrophic; and 3) dilated/failing from three different rodent models of hypertensive and pressure-overload, i.e., Dahl salt-sensitive (S), spontaneously hypertensive - heart failure prone (SHHF), and aortic banded Wistar rats. Aim 1 is to identify novel patterns of serine-threonine phosphorylated proteins that cluster with cardiac hypertrophy. After measuring cardiac size/function, we will identify phosphoprotein expression patterns that are uniquely common to hypertrophic hearts from Dahl S, SHHF rats, and aortic banded Wistar rats, and specifically not observed in normal hearts from their control counterparts: Dahl R and Wistar rats. These are candidate phosphoproteins for cardiac hypertrophy. Aim 2 is to identify novel patterns of serine-threonine phosphorylated proteins that cluster with cardiac dilatation/failure. We will identify phosphoprotein expression patterns that are uniquely common to dilated hearts from Dahl S. SHHF, and aortic-banded Wistar rats and specifically not in both normal and hypertrophic hearts from their counterparts. These will be the best candidate phosphoproteins for cardiac dilation/failure. The identification of major patterns of phosphoproteins in the heart associated with hypertrophy and dilatation/failure will provide critical and new signaling insights into pathogenesis and function in hypertensive cardiac remodeling. The results will lead to testable hypotheses for specific signaling pathways in heart failure and the development of phosphorylation signaling pathways or networks. This will move us toward our overall goal of determining new therapeutic approaches and novel targets for heart failure.      PUBLIC HEALTH RELEVANCE: Heart failure affects 2-4 million individuals in America and over 15 million people world- wide. The overall goal of this project is to discover underlying signaling pathways and molecular mechanisms important in its pathogenesis and cardiac remodeling with the overall goal of developing new therapeutic strategies and targets.           Project Narrative  Heart failure affects 2-4 million individuals in America and over 15 million people world- wide. The overall goal of this project is to discover underlying signaling pathways and molecular mechanisms important in its pathogenesis and cardiac remodeling with the overall goal of developing new therapeutic strategies and targets.",Phosphoprotein Signaling In Experimental Cardiac Remodeling,8020918,R21HL096031,"['Affect', 'Americas', 'Apoptosis', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Cells', 'Cessation of life', 'Data', 'Development', 'Dilatation - action', 'Elements', 'Failure', 'Fibrosis', 'Goals', 'Health Expenditures', 'Heart', 'Heart Hypertrophy', 'Heart failure', 'Hospitalization', 'Hypertension', 'Hypertrophy', 'Individual', 'Knowledge', 'Lead', 'Measures', 'Molecular', 'Mortality Decline', 'Muscle Cells', 'Oocytes', 'Pathogenesis', 'Pathway interactions', 'Patients', 'Pattern', 'Phenotype', 'Phosphoproteins', 'Phosphorylation', 'Phosphotransferases', 'Protein-Serine-Threonine Kinases', 'Proteins', 'Proteomics', 'Rattus', 'Recording of previous events', 'Regulation', 'Risk Factors', 'Rodent Model', 'Serine', 'Serine/Threonine Phosphorylation', 'Signal Pathway', 'Signal Transduction', 'Staging', 'Technology', 'Threonine', 'Tissues', 'United States', 'Wistar Rats', 'heart dimension/size', 'insight', 'leukemia', 'new therapeutic target', 'novel', 'novel therapeutic intervention', 'novel therapeutics', 'pressure', 'public health relevance', 'salt sensitive']",NHLBI,UNIVERSITY OF ILLINOIS AT CHICAGO,R21,2011,198733,0.08690210393183702
"Phosphoprotein Signaling In Experimental Cardiac Remodeling    DESCRIPTION (provided by applicant): Heart failure affects 2-4 million individuals in America and over 15 million people worldwide. Hypertension is the greatest risk factor with over two-thirds of heart failure patients having a history of high blood pressure. Cardiac remodeling in hypertension or pressure overload is defined by concentric cardiac hypertrophy followed by dilatation with systolic failure. Many individual signaling elements and pathways that can regulate cardiovascular remodeling have been identified, however there is a great need to integrate this data and to discover novel mechanisms which will lead to the development of new therapeutic targets and approaches to heart failure. A commonality of the findings to date is the importance of kinases and regulation of proteins by phosphorylations in cardiac hypertrophy and function. The development of proteomics technology has made it possible to simultaneously analyze the abundance of several hundred phosphoproteins in a tissue or cell without apriori knowledge of function or distribution. Advances in analytic approaches use changes in phosphoprotein expression patterns to discover new phosphorylation signaling pathways and networks. This proposal focuses solely on serine and threonine phosphorylations in hypertensive heart failure since several serine-threonine kinases, including MAPKs, are implicated in myocyte hypertrophy, fibrosis, and apoptosis. We will apply phosphoprotein profiling to three defined cardiac phenotypes; 1) normal; 2) compensated hypertrophic; and 3) dilated/failing from three different rodent models of hypertensive and pressure-overload, i.e., Dahl salt-sensitive (S), spontaneously hypertensive - heart failure prone (SHHF), and aortic banded Wistar rats. Aim 1 is to identify novel patterns of serine-threonine phosphorylated proteins that cluster with cardiac hypertrophy. After measuring cardiac size/function, we will identify phosphoprotein expression patterns that are uniquely common to hypertrophic hearts from Dahl S, SHHF rats, and aortic banded Wistar rats, and specifically not observed in normal hearts from their control counterparts: Dahl R and Wistar rats. These are candidate phosphoproteins for cardiac hypertrophy. Aim 2 is to identify novel patterns of serine-threonine phosphorylated proteins that cluster with cardiac dilatation/failure. We will identify phosphoprotein expression patterns that are uniquely common to dilated hearts from Dahl S. SHHF, and aortic-banded Wistar rats and specifically not in both normal and hypertrophic hearts from their counterparts. These will be the best candidate phosphoproteins for cardiac dilation/failure. The identification of major patterns of phosphoproteins in the heart associated with hypertrophy and dilatation/failure will provide critical and new signaling insights into pathogenesis and function in hypertensive cardiac remodeling. The results will lead to testable hypotheses for specific signaling pathways in heart failure and the development of phosphorylation signaling pathways or networks. This will move us toward our overall goal of determining new therapeutic approaches and novel targets for heart failure.      PUBLIC HEALTH RELEVANCE: Heart failure affects 2-4 million individuals in America and over 15 million people world- wide. The overall goal of this project is to discover underlying signaling pathways and molecular mechanisms important in its pathogenesis and cardiac remodeling with the overall goal of developing new therapeutic strategies and targets.           Project Narrative  Heart failure affects 2-4 million individuals in America and over 15 million people world- wide. The overall goal of this project is to discover underlying signaling pathways and molecular mechanisms important in its pathogenesis and cardiac remodeling with the overall goal of developing new therapeutic strategies and targets.",Phosphoprotein Signaling In Experimental Cardiac Remodeling,7790121,R21HL096031,"['Affect', 'Americas', 'Apoptosis', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Cells', 'Cessation of life', 'Data', 'Development', 'Dilatation - action', 'Elements', 'Failure', 'Fibrosis', 'Goals', 'Health Expenditures', 'Heart', 'Heart Hypertrophy', 'Heart failure', 'Hospitalization', 'Hypertension', 'Hypertrophy', 'Individual', 'Knowledge', 'Lead', 'Measures', 'Molecular', 'Mortality Decline', 'Muscle Cells', 'Oocytes', 'Pathogenesis', 'Pathway interactions', 'Patients', 'Pattern', 'Phenotype', 'Phosphoproteins', 'Phosphorylation', 'Phosphotransferases', 'Protein-Serine-Threonine Kinases', 'Proteins', 'Proteomics', 'Rattus', 'Recording of previous events', 'Regulation', 'Risk Factors', 'Rodent Model', 'Serine', 'Serine/Threonine Phosphorylation', 'Signal Pathway', 'Signal Transduction', 'Staging', 'Technology', 'Threonine', 'Tissues', 'United States', 'Wistar Rats', 'heart dimension/size', 'insight', 'leukemia', 'new therapeutic target', 'novel', 'novel therapeutic intervention', 'novel therapeutics', 'pressure', 'public health relevance', 'salt sensitive']",NHLBI,UNIVERSITY OF ILLINOIS AT CHICAGO,R21,2010,237983,0.08690210393183702
"Understanding and predicting cardiac events in HD using real-time EHRs DESCRIPTION (provided by applicant): The purpose of this K25 proposal is to provide Dr. Benjamin Goldstein Ph.D., M.P.H., with the necessary protected time and additional training to develop as an independent, clinical biostatistician. This proposal has two key components: (1) an innovative research plan and (2) a comprehensive training plan. It is well recognized that patients undergoing hemodialysis (HD) are at increased risk of cardiac related events which often prove fatal. While substantive research has identified risk factors for these events, little work has been performed on forecasting their occurrence. The proposed research proposes to use existing electronic health record (EHR) data available through a collaborating dialysis center, DaVita Inc, to derive such a prediction model. EHRs contain detailed information on both a patient's health history (e.g. comorbidities, medications) as well as their evolving health statu (i.e. changes in health). A particularly unique aspect of the DaVita EHR system is the availability of real-time measures of health (e.g. blood pressure, pulse) available over the course of an HD session. Through our ongoing collaboration we will have data on 10,000s of individuals each with 100s of HD sessions, presenting the opportunity to analyze millions of dialysis sessions. Within this wealth of data two particular questions will be addressed: (1) How does a patient's hemodynamics vary over the course of and across HD sessions? (2) Can we derive a predictor for the near term onset of a cardiac event? To answer question 1, sophisticated statistical methodology, referred to as functional data analysis (FDA), will be utilized. Patterns of hemodynamic measures will be compared during and across HD sessions with key features extracted. For question 2, machine learning methodology will be used to derive a prediction model for the onset of cardiac events. The final aim will be to assess the feasibility of applying such models within a clinical environment. As a Ph.D. biostatistician, Dr. Goldstein has many of the methodological and computational skills necessary to perform the proposed analyses. The proposed methods, while established, also have ample room for statistical investigation and will provide the basis for methodological research. He will be mentored by Dr. Bradley Efron, professor in the Stanford Department of Statistics, and a world recognized expert in statistical methodology. Serving as a consultant will be Drs. Trevor Hastie and John Ioannidis, fellow members of the department of statistics and experts in FDA and prediction evaluation respectively. The focus of Dr. Goldstein's training will be on developing his clinical expertise. This will be performed through a combination of didactic courses, one-on- one tutorials and clinical exposure. Dr. Wolfgang Winkelmayer, a clinical nephrologist and close collaborator of Dr. Goldstein, will supervise Dr. Goldstein's clinical knowledge development. He will be joined by Dr. Mark Hlatky, a research cardiologist, who will also provide mentorship with regards to the cardiac substance of the project. Additional consultants across the department of medicine will be used as needed. The proposed project will have a tremendous impact on Dr. Goldstein's career prospects. At the end of the 5 year period he will have begun the process of developing a research program in the analysis of EHR data. There will be ample avenues to pursue future studies, through the analysis of other predictor variables (e.g. biomarkers, psycho-social factors), outcomes (e.g. hospitalization, cost) and most importantly, implementation of the prediction models in the clinic. The clinical training period will provide him with the necessary background to succeed as a clinically-oriented biostatistician and develop as a leader in the field. PUBLIC HEALTH RELEVANCE: Electronic health records have become increasingly common in clinical settings but to this point have been underutilized for research purposes. This project will analyze real-time EHR data that are generated during a dialysis session. The focus will be on understanding patients' hemodynamic changes over the course of a three hour dialysis session and using that information to derive a prediction model for severe cardiac events.",Understanding and predicting cardiac events in HD using real-time EHRs,9324206,K25DK097279,"['Accounting', 'Acute', 'Address', 'Advertising', 'Algorithms', 'Assessment tool', 'Biological Markers', 'Blood Pressure', 'Breast Cancer Risk Assessment Tool', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Caring', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Cluster randomized trial', 'Collaborations', 'Comorbidity', 'Data', 'Data Analyses', 'Development', 'Dialysis procedure', 'Doctor of Philosophy', 'Economics', 'Education', 'Electronic Health Record', 'End stage renal failure', 'Environment', 'Evaluation', 'Event', 'Future', 'Goals', 'Grant', 'Growth', 'Health', 'Heart Arrest', 'Hemodialysis', 'Hospitalization', 'Hour', 'Individual', 'Infection', 'Investigation', 'Kidney', 'Knowledge', 'Laboratories', 'Length', 'Machine Learning', 'Master of Public Health', 'Measurement', 'Measures', 'Medical', 'Medicine', 'Mentors', 'Mentorship', 'Methodology', 'Methods', 'Mind', 'Modeling', 'Myocardial Infarction', 'National Heart, Lung, and Blood Institute', 'Outcome', 'Outpatients', 'Output', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Physiologic pulse', 'Play', 'Preventive measure', 'Process', 'Psychosocial Factor', 'Recording of previous events', 'Reporting', 'Research', 'Research Methodology', 'Risk', 'Risk Assessment', 'Risk Factors', 'Role', 'Sensitivity and Specificity', 'Specific qualifier value', 'Supervision', 'System', 'Technology', 'Time', 'Training', 'Variant', 'Work', 'base', 'cardiovascular disorder risk', 'career', 'clinical care', 'computerized tools', 'cost', 'demographics', 'disorder risk', 'health information technology', 'hemodynamics', 'high risk', 'improved', 'innovation', 'member', 'predictive modeling', 'professor', 'programs', 'prospective', 'public health relevance', 'skills', 'statistics', 'tool']",NIDDK,DUKE UNIVERSITY,K25,2017,156686,0.08402845121143004
"Understanding and predicting cardiac events in HD using real-time EHRs DESCRIPTION (provided by applicant): The purpose of this K25 proposal is to provide Dr. Benjamin Goldstein Ph.D., M.P.H., with the necessary protected time and additional training to develop as an independent, clinical biostatistician. This proposal has two key components: (1) an innovative research plan and (2) a comprehensive training plan. It is well recognized that patients undergoing hemodialysis (HD) are at increased risk of cardiac related events which often prove fatal. While substantive research has identified risk factors for these events, little work has been performed on forecasting their occurrence. The proposed research proposes to use existing electronic health record (EHR) data available through a collaborating dialysis center, DaVita Inc, to derive such a prediction model. EHRs contain detailed information on both a patient's health history (e.g. comorbidities, medications) as well as their evolving health statu (i.e. changes in health). A particularly unique aspect of the DaVita EHR system is the availability of real-time measures of health (e.g. blood pressure, pulse) available over the course of an HD session. Through our ongoing collaboration we will have data on 10,000s of individuals each with 100s of HD sessions, presenting the opportunity to analyze millions of dialysis sessions. Within this wealth of data two particular questions will be addressed: (1) How does a patient's hemodynamics vary over the course of and across HD sessions? (2) Can we derive a predictor for the near term onset of a cardiac event? To answer question 1, sophisticated statistical methodology, referred to as functional data analysis (FDA), will be utilized. Patterns of hemodynamic measures will be compared during and across HD sessions with key features extracted. For question 2, machine learning methodology will be used to derive a prediction model for the onset of cardiac events. The final aim will be to assess the feasibility of applying such models within a clinical environment. As a Ph.D. biostatistician, Dr. Goldstein has many of the methodological and computational skills necessary to perform the proposed analyses. The proposed methods, while established, also have ample room for statistical investigation and will provide the basis for methodological research. He will be mentored by Dr. Bradley Efron, professor in the Stanford Department of Statistics, and a world recognized expert in statistical methodology. Serving as a consultant will be Drs. Trevor Hastie and John Ioannidis, fellow members of the department of statistics and experts in FDA and prediction evaluation respectively. The focus of Dr. Goldstein's training will be on developing his clinical expertise. This will be performed through a combination of didactic courses, one-on- one tutorials and clinical exposure. Dr. Wolfgang Winkelmayer, a clinical nephrologist and close collaborator of Dr. Goldstein, will supervise Dr. Goldstein's clinical knowledge development. He will be joined by Dr. Mark Hlatky, a research cardiologist, who will also provide mentorship with regards to the cardiac substance of the project. Additional consultants across the department of medicine will be used as needed. The proposed project will have a tremendous impact on Dr. Goldstein's career prospects. At the end of the 5 year period he will have begun the process of developing a research program in the analysis of EHR data. There will be ample avenues to pursue future studies, through the analysis of other predictor variables (e.g. biomarkers, psycho-social factors), outcomes (e.g. hospitalization, cost) and most importantly, implementation of the prediction models in the clinic. The clinical training period will provide him with the necessary background to succeed as a clinically-oriented biostatistician and develop as a leader in the field. PUBLIC HEALTH RELEVANCE: Electronic health records have become increasingly common in clinical settings but to this point have been underutilized for research purposes. This project will analyze real-time EHR data that are generated during a dialysis session. The focus will be on understanding patients' hemodynamic changes over the course of a three hour dialysis session and using that information to derive a prediction model for severe cardiac events.",Understanding and predicting cardiac events in HD using real-time EHRs,9133363,K25DK097279,"['Accounting', 'Acute', 'Address', 'Advertising', 'Algorithms', 'Assessment tool', 'Biological Markers', 'Blood Pressure', 'Breast Cancer Risk Assessment Tool', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Caring', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Cluster randomized trial', 'Collaborations', 'Comorbidity', 'Data', 'Data Analyses', 'Development', 'Dialysis procedure', 'Doctor of Philosophy', 'Economics', 'Education', 'Electronic Health Record', 'End stage renal failure', 'Environment', 'Evaluation', 'Event', 'Future', 'Goals', 'Grant', 'Growth', 'Health', 'Heart Arrest', 'Hemodialysis', 'Hospitalization', 'Hour', 'Individual', 'Infection', 'Investigation', 'Kidney', 'Knowledge', 'Laboratories', 'Length', 'Machine Learning', 'Master of Public Health', 'Measurement', 'Measures', 'Medical', 'Medicine', 'Mentors', 'Mentorship', 'Methodology', 'Methods', 'Mind', 'Modeling', 'Myocardial Infarction', 'National Heart, Lung, and Blood Institute', 'Outcome', 'Outpatients', 'Output', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Physiologic pulse', 'Play', 'Preventive measure', 'Process', 'Recording of previous events', 'Reporting', 'Research', 'Risk', 'Risk Assessment', 'Risk Factors', 'Role', 'Sensitivity and Specificity', 'Specific qualifier value', 'System', 'Technology', 'Time', 'Training', 'Variant', 'Work', 'base', 'cardiovascular disorder risk', 'career', 'clinical care', 'computerized tools', 'cost', 'demographics', 'disorder risk', 'health information technology', 'hemodynamics', 'high risk', 'improved', 'innovation', 'member', 'predictive modeling', 'professor', 'programs', 'skills', 'social', 'statistics', 'tool']",NIDDK,DUKE UNIVERSITY,K25,2016,157765,0.08402845121143004
"Understanding and predicting cardiac events in HD using real-time EHRs DESCRIPTION (provided by applicant): The purpose of this K25 proposal is to provide Dr. Benjamin Goldstein Ph.D., M.P.H., with the necessary protected time and additional training to develop as an independent, clinical biostatistician. This proposal has two key components: (1) an innovative research plan and (2) a comprehensive training plan. It is well recognized that patients undergoing hemodialysis (HD) are at increased risk of cardiac related events which often prove fatal. While substantive research has identified risk factors for these events, little work has been performed on forecasting their occurrence. The proposed research proposes to use existing electronic health record (EHR) data available through a collaborating dialysis center, DaVita Inc, to derive such a prediction model. EHRs contain detailed information on both a patient's health history (e.g. comorbidities, medications) as well as their evolving health statu (i.e. changes in health). A particularly unique aspect of the DaVita EHR system is the availability of real-time measures of health (e.g. blood pressure, pulse) available over the course of an HD session. Through our ongoing collaboration we will have data on 10,000s of individuals each with 100s of HD sessions, presenting the opportunity to analyze millions of dialysis sessions. Within this wealth of data two particular questions will be addressed: (1) How does a patient's hemodynamics vary over the course of and across HD sessions? (2) Can we derive a predictor for the near term onset of a cardiac event? To answer question 1, sophisticated statistical methodology, referred to as functional data analysis (FDA), will be utilized. Patterns of hemodynamic measures will be compared during and across HD sessions with key features extracted. For question 2, machine learning methodology will be used to derive a prediction model for the onset of cardiac events. The final aim will be to assess the feasibility of applying such models within a clinical environment. As a Ph.D. biostatistician, Dr. Goldstein has many of the methodological and computational skills necessary to perform the proposed analyses. The proposed methods, while established, also have ample room for statistical investigation and will provide the basis for methodological research. He will be mentored by Dr. Bradley Efron, professor in the Stanford Department of Statistics, and a world recognized expert in statistical methodology. Serving as a consultant will be Drs. Trevor Hastie and John Ioannidis, fellow members of the department of statistics and experts in FDA and prediction evaluation respectively. The focus of Dr. Goldstein's training will be on developing his clinical expertise. This will be performed through a combination of didactic courses, one-on- one tutorials and clinical exposure. Dr. Wolfgang Winkelmayer, a clinical nephrologist and close collaborator of Dr. Goldstein, will supervise Dr. Goldstein's clinical knowledge development. He will be joined by Dr. Mark Hlatky, a research cardiologist, who will also provide mentorship with regards to the cardiac substance of the project. Additional consultants across the department of medicine will be used as needed. The proposed project will have a tremendous impact on Dr. Goldstein's career prospects. At the end of the 5 year period he will have begun the process of developing a research program in the analysis of EHR data. There will be ample avenues to pursue future studies, through the analysis of other predictor variables (e.g. biomarkers, psycho-social factors), outcomes (e.g. hospitalization, cost) and most importantly, implementation of the prediction models in the clinic. The clinical training period will provide him with the necessary background to succeed as a clinically-oriented biostatistician and develop as a leader in the field. PUBLIC HEALTH RELEVANCE: Electronic health records have become increasingly common in clinical settings but to this point have been underutilized for research purposes. This project will analyze real-time EHR data that are generated during a dialysis session. The focus will be on understanding patients' hemodynamic changes over the course of a three hour dialysis session and using that information to derive a prediction model for severe cardiac events.",Understanding and predicting cardiac events in HD using real-time EHRs,8921191,K25DK097279,"['Accounting', 'Acute', 'Address', 'Advertising', 'Algorithms', 'Biological Markers', 'Blood Pressure', 'Breast Cancer Risk Assessment Tool', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Caring', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Cluster randomized trial', 'Collaborations', 'Comorbidity', 'Data', 'Data Analyses', 'Development', 'Dialysis procedure', 'Doctor of Philosophy', 'Economics', 'Education', 'Electronic Health Record', 'End stage renal failure', 'Environment', 'Evaluation', 'Event', 'Future', 'Goals', 'Grant', 'Growth', 'Health', 'Heart Arrest', 'Hemodialysis', 'Hospitalization', 'Hour', 'Individual', 'Infection', 'Investigation', 'Kidney', 'Knowledge', 'Laboratories', 'Length', 'Machine Learning', 'Master of Public Health', 'Measurement', 'Measures', 'Medical', 'Medicine', 'Mentors', 'Mentorship', 'Methodology', 'Methods', 'Mind', 'Modeling', 'Myocardial Infarction', 'National Heart, Lung, and Blood Institute', 'Outcome', 'Outpatients', 'Output', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Physiologic pulse', 'Play', 'Process', 'Recording of previous events', 'Reporting', 'Research', 'Risk', 'Risk Assessment', 'Risk Factors', 'Role', 'Sensitivity and Specificity', 'Specific qualifier value', 'System', 'Technology', 'Time', 'Training', 'Variant', 'Work', 'base', 'cardiovascular disorder risk', 'career', 'clinical care', 'computerized tools', 'cost', 'demographics', 'disorder risk', 'health information technology', 'hemodynamics', 'high risk', 'improved', 'innovation', 'member', 'predictive modeling', 'professor', 'programs', 'skills', 'social', 'statistics', 'tool']",NIDDK,DUKE UNIVERSITY,K25,2015,159162,0.08402845121143004
"Understanding and predicting cardiac events in HD using real-time EHRs     DESCRIPTION (provided by applicant): The purpose of this K25 proposal is to provide Dr. Benjamin Goldstein Ph.D., M.P.H., with the necessary protected time and additional training to develop as an independent, clinical biostatistician. This proposal has two key components: (1) an innovative research plan and (2) a comprehensive training plan. It is well recognized that patients undergoing hemodialysis (HD) are at increased risk of cardiac related events which often prove fatal. While substantive research has identified risk factors for these events, little work has been performed on forecasting their occurrence. The proposed research proposes to use existing electronic health record (EHR) data available through a collaborating dialysis center, DaVita Inc, to derive such a prediction model. EHRs contain detailed information on both a patient's health history (e.g. comorbidities, medications) as well as their evolving health statu (i.e. changes in health). A particularly unique aspect of the DaVita EHR system is the availability of real-time measures of health (e.g. blood pressure, pulse) available over the course of an HD session. Through our ongoing collaboration we will have data on 10,000s of individuals each with 100s of HD sessions, presenting the opportunity to analyze millions of dialysis sessions. Within this wealth of data two particular questions will be addressed: (1) How does a patient's hemodynamics vary over the course of and across HD sessions? (2) Can we derive a predictor for the near term onset of a cardiac event? To answer question 1, sophisticated statistical methodology, referred to as functional data analysis (FDA), will be utilized. Patterns of hemodynamic measures will be compared during and across HD sessions with key features extracted. For question 2, machine learning methodology will be used to derive a prediction model for the onset of cardiac events. The final aim will be to assess the feasibility of applying such models within a clinical environment. As a Ph.D. biostatistician, Dr. Goldstein has many of the methodological and computational skills necessary to perform the proposed analyses. The proposed methods, while established, also have ample room for statistical investigation and will provide the basis for methodological research. He will be mentored by Dr. Bradley Efron, professor in the Stanford Department of Statistics, and a world recognized expert in statistical methodology. Serving as a consultant will be Drs. Trevor Hastie and John Ioannidis, fellow members of the department of statistics and experts in FDA and prediction evaluation respectively. The focus of Dr. Goldstein's training will be on developing his clinical expertise. This will be performed through a combination of didactic courses, one-on- one tutorials and clinical exposure. Dr. Wolfgang Winkelmayer, a clinical nephrologist and close collaborator of Dr. Goldstein, will supervise Dr. Goldstein's clinical knowledge development. He will be joined by Dr. Mark Hlatky, a research cardiologist, who will also provide mentorship with regards to the cardiac substance of the project. Additional consultants across the department of medicine will be used as needed. The proposed project will have a tremendous impact on Dr. Goldstein's career prospects. At the end of the 5 year period he will have begun the process of developing a research program in the analysis of EHR data. There will be ample avenues to pursue future studies, through the analysis of other predictor variables (e.g. biomarkers, psycho-social factors), outcomes (e.g. hospitalization, cost) and most importantly, implementation of the prediction models in the clinic. The clinical training period will provide him with the necessary background to succeed as a clinically-oriented biostatistician and develop as a leader in the field.     PUBLIC HEALTH RELEVANCE: Electronic health records have become increasingly common in clinical settings but to this point have been underutilized for research purposes. This project will analyze real-time EHR data that are generated during a dialysis session. The focus will be on understanding patients' hemodynamic changes over the course of a three hour dialysis session and using that information to derive a prediction model for severe cardiac events.",Understanding and predicting cardiac events in HD using real-time EHRs,8725658,K25DK097279,"['Accounting', 'Acute', 'Address', 'Advertising', 'Algorithms', 'Biological Markers', 'Blood Pressure', 'Breast Cancer Risk Assessment Tool', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Caring', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Collaborations', 'Comorbidity', 'Data', 'Data Analyses', 'Development', 'Dialysis procedure', 'Doctor of Philosophy', 'Economics', 'Education', 'Electronic Health Record', 'End stage renal failure', 'Environment', 'Evaluation', 'Event', 'Future', 'Goals', 'Grant', 'Growth', 'Health', 'Heart Arrest', 'Hemodialysis', 'Hospitalization', 'Hour', 'Individual', 'Infection', 'Investigation', 'Kidney', 'Knowledge', 'Laboratories', 'Length', 'Machine Learning', 'Master of Public Health', 'Measurement', 'Measures', 'Medical', 'Medicine', 'Mentors', 'Mentorship', 'Methodology', 'Methods', 'Metric', 'Mind', 'Modeling', 'Myocardial Infarction', 'National Heart, Lung, and Blood Institute', 'Outcome', 'Outpatients', 'Output', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Physiologic pulse', 'Play', 'Process', 'Recording of previous events', 'Reporting', 'Research', 'Risk', 'Risk Assessment', 'Risk Factors', 'Role', 'Sensitivity and Specificity', 'Specific qualifier value', 'System', 'Technology', 'Time', 'Training', 'Variant', 'Work', 'base', 'cardiovascular disorder risk', 'career', 'clinical care', 'computerized tools', 'cost', 'demographics', 'disorder risk', 'health information technology', 'hemodynamics', 'high risk', 'improved', 'innovation', 'member', 'professor', 'programs', 'public health relevance', 'randomized trial', 'skills', 'social', 'statistics', 'tool']",NIDDK,STANFORD UNIVERSITY,K25,2014,31657,0.08402845121143004
"Understanding and predicting cardiac events in HD using real-time EHRs     DESCRIPTION (provided by applicant): The purpose of this K25 proposal is to provide Dr. Benjamin Goldstein Ph.D., M.P.H., with the necessary protected time and additional training to develop as an independent, clinical biostatistician. This proposal has two key components: (1) an innovative research plan and (2) a comprehensive training plan. It is well recognized that patients undergoing hemodialysis (HD) are at increased risk of cardiac related events which often prove fatal. While substantive research has identified risk factors for these events, little work has been performed on forecasting their occurrence. The proposed research proposes to use existing electronic health record (EHR) data available through a collaborating dialysis center, DaVita Inc, to derive such a prediction model. EHRs contain detailed information on both a patient's health history (e.g. comorbidities, medications) as well as their evolving health statu (i.e. changes in health). A particularly unique aspect of the DaVita EHR system is the availability of real-time measures of health (e.g. blood pressure, pulse) available over the course of an HD session. Through our ongoing collaboration we will have data on 10,000s of individuals each with 100s of HD sessions, presenting the opportunity to analyze millions of dialysis sessions. Within this wealth of data two particular questions will be addressed: (1) How does a patient's hemodynamics vary over the course of and across HD sessions? (2) Can we derive a predictor for the near term onset of a cardiac event? To answer question 1, sophisticated statistical methodology, referred to as functional data analysis (FDA), will be utilized. Patterns of hemodynamic measures will be compared during and across HD sessions with key features extracted. For question 2, machine learning methodology will be used to derive a prediction model for the onset of cardiac events. The final aim will be to assess the feasibility of applying such models within a clinical environment. As a Ph.D. biostatistician, Dr. Goldstein has many of the methodological and computational skills necessary to perform the proposed analyses. The proposed methods, while established, also have ample room for statistical investigation and will provide the basis for methodological research. He will be mentored by Dr. Bradley Efron, professor in the Stanford Department of Statistics, and a world recognized expert in statistical methodology. Serving as a consultant will be Drs. Trevor Hastie and John Ioannidis, fellow members of the department of statistics and experts in FDA and prediction evaluation respectively. The focus of Dr. Goldstein's training will be on developing his clinical expertise. This will be performed through a combination of didactic courses, one-on- one tutorials and clinical exposure. Dr. Wolfgang Winkelmayer, a clinical nephrologist and close collaborator of Dr. Goldstein, will supervise Dr. Goldstein's clinical knowledge development. He will be joined by Dr. Mark Hlatky, a research cardiologist, who will also provide mentorship with regards to the cardiac substance of the project. Additional consultants across the department of medicine will be used as needed. The proposed project will have a tremendous impact on Dr. Goldstein's career prospects. At the end of the 5 year period he will have begun the process of developing a research program in the analysis of EHR data. There will be ample avenues to pursue future studies, through the analysis of other predictor variables (e.g. biomarkers, psycho-social factors), outcomes (e.g. hospitalization, cost) and most importantly, implementation of the prediction models in the clinic. The clinical training period will provide him with the necessary background to succeed as a clinically-oriented biostatistician and develop as a leader in the field.     PUBLIC HEALTH RELEVANCE: Electronic health records have become increasingly common in clinical settings but to this point have been underutilized for research purposes. This project will analyze real-time EHR data that are generated during a dialysis session. The focus will be on understanding patients' hemodynamic changes over the course of a three hour dialysis session and using that information to derive a prediction model for severe cardiac events.        ",Understanding and predicting cardiac events in HD using real-time EHRs,8425985,K25DK097279,"['Accounting', 'Acute', 'Address', 'Advertising', 'Algorithms', 'Biological Markers', 'Blood Pressure', 'Breast Cancer Risk Assessment Tool', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Caring', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Collaborations', 'Comorbidity', 'Data', 'Data Analyses', 'Development', 'Dialysis procedure', 'Doctor of Philosophy', 'Economics', 'Education', 'Electronic Health Record', 'End stage renal failure', 'Environment', 'Evaluation', 'Event', 'Future', 'Goals', 'Grant', 'Growth', 'Health', 'Heart Arrest', 'Hemodialysis', 'Hospitalization', 'Hour', 'Individual', 'Infection', 'Investigation', 'Kidney', 'Knowledge', 'Laboratories', 'Length', 'Machine Learning', 'Master of Public Health', 'Measurement', 'Measures', 'Medical', 'Medicine', 'Mentors', 'Mentorship', 'Methodology', 'Methods', 'Metric', 'Mind', 'Modeling', 'Myocardial Infarction', 'National Heart, Lung, and Blood Institute', 'Outcome', 'Outpatients', 'Output', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Physiologic pulse', 'Play', 'Process', 'Recording of previous events', 'Reporting', 'Research', 'Risk', 'Risk Assessment', 'Risk Factors', 'Role', 'Sensitivity and Specificity', 'Specific qualifier value', 'System', 'Technology', 'Time', 'Training', 'Variant', 'Work', 'base', 'cardiovascular disorder risk', 'career', 'clinical care', 'computerized tools', 'cost', 'demographics', 'disorder risk', 'health information technology', 'hemodynamics', 'high risk', 'improved', 'innovation', 'member', 'professor', 'programs', 'public health relevance', 'randomized trial', 'skills', 'social', 'statistics', 'tool']",NIDDK,STANFORD UNIVERSITY,K25,2013,161180,0.08402845121143004
"Understanding and predicting cardiac events in HD using real-time EHRs DESCRIPTION (provided by applicant): The purpose of this K25 proposal is to provide Dr. Benjamin Goldstein Ph.D., M.P.H., with the necessary protected time and additional training to develop as an independent, clinical biostatistician. This proposal has two key components: (1) an innovative research plan and (2) a comprehensive training plan. It is well recognized that patients undergoing hemodialysis (HD) are at increased risk of cardiac related events which often prove fatal. While substantive research has identified risk factors for these events, little work has been performed on forecasting their occurrence. The proposed research proposes to use existing electronic health record (EHR) data available through a collaborating dialysis center, DaVita Inc, to derive such a prediction model. EHRs contain detailed information on both a patient's health history (e.g. comorbidities, medications) as well as their evolving health statu (i.e. changes in health). A particularly unique aspect of the DaVita EHR system is the availability of real-time measures of health (e.g. blood pressure, pulse) available over the course of an HD session. Through our ongoing collaboration we will have data on 10,000s of individuals each with 100s of HD sessions, presenting the opportunity to analyze millions of dialysis sessions. Within this wealth of data two particular questions will be addressed: (1) How does a patient's hemodynamics vary over the course of and across HD sessions? (2) Can we derive a predictor for the near term onset of a cardiac event? To answer question 1, sophisticated statistical methodology, referred to as functional data analysis (FDA), will be utilized. Patterns of hemodynamic measures will be compared during and across HD sessions with key features extracted. For question 2, machine learning methodology will be used to derive a prediction model for the onset of cardiac events. The final aim will be to assess the feasibility of applying such models within a clinical environment. As a Ph.D. biostatistician, Dr. Goldstein has many of the methodological and computational skills necessary to perform the proposed analyses. The proposed methods, while established, also have ample room for statistical investigation and will provide the basis for methodological research. He will be mentored by Dr. Bradley Efron, professor in the Stanford Department of Statistics, and a world recognized expert in statistical methodology. Serving as a consultant will be Drs. Trevor Hastie and John Ioannidis, fellow members of the department of statistics and experts in FDA and prediction evaluation respectively. The focus of Dr. Goldstein's training will be on developing his clinical expertise. This will be performed through a combination of didactic courses, one-on- one tutorials and clinical exposure. Dr. Wolfgang Winkelmayer, a clinical nephrologist and close collaborator of Dr. Goldstein, will supervise Dr. Goldstein's clinical knowledge development. He will be joined by Dr. Mark Hlatky, a research cardiologist, who will also provide mentorship with regards to the cardiac substance of the project. Additional consultants across the department of medicine will be used as needed. The proposed project will have a tremendous impact on Dr. Goldstein's career prospects. At the end of the 5 year period he will have begun the process of developing a research program in the analysis of EHR data. There will be ample avenues to pursue future studies, through the analysis of other predictor variables (e.g. biomarkers, psycho-social factors), outcomes (e.g. hospitalization, cost) and most importantly, implementation of the prediction models in the clinic. The clinical training period will provide him with the necessary background to succeed as a clinically-oriented biostatistician and develop as a leader in the field. PUBLIC HEALTH RELEVANCE: Electronic health records have become increasingly common in clinical settings but to this point have been underutilized for research purposes. This project will analyze real-time EHR data that are generated during a dialysis session. The focus will be on understanding patients' hemodynamic changes over the course of a three hour dialysis session and using that information to derive a prediction model for severe cardiac events.",Understanding and predicting cardiac events in HD using real-time EHRs,9000970,K25DK097279,[' '],NIDDK,DUKE UNIVERSITY,K25,2014,130765,0.08402845121143004
"Functional Classification of Cardiomyocytes Derived from Stem Cells    DESCRIPTION (provided by applicant): Heart disease is the number one cause of death in the United States each year for both women and men. Although significant advances have been made in conventional drug and device therapies in recent years, they have not been able to reverse the loss of functional myocardium. Regeneration of the heart may someday be possible with the ability to derive functional cardiomyocytes from human stem cells. However, before these cells can be used for cardiac repair, more must be known about their electrophysiology and their likelihood to seamlessly integrate with native cardiac tissue. In particular, it is of critical importance to establish the electrophysiological compatibility of these cells with host myocardium to minimize the risk of arrhythmia. Despite this critical need, the classification of the electrophysiological phenotypes has been largely subjective for all cell types that have been studied so far, relying mainly on parameters related to action potential shape.  The overall goal of this project is to develop a new, analytical and automated method to classify newly differentiated cardiac cells, based on techniques developed for machine learning. The specific aims are first, to use optical mapping and microelectrode recordings to generate datasets of functional electrophysiological characteristics of human embryonic stem cell-derived cardiomyocytes (hESC-CMs), and second, to use machine learning techniques to classify the phenotypes of the hESC-CMs, based on parametric descriptions. These techniques will involve linear and nonlinear dimensionality reduction algorithms, and clustering and classification algorithms. Cells at different stages of differentiation will be evaluated at different pacing and pharmacological conditions that will help to establish the functional properties of the cells.  In summary, the proposed research will enable the classification of cardiomyocytes that are derived from human stem cells. The ability to classify and identify cardiomyocyte phenotypes will permit a quantitative assessment of the batch-to-batch variability in cell cultures, the effect of different differentiation procedures, and the evolution of phenotypes during cardiomyocyte differentiation and maturation. These are critically important issues for the future clinical application of these cells to regenerate cardiac tissue.      PUBLIC HEALTH RELEVANCE: Stem cell therapy holds great potential for treating diseased and failing hearts, but still faces significant challenges. This project addresses the electrophysiological aspects these cells, and the goal is to develop methods that can classify and identify the variety of heart cells that are derived from different kinds of stem cells.           Project Narrative  Stem cell therapy holds great potential for treating diseased and failing hearts, but still faces significant challenges. This project addresses the electrophysiological aspects these cells, and the goal is to develop methods that can classify and identify the variety of heart cells that are derived from different kinds of stem cells.",Functional Classification of Cardiomyocytes Derived from Stem Cells,8259042,R21HL108210,"['Action Potentials', 'Address', 'Adipocytes', 'Adrenergic Agents', 'Algorithms', 'Arrhythmia', 'Blood Cells', 'Bone Marrow', 'Cardiac', 'Cardiac Myocytes', 'Cause of Death', 'Cell Culture Techniques', 'Cells', 'Characteristics', 'Classification', 'Data', 'Data Set', 'Descriptor', 'Development', 'Devices', 'Discriminant Analysis', 'Electrophysiology (science)', 'Embryo', 'Evaluation', 'Evolution', 'Face', 'Frequencies', 'Future', 'Goals', 'Heart', 'Heart Atrium', 'Heart Diseases', 'Isometric Exercise', 'Machine Learning', 'Maps', 'Measurement', 'Methods', 'Microelectrodes', 'Morphology', 'Myocardium', 'Natural regeneration', 'Nodal', 'Optics', 'Pharmaceutical Preparations', 'Phenotype', 'Principal Component Analysis', 'Procedures', 'Property', 'Regenerative Medicine', 'Research', 'Research Personnel', 'Resources', 'Rest', 'Risk', 'Series', 'Shapes', 'Staging', 'Stem cells', 'Techniques', 'Testing', 'Time', 'Tissues', 'Training', 'Transplantation', 'Umbilical Cord Blood', 'United States', 'Variant', 'Ventricular', 'Woman', 'adrenergic', 'adult stem cell', 'base', 'cardiac repair', 'cell type', 'cholinergic', 'clinical application', 'functional loss', 'heart cell', 'human embryonic stem cell', 'human stem cells', 'induced pluripotent stem cell', 'innovation', 'interest', 'men', 'molecular marker', 'novel', 'public health relevance', 'research study', 'response', 'stem cell therapy', 'tissue repair']",NHLBI,JOHNS HOPKINS UNIVERSITY,R21,2012,205000,0.07027475549402527
"Functional Classification of Cardiomyocytes Derived from Stem Cells    DESCRIPTION (provided by applicant): Heart disease is the number one cause of death in the United States each year for both women and men. Although significant advances have been made in conventional drug and device therapies in recent years, they have not been able to reverse the loss of functional myocardium. Regeneration of the heart may someday be possible with the ability to derive functional cardiomyocytes from human stem cells. However, before these cells can be used for cardiac repair, more must be known about their electrophysiology and their likelihood to seamlessly integrate with native cardiac tissue. In particular, it is of critical importance to establish the electrophysiological compatibility of these cells with host myocardium to minimize the risk of arrhythmia. Despite this critical need, the classification of the electrophysiological phenotypes has been largely subjective for all cell types that have been studied so far, relying mainly on parameters related to action potential shape.  The overall goal of this project is to develop a new, analytical and automated method to classify newly differentiated cardiac cells, based on techniques developed for machine learning. The specific aims are first, to use optical mapping and microelectrode recordings to generate datasets of functional electrophysiological characteristics of human embryonic stem cell-derived cardiomyocytes (hESC-CMs), and second, to use machine learning techniques to classify the phenotypes of the hESC-CMs, based on parametric descriptions. These techniques will involve linear and nonlinear dimensionality reduction algorithms, and clustering and classification algorithms. Cells at different stages of differentiation will be evaluated at different pacing and pharmacological conditions that will help to establish the functional properties of the cells.  In summary, the proposed research will enable the classification of cardiomyocytes that are derived from human stem cells. The ability to classify and identify cardiomyocyte phenotypes will permit a quantitative assessment of the batch-to-batch variability in cell cultures, the effect of different differentiation procedures, and the evolution of phenotypes during cardiomyocyte differentiation and maturation. These are critically important issues for the future clinical application of these cells to regenerate cardiac tissue.      PUBLIC HEALTH RELEVANCE: Stem cell therapy holds great potential for treating diseased and failing hearts, but still faces significant challenges. This project addresses the electrophysiological aspects these cells, and the goal is to develop methods that can classify and identify the variety of heart cells that are derived from different kinds of stem cells.           Stem cell therapy holds great potential for treating diseased and failing hearts, but still faces significant challenges. This project addresses the electrophysiological aspects these cells, and the goal is to develop methods that can classify and identify the variety of heart cells that are derived from different kinds of stem cells.         ",Functional Classification of Cardiomyocytes Derived from Stem Cells,8095482,R21HL108210,"['Action Potentials', 'Address', 'Adipocytes', 'Adrenergic Agents', 'Algorithms', 'Arrhythmia', 'Blood Cells', 'Bone Marrow', 'Cardiac', 'Cardiac Myocytes', 'Cause of Death', 'Cell Culture Techniques', 'Cells', 'Characteristics', 'Classification', 'Data', 'Data Set', 'Descriptor', 'Development', 'Devices', 'Discriminant Analysis', 'Electrophysiology (science)', 'Embryo', 'Evaluation', 'Evolution', 'Face', 'Frequencies', 'Future', 'Goals', 'Heart', 'Heart Atrium', 'Heart Diseases', 'Isometric Exercise', 'Machine Learning', 'Maps', 'Measurement', 'Methods', 'Microelectrodes', 'Morphology', 'Myocardium', 'Natural regeneration', 'Nodal', 'Optics', 'Pharmaceutical Preparations', 'Phenotype', 'Principal Component Analysis', 'Procedures', 'Property', 'Regenerative Medicine', 'Research', 'Research Personnel', 'Resources', 'Rest', 'Risk', 'Series', 'Shapes', 'Staging', 'Stem cells', 'Techniques', 'Testing', 'Time', 'Tissues', 'Training', 'Transplantation', 'Umbilical Cord Blood', 'United States', 'Variant', 'Ventricular', 'Woman', 'Wound Healing', 'adrenergic', 'adult stem cell', 'base', 'cell type', 'cholinergic', 'clinical application', 'functional loss', 'heart cell', 'human embryonic stem cell', 'human stem cells', 'induced pluripotent stem cell', 'innovation', 'interest', 'men', 'molecular marker', 'novel', 'repaired', 'research study', 'response', 'stem cell therapy']",NHLBI,JOHNS HOPKINS UNIVERSITY,R21,2011,246000,0.07027475549402527
"Systems Analysis of Cardiac Chromatin Structure DESCRIPTION (provided by applicant): What the interphase genome looks like in vivo is unknown. Advances in sequencing over the last decade have provided new insight into sequence variants (and their expression); yet how the genome is organized in three dimensions, apart from the well-described machinations of mitosis, is only beginning to be understood. Adult cardiac myocytes reside primarily in interphase but are capable of large-scale changes in gene expression. Transcription factors, histone modifying enzymes and RNA polymerase complexes play a central role in the process of global gene expression; however, an equally important and less explored factor is endogenous chromatin structure. To be transcribed, a gene's local environment must be accessible for protein binding. The objective of this grant is to understand how this phenomenon is integrated on a genome- wide scale: how is the genome appropriately poised to have the right genes on and off under basal conditions, and what are the mechanisms that globally reorganize chromatin following a stimulus (e.g. during disease)?  Heart failure involves large-scale gene expression changes, including reactivation of genes normally silenced during development. Our data from an in vivo mouse model of pressure overload show alterations in abundance and localization of chromatin structural proteins from the linker histone H1 and high mobility group (HMG) B families, and indicate that heart failure is associated with global reprogramming of the chromatin environment for gene activation. We seek to discover universal principles for how HMGs and linker histones control bulk chromatin rearrangement and global gene expression; therefore, we will employ zebrafish, isolated myocytes and mouse hearts as model systems.  Our unifying hypothesis is that global reorganization of chromatin structure during heart failure is the result of systematic changes in the abundance, genomic localization, and protein interactions among chromatin structural proteins. We will examine how linker histones and HMGs establish the higher order structure of the genome in the cardiac nucleus and how they dynamically repackage chromatin in disease. We will use gain/loss-of-function approaches combined with super resolution STED microscopy (image chromatin packing), chromatin immunoprecipitation and DNA sequencing (localize proteins across the genome) and proteomics (determine proteins necessary for targeting). Our short-term goal is to understand the role of HMGs and linker histones in cardiac phenotype. The long-term goal is to develop an understanding of how HMGs, linker histones and other chromatin structural proteins coordinate genomic structure to facilitate specificity in gene expression. The significance in the basic realm is to develop an integrated model of chromatin packing. The significance to the clinical realm is to provide a mechanistic basis for how the genome is reprogrammed with disease, such that future therapies can target specific chromatin remodeling events. Fundamentally new strategies are needed to understand how the genome contributes to the human health problem of cardiovascular disease. We propose a novel systems approach combining chromatin immunoprecipitation plus DNA sequencing, super resolution microscopy and proteomics to examine chromatin structure in the setting of heart disease (in cells and mice) and development (in zebrafish). Our studies will test the hypothesis that genome-wide changes in gene expression are controlled by alterations in chromatin structural proteins, will reveal the principles underlying this phenomenon and have the potential to establish a new paradigm for how genomic structure affects cardiac phenotype during health and disease.",Systems Analysis of Cardiac Chromatin Structure,9091598,R01HL115238,"['Adult', 'Affect', 'Binding Proteins', 'Binding Sites', 'Biological Models', 'Cardiac', 'Cardiac Myocytes', 'Cardiac development', 'Cardiovascular Diseases', 'Cell Nucleus', 'Cell Size', 'Cell Survival', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Modeling', 'Chromatin Structure', 'Clinical', 'Complex', 'Computer Analysis', 'CpG Islands', 'DNA Sequence', 'DNA-Directed RNA Polymerase', 'Data', 'Development', 'Dimensions', 'Disease', 'Embryo', 'Enhancers', 'Environment', 'Enzymes', 'Event', 'Exons', 'Family', 'Family member', 'Figs - dietary', 'Fishes', 'Fluorescent in Situ Hybridization', 'Future', 'Gene Activation', 'Gene Expression', 'Gene Expression Process', 'Generations', 'Genes', 'Genome', 'Genomics', 'Goals', 'Grant', 'HMGB Proteins', 'Health', 'Heart', 'Heart Diseases', 'Heart failure', 'Higher Order Chromatin Structure', 'Histone H1', 'Histone H1(s)', 'Histones', 'Human', 'Individual', 'Injury', 'Intercistronic Region', 'Interphase', 'Introns', 'Length', 'Linker DNA', 'Measurement', 'Microscopy', 'Mitosis', 'Morphology', 'Mus', 'Muscle Cells', 'Nucleosomes', 'Phenotype', 'Play', 'Post-Translational Protein Processing', 'Process', 'Protein Family', 'Protein Isoforms', 'Proteins', 'Proteomics', 'Publishing', 'Regulation', 'Resolution', 'Role', 'SPT6 Protein', 'Site', 'Small Interfering RNA', 'Specificity', 'Stimulus', 'Structure', 'System', 'Systems Analysis', 'Testing', 'Variant', 'Vertebral column', 'Work', 'Zebrafish', 'base', 'chromatin immunoprecipitation', 'chromatin remodeling', 'fetal', 'genome-wide', 'in vivo', 'insight', 'interest', 'knock-down', 'loss of function', 'microscopic imaging', 'mouse development', 'mouse model', 'novel', 'overexpression', 'pressure', 'response', 'screening', 'text searching', 'transcription factor']",NHLBI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2016,385000,0.08944861136916758
"Systems Analysis of Cardiac Chromatin Structure DESCRIPTION (provided by applicant): What the interphase genome looks like in vivo is unknown. Advances in sequencing over the last decade have provided new insight into sequence variants (and their expression); yet how the genome is organized in three dimensions, apart from the well-described machinations of mitosis, is only beginning to be understood. Adult cardiac myocytes reside primarily in interphase but are capable of large-scale changes in gene expression. Transcription factors, histone modifying enzymes and RNA polymerase complexes play a central role in the process of global gene expression; however, an equally important and less explored factor is endogenous chromatin structure. To be transcribed, a gene's local environment must be accessible for protein binding. The objective of this grant is to understand how this phenomenon is integrated on a genome- wide scale: how is the genome appropriately poised to have the right genes on and off under basal conditions, and what are the mechanisms that globally reorganize chromatin following a stimulus (e.g. during disease)?  Heart failure involves large-scale gene expression changes, including reactivation of genes normally silenced during development. Our data from an in vivo mouse model of pressure overload show alterations in abundance and localization of chromatin structural proteins from the linker histone H1 and high mobility group (HMG) B families, and indicate that heart failure is associated with global reprogramming of the chromatin environment for gene activation. We seek to discover universal principles for how HMGs and linker histones control bulk chromatin rearrangement and global gene expression; therefore, we will employ zebrafish, isolated myocytes and mouse hearts as model systems.  Our unifying hypothesis is that global reorganization of chromatin structure during heart failure is the result of systematic changes in the abundance, genomic localization, and protein interactions among chromatin structural proteins. We will examine how linker histones and HMGs establish the higher order structure of the genome in the cardiac nucleus and how they dynamically repackage chromatin in disease. We will use gain/loss-of-function approaches combined with super resolution STED microscopy (image chromatin packing), chromatin immunoprecipitation and DNA sequencing (localize proteins across the genome) and proteomics (determine proteins necessary for targeting). Our short-term goal is to understand the role of HMGs and linker histones in cardiac phenotype. The long-term goal is to develop an understanding of how HMGs, linker histones and other chromatin structural proteins coordinate genomic structure to facilitate specificity in gene expression. The significance in the basic realm is to develop an integrated model of chromatin packing. The significance to the clinical realm is to provide a mechanistic basis for how the genome is reprogrammed with disease, such that future therapies can target specific chromatin remodeling events. Fundamentally new strategies are needed to understand how the genome contributes to the human health problem of cardiovascular disease. We propose a novel systems approach combining chromatin immunoprecipitation plus DNA sequencing, super resolution microscopy and proteomics to examine chromatin structure in the setting of heart disease (in cells and mice) and development (in zebrafish). Our studies will test the hypothesis that genome-wide changes in gene expression are controlled by alterations in chromatin structural proteins, will reveal the principles underlying this phenomenon and have the potential to establish a new paradigm for how genomic structure affects cardiac phenotype during health and disease.",Systems Analysis of Cardiac Chromatin Structure,8877624,R01HL115238,"['Adult', 'Affect', 'Binding Sites', 'Biological Models', 'Cardiac', 'Cardiac Myocytes', 'Cardiac development', 'Cardiovascular Diseases', 'Cell Nucleus', 'Cell Size', 'Cell Survival', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Modeling', 'Chromatin Structure', 'Clinical', 'Complex', 'CpG Islands', 'DNA Sequence', 'DNA-Directed RNA Polymerase', 'Data', 'Development', 'Dimensions', 'Disease', 'Embryo', 'Enhancers', 'Environment', 'Enzymes', 'Event', 'Exons', 'Family', 'Family member', 'Figs - dietary', 'Fishes', 'Fluorescent in Situ Hybridization', 'Future', 'Gene Activation', 'Gene Expression', 'Gene Expression Process', 'Generations', 'Genes', 'Genome', 'Genomics', 'Goals', 'Grant', 'HMGB Proteins', 'Health', 'Heart', 'Heart Diseases', 'Heart failure', 'Higher Order Chromatin Structure', 'Histone H1', 'Histone H1(s)', 'Histones', 'Human', 'Image', 'Individual', 'Injury', 'Intercistronic Region', 'Interphase', 'Introns', 'Length', 'Linker DNA', 'Measurement', 'Microscopy', 'Mitosis', 'Morphology', 'Mus', 'Muscle Cells', 'Nucleosomes', 'Phenotype', 'Play', 'Post-Translational Protein Processing', 'Process', 'Protein Binding', 'Protein Family', 'Protein Isoforms', 'Proteins', 'Proteomics', 'Publishing', 'Regulation', 'Resolution', 'Role', 'SPT6 Protein', 'Site', 'Small Interfering RNA', 'Specificity', 'Stimulus', 'Structure', 'System', 'Systems Analysis', 'Testing', 'Variant', 'Vertebral column', 'Work', 'Zebrafish', 'base', 'chromatin immunoprecipitation', 'chromatin remodeling', 'fetal', 'genome-wide', 'in vivo', 'insight', 'interest', 'knock-down', 'loss of function', 'mouse development', 'mouse model', 'novel', 'pressure', 'response', 'screening', 'text searching', 'transcription factor']",NHLBI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2015,379225,0.08944861136916758
"Systems Analysis of Cardiac Chromatin Structure     DESCRIPTION (provided by applicant): What the interphase genome looks like in vivo is unknown. Advances in sequencing over the last decade have provided new insight into sequence variants (and their expression); yet how the genome is organized in three dimensions, apart from the well-described machinations of mitosis, is only beginning to be understood. Adult cardiac myocytes reside primarily in interphase but are capable of large-scale changes in gene expression. Transcription factors, histone modifying enzymes and RNA polymerase complexes play a central role in the process of global gene expression; however, an equally important and less explored factor is endogenous chromatin structure. To be transcribed, a gene's local environment must be accessible for protein binding. The objective of this grant is to understand how this phenomenon is integrated on a genome- wide scale: how is the genome appropriately poised to have the right genes on and off under basal conditions, and what are the mechanisms that globally reorganize chromatin following a stimulus (e.g. during disease)?  Heart failure involves large-scale gene expression changes, including reactivation of genes normally silenced during development. Our data from an in vivo mouse model of pressure overload show alterations in abundance and localization of chromatin structural proteins from the linker histone H1 and high mobility group (HMG) B families, and indicate that heart failure is associated with global reprogramming of the chromatin environment for gene activation. We seek to discover universal principles for how HMGs and linker histones control bulk chromatin rearrangement and global gene expression; therefore, we will employ zebrafish, isolated myocytes and mouse hearts as model systems.  Our unifying hypothesis is that global reorganization of chromatin structure during heart failure is the result of systematic changes in the abundance, genomic localization, and protein interactions among chromatin structural proteins. We will examine how linker histones and HMGs establish the higher order structure of the genome in the cardiac nucleus and how they dynamically repackage chromatin in disease. We will use gain/loss-of-function approaches combined with super resolution STED microscopy (image chromatin packing), chromatin immunoprecipitation and DNA sequencing (localize proteins across the genome) and proteomics (determine proteins necessary for targeting). Our short-term goal is to understand the role of HMGs and linker histones in cardiac phenotype. The long-term goal is to develop an understanding of how HMGs, linker histones and other chromatin structural proteins coordinate genomic structure to facilitate specificity in gene expression. The significance in the basic realm is to develop an integrated model of chromatin packing. The significance to the clinical realm is to provide a mechanistic basis for how the genome is reprogrammed with disease, such that future therapies can target specific chromatin remodeling events.          Fundamentally new strategies are needed to understand how the genome contributes to the human health problem of cardiovascular disease. We propose a novel systems approach combining chromatin immunoprecipitation plus DNA sequencing, super resolution microscopy and proteomics to examine chromatin structure in the setting of heart disease (in cells and mice) and development (in zebrafish). Our studies will test the hypothesis that genome-wide changes in gene expression are controlled by alterations in chromatin structural proteins, will reveal the principles underlying this phenomenon and have the potential to establish a new paradigm for how genomic structure affects cardiac phenotype during health and disease.            ",Systems Analysis of Cardiac Chromatin Structure,8699830,R01HL115238,"['Adult', 'Affect', 'Binding Sites', 'Biological Models', 'Cardiac', 'Cardiac Myocytes', 'Cardiovascular Diseases', 'Cell Nucleus', 'Cell Size', 'Cell Survival', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Modeling', 'Chromatin Structure', 'Clinical', 'Complex', 'CpG Islands', 'DNA Sequence', 'DNA Sequence Rearrangement', 'DNA-Directed RNA Polymerase', 'Data', 'Development', 'Dimensions', 'Disease', 'Embryo', 'Enhancers', 'Environment', 'Enzymes', 'Event', 'Exons', 'Family', 'Family member', 'Figs - dietary', 'Fishes', 'Fluorescent in Situ Hybridization', 'Future', 'Gene Activation', 'Gene Expression', 'Gene Expression Process', 'Generations', 'Genes', 'Genome', 'Genomics', 'Goals', 'Grant', 'HMGB Proteins', 'Health', 'Heart', 'Heart Diseases', 'Heart failure', 'Higher Order Chromatin Structure', 'Histone H1', 'Histone H1(s)', 'Histones', 'Human', 'Image', 'Individual', 'Injury', 'Intercistronic Region', 'Interphase', 'Introns', 'Length', 'Linker DNA', 'Measurement', 'Microscopy', 'Mitosis', 'Morphology', 'Mus', 'Muscle Cells', 'Nucleosomes', 'Phenotype', 'Play', 'Post-Translational Protein Processing', 'Process', 'Protein Binding', 'Protein Family', 'Protein Isoforms', 'Proteins', 'Proteomics', 'Publishing', 'Regulation', 'Resolution', 'Role', 'SPT6 Protein', 'Site', 'Small Interfering RNA', 'Specificity', 'Stimulus', 'Structure', 'System', 'Systems Analysis', 'Testing', 'Variant', 'Vertebral column', 'Work', 'Zebrafish', 'base', 'chromatin immunoprecipitation', 'chromatin remodeling', 'fetal', 'genome-wide', 'in vivo', 'insight', 'interest', 'knock-down', 'loss of function', 'mouse development', 'mouse model', 'novel', 'pressure', 'response', 'screening', 'text searching', 'transcription factor']",NHLBI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2014,377300,0.08944861136916758
"Systems Analysis of Cardiac Chromatin Structure     DESCRIPTION (provided by applicant): What the interphase genome looks like in vivo is unknown. Advances in sequencing over the last decade have provided new insight into sequence variants (and their expression); yet how the genome is organized in three dimensions, apart from the well-described machinations of mitosis, is only beginning to be understood. Adult cardiac myocytes reside primarily in interphase but are capable of large-scale changes in gene expression. Transcription factors, histone modifying enzymes and RNA polymerase complexes play a central role in the process of global gene expression; however, an equally important and less explored factor is endogenous chromatin structure. To be transcribed, a gene's local environment must be accessible for protein binding. The objective of this grant is to understand how this phenomenon is integrated on a genome- wide scale: how is the genome appropriately poised to have the right genes on and off under basal conditions, and what are the mechanisms that globally reorganize chromatin following a stimulus (e.g. during disease)?  Heart failure involves large-scale gene expression changes, including reactivation of genes normally silenced during development. Our data from an in vivo mouse model of pressure overload show alterations in abundance and localization of chromatin structural proteins from the linker histone H1 and high mobility group (HMG) B families, and indicate that heart failure is associated with global reprogramming of the chromatin environment for gene activation. We seek to discover universal principles for how HMGs and linker histones control bulk chromatin rearrangement and global gene expression; therefore, we will employ zebrafish, isolated myocytes and mouse hearts as model systems.  Our unifying hypothesis is that global reorganization of chromatin structure during heart failure is the result of systematic changes in the abundance, genomic localization, and protein interactions among chromatin structural proteins. We will examine how linker histones and HMGs establish the higher order structure of the genome in the cardiac nucleus and how they dynamically repackage chromatin in disease. We will use gain/loss-of-function approaches combined with super resolution STED microscopy (image chromatin packing), chromatin immunoprecipitation and DNA sequencing (localize proteins across the genome) and proteomics (determine proteins necessary for targeting). Our short-term goal is to understand the role of HMGs and linker histones in cardiac phenotype. The long-term goal is to develop an understanding of how HMGs, linker histones and other chromatin structural proteins coordinate genomic structure to facilitate specificity in gene expression. The significance in the basic realm is to develop an integrated model of chromatin packing. The significance to the clinical realm is to provide a mechanistic basis for how the genome is reprogrammed with disease, such that future therapies can target specific chromatin remodeling events.          Fundamentally new strategies are needed to understand how the genome contributes to the human health problem of cardiovascular disease. We propose a novel systems approach combining chromatin immunoprecipitation plus DNA sequencing, super resolution microscopy and proteomics to examine chromatin structure in the setting of heart disease (in cells and mice) and development (in zebrafish). Our studies will test the hypothesis that genome-wide changes in gene expression are controlled by alterations in chromatin structural proteins, will reveal the principles underlying this phenomenon and have the potential to establish a new paradigm for how genomic structure affects cardiac phenotype during health and disease.            ",Systems Analysis of Cardiac Chromatin Structure,8516092,R01HL115238,"['Adult', 'Affect', 'Binding Sites', 'Biological Models', 'Cardiac', 'Cardiac Myocytes', 'Cardiovascular Diseases', 'Cell Nucleus', 'Cell Size', 'Cell Survival', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Modeling', 'Chromatin Structure', 'Clinical', 'Complex', 'CpG Islands', 'DNA Sequence', 'DNA Sequence Rearrangement', 'DNA-Directed RNA Polymerase', 'Data', 'Development', 'Dimensions', 'Disease', 'Embryo', 'Enhancers', 'Environment', 'Enzymes', 'Event', 'Exons', 'Family', 'Family member', 'Figs - dietary', 'Fishes', 'Fluorescent in Situ Hybridization', 'Future', 'Gene Activation', 'Gene Expression', 'Gene Expression Process', 'Generations', 'Genes', 'Genome', 'Genomics', 'Goals', 'Grant', 'HMGB Proteins', 'Health', 'Heart', 'Heart Diseases', 'Heart failure', 'Higher Order Chromatin Structure', 'Histone H1', 'Histone H1(s)', 'Histones', 'Human', 'Image', 'Individual', 'Injury', 'Intercistronic Region', 'Interphase', 'Introns', 'Length', 'Linker DNA', 'Measurement', 'Microscopy', 'Mitosis', 'Morphology', 'Mus', 'Muscle Cells', 'Nucleosomes', 'Phenotype', 'Play', 'Post-Translational Protein Processing', 'Process', 'Protein Binding', 'Protein Family', 'Protein Isoforms', 'Proteins', 'Proteomics', 'Publishing', 'Regulation', 'Resolution', 'Role', 'SPT6 Protein', 'Site', 'Small Interfering RNA', 'Specificity', 'Stimulus', 'Structure', 'System', 'Systems Analysis', 'Testing', 'Variant', 'Vertebral column', 'Work', 'Zebrafish', 'base', 'chromatin immunoprecipitation', 'chromatin remodeling', 'fetal', 'genome-wide', 'in vivo', 'insight', 'interest', 'knock-down', 'loss of function', 'mouse development', 'mouse model', 'novel', 'pressure', 'response', 'screening', 'text searching', 'transcription factor']",NHLBI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2013,366520,0.08944861136916758
"Systems Analysis of Cardiac Chromatin Structure     DESCRIPTION (provided by applicant): What the interphase genome looks like in vivo is unknown. Advances in sequencing over the last decade have provided new insight into sequence variants (and their expression); yet how the genome is organized in three dimensions, apart from the well-described machinations of mitosis, is only beginning to be understood. Adult cardiac myocytes reside primarily in interphase but are capable of large-scale changes in gene expression. Transcription factors, histone modifying enzymes and RNA polymerase complexes play a central role in the process of global gene expression; however, an equally important and less explored factor is endogenous chromatin structure. To be transcribed, a gene's local environment must be accessible for protein binding. The objective of this grant is to understand how this phenomenon is integrated on a genome- wide scale: how is the genome appropriately poised to have the right genes on and off under basal conditions, and what are the mechanisms that globally reorganize chromatin following a stimulus (e.g. during disease)?  Heart failure involves large-scale gene expression changes, including reactivation of genes normally silenced during development. Our data from an in vivo mouse model of pressure overload show alterations in abundance and localization of chromatin structural proteins from the linker histone H1 and high mobility group (HMG) B families, and indicate that heart failure is associated with global reprogramming of the chromatin environment for gene activation. We seek to discover universal principles for how HMGs and linker histones control bulk chromatin rearrangement and global gene expression; therefore, we will employ zebrafish, isolated myocytes and mouse hearts as model systems.  Our unifying hypothesis is that global reorganization of chromatin structure during heart failure is the result of systematic changes in the abundance, genomic localization, and protein interactions among chromatin structural proteins. We will examine how linker histones and HMGs establish the higher order structure of the genome in the cardiac nucleus and how they dynamically repackage chromatin in disease. We will use gain/loss-of-function approaches combined with super resolution STED microscopy (image chromatin packing), chromatin immunoprecipitation and DNA sequencing (localize proteins across the genome) and proteomics (determine proteins necessary for targeting). Our short-term goal is to understand the role of HMGs and linker histones in cardiac phenotype. The long-term goal is to develop an understanding of how HMGs, linker histones and other chromatin structural proteins coordinate genomic structure to facilitate specificity in gene expression. The significance in the basic realm is to develop an integrated model of chromatin packing. The significance to the clinical realm is to provide a mechanistic basis for how the genome is reprogrammed with disease, such that future therapies can target specific chromatin remodeling events.        PUBLIC HEALTH RELEVANCE: Fundamentally new strategies are needed to understand how the genome contributes to the human health problem of cardiovascular disease. We propose a novel systems approach combining chromatin immunoprecipitation plus DNA sequencing, super resolution microscopy and proteomics to examine chromatin structure in the setting of heart disease (in cells and mice) and development (in zebrafish). Our studies will test the hypothesis that genome-wide changes in gene expression are controlled by alterations in chromatin structural proteins, will reveal the principles underlying this phenomenon and have the potential to establish a new paradigm for how genomic structure affects cardiac phenotype during health and disease.              Fundamentally new strategies are needed to understand how the genome contributes to the human health problem of cardiovascular disease. We propose a novel systems approach combining chromatin immunoprecipitation plus DNA sequencing, super resolution microscopy and proteomics to examine chromatin structure in the setting of heart disease (in cells and mice) and development (in zebrafish). Our studies will test the hypothesis that genome-wide changes in gene expression are controlled by alterations in chromatin structural proteins, will reveal the principles underlying this phenomenon and have the potential to establish a new paradigm for how genomic structure affects cardiac phenotype during health and disease.            ",Systems Analysis of Cardiac Chromatin Structure,8348342,R01HL115238,"['Adult', 'Affect', 'Binding Sites', 'Biological Models', 'Cardiac', 'Cardiac Myocytes', 'Cardiovascular Diseases', 'Cell Nucleus', 'Cell Size', 'Cell Survival', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Modeling', 'Chromatin Structure', 'Clinical', 'Complex', 'CpG Islands', 'DNA Sequence', 'DNA Sequence Rearrangement', 'DNA-Directed RNA Polymerase', 'Data', 'Development', 'Dimensions', 'Disease', 'Embryo', 'Enhancers', 'Environment', 'Enzymes', 'Event', 'Exons', 'Family', 'Family member', 'Figs - dietary', 'Fishes', 'Fluorescent in Situ Hybridization', 'Future', 'Gene Activation', 'Gene Expression', 'Gene Expression Process', 'Generations', 'Genes', 'Genome', 'Genomics', 'Goals', 'Grant', 'HMGB Proteins', 'Health', 'Heart', 'Heart Diseases', 'Heart failure', 'Higher Order Chromatin Structure', 'Histone H1', 'Histone H1(s)', 'Histones', 'Human', 'Image', 'Individual', 'Injury', 'Intercistronic Region', 'Interphase', 'Introns', 'Length', 'Linker DNA', 'Measurement', 'Microscopy', 'Mitosis', 'Morphology', 'Mus', 'Muscle Cells', 'Nucleosomes', 'Phenotype', 'Play', 'Post-Translational Protein Processing', 'Process', 'Protein Binding', 'Protein Family', 'Protein Isoforms', 'Proteins', 'Proteomics', 'Publishing', 'Regulation', 'Resolution', 'Role', 'SPT6 Protein', 'Screening procedure', 'Site', 'Small Interfering RNA', 'Specificity', 'Stimulus', 'Structure', 'System', 'Systems Analysis', 'Testing', 'Variant', 'Vertebral column', 'Work', 'Zebrafish', 'base', 'chromatin immunoprecipitation', 'chromatin remodeling', 'fetal', 'genome-wide', 'in vivo', 'insight', 'interest', 'knock-down', 'loss of function', 'mouse development', 'mouse model', 'novel', 'pressure', 'response', 'text searching', 'transcription factor']",NHLBI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2012,385000,0.08726806537746112
"Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation DESCRIPTION (provided by applicant): Heart transplant (Tx) surgery is a well-established life-saving procedure, but is associated with post- interventional risks such as acute cardiac rejection (ACR) which is one of the leading causes of death in the first year after transplant. Beyond the first year, cardiac allograft vasculopathy (CAV) is the single greatest risk factor for 5-year mortality. Monitoring the patient for post-transplant events is thus paramount. The standard monitoring strategy, however, relies on frequent (12-16 monitoring nodes during year 1 alone) invasive and costly procedures including endomyocardial biopsies (EMB) and catheter angiography. Since EMB and catheter angiography have limited sensitivity due to sampling errors (ACR) or the diffuse nature of the disease (CAV), a reliable non-invasive alternative for the early detection of ACR and CAV would be desirable to reduce the need for invasive procedures, improve sensitivity, and reduce cost. We have recently developed and applied cardiac MRI techniques for the non-invasive assessment of myocardial edema (T2-mapping), diffuse fibrosis (pre- and post-contrast T1-mapping), myocardial velocities (tissue phase mapping), and microvascular quantitative perfusion. We have shown that these techniques can identify distinct regional structural and functional alterations in the heart that correlate with te status of the allograft. Based on these findings, a detailed cost-effective analysis using Markov modeling and decision tree analysis has demonstrated that cardiac MR has tremendous potential to reduce monitoring costs by 40-50% during the first year after Tx alone. This proposal builds on these promising findings and our aim is to develop an new 15-minute structure-function cardiac MRI protocol for the improved detection regional abnormalities associated with ACR (edema, fibrosis, dysfunction) and CAV (perfusion, dysfunction). Integration of MRI with echocardiography and intravascular Ultrasound (IVUS) will provide unique multi-modality assessment of the allograft. The application in a longitudinal clinical study coupled with state-of-the-art cost-effectiveness analysis will allow redefining the most effective post-Tx mixed monitoring strategy. The aim is to to help clinicians identify the optimal mixed monitoring strategy, i.e. the optimal combination of multi-modality imaging (structure-function MRI, echo, IVUS) and invasive procedures (EMB, catheter angiography) which provide best outcome (quality adjusted life days) and lowest cost for the individual cardiac transplant patient. PUBLIC HEALTH RELEVANCE: We propose to develop a multi-modality imaging protocol for the non-invasive characterization of tissue and function of the left and right heart in patients after heart transplantation. Our aim is to develop a new non- invasive 15 minute diagnostic test in order to provide a previously unattainable quantitative characterization of myocardial structure-function deficits in cardiac transplant patients. The application in a longitudinal clinial study coupled with cost-effectiveness analysis and decision tree modeling will allow to improve current monitoring strategies by combining cardiac MRI, echocardiography, intravascular ultrasound and invasive tests (biopsy, catheter angiography) to provide the best outcome (quality of life days, mortality) and lowest cost for the individual cardiac transplant patient.",Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation,9417961,R01HL117888,"['Acute', 'Allografting', 'Ambulatory Care Facilities', 'Angiography', 'Area', 'Biopsy', 'Blood Vessels', 'Cardiac', 'Catheters', 'Cause of Death', 'Clinical', 'Clinical Research', 'Coronary', 'Coronary Angiography', 'Cost Effectiveness Analysis', 'Cost utility', 'Coupled', 'Data', 'Decision Modeling', 'Decision Trees', 'Detection', 'Diagnostic', 'Diagnostic tests', 'Diffuse', 'Disease', 'Early Diagnosis', 'Echocardiography', 'Edema', 'Evaluation', 'Event', 'Fibrosis', 'Follow-Up Studies', 'Functional disorder', 'Goals', 'Gold', 'Healthcare', 'Heart', 'Heart Transplantation', 'Impairment', 'Individual', 'Left', 'Life', 'Longitudinal Studies', 'Magnetic Resonance Imaging', 'Modality', 'Modeling', 'Monitor', 'Multimodal Imaging', 'Myocardial', 'Nature', 'Operative Surgical Procedures', 'Outcome', 'Patient Monitoring', 'Patients', 'Perfusion', 'Phase', 'Procedures', 'Protocols documentation', 'Quality of life', 'Reference Standards', 'Resources', 'Risk', 'Risk Factors', 'Sampling Errors', 'Savings', 'Sensitivity and Specificity', 'Standardization', 'Structure', 'Techniques', 'Testing', 'Thick', 'Time', 'Tissues', 'Transplant Recipients', 'Transplantation', 'Ultrasonography', 'Vascular Diseases', 'Visit', 'base', 'comparative cost effectiveness', 'cost', 'extracellular', 'follow-up', 'heart allograft', 'heart function', 'imaging study', 'improved', 'markov model', 'mortality', 'non-invasive imaging', 'novel', 'post intervention', 'procedure cost', 'public health relevance', 'standard of care', 'two-arm study']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R01,2018,658634,0.18959920460980523
"Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation DESCRIPTION (provided by applicant): Heart transplant (Tx) surgery is a well-established life-saving procedure, but is associated with post- interventional risks such as acute cardiac rejection (ACR) which is one of the leading causes of death in the first year after transplant. Beyond the first year, cardiac allograft vasculopathy (CAV) is the single greatest risk factor for 5-year mortality. Monitoring the patient for post-transplant events is thus paramount. The standard monitoring strategy, however, relies on frequent (12-16 monitoring nodes during year 1 alone) invasive and costly procedures including endomyocardial biopsies (EMB) and catheter angiography. Since EMB and catheter angiography have limited sensitivity due to sampling errors (ACR) or the diffuse nature of the disease (CAV), a reliable non-invasive alternative for the early detection of ACR and CAV would be desirable to reduce the need for invasive procedures, improve sensitivity, and reduce cost. We have recently developed and applied cardiac MRI techniques for the non-invasive assessment of myocardial edema (T2-mapping), diffuse fibrosis (pre- and post-contrast T1-mapping), myocardial velocities (tissue phase mapping), and microvascular quantitative perfusion. We have shown that these techniques can identify distinct regional structural and functional alterations in the heart that correlate with te status of the allograft. Based on these findings, a detailed cost-effective analysis using Markov modeling and decision tree analysis has demonstrated that cardiac MR has tremendous potential to reduce monitoring costs by 40-50% during the first year after Tx alone. This proposal builds on these promising findings and our aim is to develop an new 15-minute structure-function cardiac MRI protocol for the improved detection regional abnormalities associated with ACR (edema, fibrosis, dysfunction) and CAV (perfusion, dysfunction). Integration of MRI with echocardiography and intravascular Ultrasound (IVUS) will provide unique multi-modality assessment of the allograft. The application in a longitudinal clinical study coupled with state-of-the-art cost-effectiveness analysis will allow redefining the most effective post-Tx mixed monitoring strategy. The aim is to to help clinicians identify the optimal mixed monitoring strategy, i.e. the optimal combination of multi-modality imaging (structure-function MRI, echo, IVUS) and invasive procedures (EMB, catheter angiography) which provide best outcome (quality adjusted life days) and lowest cost for the individual cardiac transplant patient. PUBLIC HEALTH RELEVANCE: We propose to develop a multi-modality imaging protocol for the non-invasive characterization of tissue and function of the left and right heart in patients after heart transplantation. Our aim is to develop a new non- invasive 15 minute diagnostic test in order to provide a previously unattainable quantitative characterization of myocardial structure-function deficits in cardiac transplant patients. The application in a longitudinal clinial study coupled with cost-effectiveness analysis and decision tree modeling will allow to improve current monitoring strategies by combining cardiac MRI, echocardiography, intravascular ultrasound and invasive tests (biopsy, catheter angiography) to provide the best outcome (quality of life days, mortality) and lowest cost for the individual cardiac transplant patient.",Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation,9229057,R01HL117888,"['Acute', 'Allografting', 'Ambulatory Care Facilities', 'Angiography', 'Area', 'Biopsy', 'Blood Vessels', 'Cardiac', 'Catheters', 'Cause of Death', 'Clinical', 'Clinical Research', 'Coronary', 'Coronary Angiography', 'Cost Effectiveness Analysis', 'Cost utility', 'Coupled', 'Data', 'Decision Modeling', 'Decision Trees', 'Detection', 'Diagnostic', 'Diagnostic tests', 'Diffuse', 'Disease', 'Early Diagnosis', 'Echocardiography', 'Edema', 'Evaluation', 'Event', 'Fibrosis', 'Follow-Up Studies', 'Functional disorder', 'Goals', 'Gold', 'Healthcare', 'Heart', 'Heart Transplantation', 'Impairment', 'Individual', 'Left', 'Life', 'Longitudinal Studies', 'Magnetic Resonance Imaging', 'Modality', 'Modeling', 'Monitor', 'Multimodal Imaging', 'Myocardial', 'Nature', 'Operative Surgical Procedures', 'Outcome', 'Patient Monitoring', 'Patients', 'Perfusion', 'Phase', 'Procedures', 'Protocols documentation', 'Quality of life', 'Reference Standards', 'Resources', 'Risk', 'Risk Factors', 'Sampling Errors', 'Savings', 'Sensitivity and Specificity', 'Standardization', 'Structure', 'Techniques', 'Testing', 'Thick', 'Time', 'Tissues', 'Transplant Recipients', 'Transplantation', 'Ultrasonography', 'Vascular Diseases', 'Visit', 'base', 'comparative cost effectiveness', 'cost', 'extracellular', 'follow-up', 'heart allograft', 'imaging study', 'improved', 'markov model', 'mortality', 'non-invasive imaging', 'novel', 'post intervention', 'public health relevance', 'standard of care', 'two-arm study']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R01,2017,680651,0.18959920460980523
"Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation DESCRIPTION (provided by applicant): Heart transplant (Tx) surgery is a well-established life-saving procedure, but is associated with post- interventional risks such as acute cardiac rejection (ACR) which is one of the leading causes of death in the first year after transplant. Beyond the first year, cardiac allograft vasculopathy (CAV) is the single greatest risk factor for 5-year mortality. Monitoring the patient for post-transplant events is thus paramount. The standard monitoring strategy, however, relies on frequent (12-16 monitoring nodes during year 1 alone) invasive and costly procedures including endomyocardial biopsies (EMB) and catheter angiography. Since EMB and catheter angiography have limited sensitivity due to sampling errors (ACR) or the diffuse nature of the disease (CAV), a reliable non-invasive alternative for the early detection of ACR and CAV would be desirable to reduce the need for invasive procedures, improve sensitivity, and reduce cost. We have recently developed and applied cardiac MRI techniques for the non-invasive assessment of myocardial edema (T2-mapping), diffuse fibrosis (pre- and post-contrast T1-mapping), myocardial velocities (tissue phase mapping), and microvascular quantitative perfusion. We have shown that these techniques can identify distinct regional structural and functional alterations in the heart that correlate with te status of the allograft. Based on these findings, a detailed cost-effective analysis using Markov modeling and decision tree analysis has demonstrated that cardiac MR has tremendous potential to reduce monitoring costs by 40-50% during the first year after Tx alone. This proposal builds on these promising findings and our aim is to develop an new 15-minute structure-function cardiac MRI protocol for the improved detection regional abnormalities associated with ACR (edema, fibrosis, dysfunction) and CAV (perfusion, dysfunction). Integration of MRI with echocardiography and intravascular Ultrasound (IVUS) will provide unique multi-modality assessment of the allograft. The application in a longitudinal clinical study coupled with state-of-the-art cost-effectiveness analysis will allow redefining the most effective post-Tx mixed monitoring strategy. The aim is to to help clinicians identify the optimal mixed monitoring strategy, i.e. the optimal combination of multi-modality imaging (structure-function MRI, echo, IVUS) and invasive procedures (EMB, catheter angiography) which provide best outcome (quality adjusted life days) and lowest cost for the individual cardiac transplant patient. PUBLIC HEALTH RELEVANCE: We propose to develop a multi-modality imaging protocol for the non-invasive characterization of tissue and function of the left and right heart in patients after heart transplantation. Our aim is to develop a new non- invasive 15 minute diagnostic test in order to provide a previously unattainable quantitative characterization of myocardial structure-function deficits in cardiac transplant patients. The application in a longitudinal clinial study coupled with cost-effectiveness analysis and decision tree modeling will allow to improve current monitoring strategies by combining cardiac MRI, echocardiography, intravascular ultrasound and invasive tests (biopsy, catheter angiography) to provide the best outcome (quality of life days, mortality) and lowest cost for the individual cardiac transplant patient.",Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation,9004651,R01HL117888,"['Acute', 'Allografting', 'Ambulatory Care Facilities', 'Angiography', 'Area', 'Biopsy', 'Blood Vessels', 'Cardiac', 'Catheters', 'Cause of Death', 'Clinical', 'Clinical Research', 'Coronary', 'Coronary Angiography', 'Cost Effectiveness Analysis', 'Cost utility', 'Coupled', 'Data', 'Decision Modeling', 'Decision Trees', 'Detection', 'Diagnostic', 'Diagnostic tests', 'Diffuse', 'Disease', 'Early Diagnosis', 'Echocardiography', 'Edema', 'Evaluation', 'Event', 'Fibrosis', 'Functional disorder', 'Goals', 'Gold', 'Health', 'Healthcare', 'Heart', 'Heart Transplantation', 'Impairment', 'Individual', 'Left', 'Life', 'Longitudinal Studies', 'Magnetic Resonance Imaging', 'Maps', 'Modality', 'Modeling', 'Monitor', 'Myocardial', 'Nature', 'Operative Surgical Procedures', 'Outcome', 'Patient Monitoring', 'Patients', 'Perfusion', 'Phase', 'Procedures', 'Protocols documentation', 'Quality of life', 'Reference Standards', 'Resources', 'Risk', 'Risk Factors', 'Risk Marker', 'Sampling Errors', 'Sensitivity and Specificity', 'Structure', 'Techniques', 'Testing', 'Thick', 'Time', 'Tissues', 'Transplant Recipients', 'Transplantation', 'Ultrasonography', 'Vascular Diseases', 'Visit', 'base', 'comparative', 'cost', 'cost effectiveness', 'extracellular', 'follow-up', 'heart allograft', 'imaging modality', 'improved', 'markov model', 'mortality', 'non-invasive imaging', 'novel', 'standard of care', 'two-arm study']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R01,2016,658634,0.18959920460980523
"Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation DESCRIPTION (provided by applicant): Heart transplant (Tx) surgery is a well-established life-saving procedure, but is associated with post- interventional risks such as acute cardiac rejection (ACR) which is one of the leading causes of death in the first year after transplant. Beyond the first year, cardiac allograft vasculopathy (CAV) is the single greatest risk factor for 5-year mortality. Monitoring the patient for post-transplant events is thus paramount. The standard monitoring strategy, however, relies on frequent (12-16 monitoring nodes during year 1 alone) invasive and costly procedures including endomyocardial biopsies (EMB) and catheter angiography. Since EMB and catheter angiography have limited sensitivity due to sampling errors (ACR) or the diffuse nature of the disease (CAV), a reliable non-invasive alternative for the early detection of ACR and CAV would be desirable to reduce the need for invasive procedures, improve sensitivity, and reduce cost. We have recently developed and applied cardiac MRI techniques for the non-invasive assessment of myocardial edema (T2-mapping), diffuse fibrosis (pre- and post-contrast T1-mapping), myocardial velocities (tissue phase mapping), and microvascular quantitative perfusion. We have shown that these techniques can identify distinct regional structural and functional alterations in the heart that correlate with te status of the allograft. Based on these findings, a detailed cost-effective analysis using Markov modeling and decision tree analysis has demonstrated that cardiac MR has tremendous potential to reduce monitoring costs by 40-50% during the first year after Tx alone. This proposal builds on these promising findings and our aim is to develop an new 15-minute structure-function cardiac MRI protocol for the improved detection regional abnormalities associated with ACR (edema, fibrosis, dysfunction) and CAV (perfusion, dysfunction). Integration of MRI with echocardiography and intravascular Ultrasound (IVUS) will provide unique multi-modality assessment of the allograft. The application in a longitudinal clinical study coupled with state-of-the-art cost-effectiveness analysis will allow redefining the most effective post-Tx mixed monitoring strategy. The aim is to to help clinicians identify the optimal mixed monitoring strategy, i.e. the optimal combination of multi-modality imaging (structure-function MRI, echo, IVUS) and invasive procedures (EMB, catheter angiography) which provide best outcome (quality adjusted life days) and lowest cost for the individual cardiac transplant patient. PUBLIC HEALTH RELEVANCE: We propose to develop a multi-modality imaging protocol for the non-invasive characterization of tissue and function of the left and right heart in patients after heart transplantation. Our aim is to develop a new non- invasive 15 minute diagnostic test in order to provide a previously unattainable quantitative characterization of myocardial structure-function deficits in cardiac transplant patients. The application in a longitudinal clinial study coupled with cost-effectiveness analysis and decision tree modeling will allow to improve current monitoring strategies by combining cardiac MRI, echocardiography, intravascular ultrasound and invasive tests (biopsy, catheter angiography) to provide the best outcome (quality of life days, mortality) and lowest cost for the individual cardiac transplant patient.",Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation,8797337,R01HL117888,"['Acute', 'Allografting', 'Ambulatory Care Facilities', 'Angiography', 'Area', 'Biopsy', 'Blood Vessels', 'Cardiac', 'Caring', 'Catheters', 'Cause of Death', 'Clinical', 'Clinical Research', 'Coronary', 'Coronary Angiography', 'Cost Effectiveness Analysis', 'Cost utility', 'Coupled', 'Data', 'Decision Modeling', 'Decision Trees', 'Detection', 'Diagnostic', 'Diagnostic tests', 'Diffuse', 'Disease', 'Early Diagnosis', 'Echocardiography', 'Edema', 'Evaluation', 'Event', 'Fibrosis', 'Functional disorder', 'Goals', 'Gold', 'Health', 'Healthcare', 'Heart', 'Heart Transplantation', 'Impairment', 'Individual', 'Left', 'Life', 'Longitudinal Studies', 'Magnetic Resonance Imaging', 'Maps', 'Modality', 'Modeling', 'Monitor', 'Myocardial', 'Nature', 'Operative Surgical Procedures', 'Outcome', 'Patient Monitoring', 'Patients', 'Perfusion', 'Phase', 'Procedures', 'Protocols documentation', 'Quality of life', 'Reference Standards', 'Resources', 'Risk', 'Risk Factors', 'Risk Marker', 'Sampling Errors', 'Sensitivity and Specificity', 'Structure', 'Techniques', 'Testing', 'Thick', 'Time', 'Tissues', 'Transplant Recipients', 'Transplantation', 'Ultrasonography', 'Vascular Diseases', 'Visit', 'base', 'comparative', 'cost', 'cost effectiveness', 'extracellular', 'follow-up', 'heart allograft', 'imaging modality', 'improved', 'markov model', 'mortality', 'non-invasive imaging', 'novel', 'two-arm study']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R01,2015,596707,0.18959920460980523
"Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation  SUMMARY / ABSTRACT Heart transplant (Tx) surgery is a well-established life-saving procedure, but is associated with post- interventional risks such as acute cardiac rejection (ACR) which is one of the leading causes of death in the first year after transplant. Beyond the first year, cardiac allograft vasculopathy (CAV) is the single greatest risk factor for 5-year mortality. Monitoring the patient for post-transplant events is thus paramount. The standard monitoring strategy, however, relies on frequent (12-16 monitoring nodes during year 1 alone) invasive and costly procedures including endomyocardial biopsies (EMB) and catheter angiography. Since EMB and catheter angiography have limited sensitivity due to sampling errors (ACR) or the diffuse nature of the disease (CAV), a reliable non-invasive alternative for the early detection of ACR and CAV would be desirable to reduce the need for invasive procedures, improve sensitivity, and reduce cost. We have recently developed and applied cardiac MRI techniques for the non-invasive assessment of myocardial edema (T2-mapping), diffuse fibrosis (pre- and post-contrast T1-mapping), myocardial velocities (tissue phase mapping), and microvascular quantitative perfusion. We have shown that these techniques can identify distinct regional structural and functional alterations in the heart that correlate with the status of the allograft. Based on these findings, a detailed cost-effective analysis using Markov modeling and decision tree analysis has demonstrated that cardiac MR has tremendous potential to reduce monitoring costs by 40-50% during the first year after Tx alone. This proposal builds on these promising findings and our aim is to develop an new 15-minute structure-function cardiac MRI protocol for the improved detection regional abnormalities associated with ACR (edema, fibrosis, dysfunction) and CAV (perfusion, dysfunction). Integration of MRI with echocardiography and intravascular Ultrasound (IVUS) will provide unique multi-modality assessment of the allograft. The application in a longitudinal clinical study coupled with state-of-the-art cost-effectiveness analysis will allow redefining the most effective post-Tx mixed monitoring strategy. The aim is to to help clinicians identify the optimal mixed monitoring strategy, i.e. the optimal combination of multi-modality imaging (structure-function MRI, echo, IVUS) and invasive procedures (EMB, catheter angiography) which provide best outcome (quality adjusted life days) and lowest cost for the individual cardiac transplant patient. PUBLIC HEALTH RELEVANCE: We propose to develop a multi-modality imaging protocol for the non-invasive characterization of tissue and function of the left and right heart in patients after heart transplantation. Our aim is to develop a new non- invasive 15 minute diagnostic test in order to provide a previously unattainable quantitative characterization of myocardial structure-function deficits in cardiac transplant patients. The application in a longitudinal clinial study coupled with cost-effectiveness analysis and decision tree modeling will allow to improve current monitoring strategies by combining cardiac MRI, echocardiography, intravascular ultrasound and invasive tests (biopsy, catheter angiography) to provide the best outcome (quality of life days, mortality) and lowest cost for the individual cardiac transplant patient.            ",Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation,8630169,R01HL117888,"['Acute', 'Allografting', 'Ambulatory Care Facilities', 'Angiography', 'Area', 'Biopsy', 'Blood Vessels', 'Cardiac', 'Caring', 'Catheters', 'Cause of Death', 'Clinical', 'Clinical Research', 'Coronary', 'Coronary Angiography', 'Cost Effectiveness Analysis', 'Coupled', 'Data', 'Decision Modeling', 'Decision Trees', 'Detection', 'Diagnostic', 'Diagnostic tests', 'Diffuse', 'Disease', 'Early Diagnosis', 'Echocardiography', 'Edema', 'Evaluation', 'Event', 'Fibrosis', 'Functional disorder', 'Goals', 'Gold', 'Healthcare', 'Heart', 'Heart Transplantation', 'Image', 'Impairment', 'Individual', 'Left', 'Life', 'Longitudinal Studies', 'Magnetic Resonance Imaging', 'Maps', 'Modality', 'Modeling', 'Monitor', 'Myocardial', 'Nature', 'Operative Surgical Procedures', 'Outcome', 'Patient Monitoring', 'Patients', 'Perfusion', 'Phase', 'Procedures', 'Protocols documentation', 'Quality of life', 'Reference Standards', 'Resources', 'Risk', 'Risk Factors', 'Risk Marker', 'Sampling Errors', 'Sensitivity and Specificity', 'Structure', 'Techniques', 'Testing', 'Thick', 'Time', 'Tissues', 'Transplant Recipients', 'Transplantation', 'Ultrasonography', 'Vascular Diseases', 'Visit', 'base', 'comparative', 'cost', 'cost effectiveness', 'extracellular', 'follow-up', 'heart allograft', 'imaging modality', 'improved', 'markov model', 'mortality', 'non-invasive imaging', 'novel', 'public health relevance', 'two-arm study']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R01,2014,467351,0.18959920460980523
"CHRiSS: Cardiac Health Risk Stratification System     DESCRIPTION (provided by applicant): SUMMARY This project aims to produce and beta-test a clinical decision support application for end- stage heart failure, titled CHRiSS: Cardiac Health Risk Stratification System. It will be designed for patients with progressive heart failure who may eventually become candidates for ventricular assist device (VAD) therapy. The software will be build upon existing machine learning and data mining technology, developed by the PI and colleagues, designed to predict 90-day mortality following VAD implantation. This Phase- 1 effort will entail development of graphic user interfaces for both patients and clinicians to incorporate personalized prognostic information into a functional decision-support utility. The inference algorithm will also be expanded to encompass adverse events, and risk of readmission. In this Phase-1 feasibility project, CHRiSS will be programmed and beta-tested at West Penn Allegheny Health System (WPAHS). This will entail semi- structured interviews to collect relevant expert knowledge, and mining the electronic medical records (EMR) to calibrate the prognostic algorithm to the institution-specific data. Successful completion of this Phase I project will lead to a multi-center trial in which the software is fully validated. Ultimate succes of this project will result in a software application that will optimize the benefit of VAD therapy to public health, while reducing cost by reducing the unacceptably high rate of adverse events and unnecessary readmissions.         PUBLIC HEALTH RELEVANCE: Narrative Heart-assist devices are becoming more commonly used to treat people with severe cardiac failure - who otherwise have few options to return to a normal life. It is estimated that tens of thousands of Americans could benefit from this therapy annually; however, only a few thousand are performed per year. This project aims to develop a software application to better inform patients and doctors about the risks and benefits of this therapy. It will assist patients and doctors to work together when weighing options - with respect to both survival and quality of life. The long-term benefits would be to improve the efficiency of delivering this therapy, thereby reducing the cost, and expanding its distribution to the many people that need it.            ",CHRiSS: Cardiac Health Risk Stratification System,8592756,R41HL120428,"['Address', 'Adoption', 'Adverse event', 'Algorithms', 'American', 'Benefits and Risks', 'Businesses', 'Cardiac', 'Caring', 'Clinical', 'Communication', 'Computer software', 'Computerized Medical Record', 'Cost Effectiveness Analysis', 'Cost Savings', 'Data', 'Development', 'Diagnosis', 'Education', 'Evaluation', 'Event', 'Feasibility Studies', 'Foundations', 'Guidelines', 'Health', 'Health Care Costs', 'Health system', 'Heart failure', 'Heart-Assist Devices', 'Hospitals', 'Incidence', 'Institution', 'Intensive Care', 'Interview', 'Knowledge', 'Lead', 'Length of Stay', 'Life', 'Life Style', 'Machine Learning', 'Marketing', 'Medical', 'Medicare', 'Methods', 'Metric', 'Mining', 'Modeling', 'Needs Assessment', 'Outcome', 'Outpatients', 'Patients', 'Phase', 'Postoperative Period', 'Public Health', 'Quality of life', 'Risk', 'Savings', 'Software Tools', 'Staging', 'Stratification', 'Structure', 'System', 'Technology', 'Testing', 'Update', 'Work', 'computer human interaction', 'cost', 'data mining', 'design', 'graphical user interface', 'implantation', 'improved', 'mortality', 'outcome forecast', 'patient population', 'preference', 'prognostic', 'programs', 'prototype', 'public health relevance', 'satisfaction', 'success', 'tool', 'trend', 'usability', 'ventricular assist device']",NHLBI,BLENDERHOUSE,R41,2013,150000,0.062023648570272365
"New generation of catheters for treatment of atrial fibrillation     DESCRIPTION (provided by applicant) Atrial fibrillation (AF) remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity & mortality primarily due to poor hemodynamics and often stroke. One of the main options to treat atrial fibrillation is to ablate abnormal sources of electrical activity using percutaneous radiofrequency (RF) catheters. RF lesions isolate the spread of abnormal electrical activity from various sites in the heart including the pulmonary veins. As a result, a cornerstone of therapy in AF ablation procedures is to electrically isolate the pulmonary veins (PVs) with RF lesions, essentially creating an electrical barrier between the arrhythmogenic foci inside the PVs and the rest of the heart. Often the cardiologist over- ablates or under-ablates leaving gaps which can still transmit the abnormal electrical activity to the rest of the heart. To date, there are limited means for real-time monitoring of tissue injury during RF ablation procedures and there are no means of directly visualizing ablated cardiac tissue to distinguish it from viable conducting tissue. Here we propose to create a new generation of imaging catheters to distinguish normal cardiac tissue from ablated cardiac tissue in real time. They operate based on spectral changes in tissue autofluorescence caused by thermal damage. Specifically, in Phase II we will expand the design of our current, 1st generation catheter, that relied on acquiring emission from a single spectral band, to include acquisition from multiple emission bands within an autofluorescence range of 380-600nm and to use post-acquisition analysis to reveal thermal damage to layers of endocardial collagen and underlying atrial muscle. The UV multispectral catheter will be then used to examine and visualize percutaneous RF ablation lesions in live large animals such as pigs. We also test on freshly excised donated human atrial tissue. The catheter will undergo extensive documentation, verification, and validation in order to be approved for use in a human study. Manufacturing process instructions will be developed and reviewed by the manufacturing partners who will construct, package, and sterilize the various catheter components. We will work with our clinical partners to develop a human study protocol, and will develop informed consent documentation, instructions for use, and other documentation necessary for ethics review and FDA approval. At the end of Phase II we aim to have a fully functional, statistically tested 12 Fr multispectral imaging catheter, approved and ready for first-in-man studies. Our ultimate long term goal is to develop a new generation of ablation catheters enabling real-time visualization of ablated cardiac tissue. This technology will pave the way for easier, faster, safer, more cost- effective, more reliable and minimally invasive AF ablation procedures by allowing cardiologists to see in real time if lesions are complete or if there are gaps that need to be filled in. in the case of a patient who has a recurrence post-ablation, the catheter will be used to quickly and efficiently identify where the gap is if one exists. PUBLIC HEALTH RELEVANCE: Atrial fibrillation is a major health concern and a primary cause of stroke and thromboembolism. Percutaneous cardiac catheter ablation is currently used to treat atrial fibrillation in order to eliminate a lifelong multidrug regimen but its main limitaion is high recurrence rate due to poor intra-procedural ablation monitoring and the inability to visualize lesions directly. We propose to develop and commercialize a new generation of imaging catheters that enable direct real-time visualization of radiofrequency ablation lesions to achieve safer, faster, cheaper, and more reliable atrial fibrillation ablation therapy. .",New generation of catheters for treatment of atrial fibrillation,9330903,R42HL120511,"['Ablation', 'Adhesives', 'Algorithmic Analysis', 'Animals', 'Arrhythmia', 'Atrial Fibrillation', 'Back', 'Blood', 'Cardiac', 'Cardiac ablation', 'Cartoons', 'Catheters', 'Chest', 'Clinical', 'Collagen', 'Documentation', 'Equilibrium', 'Ethics', 'Family suidae', 'Generations', 'Goals', 'Gray unit of radiation dose', 'Health', 'Heart', 'Heart Atrium', 'Human', 'Image', 'Image Analysis', 'Imagery', 'Individual', 'Industry', 'Informed Consent', 'Injury', 'Instruction', 'Lesion', 'Libraries', 'Light', 'Lighting', 'Medical Device', 'Metals', 'Monitor', 'Morbidity - disease rate', 'Muscle', 'Optics', 'Outcome', 'Pathology', 'Patients', 'Phase', 'Physicians', 'Plasticizers', 'Plastics', 'Principal Component Analysis', 'Procedures', 'Protocols documentation', 'Pulmonary veins', 'Quality of life', 'Radiofrequency Catheter Ablation', 'Radiofrequency Interstitial Ablation', 'Recurrence', 'Regimen', 'Reporting', 'Rest', 'Site', 'Source', 'Speed', 'Stroke', 'System', 'Technology', 'Testing', 'Thromboembolism', 'Time', 'Tissues', 'UV sensitive', 'Ultraviolet Rays', 'Work', 'authority', 'base', 'charge coupled device camera', 'cost effective', 'data acquisition', 'design', 'experimental study', 'hemodynamics', 'human study', 'image reconstruction', 'imaging capabilities', 'man', 'manufacturing process', 'minimally invasive', 'mortality', 'prototype', 'public health relevance', 'radiofrequency', 'software development', 'verification and validation']",NHLBI,"NOCTURNAL PRODUCT DEVELOPMENT, LLC",R42,2017,1100322,0.11493617233781532
"New generation of catheters for treatment of atrial fibrillation     DESCRIPTION (provided by applicant) Atrial fibrillation (AF) remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity & mortality primarily due to poor hemodynamics and often stroke. One of the main options to treat atrial fibrillation is to ablate abnormal sources of electrical activity using percutaneous radiofrequency (RF) catheters. RF lesions isolate the spread of abnormal electrical activity from various sites in the heart including the pulmonary veins. As a result, a cornerstone of therapy in AF ablation procedures is to electrically isolate the pulmonary veins (PVs) with RF lesions, essentially creating an electrical barrier between the arrhythmogenic foci inside the PVs and the rest of the heart. Often the cardiologist over- ablates or under-ablates leaving gaps which can still transmit the abnormal electrical activity to the rest of the heart. To date, there are limited means for real-time monitoring of tissue injury during RF ablation procedures and there are no means of directly visualizing ablated cardiac tissue to distinguish it from viable conducting tissue. Here we propose to create a new generation of imaging catheters to distinguish normal cardiac tissue from ablated cardiac tissue in real time. They operate based on spectral changes in tissue autofluorescence caused by thermal damage. Specifically, in Phase II we will expand the design of our current, 1st generation catheter, that relied on acquiring emission from a single spectral band, to include acquisition from multiple emission bands within an autofluorescence range of 380-600nm and to use post-acquisition analysis to reveal thermal damage to layers of endocardial collagen and underlying atrial muscle. The UV multispectral catheter will be then used to examine and visualize percutaneous RF ablation lesions in live large animals such as pigs. We also test on freshly excised donated human atrial tissue. The catheter will undergo extensive documentation, verification, and validation in order to be approved for use in a human study. Manufacturing process instructions will be developed and reviewed by the manufacturing partners who will construct, package, and sterilize the various catheter components. We will work with our clinical partners to develop a human study protocol, and will develop informed consent documentation, instructions for use, and other documentation necessary for ethics review and FDA approval. At the end of Phase II we aim to have a fully functional, statistically tested 12 Fr multispectral imaging catheter, approved and ready for first-in-man studies. Our ultimate long term goal is to develop a new generation of ablation catheters enabling real-time visualization of ablated cardiac tissue. This technology will pave the way for easier, faster, safer, more cost- effective, more reliable and minimally invasive AF ablation procedures by allowing cardiologists to see in real time if lesions are complete or if there are gaps that need to be filled in. in the case of a patient who has a recurrence post-ablation, the catheter will be used to quickly and efficiently identify where the gap is if one exists.         PUBLIC HEALTH RELEVANCE: Atrial fibrillation is a major health concern and a primary cause of stroke and thromboembolism. Percutaneous cardiac catheter ablation is currently used to treat atrial fibrillation in order to eliminate a lifelong multidrug regimen but its main limitaion is high recurrence rate due to poor intra-procedural ablation monitoring and the inability to visualize lesions directly. We propose to develop and commercialize a new generation of imaging catheters that enable direct real-time visualization of radiofrequency ablation lesions to achieve safer, faster, cheaper, and more reliable atrial fibrillation ablation therapy. .                ",New generation of catheters for treatment of atrial fibrillation,9048079,R42HL120511,"['Ablation', 'Adhesives', 'Algorithms', 'Animals', 'Arrhythmia', 'Atrial Fibrillation', 'Back', 'Blood', 'Cardiac', 'Cardiac ablation', 'Cartoons', 'Catheters', 'Chest', 'Clinical', 'Collagen', 'Documentation', 'Equilibrium', 'Ethics', 'Family suidae', 'Generations', 'Goals', 'Gray unit of radiation dose', 'Health', 'Heart', 'Heart Atrium', 'Human', 'Image', 'Image Analysis', 'Imagery', 'Individual', 'Industry', 'Informed Consent', 'Injury', 'Instruction', 'Left', 'Lesion', 'Libraries', 'Life', 'Light', 'Lighting', 'Medical Device', 'Metals', 'Monitor', 'Morbidity - disease rate', 'Muscle', 'Optics', 'Outcome', 'Pathology', 'Patients', 'Phase', 'Physicians', 'Principal Component Analysis', 'Procedures', 'Protocols documentation', 'Pulmonary veins', 'Qualifying', 'Quality of life', 'Radiofrequency Catheter Ablation', 'Radiofrequency Interstitial Ablation', 'Recurrence', 'Regimen', 'Reporting', 'Rest', 'Site', 'Source', 'Speed', 'Stroke', 'System', 'Technology', 'Testing', 'Thromboembolism', 'Time', 'Tissues', 'UV sensitive', 'Ultraviolet Rays', 'Work', 'authority', 'base', 'charge coupled device camera', 'cost effective', 'data acquisition', 'design', 'hemodynamics', 'human study', 'man', 'manufacturing process', 'meetings', 'minimally invasive', 'mortality', 'prototype', 'public health relevance', 'radiofrequency', 'research study', 'software development', 'verification and validation']",NHLBI,"NOCTURNAL PRODUCT DEVELOPMENT, LLC",R42,2016,1173082,0.11493617233781532
"Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data DESCRIPTION (provided by applicant): In-hospital cardiac arrest (IHCA) is a significant public health problem, afflicting over 200,000 patients in the United States annually with a mortality rate of approximately 80%. The majority of these patients show signs of clinical deterioration in the hours before the event. This has led to the development of vital sign-based early warning scores designed to detect high-risk patients before IHCA to trigger life-saving interventions. However, the vast majority of these risk scores were created subjectively in individual hospitals and have shown limited accuracy for detecting adverse outcomes. Developing an accurate risk score to detect patients at highest risk of IHCA is essential to decreasing preventable in-hospital death. In my prior work, I completed several studies investigating the accuracy of vital signs for predicting IHCA. These studies, previous literature, and my preliminary data have resulted in the following conclusions: 1) statistically developed risk scores are more accurate than previously published risk scores, 2) multicenter data is needed to create the most accurate and generalizable risk score, 3) additional data, such as laboratory results, will likely improve the accuracy of risk scores, and 4) a cutting-edge method for developing prediction models, called machine learning, may result in more accurate risk scores. Importantly, significant improvement in accuracy leads to better identification of patients at highest risk of IHCA and decreased resource utilization. Therefore, in this grant proposal I aim to develop and validate IHCA prediction models using different statistical techniques in a multicenter database and then estimate the impact of the most accurate risk score using simulation studies. I will do this by firt developing prediction models using classic survival analysis methods (Aim 1a) and machine learning methods, such as neural networks and decision trees (Aim 1b). Then, I will compare the models I develop to the most accurate previously published risk scores in Aim 2. Finally, I will investigate the impact of the most accurate model from Aim 2 on patient outcomes using simulation modeling (Aim 3). Completion of this proposal will result in a validated IHCA risk score that can be implemented in the electronic health record to trigger life- saving interventions to decrease preventable in-hospital death. In addition, this career development award will provide critical data to inform future R01-level awards, including a clinical trial to investigate he impact of the developed prediction model on patient outcomes. I will complete this project under the direct supervision of my mentor (Dr. David Meltzer), co-mentor (Dr. Dana Edelson), and the rest of my advisory team (Drs. Jesse Hall, Robert Gibbons, and Michael Kattan). Together, this multidisciplinary team brings nationally renowned expertise in in-hospital cardiac arrest, outcomes research, critical care, and clinical prediction modeling. In addition, they serve as Chairs of the Section of Hospital Medicine (Dr. Meltzer), Section of Pulmonary and Critical Care (Dr. Hall), and Quantitative Health Sciences at the Cleveland Clinic (Dr. Kattan), and Directors of the Center for Health and the Social Sciences (Dr. Meltzer), Center for Health Statistics (Dr. Gibbons), and Clinical Research for the Emergency Resuscitation Center (Dr. Edelson). The mentorship, expertise, and resources that they provide will ensure my success as I grow into an independent physician-scientist. My career goal is to become an independent critical care outcomes researcher with a focus on developing prediction models for clinical deterioration that will improve patient outcomes. To accomplish this long-term goal, I have three short-term goals: (1) to gain expertise in the development and implementation of clinical prediction models, (2) to create an IHCA prediction model that will identify high-risk patients on the wards to trigger life-saving interventions, and (3) to gain expertise in simulation modeling in order to study the impact of the developed prediction model. To accomplish these goals, I will build upon the foundation I developed when earning my Master's Degree in Public Health and during my initial training in the PhD program in the Department of Health Studies. Although my training to date has provided me with a strong background in epidemiology and biostatistics, further advanced training in biostatistics is crucial for my development into a successful independent researcher. An integrated program of didactic coursework, seminars, research activities, and conference participation will span the duration of the award. By accomplishing my three short- term goals, I will develop unique skills that will allow me to become a successful independent researcher. Specifically, the expertise I will gain in prediction model development, implementation, and simulation modeling can be applied not only to IHCA research but also to other areas of critical care medicine. In addition, completion of these goals will result in a validated IHCA prediction model that I will study in future implementation and cost-effectiveness studies and will serve as a basis for future R01-level grant submissions. PUBLIC HEALTH RELEVANCE: Over 200,000 in-hospital cardiac arrests occur in the United States each year, and studies suggest that many of these events may be preventable if the clinical warning signs can be identified and acted upon quickly. However, the vast majority of tools used to identify patients at high risk of cardiac arrest were created subjectively and have limited accuracy. Development of a statistically derived risk tool is essential to detect at- risk patients accurately and early in order to provide the best opportunity to improve patient outcomes and reduce preventable in-hospital death.",Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data,9393346,K08HL121080,"['Adult', 'Advisory Committees', 'Applications Grants', 'Area', 'Award', 'Biological Neural Networks', 'Biometry', 'Brain', 'Case-Control Studies', 'Categories', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Research', 'Clinical Trials', 'Complex', 'Critical Care', 'Data', 'Data Analyses', 'Data Set', 'Databases', 'Decision Trees', 'Deterioration', 'Development', 'Diastolic blood pressure', 'Doctor of Philosophy', 'Early Diagnosis', 'Electronic Health Record', 'Emergency research', 'Ensure', 'Epidemiology', 'Event', 'Foundations', 'Frequencies', 'Future', 'Goals', 'Grant', 'Health', 'Health Sciences', 'Heart Arrest', 'Hospitalization', 'Hospitals', 'Hour', 'Hylobates Genus', 'Individual', 'Intensive Care Units', 'Intervention', 'Investigation', 'K-Series Research Career Programs', 'Laboratories', 'Life', 'Literature', 'Lung', 'Machine Learning', 'Master&apos', 's Degree', 'Medicine', 'Mentors', 'Mentorship', 'Methods', 'Modeling', 'Outcome', 'Outcomes Research', 'Patient Discharge', 'Patient risk', 'Patient-Focused Outcomes', 'Patients', 'Physicians', 'Procedures', 'Public Health', 'Publishing', 'Receiver Operating Characteristics', 'Reporting', 'Research', 'Research Activity', 'Research Personnel', 'Resources', 'Rest', 'Resuscitation', 'Risk', 'Savings', 'Scientist', 'Sensitivity and Specificity', 'Social Sciences', 'Statistical Methods', 'Statistical Models', 'Supervision', 'Survival Analysis', 'Techniques', 'Testing', 'Time', 'Training', 'Uncertainty', 'United States', 'Update', 'Validation', 'Work', 'adverse outcome', 'base', 'care outcomes', 'career', 'clinical implementation', 'cost effectiveness', 'design', 'evidence base', 'high risk', 'implementation strategy', 'improved', 'learning strategy', 'model development', 'models and simulation', 'mortality', 'multidisciplinary', 'predictive modeling', 'programs', 'public health relevance', 'simulation', 'skills', 'statistics', 'success', 'symposium', 'tool', 'ward']",NHLBI,UNIVERSITY OF CHICAGO,K08,2018,163944,0.08567341434377553
"Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data DESCRIPTION (provided by applicant): In-hospital cardiac arrest (IHCA) is a significant public health problem, afflicting over 200,000 patients in the United States annually with a mortality rate of approximately 80%. The majority of these patients show signs of clinical deterioration in the hours before the event. This has led to the development of vital sign-based early warning scores designed to detect high-risk patients before IHCA to trigger life-saving interventions. However, the vast majority of these risk scores were created subjectively in individual hospitals and have shown limited accuracy for detecting adverse outcomes. Developing an accurate risk score to detect patients at highest risk of IHCA is essential to decreasing preventable in-hospital death. In my prior work, I completed several studies investigating the accuracy of vital signs for predicting IHCA. These studies, previous literature, and my preliminary data have resulted in the following conclusions: 1) statistically developed risk scores are more accurate than previously published risk scores, 2) multicenter data is needed to create the most accurate and generalizable risk score, 3) additional data, such as laboratory results, will likely improve the accuracy of risk scores, and 4) a cutting-edge method for developing prediction models, called machine learning, may result in more accurate risk scores. Importantly, significant improvement in accuracy leads to better identification of patients at highest risk of IHCA and decreased resource utilization. Therefore, in this grant proposal I aim to develop and validate IHCA prediction models using different statistical techniques in a multicenter database and then estimate the impact of the most accurate risk score using simulation studies. I will do this by firt developing prediction models using classic survival analysis methods (Aim 1a) and machine learning methods, such as neural networks and decision trees (Aim 1b). Then, I will compare the models I develop to the most accurate previously published risk scores in Aim 2. Finally, I will investigate the impact of the most accurate model from Aim 2 on patient outcomes using simulation modeling (Aim 3). Completion of this proposal will result in a validated IHCA risk score that can be implemented in the electronic health record to trigger life- saving interventions to decrease preventable in-hospital death. In addition, this career development award will provide critical data to inform future R01-level awards, including a clinical trial to investigate he impact of the developed prediction model on patient outcomes. I will complete this project under the direct supervision of my mentor (Dr. David Meltzer), co-mentor (Dr. Dana Edelson), and the rest of my advisory team (Drs. Jesse Hall, Robert Gibbons, and Michael Kattan). Together, this multidisciplinary team brings nationally renowned expertise in in-hospital cardiac arrest, outcomes research, critical care, and clinical prediction modeling. In addition, they serve as Chairs of the Section of Hospital Medicine (Dr. Meltzer), Section of Pulmonary and Critical Care (Dr. Hall), and Quantitative Health Sciences at the Cleveland Clinic (Dr. Kattan), and Directors of the Center for Health and the Social Sciences (Dr. Meltzer), Center for Health Statistics (Dr. Gibbons), and Clinical Research for the Emergency Resuscitation Center (Dr. Edelson). The mentorship, expertise, and resources that they provide will ensure my success as I grow into an independent physician-scientist. My career goal is to become an independent critical care outcomes researcher with a focus on developing prediction models for clinical deterioration that will improve patient outcomes. To accomplish this long-term goal, I have three short-term goals: (1) to gain expertise in the development and implementation of clinical prediction models, (2) to create an IHCA prediction model that will identify high-risk patients on the wards to trigger life-saving interventions, and (3) to gain expertise in simulation modeling in order to study the impact of the developed prediction model. To accomplish these goals, I will build upon the foundation I developed when earning my Master's Degree in Public Health and during my initial training in the PhD program in the Department of Health Studies. Although my training to date has provided me with a strong background in epidemiology and biostatistics, further advanced training in biostatistics is crucial for my development into a successful independent researcher. An integrated program of didactic coursework, seminars, research activities, and conference participation will span the duration of the award. By accomplishing my three short- term goals, I will develop unique skills that will allow me to become a successful independent researcher. Specifically, the expertise I will gain in prediction model development, implementation, and simulation modeling can be applied not only to IHCA research but also to other areas of critical care medicine. In addition, completion of these goals will result in a validated IHCA prediction model that I will study in future implementation and cost-effectiveness studies and will serve as a basis for future R01-level grant submissions. PUBLIC HEALTH RELEVANCE: Over 200,000 in-hospital cardiac arrests occur in the United States each year, and studies suggest that many of these events may be preventable if the clinical warning signs can be identified and acted upon quickly. However, the vast majority of tools used to identify patients at high risk of cardiac arrest were created subjectively and have limited accuracy. Development of a statistically derived risk tool is essential to detect at- risk patients accurately and early in order to provide the best opportunity to improve patient outcomes and reduce preventable in-hospital death.",Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data,9198041,K08HL121080,"['Adult', 'Advisory Committees', 'Applications Grants', 'Area', 'Award', 'Biological Neural Networks', 'Biometry', 'Brain', 'Case-Control Studies', 'Categories', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Research', 'Clinical Trials', 'Complex', 'Critical Care', 'Data', 'Data Analyses', 'Data Set', 'Databases', 'Decision Trees', 'Deterioration', 'Development', 'Diastolic blood pressure', 'Doctor of Philosophy', 'Early Diagnosis', 'Electronic Health Record', 'Emergency research', 'Ensure', 'Epidemiology', 'Event', 'Foundations', 'Frequencies', 'Future', 'Goals', 'Grant', 'Health', 'Health Sciences', 'Heart Arrest', 'Hospitalization', 'Hospitals', 'Hour', 'Hylobates Genus', 'Individual', 'Intensive Care Units', 'Intervention', 'Investigation', 'K-Series Research Career Programs', 'Laboratories', 'Life', 'Literature', 'Lung', 'Machine Learning', 'Master&apos', 's Degree', 'Medicine', 'Mentors', 'Mentorship', 'Methods', 'Modeling', 'Outcome', 'Outcomes Research', 'Patient Discharge', 'Patient risk', 'Patient-Focused Outcomes', 'Patients', 'Physicians', 'Procedures', 'Public Health', 'Publishing', 'Receiver Operating Characteristics', 'Reporting', 'Research', 'Research Activity', 'Research Personnel', 'Resources', 'Rest', 'Resuscitation', 'Risk', 'Savings', 'Scientist', 'Sensitivity and Specificity', 'Social Sciences', 'Statistical Methods', 'Statistical Models', 'Supervision', 'Survival Analysis', 'Techniques', 'Testing', 'Time', 'Training', 'Uncertainty', 'United States', 'Update', 'Validation', 'Work', 'adverse outcome', 'base', 'career', 'cost effectiveness', 'design', 'evidence base', 'high risk', 'improved', 'learning strategy', 'model development', 'models and simulation', 'mortality', 'multidisciplinary', 'predictive modeling', 'programs', 'public health relevance', 'simulation', 'skills', 'statistics', 'success', 'symposium', 'tool', 'ward']",NHLBI,UNIVERSITY OF CHICAGO,K08,2017,163944,0.08567341434377553
"Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data DESCRIPTION (provided by applicant): In-hospital cardiac arrest (IHCA) is a significant public health problem, afflicting over 200,000 patients in the United States annually with a mortality rate of approximately 80%. The majority of these patients show signs of clinical deterioration in the hours before the event. This has led to the development of vital sign-based early warning scores designed to detect high-risk patients before IHCA to trigger life-saving interventions. However, the vast majority of these risk scores were created subjectively in individual hospitals and have shown limited accuracy for detecting adverse outcomes. Developing an accurate risk score to detect patients at highest risk of IHCA is essential to decreasing preventable in-hospital death. In my prior work, I completed several studies investigating the accuracy of vital signs for predicting IHCA. These studies, previous literature, and my preliminary data have resulted in the following conclusions: 1) statistically developed risk scores are more accurate than previously published risk scores, 2) multicenter data is needed to create the most accurate and generalizable risk score, 3) additional data, such as laboratory results, will likely improve the accuracy of risk scores, and 4) a cutting-edge method for developing prediction models, called machine learning, may result in more accurate risk scores. Importantly, significant improvement in accuracy leads to better identification of patients at highest risk of IHCA and decreased resource utilization. Therefore, in this grant proposal I aim to develop and validate IHCA prediction models using different statistical techniques in a multicenter database and then estimate the impact of the most accurate risk score using simulation studies. I will do this by firt developing prediction models using classic survival analysis methods (Aim 1a) and machine learning methods, such as neural networks and decision trees (Aim 1b). Then, I will compare the models I develop to the most accurate previously published risk scores in Aim 2. Finally, I will investigate the impact of the most accurate model from Aim 2 on patient outcomes using simulation modeling (Aim 3). Completion of this proposal will result in a validated IHCA risk score that can be implemented in the electronic health record to trigger life- saving interventions to decrease preventable in-hospital death. In addition, this career development award will provide critical data to inform future R01-level awards, including a clinical trial to investigate he impact of the developed prediction model on patient outcomes. I will complete this project under the direct supervision of my mentor (Dr. David Meltzer), co-mentor (Dr. Dana Edelson), and the rest of my advisory team (Drs. Jesse Hall, Robert Gibbons, and Michael Kattan). Together, this multidisciplinary team brings nationally renowned expertise in in-hospital cardiac arrest, outcomes research, critical care, and clinical prediction modeling. In addition, they serve as Chairs of the Section of Hospital Medicine (Dr. Meltzer), Section of Pulmonary and Critical Care (Dr. Hall), and Quantitative Health Sciences at the Cleveland Clinic (Dr. Kattan), and Directors of the Center for Health and the Social Sciences (Dr. Meltzer), Center for Health Statistics (Dr. Gibbons), and Clinical Research for the Emergency Resuscitation Center (Dr. Edelson). The mentorship, expertise, and resources that they provide will ensure my success as I grow into an independent physician-scientist. My career goal is to become an independent critical care outcomes researcher with a focus on developing prediction models for clinical deterioration that will improve patient outcomes. To accomplish this long-term goal, I have three short-term goals: (1) to gain expertise in the development and implementation of clinical prediction models, (2) to create an IHCA prediction model that will identify high-risk patients on the wards to trigger life-saving interventions, and (3) to gain expertise in simulation modeling in order to study the impact of the developed prediction model. To accomplish these goals, I will build upon the foundation I developed when earning my Master's Degree in Public Health and during my initial training in the PhD program in the Department of Health Studies. Although my training to date has provided me with a strong background in epidemiology and biostatistics, further advanced training in biostatistics is crucial for my development into a successful independent researcher. An integrated program of didactic coursework, seminars, research activities, and conference participation will span the duration of the award. By accomplishing my three short- term goals, I will develop unique skills that will allow me to become a successful independent researcher. Specifically, the expertise I will gain in prediction model development, implementation, and simulation modeling can be applied not only to IHCA research but also to other areas of critical care medicine. In addition, completion of these goals will result in a validated IHCA prediction model that I will study in future implementation and cost-effectiveness studies and will serve as a basis for future R01-level grant submissions. PUBLIC HEALTH RELEVANCE: Over 200,000 in-hospital cardiac arrests occur in the United States each year, and studies suggest that many of these events may be preventable if the clinical warning signs can be identified and acted upon quickly. However, the vast majority of tools used to identify patients at high risk of cardiac arrest were created subjectively and have limited accuracy. Development of a statistically derived risk tool is essential to detect at- risk patients accurately and early in order to provide the best opportunity to improve patient outcomes and reduce preventable in-hospital death.",Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data,8984911,K08HL121080,"['Adult', 'Advisory Committees', 'Applications Grants', 'Area', 'Award', 'Biological Neural Networks', 'Biometry', 'Brain', 'Case-Control Studies', 'Categories', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Research', 'Clinical Trials', 'Complex', 'Critical Care', 'Data', 'Data Set', 'Databases', 'Decision Trees', 'Deterioration', 'Development', 'Diastolic blood pressure', 'Doctor of Philosophy', 'Early Diagnosis', 'Electronic Health Record', 'Emergency Situation', 'Ensure', 'Epidemiology', 'Event', 'Foundations', 'Frequencies', 'Future', 'Goals', 'Grant', 'Health', 'Health Sciences', 'Heart Arrest', 'Hospitalization', 'Hospitals', 'Hour', 'Hylobates Genus', 'Individual', 'Intensive Care', 'Intervention', 'Investigation', 'K-Series Research Career Programs', 'Laboratories', 'Life', 'Literature', 'Lung', 'Machine Learning', 'Master&apos', 's Degree', 'Medicine', 'Mentors', 'Mentorship', 'Methods', 'Modeling', 'Outcome', 'Outcomes Research', 'Patient Discharge', 'Patient risk', 'Patient-Focused Outcomes', 'Patients', 'Physicians', 'Procedures', 'Public Health', 'Publishing', 'Receiver Operating Characteristics', 'Reporting', 'Research', 'Research Activity', 'Research Personnel', 'Resources', 'Rest', 'Resuscitation', 'Risk', 'Scientist', 'Sensitivity and Specificity', 'Social Sciences', 'Statistical Methods', 'Statistical Models', 'Supervision', 'Survival Analysis', 'Techniques', 'Testing', 'Time', 'Training', 'Uncertainty', 'United States', 'Update', 'Validation', 'Work', 'adverse outcome', 'base', 'career', 'cost effectiveness', 'design', 'evidence base', 'high risk', 'improved', 'learning strategy', 'model development', 'models and simulation', 'mortality', 'multidisciplinary', 'programs', 'simulation', 'skills', 'statistics', 'success', 'symposium', 'tool', 'ward']",NHLBI,UNIVERSITY OF CHICAGO,K08,2016,163944,0.08567341434377553
"Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data DESCRIPTION (provided by applicant): In-hospital cardiac arrest (IHCA) is a significant public health problem, afflicting over 200,000 patients in the United States annually with a mortality rate of approximately 80%. The majority of these patients show signs of clinical deterioration in the hours before the event. This has led to the development of vital sign-based early warning scores designed to detect high-risk patients before IHCA to trigger life-saving interventions. However, the vast majority of these risk scores were created subjectively in individual hospitals and have shown limited accuracy for detecting adverse outcomes. Developing an accurate risk score to detect patients at highest risk of IHCA is essential to decreasing preventable in-hospital death. In my prior work, I completed several studies investigating the accuracy of vital signs for predicting IHCA. These studies, previous literature, and my preliminary data have resulted in the following conclusions: 1) statistically developed risk scores are more accurate than previously published risk scores, 2) multicenter data is needed to create the most accurate and generalizable risk score, 3) additional data, such as laboratory results, will likely improve the accuracy of risk scores, and 4) a cutting-edge method for developing prediction models, called machine learning, may result in more accurate risk scores. Importantly, significant improvement in accuracy leads to better identification of patients at highest risk of IHCA and decreased resource utilization. Therefore, in this grant proposal I aim to develop and validate IHCA prediction models using different statistical techniques in a multicenter database and then estimate the impact of the most accurate risk score using simulation studies. I will do this by firt developing prediction models using classic survival analysis methods (Aim 1a) and machine learning methods, such as neural networks and decision trees (Aim 1b). Then, I will compare the models I develop to the most accurate previously published risk scores in Aim 2. Finally, I will investigate the impact of the most accurate model from Aim 2 on patient outcomes using simulation modeling (Aim 3). Completion of this proposal will result in a validated IHCA risk score that can be implemented in the electronic health record to trigger life- saving interventions to decrease preventable in-hospital death. In addition, this career development award will provide critical data to inform future R01-level awards, including a clinical trial to investigate he impact of the developed prediction model on patient outcomes. I will complete this project under the direct supervision of my mentor (Dr. David Meltzer), co-mentor (Dr. Dana Edelson), and the rest of my advisory team (Drs. Jesse Hall, Robert Gibbons, and Michael Kattan). Together, this multidisciplinary team brings nationally renowned expertise in in-hospital cardiac arrest, outcomes research, critical care, and clinical prediction modeling. In addition, they serve as Chairs of the Section of Hospital Medicine (Dr. Meltzer), Section of Pulmonary and Critical Care (Dr. Hall), and Quantitative Health Sciences at the Cleveland Clinic (Dr. Kattan), and Directors of the Center for Health and the Social Sciences (Dr. Meltzer), Center for Health Statistics (Dr. Gibbons), and Clinical Research for the Emergency Resuscitation Center (Dr. Edelson). The mentorship, expertise, and resources that they provide will ensure my success as I grow into an independent physician-scientist. My career goal is to become an independent critical care outcomes researcher with a focus on developing prediction models for clinical deterioration that will improve patient outcomes. To accomplish this long-term goal, I have three short-term goals: (1) to gain expertise in the development and implementation of clinical prediction models, (2) to create an IHCA prediction model that will identify high-risk patients on the wards to trigger life-saving interventions, and (3) to gain expertise in simulation modeling in order to study the impact of the developed prediction model. To accomplish these goals, I will build upon the foundation I developed when earning my Master's Degree in Public Health and during my initial training in the PhD program in the Department of Health Studies. Although my training to date has provided me with a strong background in epidemiology and biostatistics, further advanced training in biostatistics is crucial for my development into a successful independent researcher. An integrated program of didactic coursework, seminars, research activities, and conference participation will span the duration of the award. By accomplishing my three short- term goals, I will develop unique skills that will allow me to become a successful independent researcher. Specifically, the expertise I will gain in prediction model development, implementation, and simulation modeling can be applied not only to IHCA research but also to other areas of critical care medicine. In addition, completion of these goals will result in a validated IHCA prediction model that I will study in future implementation and cost-effectiveness studies and will serve as a basis for future R01-level grant submissions. PUBLIC HEALTH RELEVANCE: Over 200,000 in-hospital cardiac arrests occur in the United States each year, and studies suggest that many of these events may be preventable if the clinical warning signs can be identified and acted upon quickly. However, the vast majority of tools used to identify patients at high risk of cardiac arrest were created subjectively and have limited accuracy. Development of a statistically derived risk tool is essential to detect at- risk patients accurately and early in order to provide the best opportunity to improve patient outcomes and reduce preventable in-hospital death.",Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data,8788442,K08HL121080,"['Adult', 'Applications Grants', 'Area', 'Award', 'Biological Neural Networks', 'Biometry', 'Brain', 'Case-Control Studies', 'Categories', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Research', 'Clinical Trials', 'Complex', 'Critical Care', 'Data', 'Data Set', 'Databases', 'Decision Trees', 'Deterioration', 'Development', 'Diastolic blood pressure', 'Doctor of Philosophy', 'Early Diagnosis', 'Electronic Health Record', 'Emergency Situation', 'Ensure', 'Epidemiology', 'Event', 'Foundations', 'Frequencies', 'Future', 'Goals', 'Grant', 'Health', 'Health Sciences', 'Heart Arrest', 'Hospitalization', 'Hospitals', 'Hour', 'Hylobates Genus', 'Individual', 'Intensive Care', 'Intervention', 'Investigation', 'K-Series Research Career Programs', 'Laboratories', 'Life', 'Literature', 'Lung', 'Machine Learning', 'Master&apos', 's Degree', 'Medicine', 'Mentors', 'Mentorship', 'Methods', 'Modeling', 'Outcome', 'Outcomes Research', 'Patient Discharge', 'Patient risk', 'Patients', 'Physicians', 'Procedures', 'Public Health', 'Publishing', 'Receiver Operating Characteristics', 'Reporting', 'Research', 'Research Activity', 'Research Personnel', 'Resources', 'Rest', 'Resuscitation', 'Risk', 'Scientist', 'Sensitivity and Specificity', 'Social Sciences', 'Statistical Methods', 'Statistical Models', 'Supervision', 'Survival Analysis', 'Techniques', 'Testing', 'Time', 'Training', 'Uncertainty', 'United States', 'Update', 'Validation', 'Work', 'adverse outcome', 'base', 'career', 'cost effectiveness', 'design', 'evidence base', 'high risk', 'improved', 'model development', 'models and simulation', 'mortality', 'multidisciplinary', 'programs', 'simulation', 'skills', 'statistics', 'success', 'symposium', 'tool', 'ward']",NHLBI,UNIVERSITY OF CHICAGO,K08,2015,129546,0.08567341434377553
"Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data     DESCRIPTION (provided by applicant): In-hospital cardiac arrest (IHCA) is a significant public health problem, afflicting over 200,000 patients in the United States annually with a mortality rate of approximately 80%. The majority of these patients show signs of clinical deterioration in the hours before the event. This has led to the development of vital sign-based early warning scores designed to detect high-risk patients before IHCA to trigger life-saving interventions. However, the vast majority of these risk scores were created subjectively in individual hospitals and have shown limited accuracy for detecting adverse outcomes. Developing an accurate risk score to detect patients at highest risk of IHCA is essential to decreasing preventable in-hospital death. In my prior work, I completed several studies investigating the accuracy of vital signs for predicting IHCA. These studies, previous literature, and my preliminary data have resulted in the following conclusions: 1) statistically developed risk scores are more accurate than previously published risk scores, 2) multicenter data is needed to create the most accurate and generalizable risk score, 3) additional data, such as laboratory results, will likely improve the accuracy of risk scores, and 4) a cutting-edge method for developing prediction models, called machine learning, may result in more accurate risk scores. Importantly, significant improvement in accuracy leads to better identification of patients at highest risk of IHCA and decreased resource utilization. Therefore, in this grant proposal I aim to develop and validate IHCA prediction models using different statistical techniques in a multicenter database and then estimate the impact of the most accurate risk score using simulation studies. I will do this by firt developing prediction models using classic survival analysis methods (Aim 1a) and machine learning methods, such as neural networks and decision trees (Aim 1b). Then, I will compare the models I develop to the most accurate previously published risk scores in Aim 2. Finally, I will investigate the impact of the most accurate model from Aim 2 on patient outcomes using simulation modeling (Aim 3). Completion of this proposal will result in a validated IHCA risk score that can be implemented in the electronic health record to trigger life- saving interventions to decrease preventable in-hospital death. In addition, this career development award will provide critical data to inform future R01-level awards, including a clinical trial to investigate he impact of the developed prediction model on patient outcomes. I will complete this project under the direct supervision of my mentor (Dr. David Meltzer), co-mentor (Dr. Dana Edelson), and the rest of my advisory team (Drs. Jesse Hall, Robert Gibbons, and Michael Kattan). Together, this multidisciplinary team brings nationally renowned expertise in in-hospital cardiac arrest, outcomes research, critical care, and clinical prediction modeling. In addition, they serve as Chairs of the Section of Hospital Medicine (Dr. Meltzer), Section of Pulmonary and Critical Care (Dr. Hall), and Quantitative Health Sciences at the Cleveland Clinic (Dr. Kattan), and Directors of the Center for Health and the Social Sciences (Dr. Meltzer), Center for Health Statistics (Dr. Gibbons), and Clinical Research for the Emergency Resuscitation Center (Dr. Edelson). The mentorship, expertise, and resources that they provide will ensure my success as I grow into an independent physician-scientist. My career goal is to become an independent critical care outcomes researcher with a focus on developing prediction models for clinical deterioration that will improve patient outcomes. To accomplish this long-term goal, I have three short-term goals: (1) to gain expertise in the development and implementation of clinical prediction models, (2) to create an IHCA prediction model that will identify high-risk patients on the wards to trigger life-saving interventions, and (3) to gain expertise in simulation modeling in order to study the impact of the developed prediction model. To accomplish these goals, I will build upon the foundation I developed when earning my Master's Degree in Public Health and during my initial training in the PhD program in the Department of Health Studies. Although my training to date has provided me with a strong background in epidemiology and biostatistics, further advanced training in biostatistics is crucial for my development into a successful independent researcher. An integrated program of didactic coursework, seminars, research activities, and conference participation will span the duration of the award. By accomplishing my three short- term goals, I will develop unique skills that will allow me to become a successful independent researcher. Specifically, the expertise I will gain in prediction model development, implementation, and simulation modeling can be applied not only to IHCA research but also to other areas of critical care medicine. In addition, completion of these goals will result in a validated IHCA prediction model that I will study in future implementation and cost-effectiveness studies and will serve as a basis for future R01-level grant submissions.         PUBLIC HEALTH RELEVANCE: Over 200,000 in-hospital cardiac arrests occur in the United States each year, and studies suggest that many of these events may be preventable if the clinical warning signs can be identified and acted upon quickly. However, the vast majority of tools used to identify patients at high risk of cardiac arrest were created subjectively and have limited accuracy. Development of a statistically derived risk tool is essential to detect at- risk patients accurately and early in order to provide the best opportunity to improve patient outcomes and reduce preventable in-hospital death.            ",Predicting In-hospital Cardiac Arrest Using Electronic Health Record Data,8617518,K08HL121080,"['Adult', 'Applications Grants', 'Area', 'Award', 'Biological Neural Networks', 'Biometry', 'Brain', 'Case-Control Studies', 'Categories', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Research', 'Clinical Trials', 'Complex', 'Critical Care', 'Data', 'Data Set', 'Databases', 'Decision Trees', 'Deterioration', 'Development', 'Diastolic blood pressure', 'Doctor of Philosophy', 'Early Diagnosis', 'Electronic Health Record', 'Emergency Situation', 'Ensure', 'Epidemiology', 'Event', 'Foundations', 'Frequencies', 'Future', 'Goals', 'Grant', 'Health', 'Health Sciences', 'Heart Arrest', 'Hospitalization', 'Hospitals', 'Hour', 'Hylobates Genus', 'Individual', 'Intensive Care', 'Intervention', 'Investigation', 'K-Series Research Career Programs', 'Laboratories', 'Life', 'Literature', 'Lung', 'Machine Learning', 'Master&apos', 's Degree', 'Medicine', 'Mentors', 'Mentorship', 'Methods', 'Modeling', 'Outcome', 'Outcomes Research', 'Patient Discharge', 'Patients', 'Physicians', 'Procedures', 'Public Health', 'Publishing', 'Receiver Operating Characteristics', 'Reporting', 'Research', 'Research Activity', 'Research Personnel', 'Resources', 'Rest', 'Resuscitation', 'Risk', 'Scientist', 'Sensitivity and Specificity', 'Social Sciences', 'Statistical Methods', 'Statistical Models', 'Supervision', 'Survival Analysis', 'Techniques', 'Testing', 'Time', 'Training', 'Uncertainty', 'United States', 'Update', 'Validation', 'Work', 'adverse outcome', 'base', 'career', 'cost effectiveness', 'design', 'evidence base', 'high risk', 'improved', 'model development', 'models and simulation', 'mortality', 'multidisciplinary', 'programs', 'public health relevance', 'simulation', 'skills', 'statistics', 'success', 'symposium', 'tool', 'ward']",NHLBI,UNIVERSITY OF CHICAGO,K08,2014,129546,0.08567341434377553
"Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging DESCRIPTION (provided by applicant): Radiation exposure of patients during medical imaging has become a major concern, with computed tomography (CT) and cardiac single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) being the biggest contributors. In this project our aim will be to dramatically reduce radiation dose in cardiac SPECT MPI based on inexpensive software techniques that can be translated readily to clinical practice. Our initial results suggest that at least an eightfold reduction in radiation doe might be possible, which could lead to an estimated reduction of 6500 cancer deaths per year in the U.S. alone.  In lay terms, cardiac SPECT MPI is used routinely to evaluate heart disease, allowing the physician to assess blood flow reaching the heart wall, the motion of the heart, and whether the heart wall's tissue is viable. This form of imaging involves administration of a radioactive pharmaceutical (tracer) to the patient, which exposes the patient to radiation; thus, i would be desirable to minimize tracer dose used during imaging. Image quality is determined by the amount of tracer used, and these levels were chosen prior to recent technological improvements that can produce high-quality images at lower dose; therefore, there is clear evidence that doses can be lowered, and indeed there is considerable current interest in doing so.  We are proposing a translational research project to thoroughly and quantitatively study the extent to which administered dose might be reduced without sacrificing image quality. This work will build, in particular, on new four-dimensional (4D) image reconstruction techniques and respiratory motion compensation approaches we have developed. Furthermore, we propose a new dosing approach we call ""personalized imaging"", in which a computer algorithm will be trained to predict, for a given patient, the minimum dose required to obtain the current level of image quality, so that the administered dose is no more than necessary.  In 4D reconstruction, a computer algorithm tracks the heart's beating motion, and uses this information to improve image quality by smoothing image noise in a way that preserves image details. In respiratory motion compensation, the patient's breathing and body motions are tracked by external sensors, and this information is used to reduce the appearance of motion blur in the images, and thereby improve diagnostic accuracy. The proposed ""personalized imaging"" approach builds on our group's extensive experience in machine learning.  We expect that the combination of these various strategies will greatly reduce radiation dose, and because the improvements are based on software, the cost of these enhancements is very low. The project will result in recommendations for image reconstruction algorithms and parameters to be used in the clinic, along with corresponding tracer dose recommendations. The ""personalized imaging"" method will be implemented as a user-friendly computer program that customizes the dose for each given patient. PUBLIC HEALTH RELEVANCE: Radiation exposure of patients via medical imaging has become a significant concern. This project will investigate software methods that may allow the radiation dose in cardiac SPECT imaging to be reduced by a factor of eight or more. This will be accomplished by: optimizing the image processing that is used, further developing new and better image processing methods, and developing a method of ""personalized imaging"", in which, for each individual patient, the minimum amount of imaging agent needed to obtain a good image is computed.",Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging,9268035,R01HL122484,"['3D ultrasound', '4D Imaging', 'Acceleration', 'Accounting', 'Address', 'Adopted', 'Algorithms', 'American', 'Appearance', 'Attention', 'Blood flow', 'Breathing', 'Cardiac', 'Cardiac Catheterization Procedures', 'Cardiology', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Protocols', 'Clinical Research', 'Communities', 'Computational algorithm', 'Computer software', 'Custom', 'Data', 'Development', 'Diagnostic', 'Dimensions', 'Discipline of Nuclear Medicine', 'Dose', 'Electromagnetic Energy', 'Evaluation', 'Financial compensation', 'Four-dimensional', 'Goals', 'Government', 'Heart', 'Heart Diseases', 'Image', 'Lead', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medical Imaging', 'Methods', 'Modeling', 'Modification', 'Motion', 'Myocardial perfusion', 'Noise', 'Nuclear', 'Obesity', 'Patients', 'Performance', 'Perfusion', 'Persons', 'Pharmacologic Substance', 'Physicians', 'Population', 'Procedures', 'Process', 'Professional Organizations', 'Protocols documentation', 'Radiation', 'Radiation Protection', 'Radiation exposure', 'Radioactive', 'Reader', 'Recommendation', 'Research Project Grants', 'Societies', 'Stress', 'Sum', 'System', 'Techniques', 'Tissues', 'Tracer', 'Training', 'Translating', 'Translational Research', 'Work', 'X-Ray Computed Tomography', 'base', 'cardiac single photon emission computed tomography', 'clinical imaging', 'clinical practice', 'computer program', 'cost', 'diagnostic accuracy', 'experience', 'heart motion', 'image processing', 'image reconstruction', 'imaging agent', 'imaging approach', 'imaging modality', 'improved', 'individual patient', 'interest', 'perfusion imaging', 'predictive modeling', 'public health relevance', 'reconstruction', 'respiratory', 'sensor', 'single photon emission computed tomography', 'user-friendly']",NHLBI,ILLINOIS INSTITUTE OF TECHNOLOGY,R01,2017,770494,0.10859652295580109
"Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging DESCRIPTION (provided by applicant): Radiation exposure of patients during medical imaging has become a major concern, with computed tomography (CT) and cardiac single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) being the biggest contributors. In this project our aim will be to dramatically reduce radiation dose in cardiac SPECT MPI based on inexpensive software techniques that can be translated readily to clinical practice. Our initial results suggest that at least an eightfold reduction in radiation doe might be possible, which could lead to an estimated reduction of 6500 cancer deaths per year in the U.S. alone.  In lay terms, cardiac SPECT MPI is used routinely to evaluate heart disease, allowing the physician to assess blood flow reaching the heart wall, the motion of the heart, and whether the heart wall's tissue is viable. This form of imaging involves administration of a radioactive pharmaceutical (tracer) to the patient, which exposes the patient to radiation; thus, i would be desirable to minimize tracer dose used during imaging. Image quality is determined by the amount of tracer used, and these levels were chosen prior to recent technological improvements that can produce high-quality images at lower dose; therefore, there is clear evidence that doses can be lowered, and indeed there is considerable current interest in doing so.  We are proposing a translational research project to thoroughly and quantitatively study the extent to which administered dose might be reduced without sacrificing image quality. This work will build, in particular, on new four-dimensional (4D) image reconstruction techniques and respiratory motion compensation approaches we have developed. Furthermore, we propose a new dosing approach we call ""personalized imaging"", in which a computer algorithm will be trained to predict, for a given patient, the minimum dose required to obtain the current level of image quality, so that the administered dose is no more than necessary.  In 4D reconstruction, a computer algorithm tracks the heart's beating motion, and uses this information to improve image quality by smoothing image noise in a way that preserves image details. In respiratory motion compensation, the patient's breathing and body motions are tracked by external sensors, and this information is used to reduce the appearance of motion blur in the images, and thereby improve diagnostic accuracy. The proposed ""personalized imaging"" approach builds on our group's extensive experience in machine learning.  We expect that the combination of these various strategies will greatly reduce radiation dose, and because the improvements are based on software, the cost of these enhancements is very low. The project will result in recommendations for image reconstruction algorithms and parameters to be used in the clinic, along with corresponding tracer dose recommendations. The ""personalized imaging"" method will be implemented as a user-friendly computer program that customizes the dose for each given patient. PUBLIC HEALTH RELEVANCE: Radiation exposure of patients via medical imaging has become a significant concern. This project will investigate software methods that may allow the radiation dose in cardiac SPECT imaging to be reduced by a factor of eight or more. This will be accomplished by: optimizing the image processing that is used, further developing new and better image processing methods, and developing a method of ""personalized imaging"", in which, for each individual patient, the minimum amount of imaging agent needed to obtain a good image is computed.",Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging,9476341,R01HL122484,"['3D ultrasound', '4D Imaging', 'Acceleration', 'Accounting', 'Address', 'Adopted', 'Algorithms', 'American', 'Appearance', 'Attention', 'Blood flow', 'Breathing', 'Cardiac', 'Cardiac Catheterization Procedures', 'Cardiology', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Protocols', 'Clinical Research', 'Communities', 'Computational algorithm', 'Computer software', 'Custom', 'Data', 'Development', 'Diagnostic', 'Dimensions', 'Discipline of Nuclear Medicine', 'Dose', 'Electromagnetic Energy', 'Evaluation', 'Financial compensation', 'Four-dimensional', 'Goals', 'Government', 'Heart', 'Heart Diseases', 'Image', 'Lead', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medical Imaging', 'Methods', 'Modeling', 'Modification', 'Motion', 'Myocardial perfusion', 'Noise', 'Nuclear', 'Obesity', 'Patients', 'Performance', 'Perfusion', 'Persons', 'Pharmacologic Substance', 'Physicians', 'Population', 'Procedures', 'Process', 'Professional Organizations', 'Protocols documentation', 'Radiation', 'Radiation Protection', 'Radiation exposure', 'Radioactive', 'Reader', 'Recommendation', 'Research Project Grants', 'Societies', 'Stress', 'Sum', 'System', 'Techniques', 'Tissues', 'Tracer', 'Training', 'Translating', 'Translational Research', 'Work', 'X-Ray Computed Tomography', 'base', 'cardiac single photon emission computed tomography', 'clinical imaging', 'clinical practice', 'computer program', 'cost', 'diagnostic accuracy', 'experience', 'heart motion', 'image processing', 'image reconstruction', 'imaging agent', 'imaging approach', 'imaging modality', 'improved', 'individual patient', 'interest', 'perfusion imaging', 'predictive modeling', 'public health relevance', 'reconstruction', 'respiratory', 'sensor', 'single photon emission computed tomography', 'user-friendly']",NHLBI,ILLINOIS INSTITUTE OF TECHNOLOGY,R01,2018,770494,0.10859652295580109
"Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging DESCRIPTION (provided by applicant): Radiation exposure of patients during medical imaging has become a major concern, with computed tomography (CT) and cardiac single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) being the biggest contributors. In this project our aim will be to dramatically reduce radiation dose in cardiac SPECT MPI based on inexpensive software techniques that can be translated readily to clinical practice. Our initial results suggest that at least an eightfold reduction in radiation doe might be possible, which could lead to an estimated reduction of 6500 cancer deaths per year in the U.S. alone.  In lay terms, cardiac SPECT MPI is used routinely to evaluate heart disease, allowing the physician to assess blood flow reaching the heart wall, the motion of the heart, and whether the heart wall's tissue is viable. This form of imaging involves administration of a radioactive pharmaceutical (tracer) to the patient, which exposes the patient to radiation; thus, i would be desirable to minimize tracer dose used during imaging. Image quality is determined by the amount of tracer used, and these levels were chosen prior to recent technological improvements that can produce high-quality images at lower dose; therefore, there is clear evidence that doses can be lowered, and indeed there is considerable current interest in doing so.  We are proposing a translational research project to thoroughly and quantitatively study the extent to which administered dose might be reduced without sacrificing image quality. This work will build, in particular, on new four-dimensional (4D) image reconstruction techniques and respiratory motion compensation approaches we have developed. Furthermore, we propose a new dosing approach we call ""personalized imaging"", in which a computer algorithm will be trained to predict, for a given patient, the minimum dose required to obtain the current level of image quality, so that the administered dose is no more than necessary.  In 4D reconstruction, a computer algorithm tracks the heart's beating motion, and uses this information to improve image quality by smoothing image noise in a way that preserves image details. In respiratory motion compensation, the patient's breathing and body motions are tracked by external sensors, and this information is used to reduce the appearance of motion blur in the images, and thereby improve diagnostic accuracy. The proposed ""personalized imaging"" approach builds on our group's extensive experience in machine learning.  We expect that the combination of these various strategies will greatly reduce radiation dose, and because the improvements are based on software, the cost of these enhancements is very low. The project will result in recommendations for image reconstruction algorithms and parameters to be used in the clinic, along with corresponding tracer dose recommendations. The ""personalized imaging"" method will be implemented as a user-friendly computer program that customizes the dose for each given patient. PUBLIC HEALTH RELEVANCE: Radiation exposure of patients via medical imaging has become a significant concern. This project will investigate software methods that may allow the radiation dose in cardiac SPECT imaging to be reduced by a factor of eight or more. This will be accomplished by: optimizing the image processing that is used, further developing new and better image processing methods, and developing a method of ""personalized imaging"", in which, for each individual patient, the minimum amount of imaging agent needed to obtain a good image is computed.",Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging,9061011,R01HL122484,"['4D Imaging', 'Acceleration', 'Accounting', 'Address', 'Adopted', 'Algorithms', 'American', 'Appearance', 'Attention', 'Blood flow', 'Breathing', 'Cardiac', 'Cardiac Catheterization Procedures', 'Cardiology', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Protocols', 'Clinical Research', 'Communities', 'Computational algorithm', 'Computer software', 'Data', 'Development', 'Diagnostic', 'Discipline of Nuclear Medicine', 'Dose', 'Dose-Limiting', 'Electromagnetic Energy', 'Evaluation', 'Financial compensation', 'Four-dimensional', 'Goals', 'Government', 'Health', 'Heart', 'Heart Diseases', 'Image', 'Lead', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medical Imaging', 'Methods', 'Modeling', 'Modification', 'Motion', 'Myocardial perfusion', 'Noise', 'Nuclear', 'Obesity', 'Patients', 'Performance', 'Perfusion', 'Persons', 'Pharmacologic Substance', 'Physicians', 'Population', 'Procedures', 'Process', 'Professional Organizations', 'Protocols documentation', 'Radiation', 'Radiation Protection', 'Radioactive', 'Reader', 'Recommendation', 'Research Project Grants', 'Societies', 'Stress', 'Sum', 'System', 'Techniques', 'Tissues', 'Tracer', 'Training', 'Translating', 'Translational Research', 'Ultrasonography', 'Work', 'X-Ray Computed Tomography', 'base', 'cardiac single photon emission computed tomography', 'clinical practice', 'computer program', 'cost', 'diagnostic accuracy', 'experience', 'heart motion', 'image processing', 'image reconstruction', 'imaging agent', 'imaging modality', 'improved', 'individual patient', 'interest', 'predictive modeling', 'reconstruction', 'respiratory', 'sensor', 'single photon emission computed tomography', 'user-friendly']",NHLBI,ILLINOIS INSTITUTE OF TECHNOLOGY,R01,2016,770494,0.10859652295580109
"Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging DESCRIPTION (provided by applicant): Radiation exposure of patients during medical imaging has become a major concern, with computed tomography (CT) and cardiac single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) being the biggest contributors. In this project our aim will be to dramatically reduce radiation dose in cardiac SPECT MPI based on inexpensive software techniques that can be translated readily to clinical practice. Our initial results suggest that at least an eightfold reduction in radiation doe might be possible, which could lead to an estimated reduction of 6500 cancer deaths per year in the U.S. alone.  In lay terms, cardiac SPECT MPI is used routinely to evaluate heart disease, allowing the physician to assess blood flow reaching the heart wall, the motion of the heart, and whether the heart wall's tissue is viable. This form of imaging involves administration of a radioactive pharmaceutical (tracer) to the patient, which exposes the patient to radiation; thus, i would be desirable to minimize tracer dose used during imaging. Image quality is determined by the amount of tracer used, and these levels were chosen prior to recent technological improvements that can produce high-quality images at lower dose; therefore, there is clear evidence that doses can be lowered, and indeed there is considerable current interest in doing so.  We are proposing a translational research project to thoroughly and quantitatively study the extent to which administered dose might be reduced without sacrificing image quality. This work will build, in particular, on new four-dimensional (4D) image reconstruction techniques and respiratory motion compensation approaches we have developed. Furthermore, we propose a new dosing approach we call ""personalized imaging"", in which a computer algorithm will be trained to predict, for a given patient, the minimum dose required to obtain the current level of image quality, so that the administered dose is no more than necessary.  In 4D reconstruction, a computer algorithm tracks the heart's beating motion, and uses this information to improve image quality by smoothing image noise in a way that preserves image details. In respiratory motion compensation, the patient's breathing and body motions are tracked by external sensors, and this information is used to reduce the appearance of motion blur in the images, and thereby improve diagnostic accuracy. The proposed ""personalized imaging"" approach builds on our group's extensive experience in machine learning.  We expect that the combination of these various strategies will greatly reduce radiation dose, and because the improvements are based on software, the cost of these enhancements is very low. The project will result in recommendations for image reconstruction algorithms and parameters to be used in the clinic, along with corresponding tracer dose recommendations. The ""personalized imaging"" method will be implemented as a user-friendly computer program that customizes the dose for each given patient. PUBLIC HEALTH RELEVANCE: Radiation exposure of patients via medical imaging has become a significant concern. This project will investigate software methods that may allow the radiation dose in cardiac SPECT imaging to be reduced by a factor of eight or more. This will be accomplished by: optimizing the image processing that is used, further developing new and better image processing methods, and developing a method of ""personalized imaging"", in which, for each individual patient, the minimum amount of imaging agent needed to obtain a good image is computed.",Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging,8842707,R01HL122484,"['4D Imaging', 'Acceleration', 'Accounting', 'Address', 'Adopted', 'Algorithms', 'American', 'Appearance', 'Attention', 'Blood flow', 'Breathing', 'Cardiac', 'Cardiac Catheterization Procedures', 'Cardiology', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Protocols', 'Clinical Research', 'Communities', 'Computational algorithm', 'Computer software', 'Data', 'Development', 'Diagnostic', 'Discipline of Nuclear Medicine', 'Dose', 'Dose-Limiting', 'Electromagnetic Energy', 'Evaluation', 'Financial compensation', 'Four-dimensional', 'Goals', 'Government', 'Health', 'Heart', 'Heart Diseases', 'Image', 'Individual', 'Lead', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medical Imaging', 'Methods', 'Modeling', 'Modification', 'Motion', 'Myocardial perfusion', 'Noise', 'Nuclear', 'Obesity', 'Patients', 'Performance', 'Perfusion', 'Persons', 'Pharmacologic Substance', 'Physicians', 'Population', 'Procedures', 'Process', 'Protocols documentation', 'Radiation', 'Radiation Protection', 'Radioactive', 'Reader', 'Recommendation', 'Research Project Grants', 'Societies', 'Stress', 'Sum', 'System', 'Techniques', 'Tissues', 'Tracer', 'Training', 'Translating', 'Translational Research', 'Ultrasonography', 'Work', 'X-Ray Computed Tomography', 'base', 'cardiac single photon emission computed tomography', 'clinical practice', 'computer program', 'cost', 'diagnostic accuracy', 'experience', 'heart motion', 'image processing', 'image reconstruction', 'imaging agent', 'imaging modality', 'improved', 'interest', 'predictive modeling', 'reconstruction', 'respiratory', 'sensor', 'single photon emission computed tomography', 'user-friendly']",NHLBI,ILLINOIS INSTITUTE OF TECHNOLOGY,R01,2015,758935,0.10859652295580109
"Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging     DESCRIPTION (provided by applicant): Radiation exposure of patients during medical imaging has become a major concern, with computed tomography (CT) and cardiac single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) being the biggest contributors. In this project our aim will be to dramatically reduce radiation dose in cardiac SPECT MPI based on inexpensive software techniques that can be translated readily to clinical practice. Our initial results suggest that at least an eightfold reduction in radiation doe might be possible, which could lead to an estimated reduction of 6500 cancer deaths per year in the U.S. alone.  In lay terms, cardiac SPECT MPI is used routinely to evaluate heart disease, allowing the physician to assess blood flow reaching the heart wall, the motion of the heart, and whether the heart wall's tissue is viable. This form of imaging involves administration of a radioactive pharmaceutical (tracer) to the patient, which exposes the patient to radiation; thus, i would be desirable to minimize tracer dose used during imaging. Image quality is determined by the amount of tracer used, and these levels were chosen prior to recent technological improvements that can produce high-quality images at lower dose; therefore, there is clear evidence that doses can be lowered, and indeed there is considerable current interest in doing so.  We are proposing a translational research project to thoroughly and quantitatively study the extent to which administered dose might be reduced without sacrificing image quality. This work will build, in particular, on new four-dimensional (4D) image reconstruction techniques and respiratory motion compensation approaches we have developed. Furthermore, we propose a new dosing approach we call ""personalized imaging"", in which a computer algorithm will be trained to predict, for a given patient, the minimum dose required to obtain the current level of image quality, so that the administered dose is no more than necessary.  In 4D reconstruction, a computer algorithm tracks the heart's beating motion, and uses this information to improve image quality by smoothing image noise in a way that preserves image details. In respiratory motion compensation, the patient's breathing and body motions are tracked by external sensors, and this information is used to reduce the appearance of motion blur in the images, and thereby improve diagnostic accuracy. The proposed ""personalized imaging"" approach builds on our group's extensive experience in machine learning.  We expect that the combination of these various strategies will greatly reduce radiation dose, and because the improvements are based on software, the cost of these enhancements is very low. The project will result in recommendations for image reconstruction algorithms and parameters to be used in the clinic, along with corresponding tracer dose recommendations. The ""personalized imaging"" method will be implemented as a user-friendly computer program that customizes the dose for each given patient.         PUBLIC HEALTH RELEVANCE: Radiation exposure of patients via medical imaging has become a significant concern. This project will investigate software methods that may allow the radiation dose in cardiac SPECT imaging to be reduced by a factor of eight or more. This will be accomplished by: optimizing the image processing that is used, further developing new and better image processing methods, and developing a method of ""personalized imaging"", in which, for each individual patient, the minimum amount of imaging agent needed to obtain a good image is computed.            ",Probing Dose Limits in Cardiac SPECT with Reconstruction and Personalized Imaging,8674683,R01HL122484,"['4D Imaging', 'Acceleration', 'Accounting', 'Address', 'Adopted', 'Algorithms', 'American', 'Appearance', 'Attention', 'Blood flow', 'Breathing', 'Cardiac', 'Cardiac Catheterization Procedures', 'Cardiology', 'Cessation of life', 'Characteristics', 'Clinic', 'Clinical', 'Clinical Protocols', 'Clinical Research', 'Communities', 'Computational algorithm', 'Computer software', 'Data', 'Development', 'Diagnostic', 'Discipline of Nuclear Medicine', 'Dose', 'Dose-Limiting', 'Electromagnetic Energy', 'Evaluation', 'Financial compensation', 'Four-dimensional', 'Goals', 'Government', 'Heart', 'Heart Diseases', 'Image', 'Individual', 'Lead', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medical Imaging', 'Methods', 'Modeling', 'Modification', 'Motion', 'Myocardial perfusion', 'Noise', 'Nuclear', 'Obesity', 'Patients', 'Performance', 'Perfusion', 'Persons', 'Pharmacologic Substance', 'Physicians', 'Population', 'Procedures', 'Process', 'Protocols documentation', 'Radiation', 'Radiation Protection', 'Radioactive', 'Reader', 'Recommendation', 'Research Project Grants', 'Societies', 'Stress', 'Sum', 'System', 'Techniques', 'Tissues', 'Tracer', 'Training', 'Translating', 'Translational Research', 'Ultrasonography', 'Work', 'X-Ray Computed Tomography', 'base', 'clinical practice', 'computer program', 'cost', 'diagnostic accuracy', 'experience', 'heart motion', 'image processing', 'image reconstruction', 'imaging modality', 'improved', 'interest', 'predictive modeling', 'public health relevance', 'reconstruction', 'respiratory', 'sensor', 'single photon emission computed tomography', 'user-friendly']",NHLBI,ILLINOIS INSTITUTE OF TECHNOLOGY,R01,2014,782871,0.10859652295580109
"Refining repeat screening for coronary artery disease in kidney transplant candidates 7. Project Summary This K23 proposal will provide Xingxing S. Cheng, MD, MS with the protected time, mentorship, training, and research experience to become an independent clinical investigator. Dr. Cheng is a board-certified nephrologist and accredited transplant nephrologist, with a long-term vision of improving the effectiveness of health care for kidney transplant patients. She seeks to combine patient-oriented research and decision science to find innovative solutions to clinical problems. Skills she will acquire in this grant, under the guidance of a strong mentorship team, include 1) integration of patient-oriented research and decision analytic models; 2) assessing the heterogeneity of response in different patient subgroups; and 3) advanced modelling skills. This grant proposes to refine the process of screening of coronary artery disease in patients with chronic kidney disease on the wait-list awaiting kidney transplantation. Currently, patients undergo repeat cardiac screening tests at frequent intervals, few of which result in interventions. These tests impose a high treatment burden on patients and potentially delay time to transplant, while bringing unclear benefit to the patient. This grant proposes to refine the cardiac screening strategy and personalize it for specific patient subgroups (e.g. elderly patients with diabetes mellitus). It will examine strategies that vary the frequency of cardiac testing and risk stratification for cardiac testing based on a simple, inexpensive, and non-invasive test that can be performed in routine clinical settings, a 6-minute walk test (6MWT). This project will achieve this broad aim by three specific aims: 1) to characterize the 6MWT in identifying low-risk patients who do not additional cardiac testing; 2) to model strategies varying the frequency of cardiac testing and use of 6MWT; 3) to design strategies personalized for specific patient subgroups and model them in the entire kidney transplant candidate population of the United States (US). The first two aims will arise from a well-characterized cohort of patients at Dr. Chengs institution. Machine-learning systems will be used to identify which patient subgroups are best served by which strategies (i.e. the heterogeneity of response). The third aim will leverage the US Renal Data System, which Dr. Chengs mentors and institution has a track record of leveraging for innovative research. The proposed work has high potential to make a significant clinical impact. Its completion will enable the identification and characterization of rational strategies for pre-transplant screening of coronary artery disease that may be incorporated into clinical practice or pave the way for a future multi-center comparative effectiveness trial. The proposed work is realistic and feasible within the award period, and will allow Dr. Cheng to build research skills, advance and disseminate scientific knowledge, create additional collaborative networks, and compete for R01 or equivalent funding. In summary, the K23 award will provide the support to enable Dr. Cheng to become a successful independent clinical investigator. 8. Project Narrative Currently, patients on the kidney transplant waitlist undergo repeat cardiac screening tests at frequent intervals, but relatively few interventions result. This project proposes to refine the cardiac screening strategy and personalize it for specific patient subgroups (e.g. elderly patients without diabetes mellitus), by examining strategies that reduce the frequency of cardiac testing and use performance-based risk stratification to reduce the number of patients who need cardiac testing. If successful, this project will reduce the cardiac testing burden and facilitate activation for transplant for patients on the kidney transplant waitlist.",Refining repeat screening for coronary artery disease in kidney transplant candidates,9871208,K23DK123410,"['Accreditation', 'Age', 'Award', 'Cardiac', 'Cardiopulmonary', 'Caring', 'Characteristics', 'Chronic Kidney Failure', 'Clinical', 'Clinical Investigator', 'Coronary Arteriosclerosis', 'Diabetes Mellitus', 'Effectiveness', 'Eligibility Determination', 'Evaluation', 'Event', 'Frequencies', 'Funding', 'Future', 'Goals', 'Grant', 'Guidelines', 'Healthcare', 'Heterogeneity', 'Hybrids', 'Information Systems', 'Institution', 'Intervention', 'Intervention Trial', 'Kidney', 'Kidney Transplantation', 'Knowledge', 'Lead', 'Machine Learning', 'Measures', 'Mentored Patient-Oriented Research Career Development Award', 'Mentors', 'Mentorship', 'Modeling', 'Outcome', 'Patients', 'Performance', 'Phase', 'Physical Performance', 'Population', 'Process', 'Quality-Adjusted Life Years', 'Research', 'Risk', 'Risk Factors', 'Risk stratification', 'Science', 'Specificity', 'Sum', 'System', 'Testing', 'Time', 'Training', 'Transplant Recipients', 'Transplantation', 'United States', 'Vision', 'Wait Time', 'Waiting Lists', 'Walking', 'Work', 'analytical method', 'base', 'career', 'clinical practice', 'clinical risk', 'cohort', 'comparative effectiveness trial', 'cost', 'design', 'experience', 'fitness', 'follow-up', 'high risk', 'improved', 'innovation', 'older patient', 'patient oriented research', 'patient subsets', 'personalized strategies', 'predictive test', 'prognostic value', 'prospective', 'recruit', 'relative effectiveness', 'response', 'screening', 'skills']",NIDDK,STANFORD UNIVERSITY,K23,2020,166536,0.02110467654660697
"High-throughput, all-optical assay in human cardiomyoctes for clinically relevant prediction of drug induced cardiotoxity.     DESCRIPTION (provided by applicant): Toxicity accounts for approximately 20% of drug attrition, of which nearly one third is attributed to cardiovascular issues, in particular arrhythmias.1 The cost of bringing a new drug to market can exceed $1.2 billion and require more than 10 years of research. Thus, it is critical to identify cardiotoxicity early in developmen. Current in vitro screening assays for pro-arrhythmic drug effects focus on measuring inhibition of the hERG potassium channel, which has been linked to potentially lethal Torsades de Pointes arrhythmias (TdP).2 The hERG assay, however, lacks high sensitivity and specificity: not all QT prolongation is due to block of hERG alone and not all hERG blockers result in QT prolongation or induce TdP. To address these limitations, regulatory bodies have created the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative2, which proposes use of cardiomyocytes derived from human stem cells as an in vitro model for arrhythmogenic drug potential. Establishment of this model for toxicity screening requires detailed characterization of the cardiomyocyte action potential (AP) and calcium transient (CT), the response of APs/CTs to drugs, and the correlation to clinical outcomes in humans. High-throughput tools needed for performing these measurements, however, have been lacking. Here we propose to develop a high-throughput, all-optical electrophysiology platform for cardiotoxicity screening in sem cell-derived cardiomyocytes. With our Phase I award, we demonstrated that the Optopatch platform could be used to detect changes in the electrophysiological characteristics of human derived CMs following both acute and chronic drug treatment, albeit with the throughput of a single well per recording. To highly parallelize these measurements, we propose building a 96-well plate Optopatch instrument for simultaneous recording of voltage and calcium waveforms under paced conditions from 24 wells. This geometry will provide nearly two orders of magnitude improvement in throughput of our assay. Optopatch constructs will be optimized to allow for incorporation of the actuator and reporter proteins in each cell. We will utilize this platform to screen 50 compounds with known risk scores for Torsades de Pointes in different sources of human cardiomyocytes and use this data to develop a predictive algorithm of arrhythmogenicity. PUBLIC HEALTH RELEVANCE:  QState's technology will allow better prediction of a drug candidate's potential adverse effects to the human heart than the assays mandated by the current cardiac safety guidance ICH S7B.   It will contribute to bringing effective healthcare solutions to market at lower cost and higher productivity, by preventing drugs with cardiotoxicity from reaching the market and preventing the development of valuable therapeutics from being wrongly terminated, which is one of the concerns about the current S7B assays. Making Q-State instrumentation and reagents available to the academic research community will facilitate better mechanistic studies and therapeutics development to benefit patients with cardiac conditions.","High-throughput, all-optical assay in human cardiomyoctes for clinically relevant prediction of drug induced cardiotoxity.",9247825,R44HL126314,"['Action Potentials', 'Acute', 'Address', 'Adult', 'Adverse effects', 'Algorithmic Analysis', 'Algorithms', 'Arrhythmia', 'Award', 'Biological Assay', 'Biological Sciences', 'Blinded', 'Calcium', 'Cardiac', 'Cardiac Myocytes', 'Cardiotoxicity', 'Cardiovascular system', 'Cell Maturation', 'Cells', 'Characteristics', 'Chronic', 'Clinical', 'Collaborations', 'Communities', 'Computer software', 'Contracts', 'Data', 'Detection', 'Development', 'Drug usage', 'Ecology', 'Electrophysiology (science)', 'Engineering', 'Frequencies', 'Funding', 'Geometry', 'Health', 'Healthcare', 'Heart', 'Hour', 'Human', 'Human Characteristics', 'Image', 'In Vitro', 'Institutes', 'Ion Channel', 'Lead', 'Link', 'Machine Learning', 'Manuals', 'Measurement', 'Measures', 'Modeling', 'Molecular', 'Molecular Profiling', 'Optics', 'Outcome', 'Paper', 'Patients', 'Pharmaceutical Preparations', 'Pharmacotherapy', 'Phase', 'Phototoxicity', 'Positioning Attribute', 'Potassium Channel', 'Production', 'Productivity', 'Proteins', 'Protocols documentation', 'Provider', 'RNA', 'Reagent', 'Reporter', 'Reporting', 'Research', 'Resolution', 'Risk', 'Safety', 'Sensitivity and Specificity', 'Services', 'Source', 'System', 'Techniques', 'Technology', 'Testing', 'Therapeutic', 'Time', 'Tissues', 'Torsades de Pointes', 'Toxic effect', 'United States Food and Drug Administration', 'Vendor', 'Work', 'clinically relevant', 'cost', 'drug candidate', 'drug discovery', 'human stem cells', 'in vitro Model', 'induced pluripotent stem cell', 'instrument', 'instrumentation', 'novel therapeutics', 'optogenetics', 'patch clamp', 'phase 1 study', 'prediction algorithm', 'prevent', 'public health relevance', 'rate of change', 'response', 'screening', 'spatiotemporal', 'stem cell biology', 'success', 'therapeutic development', 'tool', 'voltage']",NHLBI,"Q-STATE BIOSCIENCES, INC.",R44,2017,369580,0.009348189663499222
"High-throughput, all-optical assay in human cardiomyoctes for clinically relevant prediction of drug induced cardiotoxity.     DESCRIPTION (provided by applicant): Toxicity accounts for approximately 20% of drug attrition, of which nearly one third is attributed to cardiovascular issues, in particular arrhythmias.1 The cost of bringing a new drug to market can exceed $1.2 billion and require more than 10 years of research. Thus, it is critical to identify cardiotoxicity early in developmen. Current in vitro screening assays for pro-arrhythmic drug effects focus on measuring inhibition of the hERG potassium channel, which has been linked to potentially lethal Torsades de Pointes arrhythmias (TdP).2 The hERG assay, however, lacks high sensitivity and specificity: not all QT prolongation is due to block of hERG alone and not all hERG blockers result in QT prolongation or induce TdP. To address these limitations, regulatory bodies have created the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative2, which proposes use of cardiomyocytes derived from human stem cells as an in vitro model for arrhythmogenic drug potential. Establishment of this model for toxicity screening requires detailed characterization of the cardiomyocyte action potential (AP) and calcium transient (CT), the response of APs/CTs to drugs, and the correlation to clinical outcomes in humans. High-throughput tools needed for performing these measurements, however, have been lacking. Here we propose to develop a high-throughput, all-optical electrophysiology platform for cardiotoxicity screening in sem cell-derived cardiomyocytes. With our Phase I award, we demonstrated that the Optopatch platform could be used to detect changes in the electrophysiological characteristics of human derived CMs following both acute and chronic drug treatment, albeit with the throughput of a single well per recording. To highly parallelize these measurements, we propose building a 96-well plate Optopatch instrument for simultaneous recording of voltage and calcium waveforms under paced conditions from 24 wells. This geometry will provide nearly two orders of magnitude improvement in throughput of our assay. Optopatch constructs will be optimized to allow for incorporation of the actuator and reporter proteins in each cell. We will utilize this platform to screen 50 compounds with known risk scores for Torsades de Pointes in different sources of human cardiomyocytes and use this data to develop a predictive algorithm of arrhythmogenicity.             PUBLIC HEALTH RELEVANCE:  QState's technology will allow better prediction of a drug candidate's potential adverse effects to the human heart than the assays mandated by the current cardiac safety guidance ICH S7B.   It will contribute to bringing effective healthcare solutions to market at lower cost and higher productivity, by preventing drugs with cardiotoxicity from reaching the market and preventing the development of valuable therapeutics from being wrongly terminated, which is one of the concerns about the current S7B assays. Making Q-State instrumentation and reagents available to the academic research community will facilitate better mechanistic studies and therapeutics development to benefit patients with cardiac conditions.               ","High-throughput, all-optical assay in human cardiomyoctes for clinically relevant prediction of drug induced cardiotoxity.",9138354,R44HL126314,"['Accounting', 'Action Potentials', 'Acute', 'Address', 'Adult', 'Adverse effects', 'Algorithms', 'Arrhythmia', 'Award', 'Biological Assay', 'Biological Sciences', 'Blinded', 'Calcium', 'Cardiac', 'Cardiac Myocytes', 'Cardiotoxicity', 'Cardiovascular system', 'Cell Maturation', 'Cells', 'Characteristics', 'Chronic', 'Clinical', 'Collaborations', 'Communities', 'Contracts', 'Data', 'Detection', 'Development', 'Electrophysiology (science)', 'Engineering', 'Environmental Health', 'Frequencies', 'Funding', 'Genetic Transcription', 'Geometry', 'Healthcare', 'Heart', 'Hour', 'Human', 'Human Characteristics', 'Image', 'In Vitro', 'Institutes', 'Ion Channel', 'Lead', 'Link', 'Machine Learning', 'Manuals', 'Marketing', 'Measurement', 'Measures', 'Modeling', 'Molecular', 'Molecular Profiling', 'Optics', 'Outcome', 'Paper', 'Patients', 'Pharmaceutical Preparations', 'Pharmacotherapy', 'Phase', 'Phototoxicity', 'Positioning Attribute', 'Potassium Channel', 'Production', 'Productivity', 'Proteins', 'Protocols documentation', 'Provider', 'Reagent', 'Reporter', 'Reporting', 'Research', 'Resolution', 'Risk', 'Safety', 'Sensitivity and Specificity', 'Services', 'Software Engineering', 'Source', 'Staging', 'System', 'Techniques', 'Technology', 'Testing', 'Therapeutic', 'Time', 'Torsades de Pointes', 'Toxic effect', 'United States Food and Drug Administration', 'Vendor', 'Work', 'clinically relevant', 'cost', 'drug candidate', 'drug discovery', 'human stem cells', 'in vitro Model', 'induced pluripotent stem cell', 'instrument', 'instrumentation', 'novel therapeutics', 'optogenetics', 'patch clamp', 'phase 1 study', 'prediction algorithm', 'prevent', 'public health relevance', 'rate of change', 'response', 'screening', 'spatiotemporal', 'stem cell biology', 'success', 'therapeutic development', 'tool', 'voltage']",NHLBI,"Q-STATE BIOSCIENCES, INC.",R44,2016,602645,0.009348189663499222
"Innovative MRI-based Characterization of Cardiac Dyssynchrony     DESCRIPTION (provided by applicant): Cardiac dyssynchrony deteriorates cardiac function and often cannot be treated effectively. The goal of this proposal is to develop and provide a new analysis technique for understanding the complex cardiac motion patterns (in time and space) of patients with cardiac dyssynchrony, with the hope of improving its treatment outcomes, specifically with respect to cardiac resynchronization therapy (CRT). CRT, the most effective treatment for dyssynchrony with worsening heart failure, significantly improves outcome in only ~66% of heart failure patients selected for the treatment, which is based on ECG criteria. Selection criteria based on imaging are essential to improving the success rate. Unfortunately, response rates are not higher with selection criteria based on echocardiography, the most popular cardiac imaging technique. Cine cardiovascular magnetic resonance (CMR) has the potential to better characterize dyssynchrony, as it shows cardiac mechanics and intramural wall motion with much higher spatial resolution than echocardiography. However, quantitative assessments of CMR have been mostly limited to global volumetric measures, which ignore most of the motion information captured by the images. For example, studies of a number of distinctive motion features of dyssynchrony (such as septal flash and apical rocking) have been confined to qualitative assessment, limiting inference of their potential utility for improving CRT treatment. To accurately quantify cardiac function through CMR, we have developed biomechanical models for describing cardiac function and machine learning technology for identifying morphological and functional patterns atypical for healthy hearts. We propose to combine these two technologies to accurately quantify cardiac dyssynchrony within the Left Ventricle (LV). Specifically, our methods will extract a rich description of LV motion and strain from the CMRs of a set of retrospectively selected subjects with synchronous or dyssynchronous LV motion. We will then use machine learning methods to identify local and global motion patterns specific to dyssynchrony. Finally, we will correlate these patterns to already existing clinical scores to find potentially predictive markers with respect to CRT outcome. We hypothesize that these markers will have a higher correlation to CRT outcome than current clinical markers alone. Identifying these markers will have the potential to further stratify the disease with respect to the expected outcome of CRT, which then can be used to derive new selection criteria that lead to higher success rates. The project will also disseminate our novel, data-driven methodology for quantifying that motion. Other research groups can apply our tools to specifically study dyssynchrony, as well as other cardiac diseases impacting LV motion in general. PUBLIC HEALTH RELEVANCE: A significant proportion of patients with heart failure and cardiac dyssynchrony fail to positively respond to cardiac resynchronization therapy, as the current clinical selection criteria are too broad. Our goal is to more accurately characterize the complex shape and motion patterns of cardiac dyssynchrony, through new machine learning technology applied to dynamic cardiovascular magnetic resonance images. We envision that our findings would further improve both our understanding of cardiac dyssynchrony in relation to heart failure and the ability to predict its response to resynchronization therapy, potentially leading to new clinical guidelines and improved clinical outcomes.",Innovative MRI-based Characterization of Cardiac Dyssynchrony,9475862,R01HL127661,"['Apical', 'Cardiac', 'Cardiovascular system', 'Clinical', 'Clinical Markers', 'Clinical Research', 'Complex', 'Data', 'Databases', 'Disease', 'Echocardiography', 'Electrocardiogram', 'Goals', 'Guidelines', 'Heart', 'Heart Diseases', 'Heart failure', 'Image', 'Imaging Techniques', 'Individual', 'Lead', 'Left ventricular structure', 'Machine Learning', 'Magnetic Resonance', 'Magnetic Resonance Imaging', 'Measurement', 'Measures', 'Mechanics', 'Methodology', 'Methods', 'Modeling', 'Morphology', 'Motion', 'Movement', 'Outcome', 'Output', 'Patients', 'Pattern', 'Research', 'Resolution', 'Selection Criteria', 'Shapes', 'Structure', 'Techniques', 'Technology', 'Testing', 'Time', 'Treatment outcome', 'base', 'biomechanical model', 'cardiac resynchronization therapy', 'effective therapy', 'heart function', 'heart imaging', 'heart motion', 'improved', 'improved outcome', 'innovation', 'learning strategy', 'novel', 'predictive marker', 'public health relevance', 'response', 'spatiotemporal', 'success', 'therapy outcome', 'tool']",NHLBI,"RUTGERS, THE STATE UNIV OF N.J.",R01,2018,589455,0.20816365076197285
"Innovative MRI-based Characterization of Cardiac Dyssynchrony     DESCRIPTION (provided by applicant): Cardiac dyssynchrony deteriorates cardiac function and often cannot be treated effectively. The goal of this proposal is to develop and provide a new analysis technique for understanding the complex cardiac motion patterns (in time and space) of patients with cardiac dyssynchrony, with the hope of improving its treatment outcomes, specifically with respect to cardiac resynchronization therapy (CRT). CRT, the most effective treatment for dyssynchrony with worsening heart failure, significantly improves outcome in only ~66% of heart failure patients selected for the treatment, which is based on ECG criteria. Selection criteria based on imaging are essential to improving the success rate. Unfortunately, response rates are not higher with selection criteria based on echocardiography, the most popular cardiac imaging technique. Cine cardiovascular magnetic resonance (CMR) has the potential to better characterize dyssynchrony, as it shows cardiac mechanics and intramural wall motion with much higher spatial resolution than echocardiography. However, quantitative assessments of CMR have been mostly limited to global volumetric measures, which ignore most of the motion information captured by the images. For example, studies of a number of distinctive motion features of dyssynchrony (such as septal flash and apical rocking) have been confined to qualitative assessment, limiting inference of their potential utility for improving CRT treatment. To accurately quantify cardiac function through CMR, we have developed biomechanical models for describing cardiac function and machine learning technology for identifying morphological and functional patterns atypical for healthy hearts. We propose to combine these two technologies to accurately quantify cardiac dyssynchrony within the Left Ventricle (LV). Specifically, our methods will extract a rich description of LV motion and strain from the CMRs of a set of retrospectively selected subjects with synchronous or dyssynchronous LV motion. We will then use machine learning methods to identify local and global motion patterns specific to dyssynchrony. Finally, we will correlate these patterns to already existing clinical scores to find potentially predictive markers with respect to CRT outcome. We hypothesize that these markers will have a higher correlation to CRT outcome than current clinical markers alone. Identifying these markers will have the potential to further stratify the disease with respect to the expected outcome of CRT, which then can be used to derive new selection criteria that lead to higher success rates. The project will also disseminate our novel, data-driven methodology for quantifying that motion. Other research groups can apply our tools to specifically study dyssynchrony, as well as other cardiac diseases impacting LV motion in general. PUBLIC HEALTH RELEVANCE: A significant proportion of patients with heart failure and cardiac dyssynchrony fail to positively respond to cardiac resynchronization therapy, as the current clinical selection criteria are too broad. Our goal is to more accurately characterize the complex shape and motion patterns of cardiac dyssynchrony, through new machine learning technology applied to dynamic cardiovascular magnetic resonance images. We envision that our findings would further improve both our understanding of cardiac dyssynchrony in relation to heart failure and the ability to predict its response to resynchronization therapy, potentially leading to new clinical guidelines and improved clinical outcomes.",Innovative MRI-based Characterization of Cardiac Dyssynchrony,9281894,R01HL127661,"['Apical', 'Cardiac', 'Cardiovascular system', 'Clinical', 'Clinical Markers', 'Clinical Research', 'Complex', 'Data', 'Databases', 'Disease', 'Echocardiography', 'Electrocardiogram', 'Goals', 'Guidelines', 'Heart', 'Heart Diseases', 'Heart failure', 'Image', 'Imaging Techniques', 'Individual', 'Lead', 'Left ventricular structure', 'Machine Learning', 'Magnetic Resonance', 'Magnetic Resonance Imaging', 'Measurement', 'Measures', 'Mechanics', 'Methodology', 'Methods', 'Modeling', 'Morphology', 'Motion', 'Movement', 'Outcome', 'Output', 'Patients', 'Pattern', 'Research', 'Resolution', 'Selection Criteria', 'Shapes', 'Structure', 'Techniques', 'Technology', 'Testing', 'Time', 'Treatment outcome', 'base', 'biomechanical model', 'cardiac resynchronization therapy', 'cardiovascular visualization', 'effective therapy', 'heart motion', 'improved', 'improved outcome', 'innovation', 'learning strategy', 'novel', 'predictive marker', 'public health relevance', 'response', 'spatiotemporal', 'success', 'therapy outcome', 'tool']",NHLBI,"RUTGERS, THE STATE UNIV OF N.J.",R01,2017,593963,0.20816365076197285
"Machine Learning and Deformable Model-based 4D Characterization of Cardiac Dyssynchrony from MRI Summary/Abstract In the presence of diseases such as ischemic heart disease (IHD), cardiac dyssynchrony deteriorates cardiac function and often cannot be treated effectively. However, while imaging methods such as cardiovascular magnetic resonance (CMR) can provide high quality images of the moving heart, conventional clinical quantitative analysis of cardiac function is largely limited to global function analysis of the left ventricle (LV), with only qualitative and subjective characterization of regional function. An obstacle to better quantification of regional function is the complex 3D structure and motion of the heart wall, which has typically necessitated time-consuming user-guided processing of the images to carry out the associated 3D-motion analysis.  Recent advances in machine-learning (ML) approaches for image analysis are promising as new means to speed up the processing of cardiac images, as well as to analyze the underlying regional motion patterns. However, current Deep ML (DML) approaches to image analysis largely function as black boxes, without clear indications of which features contribute most to the analysis results, thus limiting their clinical utility. In the initial funded period of this research project, we have been developing integrated approaches to the segmentation, 3D reconstruction, and analysis of CMR data, with application to the evaluation of cardiac dyssynchrony. Today, treatment of dyssynchrony in HF with cardiac resynchronization therapy (CRT) leads to improvement in only ~2/3 patients selected with conventional criteria (usually by electrocardiogram [ECG]). Our initial results show encouraging results of correlation between MRI evaluation of dyssynchrony and cardiac resynchronization therapy (CRT) outcomes. In the new proposed research, we will further develop these methods, with the goal of automating the cardiac analysis methods. This will include the introduction of new ML-based methods, which will incorporate information on the specific cardiac motion factors that lead to classification of different disease states in dyssynchrony. Our Hypothesis is that by using these new ML-based methods for cardiac motion analysis, we will discover and evaluate significant quantitative correlations between different cardiac dyssynchrony motion patterns and CRT outcomes. Also, late-gadolinium enhancement (LGE) provides images for infarction visualization. Incorporation of tissue characterization into the motion-pattern analysis could lead to increased understanding of how infarcted areas affect regional motion in concert with dyssynchrony. The unearthing of these findings will allow us to validate them in future clinical studies. The project will also disseminate our novel, coupled DML and model-based methodology for quantifying and classifying cardiac motion in diseases affecting regional wall motion. Other research groups can then apply our tools to specifically study dyssynchrony, as well as other cardiac diseases affecting LV motion. Project Narrative A significant proportion of patients with heart failure and cardiac dyssynchrony fail to positively respond to cardiac resynchronization therapy (CRT), as the current clinical selection criteria do not take into account regional cardiac function. We will develop improved methods for 4D-analysis and -visualization of both global and regional cardiac function from cardiovascular magnetic resonance (CMR) data, including novel deep learning methods that will provide additional information on the salient features that contribute most to characterization of cardiac dyssynchrony. These new methods will be applied to the analysis of CMR data from both a stratified sample of normal subjects and patients with cardiac dyssynchrony (with and without infarction), with correlation with therapeutic results following CRT, potentially leading to improved clinical guidelines and clinical outcomes, as well as increased understanding of cardiac physiology and pathophysiology.",Machine Learning and Deformable Model-based 4D Characterization of Cardiac Dyssynchrony from MRI,10052934,R01HL127661,"['3-Dimensional', 'Affect', 'Area', 'Attention', 'Automation', 'Cardiac', 'Cardiovascular Physiology', 'Cardiovascular system', 'Classification', 'Clinical', 'Clinical Research', 'Complex', 'Consumption', 'Coupled', 'Data', 'Data Analyses', 'Data Set', 'Disease', 'EKG QRS Complex', 'Echocardiography', 'Electrocardiogram', 'Evaluation', 'Functional disorder', 'Funding', 'Future', 'Gadolinium', 'Goals', 'Guidelines', 'Heart', 'Heart Diseases', 'Heart failure', 'Image', 'Image Analysis', 'Image Enhancement', 'Infarction', 'Ischemia', 'Lead', 'Left ventricular structure', 'Location', 'Machine Learning', 'Magnetic Resonance', 'Magnetic Resonance Imaging', 'Measures', 'Methodology', 'Methods', 'Modeling', 'Motion', 'Myocardial Ischemia', 'Outcome', 'Output', 'Patient Selection', 'Patients', 'Pattern', 'Performance', 'Physiology', 'Prospective Studies', 'Pump', 'Research', 'Research Project Grants', 'Resolution', 'Sampling', 'Schedule', 'Selection Criteria', 'Speed', 'Sweden', 'Testing', 'Therapeutic', 'Time', 'Tissues', 'Treatment outcome', 'Universities', 'Visualization', 'Width', 'base', 'cardiac resynchronization therapy', 'deep learning', 'effective therapy', 'heart function', 'heart imaging', 'heart motion', 'image processing', 'imaging approach', 'imaging modality', 'improved', 'improved outcome', 'learning strategy', 'machine learning method', 'novel', 'patient subsets', 'reconstruction', 'response', 'spatiotemporal', 'success', 'therapy outcome', 'three dimensional structure', 'tool']",NHLBI,"RUTGERS, THE STATE UNIV OF N.J.",R01,2020,763531,0.25290258331733195
"Innovative MRI-based Characterization of Cardiac Dyssynchrony     DESCRIPTION (provided by applicant): Cardiac dyssynchrony deteriorates cardiac function and often cannot be treated effectively. The goal of this proposal is to develop and provide a new analysis technique for understanding the complex cardiac motion patterns (in time and space) of patients with cardiac dyssynchrony, with the hope of improving its treatment outcomes, specifically with respect to cardiac resynchronization therapy (CRT). CRT, the most effective treatment for dyssynchrony with worsening heart failure, significantly improves outcome in only ~66% of heart failure patients selected for the treatment, which is based on ECG criteria. Selection criteria based on imaging are essential to improving the success rate. Unfortunately, response rates are not higher with selection criteria based on echocardiography, the most popular cardiac imaging technique. Cine cardiovascular magnetic resonance (CMR) has the potential to better characterize dyssynchrony, as it shows cardiac mechanics and intramural wall motion with much higher spatial resolution than echocardiography. However, quantitative assessments of CMR have been mostly limited to global volumetric measures, which ignore most of the motion information captured by the images. For example, studies of a number of distinctive motion features of dyssynchrony (such as septal flash and apical rocking) have been confined to qualitative assessment, limiting inference of their potential utility for improving CRT treatment. To accurately quantify cardiac function through CMR, we have developed biomechanical models for describing cardiac function and machine learning technology for identifying morphological and functional patterns atypical for healthy hearts. We propose to combine these two technologies to accurately quantify cardiac dyssynchrony within the Left Ventricle (LV). Specifically, our methods will extract a rich description of LV motion and strain from the CMRs of a set of retrospectively selected subjects with synchronous or dyssynchronous LV motion. We will then use machine learning methods to identify local and global motion patterns specific to dyssynchrony. Finally, we will correlate these patterns to already existing clinical scores to find potentially predictive markers with respect to CRT outcome. We hypothesize that these markers will have a higher correlation to CRT outcome than current clinical markers alone. Identifying these markers will have the potential to further stratify the disease with respect to the expected outcome of CRT, which then can be used to derive new selection criteria that lead to higher success rates. The project will also disseminate our novel, data-driven methodology for quantifying that motion. Other research groups can apply our tools to specifically study dyssynchrony, as well as other cardiac diseases impacting LV motion in general. PUBLIC HEALTH RELEVANCE: A significant proportion of patients with heart failure and cardiac dyssynchrony fail to positively respond to cardiac resynchronization therapy, as the current clinical selection criteria are too broad. Our goal is to more accurately characterize the complex shape and motion patterns of cardiac dyssynchrony, through new machine learning technology applied to dynamic cardiovascular magnetic resonance images. We envision that our findings would further improve both our understanding of cardiac dyssynchrony in relation to heart failure and the ability to predict its response to resynchronization therapy, potentially leading to new clinical guidelines and improved clinical outcomes.",Innovative MRI-based Characterization of Cardiac Dyssynchrony,9043186,R01HL127661,"['Apical', 'Cardiac', 'Cardiovascular system', 'Clinical', 'Clinical Markers', 'Clinical Research', 'Complex', 'Data', 'Databases', 'Disease', 'Echocardiography', 'Electrocardiogram', 'Goals', 'Guidelines', 'Health', 'Heart', 'Heart Diseases', 'Heart failure', 'Image', 'Imaging Techniques', 'Individual', 'Lead', 'Left ventricular structure', 'Machine Learning', 'Magnetic Resonance', 'Magnetic Resonance Imaging', 'Measurement', 'Measures', 'Mechanics', 'Methodology', 'Methods', 'Modeling', 'Motion', 'Movement', 'Outcome', 'Output', 'Patients', 'Pattern', 'Research', 'Resolution', 'Selection Criteria', 'Shapes', 'Structure', 'Techniques', 'Technology', 'Testing', 'Time', 'Treatment outcome', 'base', 'biomechanical model', 'cardiac resynchronization therapy', 'cardiovascular visualization', 'effective therapy', 'heart motion', 'improved', 'improved outcome', 'innovation', 'learning strategy', 'novel', 'predictive marker', 'response', 'spatiotemporal', 'success', 'therapy outcome', 'tool']",NHLBI,"RUTGERS, THE STATE UNIV OF N.J.",R01,2016,599020,0.20816365076197285
"Innovative MRI-based Characterization of Cardiac Dyssynchrony     DESCRIPTION (provided by applicant): Cardiac dyssynchrony deteriorates cardiac function and often cannot be treated effectively. The goal of this proposal is to develop and provide a new analysis technique for understanding the complex cardiac motion patterns (in time and space) of patients with cardiac dyssynchrony, with the hope of improving its treatment outcomes, specifically with respect to cardiac resynchronization therapy (CRT). CRT, the most effective treatment for dyssynchrony with worsening heart failure, significantly improves outcome in only ~66% of heart failure patients selected for the treatment, which is based on ECG criteria. Selection criteria based on imaging are essential to improving the success rate. Unfortunately, response rates are not higher with selection criteria based on echocardiography, the most popular cardiac imaging technique. Cine cardiovascular magnetic resonance (CMR) has the potential to better characterize dyssynchrony, as it shows cardiac mechanics and intramural wall motion with much higher spatial resolution than echocardiography. However, quantitative assessments of CMR have been mostly limited to global volumetric measures, which ignore most of the motion information captured by the images. For example, studies of a number of distinctive motion features of dyssynchrony (such as septal flash and apical rocking) have been confined to qualitative assessment, limiting inference of their potential utility for improving CRT treatment. To accurately quantify cardiac function through CMR, we have developed biomechanical models for describing cardiac function and machine learning technology for identifying morphological and functional patterns atypical for healthy hearts. We propose to combine these two technologies to accurately quantify cardiac dyssynchrony within the Left Ventricle (LV). Specifically, our methods will extract a rich description of LV motion and strain from the CMRs of a set of retrospectively selected subjects with synchronous or dyssynchronous LV motion. We will then use machine learning methods to identify local and global motion patterns specific to dyssynchrony. Finally, we will correlate these patterns to already existing clinical scores to find potentially predictive markers with respect to CRT outcome. We hypothesize that these markers will have a higher correlation to CRT outcome than current clinical markers alone. Identifying these markers will have the potential to further stratify the disease with respect to the expected outcome of CRT, which then can be used to derive new selection criteria that lead to higher success rates. The project will also disseminate our novel, data-driven methodology for quantifying that motion. Other research groups can apply our tools to specifically study dyssynchrony, as well as other cardiac diseases impacting LV motion in general.         PUBLIC HEALTH RELEVANCE: A significant proportion of patients with heart failure and cardiac dyssynchrony fail to positively respond to cardiac resynchronization therapy, as the current clinical selection criteria are too broad. Our goal is to more accurately characterize the complex shape and motion patterns of cardiac dyssynchrony, through new machine learning technology applied to dynamic cardiovascular magnetic resonance images. We envision that our findings would further improve both our understanding of cardiac dyssynchrony in relation to heart failure and the ability to predict its response to resynchronization therapy, potentially leading to new clinical guidelines and improved clinical outcomes.            ",Innovative MRI-based Characterization of Cardiac Dyssynchrony,8875394,R01HL127661,"['Apical', 'Cardiac', 'Cardiovascular system', 'Clinical', 'Clinical Markers', 'Clinical Research', 'Complex', 'Data', 'Databases', 'Disease', 'Echocardiography', 'Electrocardiogram', 'Goals', 'Guidelines', 'Heart', 'Heart Diseases', 'Heart failure', 'Image', 'Imaging Techniques', 'Individual', 'Lead', 'Left ventricular structure', 'Machine Learning', 'Magnetic Resonance', 'Magnetic Resonance Imaging', 'Measurement', 'Measures', 'Mechanics', 'Methodology', 'Methods', 'Modeling', 'Motion', 'Movement', 'Outcome', 'Output', 'Patients', 'Pattern', 'Research', 'Resolution', 'Selection Criteria', 'Shapes', 'Solutions', 'Structure', 'Techniques', 'Technology', 'Testing', 'Time', 'Treatment outcome', 'base', 'biomechanical model', 'cardiovascular visualization', 'effective therapy', 'heart motion', 'improved', 'innovation', 'novel', 'predictive marker', 'public health relevance', 'response', 'spatiotemporal', 'success', 'therapy outcome', 'tool']",NHLBI,"RUTGERS, THE STATE UNIV OF N.J.",R01,2015,634258,0.20816365076197285
"Automated quantitative CT imaging of epicardial adipose tissue and risk of cardiac events PROJECT SUMMARY Coronary artery disease remains the leading cause of death worldwide, and more than half of the individuals suffering acute myocardial infarction have no prior symptoms. Coronary calcium scoring with non-contrast CT is increasingly used for cardiovascular risk stratification in the asymptomatic population. Epicardial adipose tissue (EAT), a local visceral fat depot surrounding the heart, has been recently reported as a significant imaging biomarker for cardiovascular risk stratification. Despite being routinely imaged noninvasively by non-contrast cardiac CT for coronary calcium scoring, EAT features are currently not measured or reported, primarily due to the absence of robust, automated quantification methods.  We propose to employ novel image processing algorithms to achieve fully automated, robust quantification of EAT features from cardiac CT, and to apply machine learning methods to efficiently combine patient clinical data, coronary calcium and EAT features into a new integrated risk score to predict future cardiac events. We will evaluate this risk score in two existing, prospective registries of asymptomatic patients with available coronary calcium scans, clinical data, and followup for cardiac events (myocardial infarction, cardiac death, late revascularization). These rich resources are: the Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research [EISNER] registry (2614 patients) and the St. Francis Heart Study (4613 patients). We propose three specific aims: 1) To develop and evaluate the accuracy and reproducibility of new computational algorithms for automated quantification of EAT measures; 2) To evaluate the prognostic value of automatically-quantified EAT features, relative to atherosclerotic plaque burden and measures of obesity, for the prediction of future cardiac events in asymptomatic patients in the EISNER registry and the St. Francis Heart Study; 3) To derive and evaluate a new, integrated risk scorecombining standard risk factors, coronary calcium score and EAT measures using machine learningfor the prediction of future cardiac events in the EISNER registry, and further, to additionally evaluate this risk score externally in the St. Francis Heart Study patient cohort.  This work in this proposal will provide a novel, personalized paradigm that will objectively and accurately identify asymptomatic patients undergoing coronary calcium scanning who are at increased risk for future cardiac events, without any additional imaging or risk to the patient. PROJECT NARRATIVE (lay language) CT scanning of the heart for coronary calcium scoring is a simple, widely-used, low-cost test with low radiation dose. Using these scans, the researchers propose to establish automated analysis of fat which surrounds the heart, as well as novel computerized scores that identify the patients who are at highest risk of suffering a heart attack. This new research will allow doctors to better identify patients for whom appropriate treatment could be prescribed, to avoid a heart attack or sudden cardiac death.",Automated quantitative CT imaging of epicardial adipose tissue and risk of cardiac events,9688580,R01HL133616,"['Acute myocardial infarction', 'Adipose tissue', 'Algorithms', 'American', 'Arterial Fatty Streak', 'Atherosclerosis', 'Cardiac', 'Cardiac Death', 'Cardiovascular system', 'Categories', 'Cause of Death', 'Clinical Data', 'Cohort Studies', 'Computational algorithm', 'Coronary', 'Coronary Arteriosclerosis', 'Coronary artery', 'Data', 'Development', 'Dose', 'Early identification', 'Event', 'Expressed Sequence Tags', 'Fatty acid glycerol esters', 'Future', 'Heart', 'Image', 'Individual', 'Inflammation Mediators', 'Institution', 'Interleukin-1 beta', 'Interleukin-6', 'Language', 'Length', 'Lipids', 'Low Dose Radiation', 'Machine Learning', 'Manuals', 'Measurement', 'Measures', 'Metabolic', 'Methods', 'Myocardial Infarction', 'Obesity', 'Patients', 'Population', 'Reader', 'Registries', 'Reporting', 'Reproducibility', 'Research', 'Research Personnel', 'Resources', 'Risk', 'Risk Assessment', 'Risk Factors', 'Risk stratification', 'Scanning', 'Source', 'Standardization', 'Stenosis', 'Symptoms', 'TNF gene', 'Testing', 'Trees', 'Visceral fat', 'Woman', 'Work', 'X-Ray Computed Tomography', 'automated analysis', 'cardiovascular risk factor', 'clinical practice', 'cohort', 'computerized', 'coronary artery calcium', 'coronary calcium scoring', 'coronary vasculature', 'cost', 'density', 'experience', 'follow-up', 'heart imaging', 'high risk', 'image processing', 'imaging biomarker', 'improved', 'indexing', 'learning strategy', 'men', 'non-invasive imaging', 'novel', 'pericardial sac', 'predictive marker', 'prognostic value', 'prospective', 'routine imaging', 'sudden cardiac death']",NHLBI,CEDARS-SINAI MEDICAL CENTER,R01,2019,653101,0.16028166966282237
"Automated quantitative CT imaging of epicardial adipose tissue and risk of cardiac events PROJECT SUMMARY Coronary artery disease remains the leading cause of death worldwide, and more than half of the individuals suffering acute myocardial infarction have no prior symptoms. Coronary calcium scoring with non-contrast CT is increasingly used for cardiovascular risk stratification in the asymptomatic population. Epicardial adipose tissue (EAT), a local visceral fat depot surrounding the heart, has been recently reported as a significant imaging biomarker for cardiovascular risk stratification. Despite being routinely imaged noninvasively by non-contrast cardiac CT for coronary calcium scoring, EAT features are currently not measured or reported, primarily due to the absence of robust, automated quantification methods.  We propose to employ novel image processing algorithms to achieve fully automated, robust quantification of EAT features from cardiac CT, and to apply machine learning methods to efficiently combine patient clinical data, coronary calcium and EAT features into a new integrated risk score to predict future cardiac events. We will evaluate this risk score in two existing, prospective registries of asymptomatic patients with available coronary calcium scans, clinical data, and followup for cardiac events (myocardial infarction, cardiac death, late revascularization). These rich resources are: the Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research [EISNER] registry (2614 patients) and the St. Francis Heart Study (4613 patients). We propose three specific aims: 1) To develop and evaluate the accuracy and reproducibility of new computational algorithms for automated quantification of EAT measures; 2) To evaluate the prognostic value of automatically-quantified EAT features, relative to atherosclerotic plaque burden and measures of obesity, for the prediction of future cardiac events in asymptomatic patients in the EISNER registry and the St. Francis Heart Study; 3) To derive and evaluate a new, integrated risk scorecombining standard risk factors, coronary calcium score and EAT measures using machine learningfor the prediction of future cardiac events in the EISNER registry, and further, to additionally evaluate this risk score externally in the St. Francis Heart Study patient cohort.  This work in this proposal will provide a novel, personalized paradigm that will objectively and accurately identify asymptomatic patients undergoing coronary calcium scanning who are at increased risk for future cardiac events, without any additional imaging or risk to the patient. PROJECT NARRATIVE (lay language) CT scanning of the heart for coronary calcium scoring is a simple, widely-used, low-cost test with low radiation dose. Using these scans, the researchers propose to establish automated analysis of fat which surrounds the heart, as well as novel computerized scores that identify the patients who are at highest risk of suffering a heart attack. This new research will allow doctors to better identify patients for whom appropriate treatment could be prescribed, to avoid a heart attack or sudden cardiac death.",Automated quantitative CT imaging of epicardial adipose tissue and risk of cardiac events,9310380,R01HL133616,"['Acute myocardial infarction', 'Adipose tissue', 'Algorithms', 'American', 'Arterial Fatty Streak', 'Atherosclerosis', 'Calcium', 'Cardiac', 'Cardiac Death', 'Cardiovascular system', 'Categories', 'Cause of Death', 'Clinical Data', 'Cohort Studies', 'Computational algorithm', 'Coronary', 'Coronary Arteriosclerosis', 'Coronary artery', 'Data', 'Development', 'Dose', 'Early identification', 'Event', 'Expressed Sequence Tags', 'Fatty acid glycerol esters', 'Future', 'Heart', 'Image', 'Individual', 'Inflammation Mediators', 'Institution', 'Interleukin-1 beta', 'Interleukin-6', 'Language', 'Length', 'Lipids', 'Low Dose Radiation', 'Machine Learning', 'Manuals', 'Measurement', 'Measures', 'Metabolic', 'Methods', 'Myocardial Infarction', 'Obesity', 'Patients', 'Population', 'Reader', 'Registries', 'Reporting', 'Reproducibility', 'Research', 'Research Personnel', 'Resources', 'Risk', 'Risk Assessment', 'Risk Factors', 'Risk stratification', 'Scanning', 'Source', 'Standardization', 'Stenosis', 'Symptoms', 'TNF gene', 'Testing', 'Trees', 'Visceral', 'Woman', 'Work', 'X-Ray Computed Tomography', 'cardiovascular risk factor', 'clinical practice', 'cohort', 'computerized', 'cost', 'density', 'experience', 'heart imaging', 'high risk', 'image processing', 'imaging biomarker', 'improved', 'indexing', 'learning strategy', 'men', 'non-invasive imaging', 'novel', 'pericardial sac', 'predictive marker', 'prognostic value', 'prospective', 'routine imaging', 'sudden cardiac death']",NHLBI,CEDARS-SINAI MEDICAL CENTER,R01,2017,653101,0.16028166966282237
"Automated quantitative CT imaging of epicardial adipose tissue and risk of cardiac events PROJECT SUMMARY Coronary artery disease remains the leading cause of death worldwide, and more than half of the individuals suffering acute myocardial infarction have no prior symptoms. Coronary calcium scoring with non-contrast CT is increasingly used for cardiovascular risk stratification in the asymptomatic population. Epicardial adipose tissue (EAT), a local visceral fat depot surrounding the heart, has been recently reported as a significant imaging biomarker for cardiovascular risk stratification. Despite being routinely imaged noninvasively by non-contrast cardiac CT for coronary calcium scoring, EAT features are currently not measured or reported, primarily due to the absence of robust, automated quantification methods.  We propose to employ novel image processing algorithms to achieve fully automated, robust quantification of EAT features from cardiac CT, and to apply machine learning methods to efficiently combine patient clinical data, coronary calcium and EAT features into a new integrated risk score to predict future cardiac events. We will evaluate this risk score in two existing, prospective registries of asymptomatic patients with available coronary calcium scans, clinical data, and followup for cardiac events (myocardial infarction, cardiac death, late revascularization). These rich resources are: the Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research [EISNER] registry (2614 patients) and the St. Francis Heart Study (4613 patients). We propose three specific aims: 1) To develop and evaluate the accuracy and reproducibility of new computational algorithms for automated quantification of EAT measures; 2) To evaluate the prognostic value of automatically-quantified EAT features, relative to atherosclerotic plaque burden and measures of obesity, for the prediction of future cardiac events in asymptomatic patients in the EISNER registry and the St. Francis Heart Study; 3) To derive and evaluate a new, integrated risk scorecombining standard risk factors, coronary calcium score and EAT measures using machine learningfor the prediction of future cardiac events in the EISNER registry, and further, to additionally evaluate this risk score externally in the St. Francis Heart Study patient cohort.  This work in this proposal will provide a novel, personalized paradigm that will objectively and accurately identify asymptomatic patients undergoing coronary calcium scanning who are at increased risk for future cardiac events, without any additional imaging or risk to the patient. PROJECT NARRATIVE (lay language) CT scanning of the heart for coronary calcium scoring is a simple, widely-used, low-cost test with low radiation dose. Using these scans, the researchers propose to establish automated analysis of fat which surrounds the heart, as well as novel computerized scores that identify the patients who are at highest risk of suffering a heart attack. This new research will allow doctors to better identify patients for whom appropriate treatment could be prescribed, to avoid a heart attack or sudden cardiac death.",Automated quantitative CT imaging of epicardial adipose tissue and risk of cardiac events,9475874,R01HL133616,"['Acute myocardial infarction', 'Adipose tissue', 'Algorithms', 'American', 'Arterial Fatty Streak', 'Atherosclerosis', 'Cardiac', 'Cardiac Death', 'Cardiovascular system', 'Categories', 'Cause of Death', 'Clinical Data', 'Cohort Studies', 'Computational algorithm', 'Coronary', 'Coronary Arteriosclerosis', 'Coronary artery', 'Data', 'Development', 'Dose', 'Early identification', 'Event', 'Expressed Sequence Tags', 'Fatty acid glycerol esters', 'Future', 'Heart', 'Image', 'Individual', 'Inflammation Mediators', 'Institution', 'Interleukin-1 beta', 'Interleukin-6', 'Language', 'Length', 'Lipids', 'Low Dose Radiation', 'Machine Learning', 'Manuals', 'Measurement', 'Measures', 'Metabolic', 'Methods', 'Myocardial Infarction', 'Obesity', 'Patients', 'Population', 'Reader', 'Registries', 'Reporting', 'Reproducibility', 'Research', 'Research Personnel', 'Resources', 'Risk', 'Risk Assessment', 'Risk Factors', 'Risk stratification', 'Scanning', 'Source', 'Standardization', 'Stenosis', 'Symptoms', 'TNF gene', 'Testing', 'Trees', 'Visceral', 'Woman', 'Work', 'X-Ray Computed Tomography', 'cardiovascular risk factor', 'clinical practice', 'cohort', 'computerized', 'coronary artery calcium', 'coronary calcium scoring', 'coronary vasculature', 'cost', 'density', 'experience', 'heart imaging', 'high risk', 'image processing', 'imaging biomarker', 'improved', 'indexing', 'learning strategy', 'men', 'non-invasive imaging', 'novel', 'pericardial sac', 'predictive marker', 'prognostic value', 'prospective', 'routine imaging', 'sudden cardiac death']",NHLBI,CEDARS-SINAI MEDICAL CENTER,R01,2018,653101,0.16028166966282237
"Automated quantitative CT imaging of epicardial adipose tissue and risk of cardiac events PROJECT SUMMARY Coronary artery disease remains the leading cause of death worldwide, and more than half of the individuals suffering acute myocardial infarction have no prior symptoms. Coronary calcium scoring with non-contrast CT is increasingly used for cardiovascular risk stratification in the asymptomatic population. Epicardial adipose tissue (EAT), a local visceral fat depot surrounding the heart, has been recently reported as a significant imaging biomarker for cardiovascular risk stratification. Despite being routinely imaged noninvasively by non-contrast cardiac CT for coronary calcium scoring, EAT features are currently not measured or reported, primarily due to the absence of robust, automated quantification methods.  We propose to employ novel image processing algorithms to achieve fully automated, robust quantification of EAT features from cardiac CT, and to apply machine learning methods to efficiently combine patient clinical data, coronary calcium and EAT features into a new integrated risk score to predict future cardiac events. We will evaluate this risk score in two existing, prospective registries of asymptomatic patients with available coronary calcium scans, clinical data, and followup for cardiac events (myocardial infarction, cardiac death, late revascularization). These rich resources are: the Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research [EISNER] registry (2614 patients) and the St. Francis Heart Study (4613 patients). We propose three specific aims: 1) To develop and evaluate the accuracy and reproducibility of new computational algorithms for automated quantification of EAT measures; 2) To evaluate the prognostic value of automatically-quantified EAT features, relative to atherosclerotic plaque burden and measures of obesity, for the prediction of future cardiac events in asymptomatic patients in the EISNER registry and the St. Francis Heart Study; 3) To derive and evaluate a new, integrated risk scorecombining standard risk factors, coronary calcium score and EAT measures using machine learningfor the prediction of future cardiac events in the EISNER registry, and further, to additionally evaluate this risk score externally in the St. Francis Heart Study patient cohort.  This work in this proposal will provide a novel, personalized paradigm that will objectively and accurately identify asymptomatic patients undergoing coronary calcium scanning who are at increased risk for future cardiac events, without any additional imaging or risk to the patient. PROJECT NARRATIVE (lay language) CT scanning of the heart for coronary calcium scoring is a simple, widely-used, low-cost test with low radiation dose. Using these scans, the researchers propose to establish automated analysis of fat which surrounds the heart, as well as novel computerized scores that identify the patients who are at highest risk of suffering a heart attack. This new research will allow doctors to better identify patients for whom appropriate treatment could be prescribed, to avoid a heart attack or sudden cardiac death.",Automated quantitative CT imaging of epicardial adipose tissue and risk of cardiac events,9159185,R01HL133616,"['Acute myocardial infarction', 'Adipose tissue', 'Algorithms', 'American', 'Arterial Fatty Streak', 'Atherosclerosis', 'Calcium', 'Cardiac', 'Cardiac Death', 'Cardiovascular system', 'Categories', 'Cause of Death', 'Clinical Data', 'Cohort Studies', 'Computational algorithm', 'Coronary', 'Coronary Arteriosclerosis', 'Coronary artery', 'Data', 'Development', 'Dose', 'Early identification', 'Event', 'Fatty acid glycerol esters', 'Future', 'Heart', 'Image', 'Individual', 'Inflammation Mediators', 'Institution', 'Interleukin-1 beta', 'Interleukin-6', 'Investigation', 'Language', 'Length', 'Lipids', 'Low Dose Radiation', 'Machine Learning', 'Manuals', 'Measurement', 'Measures', 'Methods', 'Myocardial Infarction', 'Obesity', 'Patients', 'Population', 'Process', 'Reader', 'Registries', 'Reporting', 'Reproducibility', 'Research', 'Research Personnel', 'Resources', 'Risk', 'Risk Assessment', 'Risk Factors', 'Scanning', 'Source', 'Stenosis', 'Stratification', 'Symptoms', 'TNF gene', 'Testing', 'Trees', 'Visceral', 'Woman', 'Work', 'X-Ray Computed Tomography', 'cardiovascular risk factor', 'clinical practice', 'cohort', 'computerized', 'cost', 'density', 'experience', 'high risk', 'image processing', 'imaging biomarker', 'improved', 'indexing', 'learning strategy', 'men', 'non-invasive imaging', 'novel', 'pericardial sac', 'predictive marker', 'prognostic value', 'prospective', 'sudden cardiac death']",NHLBI,CEDARS-SINAI MEDICAL CENTER,R01,2016,671851,0.16028166966282237
"HLS-Cardiac Safety AI Trained Human Heart and Micro Heart Model HLS17-12. The US FDA is considering to establish a new cardiac safety assessment approach  defined by a new paradigm called, Comprehensive in vitro Proarrhythmia Assay (CIPA). The CIPA will 1) assess drug effects on each cardiac ion channel type individually using a high- throughput assay ion channel assays, 2) compute net effect on repolarization and risks for  torsade pointes (TdP) using a mathematical model, and 3) confirm the computational prediction by measuring the drugs effects on action potentials in induced pluripotent stem cell (iPSC) derived human cardiac myocytes (CMs). This paradigm shift, if successful, could reduce the cost of  cardiac safety analyses by replacing or lowering the requirement to perform an expensive ($2-4 million) thorough QT study during clinical trials. Protecting consumers from drug induced  arrhythmia and sudden deaths is a paramount importance for the regulators and pharmaceutical companies as well as lowing the cost of drug development. Many cardiac safety scientists, however, are skeptical about CIPAs approach since CMs derived from human iPSCs exhibit a poor excitation-contraction coupling due to their immaturity. In addition, a proposed CIPA mathematical model was developed to simulate electrophysiology of human adult CMs, so there is a mismatch between experimental system and computational tool. To address these concerns, we proposed three specific aims in tw0 phases by following Fast- Track SBIR processes. Phase I feasibility Aim 1 will measure drug-induced changes in AP and CaT using human adult heart slices isolated from human donors. Here we will confirm our  successful handling and analyzing human adult heart slices, which will be based on a recently  published protocol by our collaborator, Dr. Igor Efimov, at George Washington University. After this validation, we will move on to perform the following two studies: Aim 2. Compare drug-induced changes in AP and CaT in NuHearts generated from adult CMs and cardiac fibroblasts from same human donor hearts; Aim 3. Validate and improve the computational models and train an artificial intelligence to predict cardiac safety risks of unknow compounds. After our successful completion proposed projects, we can establish an unprecedented cardiac safety assessment platform that can predict safety issues using a well-trained AI without doing any experiments using human heart slices that are rarely accessible for most of the safety  laboratories or biotech firms. Because nearly one third of drug candidates fails to reach market due to its cardiac safety concerns, a better safety assessment approach without increasing its cost is needed to improve productivity of pharmaceutical industry. The proposed project combines computational and experimental analyses of cardiac safety parameters using adult heart cells isolated from a donor heart and its stem cell derived heart muscle cells to build a better but cost-effective cardiac safety assessment system. A successfully validated system enables drug developers to arcuately predict a new drugs cardiac safety profile by only running cost-effective experiments using stem cell derived heart muscle cells that are accessible to many drug developers.",HLS-Cardiac Safety AI Trained Human Heart and Micro Heart Model,9948757,R44HL139248,"['3-Dimensional', 'Action Potentials', 'Address', 'Adult', 'Arrhythmia', 'Artificial Intelligence', 'Biological Assay', 'Biomedical Research', 'Biotechnology', 'Calcium', 'Cardiac', 'Cardiac Myocytes', 'Cardiotoxicity', 'Cells', 'Clinical', 'Clinical Trials', 'Communities', 'Computer Analysis', 'Computer Models', 'Contracts', 'Coupling', 'DNA Sequence Alteration', 'Data', 'Development', 'Dose', 'Drug Costs', 'Drug Industry', 'Electrophysiology (science)', 'Exhibits', 'Expert Systems', 'Fibroblasts', 'Gene Expression', 'Generations', 'Genetic', 'Genetic Predisposition to Disease', 'Guidelines', 'Heart', 'Human', 'In Vitro', 'Individual', 'Ion Channel', 'Laboratories', 'Marketing', 'Measures', 'Methods', 'Michigan', 'Mitochondria', 'Modeling', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'Pharmacology', 'Phase', 'Phenotype', 'Physiology', 'Population Heterogeneity', 'Preclinical Testing', 'Probability', 'Process', 'Productivity', 'Protocols documentation', 'Publishing', 'Pump', 'Reproducibility', 'Risk', 'Running', 'Safety', 'Sample Size', 'Sampling', 'Scientist', 'Shipping', 'Ships', 'Slice', 'Small Business Innovation Research Grant', 'Statistical Data Interpretation', 'Sudden Death', 'System', 'Testing', 'Tissues', 'Training', 'Universities', 'Validation', 'Washington', 'Work', 'base', 'cardiac tissue engineering', 'commercialization', 'computerized tools', 'cost', 'cost effective', 'data archive', 'drug candidate', 'drug development', 'drug discovery', 'experimental analysis', 'experimental study', 'heart cell', 'heart preservation', 'high throughput screening', 'human data', 'improved', 'in vitro Assay', 'induced pluripotent stem cell', 'mathematical model', 'novel therapeutics', 'personalized medicine', 'precision drugs', 'response', 'safety assessment', 'screening', 'side effect', 'simulation', 'stem cells', 'success']",NHLBI,"INVIVOSCIENCES, INC.",R44,2020,861204,0.14236692145263974
"HLS-Cardiac Safety AI Trained Human Heart and Micro Heart Model HLS17-12. The US FDA is considering to establish a new cardiac safety assessment approach  defined by a new paradigm called, Comprehensive in vitro Proarrhythmia Assay (CIPA). The CIPA will 1) assess drug effects on each cardiac ion channel type individually using a high- throughput assay ion channel assays, 2) compute net effect on repolarization and risks for  torsade pointes (TdP) using a mathematical model, and 3) confirm the computational prediction by measuring the drugs effects on action potentials in induced pluripotent stem cell (iPSC) derived human cardiac myocytes (CMs). This paradigm shift, if successful, could reduce the cost of  cardiac safety analyses by replacing or lowering the requirement to perform an expensive ($2-4 million) thorough QT study during clinical trials. Protecting consumers from drug induced  arrhythmia and sudden deaths is a paramount importance for the regulators and pharmaceutical companies as well as lowing the cost of drug development. Many cardiac safety scientists, however, are skeptical about CIPAs approach since CMs derived from human iPSCs exhibit a poor excitation-contraction coupling due to their immaturity. In addition, a proposed CIPA mathematical model was developed to simulate electrophysiology of human adult CMs, so there is a mismatch between experimental system and computational tool. To address these concerns, we proposed three specific aims in tw0 phases by following Fast- Track SBIR processes. Phase I feasibility Aim 1 will measure drug-induced changes in AP and CaT using human adult heart slices isolated from human donors. Here we will confirm our  successful handling and analyzing human adult heart slices, which will be based on a recently  published protocol by our collaborator, Dr. Igor Efimov, at George Washington University. After this validation, we will move on to perform the following two studies: Aim 2. Compare drug-induced changes in AP and CaT in NuHearts generated from adult CMs and cardiac fibroblasts from same human donor hearts; Aim 3. Validate and improve the computational models and train an artificial intelligence to predict cardiac safety risks of unknow compounds. After our successful completion proposed projects, we can establish an unprecedented cardiac safety assessment platform that can predict safety issues using a well-trained AI without doing any experiments using human heart slices that are rarely accessible for most of the safety  laboratories or biotech firms. Because nearly one third of drug candidates fails to reach market due to its cardiac safety concerns, a better safety assessment approach without increasing its cost is needed to improve productivity of pharmaceutical industry. The proposed project combines computational and experimental analyses of cardiac safety parameters using adult heart cells isolated from a donor heart and its stem cell derived heart muscle cells to build a better but cost-effective cardiac safety assessment system. A successfully validated system enables drug developers to arcuately predict a new drugs cardiac safety profile by only running cost-effective experiments using stem cell derived heart muscle cells that are accessible to many drug developers.",HLS-Cardiac Safety AI Trained Human Heart and Micro Heart Model,9764845,R44HL139248,"['3-Dimensional', 'Action Potentials', 'Address', 'Adult', 'Arrhythmia', 'Artificial Intelligence', 'Biological Assay', 'Biomedical Research', 'Biotechnology', 'Calcium', 'Cardiac', 'Cardiac Myocytes', 'Cardiotoxicity', 'Cells', 'Clinical', 'Clinical Trials', 'Communities', 'Computer Analysis', 'Computer Simulation', 'Contracts', 'Coupling', 'DNA Sequence Alteration', 'Data', 'Development', 'Dose', 'Drug Costs', 'Drug Industry', 'Electrophysiology (science)', 'Exhibits', 'Expert Systems', 'Fibroblasts', 'Gene Expression', 'Generations', 'Genetic', 'Genetic Predisposition to Disease', 'Guidelines', 'Heart', 'Human', 'In Vitro', 'Individual', 'Ion Channel', 'Laboratories', 'Libraries', 'Marketing', 'Measures', 'Methods', 'Michigan', 'Mitochondria', 'Modeling', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'Pharmacology', 'Phase', 'Phenotype', 'Physiology', 'Population Heterogeneity', 'Preclinical Testing', 'Probability', 'Process', 'Productivity', 'Protocols documentation', 'Publishing', 'Pump', 'Reproducibility', 'Risk', 'Running', 'Safety', 'Sample Size', 'Sampling', 'Scientist', 'Shipping', 'Ships', 'Slice', 'Small Business Innovation Research Grant', 'Statistical Data Interpretation', 'Stem cells', 'Sudden Death', 'System', 'Testing', 'Tissues', 'Training', 'Universities', 'Validation', 'Washington', 'Work', 'base', 'cardiac tissue engineering', 'commercialization', 'computerized tools', 'cost', 'cost effective', 'drug candidate', 'drug development', 'drug discovery', 'experimental analysis', 'experimental study', 'heart cell', 'heart preservation', 'high throughput screening', 'human data', 'improved', 'in vitro Assay', 'induced pluripotent stem cell', 'mathematical model', 'novel therapeutics', 'personalized medicine', 'response', 'safety assessment', 'screening', 'side effect', 'simulation', 'success']",NHLBI,"INVIVOSCIENCES, INC.",R44,2019,881652,0.14236692145263974
"HLS-Cardiac Safety AI Trained Human Heart and Micro Heart Model HLS17-12. The US FDA is considering to establish a new cardiac safety assessment approach de- fined by a new paradigm called, Comprehensive in vitro Proarrhythmia Assay (CIPA). The CIPA will 1) assess drug effects on each cardiac ion channel type individually using a high- throughput assay ion channel assays, 2) compute net effect on repolarization and risks for tor- sade pointes (TdP) using a mathematical model, and 3) confirm the computational prediction by measuring the drugs effects on action potentials in induced pluripotent stem cell (iPSC) derived human cardiac myocytes (CMs). This paradigm shift, if successful, could reduce the cost of car- diac safety analyses by replacing or lowering the requirement to perform an expensive ($2-4 million) thorough QT study during clinical trials. Protecting consumers from drug induced ar- rhythmia and sudden deaths is a paramount importance for the regulators and pharmaceutical companies as well as lowing the cost of drug development. Many cardiac safety scientists, however, are skeptical about CIPAs approach since CMs derived from human iPSCs exhibit a poor excitation-contraction coupling due to their immaturity. In addition, a proposed CIPA mathematical model was developed to simulate electrophysiology of human adult CMs, so there is a mismatch between experimental system and computational tool. To address these concerns, we proposed three specific aims in tw0 phases by following Fast- Track SBIR processes. Phase I feasibility Aim 1 will measure drug-induced changes in AP and CaT using human adult heart slices isolated from human donors. Here we will confirm our suc- cessful handling and analyzing human adult heart slices, which will be based on a recently pub- lished protocol by our collaborator, Dr. Igor Efimov, at George Washington University. After this validation, we will move on to perform the following two studies: Aim 2. Compare drug-induced changes in AP and CaT in NuHearts generated from adult CMs and cardiac fibroblasts from same human donor hearts; Aim 3. Validate and improve the computational models and train an artificial intelligence to predict cardiac safety risks of unknow compounds. After our successful completion proposed projects, we can establish an unprecedented cardiac safety assessment platform that can predict safety issues using a well-trained AI without doing any experiments using human heart slices that are rarely accessible for most of the safety labor- atories or biotech firms. Because nearly one third of drug candidates fails to reach market due to its cardiac safety concerns, a better safety assessment approach without increasing its cost is needed to improve productivity of pharmaceutical industry. The proposed project combines computational and experimental analyses of cardiac safety parameters using adult heart cells isolated from a donor heart and its stem cell derived heart muscle cells to build a better but cost-effective cardiac safety assessment system. A successfully validated system enables drug developers to arcuately predict a new drugs cardiac safety profile by only running cost-effective experiments using stem cell derived heart muscle cells that are accessible to many drug developers.",HLS-Cardiac Safety AI Trained Human Heart and Micro Heart Model,9555779,R44HL139248,"['Action Potentials', 'Address', 'Adult', 'Adverse effects', 'Artificial Intelligence', 'Biological Assay', 'Biomedical Research', 'Biotechnology', 'Calcium', 'Cardiac', 'Cardiac Myocytes', 'Cardiotoxicity', 'Cells', 'Clinical', 'Clinical Trials', 'Communities', 'Computer Analysis', 'Computer Simulation', 'Contracts', 'Coupling', 'DNA Sequence Alteration', 'Data', 'Development', 'Dose', 'Drug Costs', 'Drug Industry', 'Electrophysiology (science)', 'Exhibits', 'Fibroblasts', 'Gene Expression', 'Generations', 'Genetic', 'Genetic Predisposition to Disease', 'Guidelines', 'Heart', 'Human', 'In Vitro', 'Individual', 'Ion Channel', 'Laboratories', 'Libraries', 'Marketing', 'Measures', 'Methods', 'Michigan', 'Mitochondria', 'Modeling', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'Pharmacology', 'Phase', 'Phenotype', 'Physiology', 'Pluripotent Stem Cells', 'Population Heterogeneity', 'Preclinical Testing', 'Probability', 'Process', 'Productivity', 'Protocols documentation', 'Publishing', 'Pump', 'Reproducibility', 'Risk', 'Running', 'Safety', 'Sample Size', 'Sampling', 'Scientist', 'Shipping', 'Ships', 'Slice', 'Small Business Innovation Research Grant', 'Statistical Data Interpretation', 'Stem cells', 'Sudden Death', 'System', 'Testing', 'Tissues', 'Training', 'Universities', 'Validation', 'Washington', 'Work', 'base', 'cardiac tissue engineering', 'commercialization', 'computerized tools', 'cost', 'cost effective', 'drug candidate', 'drug development', 'drug discovery', 'experimental analysis', 'experimental study', 'heart cell', 'high throughput screening', 'human data', 'improved', 'in vitro Assay', 'induced pluripotent stem cell', 'man', 'mathematical model', 'novel therapeutics', 'personalized medicine', 'response', 'screening', 'simulation', 'success']",NHLBI,"INVIVOSCIENCES, INC.",R44,2018,349385,0.1309691013997436
"Machine learning for the automated identification and tracking of rare myocardial diseases PROJECT SUMMARY Although cardiac amyloidosis and hypertrophic cardiomyopathy (HCM) are relatively rare causes of heart failure (HF), they are particularly challenging to detect and treat for several shared reasons: (1) on routine clinical imaging (i.e., echocardiography [echo]), they can be difficult to distinguish from superficially similar, more common forms of cardiac disease that cause left ventricular (LV) hypertrophy; (2) the diagnoses are often missed and thus patients can present late in the course of disease at a time when treatment is difficult; (3) objective, noninvasive metrics that reliably reflect disease progression have not been identified; and (4) the small number of known patients with these diseases can make epidemiology studies and clinical trials difficult to organize and conduct. For both cardiac amyloidosis and HCM, echo plays a critical role in both diagnosis and longitudinal monitoring given its ubiquitous clinical availability, safety, and low cost. More broadly, echo dominates the current landscape of routine cardiac imaging, with tens of millions of echos performed in the United States each year. However, the clinical challenges described above highlight several shortcomings of echo: it is limited in its ability to (1) diagnose disease at its early stages; (2) discriminate between morphologically similar diseases; and (3) quantify disease progression. This proposal seeks to address deficiencies in the current echo reading workflow, which is subjective and captures only a small fraction of the data available in each study. The overall objective of this application is to use advances in machine learning to develop and validate fully-automated echo image analytic approaches to diagnose and track rare cardiomyopathies, focusing on cardiac amyloidosis and HCM. Our proposal is centered on the hypothesis that highly scalable computer vision methods can be applied to echo studies to overcome limitations of the standard clinical echo reading workflow. Accordingly our aims are: (1) Apply an automated method for echo quantification and disease identification to detect and differentiate cardiac diseases that cause increased LV wall thickness; and (2) Characterize quantifiable echo measures of disease progression in cardiac amyloidosis and HCM and associate these with clinical outcomes. Our multidisciplinary team, which is composed of experts in cardiomyopathies, echocardiography, computer vision, and machine learning, will analyze echos and patient data from 2 large patient registries: the Multicenter Amyloid Phenotyping Study (MAPS) and the Sarcomeric Human Cardiomyopathy Registry (SHaRe) HCM Network, with validation using a repository of nearly 400,000 echos. The successful completion of our aims will result in an innovative tool for early diagnosis of myocardial diseases and tracking of disease progression. Importantly, our project will set the stage for conducting larger epidemiology studies of rare myocardial diseases by automating the identification of these patients, and thereby developing previously unattainable broad-based cohorts for these conditions. PROJECT NARRATIVE Rare heart diseases such as amyloidosis (due to abnormal deposition of a protein into the heart muscle) and hypertrophic cardiomyopathy (due to a genetic mutation) are important causes of heart failure and sudden death in the general population. These heart diseases are difficult to diagnose, monitor, and treat because: (1) they appear superficially similar to more common forms of heart disease (e.g., high blood pressure) on imaging tests; (2) the optimal monitoring of disease progression over time has not been established; and (3) there is a lack of large-scale studies of patients with these diseases given their rarity. This project aims to use machine learning (artificial intelligence) of digital echocardiographic images to create a completely automated method for diagnosing and tracking these rare heart diseases with the ultimate goal of broad deployment of artificial intelligence algorithms in hospitals and clinics to help identify patients with these rare heart diseases earlier, better predict adverse outcomes, and increase the size and scope of patient registries to enhance research of these conditions.",Machine learning for the automated identification and tracking of rare myocardial diseases,9739345,R01HL140731,"['Address', 'Affect', 'Algorithm Design', 'Amyloid', 'Amyloidosis', 'Arrhythmia', 'Artificial Intelligence', 'Cardiac', 'Cardiomyopathies', 'Cardiovascular system', 'Cessation of life', 'Clinical', 'Clinical Trials', 'Clinics and Hospitals', 'Cohort Studies', 'Communities', 'Computer Vision Systems', 'Coronary heart disease', 'DNA Sequence Alteration', 'Data', 'Deposition', 'Detection', 'Development', 'Diagnosis', 'Disease', 'Disease Progression', 'Early Diagnosis', 'Echocardiography', 'Face', 'General Population', 'Goals', 'Heart Diseases', 'Heart failure', 'Hospitalization', 'Human', 'Hypertension', 'Hypertrophic Cardiomyopathy', 'Image', 'Image Analysis', 'Individual', 'Information Retrieval', 'Inherited', 'Left', 'Left Ventricular Hypertrophy', 'Machine Learning', 'Manuals', 'Measurement', 'Measures', 'Methods', 'Molecular', 'Monitor', 'Morphology', 'Myocardium', 'Outcome', 'Output', 'Patients', 'Phenotype', 'Play', 'Process', 'Proteins', 'Reader', 'Reading', 'Registries', 'Research', 'Research Personnel', 'Role', 'Safety', 'Standardization', 'Structure', 'Sudden Death', 'Symptoms', 'Testing', 'Thick', 'Time', 'Two-Dimensional Echocardiography', 'United States', 'Validation', 'Ventricular', 'adverse outcome', 'automated image analysis', 'base', 'career', 'clinical care', 'clinical imaging', 'cohort', 'comorbidity', 'cost', 'digital', 'disease diagnosis', 'epidemiology study', 'heart imaging', 'hypertensive heart disease', 'image processing', 'innovation', 'intelligent algorithm', 'interest', 'multidisciplinary', 'novel therapeutics', 'particle', 'patient registry', 'repository', 'response', 'statistical learning', 'tool']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,R01,2020,687210,0.10544944141152846
"Machine learning for the automated identification and tracking of rare myocardial diseases PROJECT SUMMARY Although cardiac amyloidosis and hypertrophic cardiomyopathy (HCM) are relatively rare causes of heart failure (HF), they are particularly challenging to detect and treat for several shared reasons: (1) on routine clinical imaging (i.e., echocardiography [echo]), they can be difficult to distinguish from superficially similar, more common forms of cardiac disease that cause left ventricular (LV) hypertrophy; (2) the diagnoses are often missed and thus patients can present late in the course of disease at a time when treatment is difficult; (3) objective, noninvasive metrics that reliably reflect disease progression have not been identified; and (4) the small number of known patients with these diseases can make epidemiology studies and clinical trials difficult to organize and conduct. For both cardiac amyloidosis and HCM, echo plays a critical role in both diagnosis and longitudinal monitoring given its ubiquitous clinical availability, safety, and low cost. More broadly, echo dominates the current landscape of routine cardiac imaging, with tens of millions of echos performed in the United States each year. However, the clinical challenges described above highlight several shortcomings of echo: it is limited in its ability to (1) diagnose disease at its early stages; (2) discriminate between morphologically similar diseases; and (3) quantify disease progression. This proposal seeks to address deficiencies in the current echo reading workflow, which is subjective and captures only a small fraction of the data available in each study. The overall objective of this application is to use advances in machine learning to develop and validate fully-automated echo image analytic approaches to diagnose and track rare cardiomyopathies, focusing on cardiac amyloidosis and HCM. Our proposal is centered on the hypothesis that highly scalable computer vision methods can be applied to echo studies to overcome limitations of the standard clinical echo reading workflow. Accordingly our aims are: (1) Apply an automated method for echo quantification and disease identification to detect and differentiate cardiac diseases that cause increased LV wall thickness; and (2) Characterize quantifiable echo measures of disease progression in cardiac amyloidosis and HCM and associate these with clinical outcomes. Our multidisciplinary team, which is composed of experts in cardiomyopathies, echocardiography, computer vision, and machine learning, will analyze echos and patient data from 2 large patient registries: the Multicenter Amyloid Phenotyping Study (MAPS) and the Sarcomeric Human Cardiomyopathy Registry (SHaRe) HCM Network, with validation using a repository of nearly 400,000 echos. The successful completion of our aims will result in an innovative tool for early diagnosis of myocardial diseases and tracking of disease progression. Importantly, our project will set the stage for conducting larger epidemiology studies of rare myocardial diseases by automating the identification of these patients, and thereby developing previously unattainable broad-based cohorts for these conditions. PROJECT NARRATIVE Rare heart diseases such as amyloidosis (due to abnormal deposition of a protein into the heart muscle) and hypertrophic cardiomyopathy (due to a genetic mutation) are important causes of heart failure and sudden death in the general population. These heart diseases are difficult to diagnose, monitor, and treat because: (1) they appear superficially similar to more common forms of heart disease (e.g., high blood pressure) on imaging tests; (2) the optimal monitoring of disease progression over time has not been established; and (3) there is a lack of large-scale studies of patients with these diseases given their rarity. This project aims to use machine learning (artificial intelligence) of digital echocardiographic images to create a completely automated method for diagnosing and tracking these rare heart diseases with the ultimate goal of broad deployment of artificial intelligence algorithms in hospitals and clinics to help identify patients with these rare heart diseases earlier, better predict adverse outcomes, and increase the size and scope of patient registries to enhance research of these conditions.",Machine learning for the automated identification and tracking of rare myocardial diseases,9838368,R01HL140731,"['Address', 'Affect', 'Algorithm Design', 'Algorithms', 'Amyloid', 'Amyloidosis', 'Arrhythmia', 'Artificial Intelligence', 'Cardiac', 'Cardiomyopathies', 'Cardiovascular system', 'Cessation of life', 'Clinical', 'Clinical Trials', 'Clinics and Hospitals', 'Cohort Studies', 'Communities', 'Comorbidity', 'Computer Vision Systems', 'Coronary heart disease', 'DNA Sequence Alteration', 'Data', 'Deposition', 'Detection', 'Development', 'Diagnosis', 'Disease', 'Disease Progression', 'Early Diagnosis', 'Echocardiography', 'Face', 'General Population', 'Goals', 'Heart Diseases', 'Heart failure', 'Hospitalization', 'Human', 'Hypertension', 'Hypertrophic Cardiomyopathy', 'Image', 'Image Analysis', 'Individual', 'Inherited', 'Left', 'Left Ventricular Hypertrophy', 'Machine Learning', 'Manuals', 'Measurement', 'Measures', 'Methods', 'Molecular', 'Monitor', 'Morphology', 'Myocardium', 'Outcome', 'Output', 'Patients', 'Phenotype', 'Play', 'Process', 'Proteins', 'Reader', 'Reading', 'Registries', 'Research', 'Research Personnel', 'Role', 'Safety', 'Standardization', 'Structure', 'Sudden Death', 'Symptoms', 'Testing', 'Thick', 'Time', 'Two-Dimensional Echocardiography', 'United States', 'Validation', 'Ventricular', 'adverse outcome', 'automated image analysis', 'base', 'career', 'clinical care', 'clinical imaging', 'cohort', 'cost', 'digital', 'disease diagnosis', 'epidemiology study', 'heart imaging', 'hypertensive heart disease', 'image processing', 'innovation', 'interest', 'multidisciplinary', 'novel therapeutics', 'particle', 'patient registry', 'repository', 'response', 'tool']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,R01,2019,687155,0.10544944141152846
"Machine learning for the automated identification and tracking of rare myocardial diseases PROJECT SUMMARY Although cardiac amyloidosis and hypertrophic cardiomyopathy (HCM) are relatively rare causes of heart failure (HF), they are particularly challenging to detect and treat for several shared reasons: (1) on routine clinical imaging (i.e., echocardiography [echo]), they can be difficult to distinguish from superficially similar, more common forms of cardiac disease that cause left ventricular (LV) hypertrophy; (2) the diagnoses are often missed and thus patients can present late in the course of disease at a time when treatment is difficult; (3) objective, noninvasive metrics that reliably reflect disease progression have not been identified; and (4) the small number of known patients with these diseases can make epidemiology studies and clinical trials difficult to organize and conduct. For both cardiac amyloidosis and HCM, echo plays a critical role in both diagnosis and longitudinal monitoring given its ubiquitous clinical availability, safety, and low cost. More broadly, echo dominates the current landscape of routine cardiac imaging, with tens of millions of echos performed in the United States each year. However, the clinical challenges described above highlight several shortcomings of echo: it is limited in its ability to (1) diagnose disease at its early stages; (2) discriminate between morphologically similar diseases; and (3) quantify disease progression. This proposal seeks to address deficiencies in the current echo reading workflow, which is subjective and captures only a small fraction of the data available in each study. The overall objective of this application is to use advances in machine learning to develop and validate fully-automated echo image analytic approaches to diagnose and track rare cardiomyopathies, focusing on cardiac amyloidosis and HCM. Our proposal is centered on the hypothesis that highly scalable computer vision methods can be applied to echo studies to overcome limitations of the standard clinical echo reading workflow. Accordingly our aims are: (1) Apply an automated method for echo quantification and disease identification to detect and differentiate cardiac diseases that cause increased LV wall thickness; and (2) Characterize quantifiable echo measures of disease progression in cardiac amyloidosis and HCM and associate these with clinical outcomes. Our multidisciplinary team, which is composed of experts in cardiomyopathies, echocardiography, computer vision, and machine learning, will analyze echos and patient data from 2 large patient registries: the Multicenter Amyloid Phenotyping Study (MAPS) and the Sarcomeric Human Cardiomyopathy Registry (SHaRe) HCM Network, with validation using a repository of nearly 400,000 echos. The successful completion of our aims will result in an innovative tool for early diagnosis of myocardial diseases and tracking of disease progression. Importantly, our project will set the stage for conducting larger epidemiology studies of rare myocardial diseases by automating the identification of these patients, and thereby developing previously unattainable broad-based cohorts for these conditions. PROJECT NARRATIVE Rare heart diseases such as amyloidosis (due to abnormal deposition of a protein into the heart muscle) and hypertrophic cardiomyopathy (due to a genetic mutation) are important causes of heart failure and sudden death in the general population. These heart diseases are difficult to diagnose, monitor, and treat because: (1) they appear superficially similar to more common forms of heart disease (e.g., high blood pressure) on imaging tests; (2) the optimal monitoring of disease progression over time has not been established; and (3) there is a lack of large-scale studies of patients with these diseases given their rarity. This project aims to use machine learning (artificial intelligence) of digital echocardiographic images to create a completely automated method for diagnosing and tracking these rare heart diseases with the ultimate goal of broad deployment of artificial intelligence algorithms in hospitals and clinics to help identify patients with these rare heart diseases earlier, better predict adverse outcomes, and increase the size and scope of patient registries to enhance research of these conditions.",Machine learning for the automated identification and tracking of rare myocardial diseases,9614825,R01HL140731,"['Address', 'Affect', 'Algorithm Design', 'Algorithms', 'Amyloid', 'Amyloidosis', 'Arrhythmia', 'Artificial Intelligence', 'Cardiac', 'Cardiomyopathies', 'Cardiovascular system', 'Cessation of life', 'Clinical', 'Clinical Trials', 'Clinics and Hospitals', 'Cohort Studies', 'Communities', 'Comorbidity', 'Computer Vision Systems', 'Coronary heart disease', 'DNA Sequence Alteration', 'Data', 'Deposition', 'Detection', 'Development', 'Diagnosis', 'Disease', 'Disease Progression', 'Early Diagnosis', 'Echocardiography', 'Face', 'General Population', 'Goals', 'Heart Diseases', 'Heart failure', 'Hospitalization', 'Human', 'Hypertension', 'Hypertrophic Cardiomyopathy', 'Image', 'Image Analysis', 'Individual', 'Inherited', 'Left', 'Left Ventricular Hypertrophy', 'Machine Learning', 'Manuals', 'Measurement', 'Measures', 'Methods', 'Molecular', 'Monitor', 'Morphology', 'Myocardium', 'Outcome', 'Output', 'Patients', 'Phenotype', 'Play', 'Process', 'Proteins', 'Reader', 'Reading', 'Registries', 'Research', 'Research Personnel', 'Role', 'Safety', 'Standardization', 'Structure', 'Sudden Death', 'Symptoms', 'Testing', 'Thick', 'Time', 'Two-Dimensional Echocardiography', 'United States', 'Validation', 'Ventricular', 'adverse outcome', 'base', 'career', 'clinical care', 'clinical imaging', 'cohort', 'cost', 'digital', 'disease diagnosis', 'epidemiology study', 'heart imaging', 'hypertensive heart disease', 'image processing', 'innovation', 'interest', 'multidisciplinary', 'novel therapeutics', 'particle', 'patient registry', 'repository', 'response', 'tool']",NHLBI,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",R01,2018,826025,0.10544944141152846
"Systems Biology Analysis of Cardiac Electrical Activity and Arrhythmias. Cardiac arrhythmias are a leading cause of morbidity and mortality in the United States. Abnormalities in heart rate, cardiac conduction (PR and QRS) and repolarization (QT) measured on the ECG predispose to the clinically important cardiac arrhythmias of atrial fibrillation (AF) and ventricular fibrillation (VF) / sudden cardiac death (SCD). We examine the genomic basis of these ECG endophenotypes in order to deconstruct arrhythmias into more proximate traits and discrete components, allowing us to better understand underlying mechanisms, provide insight into arrhythmia generation, and help target development of novel therapies.  The molecular architecture of cardiac electrical activity and arrhythmias is not fully understood, but likely involves genomic, epigenomic, and environmental influences. Over the past 10 years, we have identified numerous common loci associated with cardiac electrical activity and arrhythmias, yet these common variants account for only a portion of the heritability of electrophysiologic and arrhythmic phenotypes. The agnostic examination of genotype-phenotype associations employed in genome- wide association studies (GWAS) does not incorporate knowledge of functional genomic regions or important biologic relationships. Additionally, we currently lack an understanding of the molecular mechanisms connecting mostly intergenic and intronic GWAS signals to phenotype. We therefore hypothesize that a systems biology approach integrating genetic sequence variation with omic data (epigenomic, transcriptomic, and proteomic data) will uncover novel associations and elucidate biologic mechanisms associated with arrhythmia-related phenotypes. We further hypothesize that examining the simultaneous association between sequence variation and multiple cardiac electrophysiologic phenotypes will help uncover additional novel mechanisms associated with cardiac electrical activity and arrhythmias.  TOPMed's combination of rich phenotype data, with whole genome sequence (WGS), epigenomic, transcriptomic, and proteomic data, provides a unique opportunity to more comprehensively explore these hypotheses. We leverage sequence, omic, and phenotype data from multiple cohort studies to efficiently and cost-effectively examine and dissect association of omic factors with cardiac electrophysiology and arrhythmia risk. Our application is an ambitious yet eminently feasible effort that integrates clinical, genetic, and systems biology expertise. We aim to discover associations using omics data (Aims 1 and 2) and elucidate specific genes and biologic pathways underlying these associations (Aims 3 and 4). Our ultimate goal is to identify pathways, genes, and genetic variation that are clinically relevant, and therefore potentially the target of new therapies, diagnostics, or risk predictions. Narrative Cardiac arrhythmias are a major cause of morbidity and mortality in the United States. This proposal aims to use genomic, epigenomic, transcriptomic, and proteomic data, combined with complex systems biology and pleiotropic analyses, to better understand the underlying pathways and genes involved in normal electrophysiology and arrhythmia formation. The identification of biologic factors that influence cardiac electrical activity and arrhythmias will provide insight into the mechanisms of arrhythmia generation, and perhaps identify better targets for drug development and prevention.",Systems Biology Analysis of Cardiac Electrical Activity and Arrhythmias.,9921462,R01HL141989,"['Address', 'Affect', 'Architecture', 'Arrhythmia', 'Atrial Fibrillation', 'Bayesian Modeling', 'Biological', 'Biological Factors', 'Biological Process', 'Cardiac', 'Cardiac Electrophysiologic Techniques', 'Clinical', 'Cohort Studies', 'Complex', 'Data', 'Development', 'Diagnostic', 'Drug Targeting', 'Electrocardiogram', 'Electrophysiology (science)', 'Gene Expression Regulation', 'Generations', 'Genes', 'Genetic', 'Genetic Transcription', 'Genetic Variation', 'Genomic Segment', 'Genomics', 'Genotype', 'Genotype-Tissue Expression Project', 'Goals', 'Grouping', 'Heart', 'Heart Rate', 'Heritability', 'Knowledge', 'Machine Learning', 'Measures', 'Mediating', 'Mediation', 'Medical Genetics', 'Methods', 'Methylation', 'Modeling', 'Molecular', 'Morbidity - disease rate', 'Multiomic Data', 'Pathway interactions', 'Pattern', 'Phenotype', 'Population', 'Prevention', 'Proteins', 'Proteomics', 'Regulator Genes', 'Risk', 'Signal Transduction', 'Site', 'Systems Biology', 'Testing', 'Trans-Omics for Precision Medicine', 'United States', 'Variant', 'Ventricular Fibrillation', 'base', 'causal variant', 'clinical phenotype', 'clinically relevant', 'cost', 'drug development', 'endophenotype', 'epigenomics', 'functional genomics', 'genome wide association study', 'heart electrical activity', 'insight', 'mortality', 'new therapeutic target', 'novel', 'novel therapeutics', 'phenotypic data', 'pleiotropism', 'rare variant', 'sudden cardiac death', 'trait', 'transcriptomics', 'whole genome']",NHLBI,UNIVERSITY OF WASHINGTON,R01,2020,476969,0.24571048240292478
"Systems Biology Analysis of Cardiac Electrical Activity and Arrhythmias. Cardiac arrhythmias are a leading cause of morbidity and mortality in the United States. Abnormalities in heart rate, cardiac conduction (PR and QRS) and repolarization (QT) measured on the ECG predispose to the clinically important cardiac arrhythmias of atrial fibrillation (AF) and ventricular fibrillation (VF) / sudden cardiac death (SCD). We examine the genomic basis of these ECG endophenotypes in order to deconstruct arrhythmias into more proximate traits and discrete components, allowing us to better understand underlying mechanisms, provide insight into arrhythmia generation, and help target development of novel therapies.  The molecular architecture of cardiac electrical activity and arrhythmias is not fully understood, but likely involves genomic, epigenomic, and environmental influences. Over the past 10 years, we have identified numerous common loci associated with cardiac electrical activity and arrhythmias, yet these common variants account for only a portion of the heritability of electrophysiologic and arrhythmic phenotypes. The agnostic examination of genotype-phenotype associations employed in genome- wide association studies (GWAS) does not incorporate knowledge of functional genomic regions or important biologic relationships. Additionally, we currently lack an understanding of the molecular mechanisms connecting mostly intergenic and intronic GWAS signals to phenotype. We therefore hypothesize that a systems biology approach integrating genetic sequence variation with omic data (epigenomic, transcriptomic, and proteomic data) will uncover novel associations and elucidate biologic mechanisms associated with arrhythmia-related phenotypes. We further hypothesize that examining the simultaneous association between sequence variation and multiple cardiac electrophysiologic phenotypes will help uncover additional novel mechanisms associated with cardiac electrical activity and arrhythmias.  TOPMed's combination of rich phenotype data, with whole genome sequence (WGS), epigenomic, transcriptomic, and proteomic data, provides a unique opportunity to more comprehensively explore these hypotheses. We leverage sequence, omic, and phenotype data from multiple cohort studies to efficiently and cost-effectively examine and dissect association of omic factors with cardiac electrophysiology and arrhythmia risk. Our application is an ambitious yet eminently feasible effort that integrates clinical, genetic, and systems biology expertise. We aim to discover associations using omics data (Aims 1 and 2) and elucidate specific genes and biologic pathways underlying these associations (Aims 3 and 4). Our ultimate goal is to identify pathways, genes, and genetic variation that are clinically relevant, and therefore potentially the target of new therapies, diagnostics, or risk predictions. Narrative Cardiac arrhythmias are a major cause of morbidity and mortality in the United States. This proposal aims to use genomic, epigenomic, transcriptomic, and proteomic data, combined with complex systems biology and pleiotropic analyses, to better understand the underlying pathways and genes involved in normal electrophysiology and arrhythmia formation. The identification of biologic factors that influence cardiac electrical activity and arrhythmias will provide insight into the mechanisms of arrhythmia generation, and perhaps identify better targets for drug development and prevention.",Systems Biology Analysis of Cardiac Electrical Activity and Arrhythmias.,9737693,R01HL141989,"['Address', 'Affect', 'Architecture', 'Arrhythmia', 'Atrial Fibrillation', 'Bayesian Modeling', 'Biological', 'Biological Factors', 'Biological Process', 'Cardiac', 'Cardiac Electrophysiologic Techniques', 'Clinical', 'Cohort Studies', 'Complex', 'Data', 'Development', 'Diagnostic', 'Drug Targeting', 'Electrocardiogram', 'Electrophysiology (science)', 'Gene Expression Regulation', 'Generations', 'Genes', 'Genetic', 'Genetic Transcription', 'Genetic Variation', 'Genomic Segment', 'Genomics', 'Genotype', 'Genotype-Tissue Expression Project', 'Goals', 'Grouping', 'Heart', 'Heart Rate', 'Heritability', 'Knowledge', 'Machine Learning', 'Measures', 'Mediating', 'Mediation', 'Medical Genetics', 'Methods', 'Methylation', 'Modeling', 'Molecular', 'Morbidity - disease rate', 'Multiomic Data', 'Pathway interactions', 'Pattern', 'Phenotype', 'Population', 'Prevention', 'Proteins', 'Proteomics', 'Regulator Genes', 'Risk', 'Signal Transduction', 'Site', 'Systems Biology', 'Testing', 'Trans-Omics for Precision Medicine', 'United States', 'Variant', 'Ventricular Fibrillation', 'base', 'causal variant', 'clinical phenotype', 'clinically relevant', 'cost', 'drug development', 'endophenotype', 'epigenomics', 'functional genomics', 'genome wide association study', 'heart electrical activity', 'insight', 'mortality', 'new therapeutic target', 'novel', 'novel therapeutics', 'phenotypic data', 'pleiotropism', 'rare variant', 'sudden cardiac death', 'trait', 'transcriptomics', 'whole genome']",NHLBI,UNIVERSITY OF WASHINGTON,R01,2019,490901,0.24571048240292478
"A novel computing framework to automatically process cardiac valve image data and predict treatment outcomes PROJECT SUMMARY  There is a massive amount of clinical three-dimensional (3D) cardiac image data available today in numerous hospitals, but such data has been considerably underutilized in both clinical and engineering analyses of cardiac function. These 3D data offers unique and valuable information, allowing researchers to develop innovative, personalized approaches to treat diseases. Furthermore, using these 3D datasets as input to computational models can facilitate a population-based analysis that can be used to quantify uncertainty in treatment procedures, and can be utilized for virtual clinical trials for innovative device development. However, there are several critical technical bottlenecks preventing simulation-based clinical evaluation a reality: 1) difficulty in automatic 3D reconstruction of thin complex structures such as heart valve leaflets from clinical images, 2) computational models are constructed without mesh correspondence, which makes it challenging to run batch simulations and conduct large patient population data analyses due to inconsistencies in model setups, and 3) computing time is long, which inhibits prompt feedback for clinical use.  A potential paradigm-changing solution to the challenges is to incorporate machine learning algorithms to expedite the geometry reconstruction and computational analysis procedures. Therefore, the objective of this proposal is to develop a novel computing framework, using advanced tissue modeling and machine learning techniques, to automatically process pre-operative clinical image data and predict post-operative clinical outcomes. Transcatheter aortic valve replacement (TAVR) intervention will serve as a testbed for the modeling methods. In Aim 1, we will develop novel shape dictionary learning (SDL) based methods for automatic reconstruction of TAVR patient aortic valves. Through the modeling process, mesh correspondence will be established across the patient geometric models. The distribution and variation of TAVR patient geometries will be described by statistical shape models (SSMs). In Aim 2, population-based FE analysis of the TAVR procedure will be conducted on thousands of virtual patient models generated by the SSMs (Aim 1). A deep neural network (DNN) will be developed and trained to learn the relationship between the TAVR FE inputs and outputs. Successful completion of this study will result in a ML-FE surrogate for TAVR analysis, combining the automated TAVR patient geometry reconstruction algorithms and the trained DNN, to provide fast TAVR biomechanics analysis without extensive re-computing of the model. Furthermore, the algorithms developed in this study can be generalized for other applications and devices. PROJECT NARRATIVE Current clinical image modalities can be utilized to develop patient-specific computational models to pre-operatively plan transcatheter aortic valve replacement (TAVR) procedures. However, the computational modeling and simulation processes are time-consuming, which limits clinical translatability. Thus, the objective of this proposal is to develop algorithms using machine learning techniques to rapidly process and predict TAVR computational simulation outcomes directly from clinical image data.",A novel computing framework to automatically process cardiac valve image data and predict treatment outcomes,9973167,R01HL142036,"['3-Dimensional', 'Adverse event', 'Algorithms', 'Anatomy', 'Area', 'Artificial Intelligence', 'Attention', 'Biomechanics', 'Biomedical Computing', 'Clinical', 'Clinical Engineering', 'Complex', 'Computer Analysis', 'Computer Models', 'Computer Simulation', 'Consumption', 'Coronary Occlusions', 'Data', 'Data Analyses', 'Data Set', 'Development', 'Device Designs', 'Device or Instrument Development', 'Devices', 'Dictionary', 'Disease', 'Elements', 'Evaluation', 'Extravasation', 'Feedback', 'Finite Element Analysis', 'Generations', 'Geometry', 'Goals', 'Guidelines', 'Heart Valves', 'Hospitals', 'Hour', 'Human', 'Image', 'Intervention', 'Laboratories', 'Language', 'Learning', 'Left ventricular structure', 'Machine Learning', 'Manuals', 'Methods', 'Mitral Valve', 'Modeling', 'Outcome', 'Output', 'Patient-Focused Outcomes', 'Patients', 'Performance', 'Plant Roots', 'Postoperative Period', 'Problem Sets', 'Procedures', 'Process', 'Property', 'Research Personnel', 'Response Elements', 'Running', 'Rupture', 'Sampling', 'Shapes', 'Statistical Data Interpretation', 'Stents', 'Structure', 'Techniques', 'Testing', 'Thinness', 'Time', 'Tissue Model', 'Training', 'Translations', 'Treatment outcome', 'Uncertainty', 'Variant', 'X-Ray Computed Tomography', 'algorithm training', 'aortic valve', 'aortic valve replacement', 'ascending aorta', 'base', 'calcification', 'clinical application', 'clinical imaging', 'clinical practice', 'clinically translatable', 'deep learning', 'deep neural network', 'heart function', 'heart imaging', 'imaging modality', 'improved', 'innovation', 'machine learning algorithm', 'models and simulation', 'novel', 'patient population', 'personalized approach', 'population based', 'prevent', 'reconstruction', 'research clinical testing', 'simulation', 'speech recognition', 'time resolved data', 'two-dimensional', 'virtual', 'virtual clinical trial']",NHLBI,GEORGIA INSTITUTE OF TECHNOLOGY,R01,2020,383601,0.10794397091012649
"A novel computing framework to automatically process cardiac valve image data and predict treatment outcomes PROJECT SUMMARY  There is a massive amount of clinical three-dimensional (3D) cardiac image data available today in numerous hospitals, but such data has been considerably underutilized in both clinical and engineering analyses of cardiac function. These 3D data offers unique and valuable information, allowing researchers to develop innovative, personalized approaches to treat diseases. Furthermore, using these 3D datasets as input to computational models can facilitate a population-based analysis that can be used to quantify uncertainty in treatment procedures, and can be utilized for virtual clinical trials for innovative device development. However, there are several critical technical bottlenecks preventing simulation-based clinical evaluation a reality: 1) difficulty in automatic 3D reconstruction of thin complex structures such as heart valve leaflets from clinical images, 2) computational models are constructed without mesh correspondence, which makes it challenging to run batch simulations and conduct large patient population data analyses due to inconsistencies in model setups, and 3) computing time is long, which inhibits prompt feedback for clinical use.  A potential paradigm-changing solution to the challenges is to incorporate machine learning algorithms to expedite the geometry reconstruction and computational analysis procedures. Therefore, the objective of this proposal is to develop a novel computing framework, using advanced tissue modeling and machine learning techniques, to automatically process pre-operative clinical image data and predict post-operative clinical outcomes. Transcatheter aortic valve replacement (TAVR) intervention will serve as a testbed for the modeling methods. In Aim 1, we will develop novel shape dictionary learning (SDL) based methods for automatic reconstruction of TAVR patient aortic valves. Through the modeling process, mesh correspondence will be established across the patient geometric models. The distribution and variation of TAVR patient geometries will be described by statistical shape models (SSMs). In Aim 2, population-based FE analysis of the TAVR procedure will be conducted on thousands of virtual patient models generated by the SSMs (Aim 1). A deep neural network (DNN) will be developed and trained to learn the relationship between the TAVR FE inputs and outputs. Successful completion of this study will result in a ML-FE surrogate for TAVR analysis, combining the automated TAVR patient geometry reconstruction algorithms and the trained DNN, to provide fast TAVR biomechanics analysis without extensive re-computing of the model. Furthermore, the algorithms developed in this study can be generalized for other applications and devices. PROJECT NARRATIVE Current clinical image modalities can be utilized to develop patient-specific computational models to pre-operatively plan transcatheter aortic valve replacement (TAVR) procedures. However, the computational modeling and simulation processes are time-consuming, which limits clinical translatability. Thus, the objective of this proposal is to develop algorithms using machine learning techniques to rapidly process and predict TAVR computational simulation outcomes directly from clinical image data.",A novel computing framework to automatically process cardiac valve image data and predict treatment outcomes,9706921,R01HL142036,"['3-Dimensional', 'Adverse event', 'Algorithms', 'Anatomy', 'Area', 'Artificial Intelligence', 'Attention', 'Biomechanics', 'Biomedical Computing', 'Clinical', 'Clinical Engineering', 'Complex', 'Computer Analysis', 'Computer Simulation', 'Consumption', 'Coronary Occlusions', 'Data', 'Data Analyses', 'Data Set', 'Development', 'Device Designs', 'Device or Instrument Development', 'Devices', 'Dictionary', 'Dimensions', 'Disease', 'Elements', 'Evaluation', 'Extravasation', 'Feedback', 'Finite Element Analysis', 'Generations', 'Geometry', 'Goals', 'Guidelines', 'Heart Valves', 'Hospitals', 'Hour', 'Human', 'Image', 'Intervention', 'Laboratories', 'Language', 'Learning', 'Left ventricular structure', 'Machine Learning', 'Manuals', 'Methods', 'Mitral Valve', 'Modeling', 'Outcome', 'Output', 'Patient-Focused Outcomes', 'Patients', 'Performance', 'Plant Roots', 'Postoperative Period', 'Problem Sets', 'Procedures', 'Process', 'Property', 'Research Personnel', 'Response Elements', 'Running', 'Rupture', 'Sampling', 'Shapes', 'Statistical Data Interpretation', 'Stents', 'Structure', 'Techniques', 'Testing', 'Thinness', 'Time', 'Tissue Model', 'Training', 'Translations', 'Treatment outcome', 'Uncertainty', 'Variant', 'X-Ray Computed Tomography', 'aortic valve', 'aortic valve replacement', 'ascending aorta', 'base', 'calcification', 'clinical application', 'clinical imaging', 'clinical practice', 'clinically translatable', 'deep learning', 'deep neural network', 'heart function', 'heart imaging', 'imaging modality', 'improved', 'innovation', 'machine learning algorithm', 'models and simulation', 'novel', 'patient population', 'personalized approach', 'population based', 'prevent', 'reconstruction', 'research clinical testing', 'simulation', 'speech recognition', 'time resolved data', 'two-dimensional', 'virtual', 'virtual clinical trial']",NHLBI,GEORGIA INSTITUTE OF TECHNOLOGY,R01,2019,381629,0.10794397091012649
"A novel computing framework to automatically process cardiac valve image data and predict treatment outcomes PROJECT SUMMARY  There is a massive amount of clinical three-dimensional (3D) cardiac image data available today in numerous hospitals, but such data has been considerably underutilized in both clinical and engineering analyses of cardiac function. These 3D data offers unique and valuable information, allowing researchers to develop innovative, personalized approaches to treat diseases. Furthermore, using these 3D datasets as input to computational models can facilitate a population-based analysis that can be used to quantify uncertainty in treatment procedures, and can be utilized for virtual clinical trials for innovative device development. However, there are several critical technical bottlenecks preventing simulation-based clinical evaluation a reality: 1) difficulty in automatic 3D reconstruction of thin complex structures such as heart valve leaflets from clinical images, 2) computational models are constructed without mesh correspondence, which makes it challenging to run batch simulations and conduct large patient population data analyses due to inconsistencies in model setups, and 3) computing time is long, which inhibits prompt feedback for clinical use.  A potential paradigm-changing solution to the challenges is to incorporate machine learning algorithms to expedite the geometry reconstruction and computational analysis procedures. Therefore, the objective of this proposal is to develop a novel computing framework, using advanced tissue modeling and machine learning techniques, to automatically process pre-operative clinical image data and predict post-operative clinical outcomes. Transcatheter aortic valve replacement (TAVR) intervention will serve as a testbed for the modeling methods. In Aim 1, we will develop novel shape dictionary learning (SDL) based methods for automatic reconstruction of TAVR patient aortic valves. Through the modeling process, mesh correspondence will be established across the patient geometric models. The distribution and variation of TAVR patient geometries will be described by statistical shape models (SSMs). In Aim 2, population-based FE analysis of the TAVR procedure will be conducted on thousands of virtual patient models generated by the SSMs (Aim 1). A deep neural network (DNN) will be developed and trained to learn the relationship between the TAVR FE inputs and outputs. Successful completion of this study will result in a ML-FE surrogate for TAVR analysis, combining the automated TAVR patient geometry reconstruction algorithms and the trained DNN, to provide fast TAVR biomechanics analysis without extensive re-computing of the model. Furthermore, the algorithms developed in this study can be generalized for other applications and devices. PROJECT NARRATIVE Current clinical image modalities can be utilized to develop patient-specific computational models to pre-operatively plan transcatheter aortic valve replacement (TAVR) procedures. However, the computational modeling and simulation processes are time-consuming, which limits clinical translatability. Thus, the objective of this proposal is to develop algorithms using machine learning techniques to rapidly process and predict TAVR computational simulation outcomes directly from clinical image data.",A novel computing framework to automatically process cardiac valve image data and predict treatment outcomes,9518217,R01HL142036,"['Adverse event', 'Algorithms', 'Anatomy', 'Area', 'Artificial Intelligence', 'Attention', 'Biomechanics', 'Biomedical Computing', 'Clinical', 'Clinical Engineering', 'Complex', 'Computer Analysis', 'Computer Simulation', 'Coronary Occlusions', 'Data', 'Data Analyses', 'Data Set', 'Development', 'Device Designs', 'Device or Instrument Development', 'Devices', 'Dictionary', 'Dimensions', 'Disease', 'Elements', 'Evaluation', 'Extravasation', 'Feedback', 'Finite Element Analysis', 'Generations', 'Geometry', 'Goals', 'Guidelines', 'Heart Valves', 'Hospitals', 'Hour', 'Human', 'Image', 'Intervention', 'Laboratories', 'Language', 'Learning', 'Left ventricular structure', 'Machine Learning', 'Manuals', 'Methods', 'Mitral Valve', 'Modeling', 'Outcome', 'Output', 'Patient-Focused Outcomes', 'Patients', 'Performance', 'Plant Roots', 'Postoperative Period', 'Problem Sets', 'Procedures', 'Process', 'Property', 'Research Personnel', 'Response Elements', 'Running', 'Rupture', 'Sampling', 'Shapes', 'Statistical Data Interpretation', 'Stents', 'Structure', 'Techniques', 'Testing', 'Thinness', 'Time', 'Tissue Model', 'Training', 'Translations', 'Treatment outcome', 'Uncertainty', 'Variant', 'X-Ray Computed Tomography', 'aortic valve', 'aortic valve replacement', 'ascending aorta', 'base', 'calcification', 'clinical application', 'clinical imaging', 'clinical practice', 'clinically translatable', 'deep learning', 'deep neural network', 'heart function', 'heart imaging', 'imaging modality', 'improved', 'innovation', 'models and simulation', 'novel', 'patient population', 'personalized approach', 'population based', 'prevent', 'reconstruction', 'research clinical testing', 'simulation', 'speech recognition', 'time resolved data', 'two-dimensional', 'virtual', 'virtual clinical trial']",NHLBI,GEORGIA INSTITUTE OF TECHNOLOGY,R01,2018,392932,0.10794397091012649
"Sudden Cardiac Arrest (SCA): Prediction and Prevention Project Summary: The recent advances in information technologies and biotechnologies is an opportunity to substantially improve healthcare. To exploit the power of data to benefit patients, however, effective clinical decision support tools and novel, individualized interventions must be designed, tested, and implemented. Although there has been progress in the development of statistical/machine learning methods, numerous challenges remain to tailor and translate them into useful clinical decision support tools. Sudden cardiac arrest (SCA) accounts for 15-20% of all adult deaths and is the industrial worlds leading cause of death. Clinical studies of SCA produce repeated measures on risk factors and multiple different kinds of events over time. We refer to these data as survival, longitudinal, and multivariate (SLAM) data. In this project, we will develop novel statistical learning methods for SLAM data and apply them to two distinct aspects of the SCA problem. First, we propose to develop novel statistical learning algorithms that better predict an individuals multivariate longitudinal data with a focus on the risk of first and subsequent SCA. Second, we propose to develop micro-randomization and just-in-time adaptive intervention trial designs to reduce behavioral risk factors for SCA among persons at high risk. The methods that we propose to develop will be applicable in many areas of medicine. However, they are motivated by and applied to SCA in this project. Our team has expertise in statistics including causal inference, longitudinal data and survival analyses, plus machine learning, epidemiology, cardiology, and behavioral interventions through mobile health (mHealth). This proposed collaboration has the following specific aims: Aim 1: Develop and test statistical learning tools for real-time risk prediction of survival, longitudinal, and multivariate (SLAM) outcome data. Aim 2: Estimate the risk of SCA and its dependence on dynamic modifiable and non-modifiable factors in population-based and clinical cohorts. Aim 3: Plan and conduct a feasibility-usability study of micro-randomization and just-in-time adaptive intervention trial designs for behavioral change to reduce SCA risk. Upon successful completion of these aims, we will have contributed to the progress of healthcare delivery through the application of computational statistics to medicine. ! ! Project Narrative: Although sudden cardiac arrest (SCA) is the industrial worlds leading cause of death, SCA prediction and prevention strategies remain limited. In this project, we contribute towards addressing the global burden of SCAs through the development of novel statistical/machine learning methods for SCA risk prediction and the design of mobile health (mHealth) interventions for risk reduction. While developed in the context of SCA, these methods will be applicable in many areas of medicine and public health. !",Sudden Cardiac Arrest (SCA): Prediction and Prevention,9986884,F30HL142131,"['Address', 'Adult', 'Algorithms', 'Archives', 'Area', 'Atherosclerosis Risk in Communities', 'Behavior Therapy', 'Behavioral', 'Biomedical Technology', 'Biotechnology', 'Cardiac health', 'Cardiology', 'Cause of Death', 'Cessation of life', 'Clinical', 'Clinical Research', 'Clinical assessments', 'Collaborations', 'Data', 'Data Analyses', 'Dependence', 'Development', 'Epidemiology', 'Evaluation', 'Event', 'Future', 'Growth', 'Health Promotion', 'Health Technology', 'Healthcare', 'Heart Arrest', 'Heart failure', 'Hospitalization', 'Implantable Defibrillators', 'Individual', 'Industrialization', 'Information Technology', 'Interdisciplinary Study', 'Intervention', 'Machine Learning', 'Measures', 'Medicine', 'Methods', 'Modernization', 'Myocardial Infarction', 'Observational Study', 'Outcome', 'Patients', 'Performance', 'Persons', 'Physicians', 'Prevention', 'Prevention strategy', 'Preventive Medicine', 'Public Health', 'Randomized', 'Recovery', 'Research', 'Research Proposals', 'Risk', 'Risk Assessment', 'Risk Estimate', 'Risk Factors', 'Risk Reduction', 'Science', 'Scientist', 'Subgroup', 'Survival Analysis', 'Testing', 'Time', 'Training', 'Translating', 'adaptive intervention', 'career', 'clinical decision support', 'clinical decision-making', 'cohort', 'design', 'health care delivery', 'high risk', 'improved', 'interest', 'learning algorithm', 'learning strategy', 'mHealth', 'machine learning method', 'mobile application', 'modifiable risk', 'novel', 'open source', 'population based', 'prospective', 'randomized trial', 'statistical and machine learning', 'statistical learning', 'statistics', 'support tools', 'survival prediction', 'time use', 'tool', 'trial design', 'usability']",NHLBI,JOHNS HOPKINS UNIVERSITY,F30,2020,35760,0.08683186946625134
"Sudden Cardiac Arrest (SCA): Prediction and Prevention Project Summary: The recent advances in information technologies and biotechnologies is an opportunity to substantially improve healthcare. To exploit the power of data to benefit patients, however, effective clinical decision support tools and novel, individualized interventions must be designed, tested, and implemented. Although there has been progress in the development of statistical/machine learning methods, numerous challenges remain to tailor and translate them into useful clinical decision support tools. Sudden cardiac arrest (SCA) accounts for 15-20% of all adult deaths and is the industrial worlds leading cause of death. Clinical studies of SCA produce repeated measures on risk factors and multiple different kinds of events over time. We refer to these data as survival, longitudinal, and multivariate (SLAM) data. In this project, we will develop novel statistical learning methods for SLAM data and apply them to two distinct aspects of the SCA problem. First, we propose to develop novel statistical learning algorithms that better predict an individuals multivariate longitudinal data with a focus on the risk of first and subsequent SCA. Second, we propose to develop micro-randomization and just-in-time adaptive intervention trial designs to reduce behavioral risk factors for SCA among persons at high risk. The methods that we propose to develop will be applicable in many areas of medicine. However, they are motivated by and applied to SCA in this project. Our team has expertise in statistics including causal inference, longitudinal data and survival analyses, plus machine learning, epidemiology, cardiology, and behavioral interventions through mobile health (mHealth). This proposed collaboration has the following specific aims: Aim 1: Develop and test statistical learning tools for real-time risk prediction of survival, longitudinal, and multivariate (SLAM) outcome data. Aim 2: Estimate the risk of SCA and its dependence on dynamic modifiable and non-modifiable factors in population-based and clinical cohorts. Aim 3: Plan and conduct a feasibility-usability study of micro-randomization and just-in-time adaptive intervention trial designs for behavioral change to reduce SCA risk. Upon successful completion of these aims, we will have contributed to the progress of healthcare delivery through the application of computational statistics to medicine. ! ! Project Narrative: Although sudden cardiac arrest (SCA) is the industrial worlds leading cause of death, SCA prediction and prevention strategies remain limited. In this project, we contribute towards addressing the global burden of SCAs through the development of novel statistical/machine learning methods for SCA risk prediction and the design of mobile health (mHealth) interventions for risk reduction. While developed in the context of SCA, these methods will be applicable in many areas of medicine and public health. !",Sudden Cardiac Arrest (SCA): Prediction and Prevention,9790928,F30HL142131,"['Address', 'Adult', 'Algorithms', 'Archives', 'Area', 'Atherosclerosis Risk in Communities', 'Behavior Therapy', 'Behavioral', 'Biomedical Technology', 'Biotechnology', 'Cardiac health', 'Cardiology', 'Cause of Death', 'Cessation of life', 'Clinical', 'Clinical Research', 'Clinical assessments', 'Collaborations', 'Data', 'Data Analyses', 'Dependence', 'Development', 'Epidemiology', 'Evaluation', 'Event', 'Future', 'Growth', 'Health Promotion', 'Health Technology', 'Healthcare', 'Heart Arrest', 'Heart failure', 'Hospitalization', 'Implantable Defibrillators', 'Individual', 'Industrialization', 'Information Technology', 'Interdisciplinary Study', 'Intervention', 'Machine Learning', 'Measures', 'Medicine', 'Methods', 'Modernization', 'Myocardial Infarction', 'Observational Study', 'Outcome', 'Patients', 'Performance', 'Persons', 'Physicians', 'Prevention', 'Prevention strategy', 'Preventive Medicine', 'Public Health', 'Randomized', 'Recovery', 'Research', 'Research Proposals', 'Risk', 'Risk Assessment', 'Risk Estimate', 'Risk Factors', 'Risk Reduction', 'Science', 'Scientist', 'Subgroup', 'Survival Analysis', 'Testing', 'Time', 'Training', 'Translating', 'adaptive intervention', 'career', 'clinical decision support', 'clinical decision-making', 'cohort', 'design', 'health care delivery', 'high risk', 'improved', 'interest', 'learning algorithm', 'learning strategy', 'mHealth', 'mobile application', 'modifiable risk', 'novel', 'open source', 'population based', 'prospective', 'randomized trial', 'statistics', 'support tools', 'survival prediction', 'time use', 'tool', 'trial design', 'usability']",NHLBI,JOHNS HOPKINS UNIVERSITY,F30,2019,50016,0.08683186946625134
"Sudden Cardiac Arrest (SCA): Prediction and Prevention Project Summary: The recent advances in information technologies and biotechnologies is an opportunity to substantially improve healthcare. To exploit the power of data to benefit patients, however, effective clinical decision support tools and novel, individualized interventions must be designed, tested, and implemented. Although there has been progress in the development of statistical/machine learning methods, numerous challenges remain to tailor and translate them into useful clinical decision support tools. Sudden cardiac arrest (SCA) accounts for 15-20% of all adult deaths and is the industrial worlds leading cause of death. Clinical studies of SCA produce repeated measures on risk factors and multiple different kinds of events over time. We refer to these data as survival, longitudinal, and multivariate (SLAM) data. In this project, we will develop novel statistical learning methods for SLAM data and apply them to two distinct aspects of the SCA problem. First, we propose to develop novel statistical learning algorithms that better predict an individuals multivariate longitudinal data with a focus on the risk of first and subsequent SCA. Second, we propose to develop micro-randomization and just-in-time adaptive intervention trial designs to reduce behavioral risk factors for SCA among persons at high risk. The methods that we propose to develop will be applicable in many areas of medicine. However, they are motivated by and applied to SCA in this project. Our team has expertise in statistics including causal inference, longitudinal data and survival analyses, plus machine learning, epidemiology, cardiology, and behavioral interventions through mobile health (mHealth). This proposed collaboration has the following specific aims: Aim 1: Develop and test statistical learning tools for real-time risk prediction of survival, longitudinal, and multivariate (SLAM) outcome data. Aim 2: Estimate the risk of SCA and its dependence on dynamic modifiable and non-modifiable factors in population-based and clinical cohorts. Aim 3: Plan and conduct a feasibility-usability study of micro-randomization and just-in-time adaptive intervention trial designs for behavioral change to reduce SCA risk. Upon successful completion of these aims, we will have contributed to the progress of healthcare delivery through the application of computational statistics to medicine. ! ! Project Narrative: Although sudden cardiac arrest (SCA) is the industrial worlds leading cause of death, SCA prediction and prevention strategies remain limited. In this project, we contribute towards addressing the global burden of SCAs through the development of novel statistical/machine learning methods for SCA risk prediction and the design of mobile health (mHealth) interventions for risk reduction. While developed in the context of SCA, these methods will be applicable in many areas of medicine and public health. !",Sudden Cardiac Arrest (SCA): Prediction and Prevention,9540118,F30HL142131,"['Address', 'Adult', 'Algorithms', 'Archives', 'Area', 'Atherosclerosis Risk in Communities', 'Behavior Therapy', 'Behavioral', 'Biomedical Technology', 'Biotechnology', 'Cardiac health', 'Cardiology', 'Cause of Death', 'Cessation of life', 'Clinical', 'Clinical Research', 'Clinical assessments', 'Collaborations', 'Data', 'Data Analyses', 'Dependence', 'Development', 'Epidemiology', 'Evaluation', 'Event', 'Future', 'Growth', 'Health Promotion', 'Health Technology', 'Healthcare', 'Heart Arrest', 'Heart failure', 'Hospitalization', 'Implantable Defibrillators', 'Individual', 'Industrialization', 'Information Technology', 'Interdisciplinary Study', 'Intervention', 'Intervention Trial', 'Machine Learning', 'Measures', 'Medicine', 'Methods', 'Modernization', 'Myocardial Infarction', 'Observational Study', 'Outcome', 'Patients', 'Performance', 'Persons', 'Physicians', 'Prevention', 'Prevention strategy', 'Preventive Medicine', 'Public Health', 'Randomized', 'Recovery', 'Research', 'Research Proposals', 'Risk', 'Risk Assessment', 'Risk Estimate', 'Risk Factors', 'Risk Reduction', 'Science', 'Scientist', 'Subgroup', 'Survival Analysis', 'Testing', 'Time', 'Training', 'Translating', 'career', 'clinical decision support', 'clinical decision-making', 'cohort', 'design', 'health care delivery', 'high risk', 'improved', 'interest', 'learning strategy', 'mHealth', 'mobile application', 'modifiable risk', 'novel', 'open source', 'population based', 'prospective', 'randomized trial', 'statistics', 'support tools', 'survival prediction', 'time use', 'tool', 'trial design', 'usability']",NHLBI,JOHNS HOPKINS UNIVERSITY,F30,2018,49524,0.08683186946625134
"Single cell molecular network mechanisms of cardiotoxicity induced by tyrosine kinase inhibitors As the number of cancer patients with stable disease increases, the long-term cardiotoxic effects of treatment with anti-cancer drugs become increasingly apparent. Cardiovascular-related mortality is 7-fold higher in childhood cancer survivors than expected from an age matched normal population and ~12% of breast cancer survivors suffer heart failure within three years of treatment. Tyrosine kinase inhibitors (TKIs) are exemplars of promising anti-cancer drugs whose use is complicated by cardiotoxicity. Whether this reflects drug-mediated inhibition of the same signaling pathways as the anti-oncogenic effects of these drugs is unclear. Cardiotoxic phenotypes induced by chemically diverse TKIs include life-threatening heart failure and cardiac infarction, and are likely to include targets that are not the nominal ones; this is particularly true of poly- selective TKIs. Identifying the precise mechanisms of TKI-mediated cardiotoxicity has the potential to substantially improve cancer care and also reveal fundamental aspects of cardiac cell biology.  My project exploits the recent development of reproducible means to transdifferentiate human induced pluripotent stem cell into cardiomyocytes (hiPSC-CMs) and probe the biology of these cells using omic and systems biology methods. I have collected extensive preliminary data on hiPSC-CMs responses to over 50 different drug perturbations and am in the midst of using statistical regression and machine learning algorithms to define and study the molecular networks associated with TKI-induced cardiotoxicity. I have already found that cardiac energy metabolism is dysregulated by many cardiotoxic drugs and could be biomarker of cardiotoxicity more broadly. In this proposal, I will build on my profiling data through focused study of Sorafenib, a drug that I have shown to increase anaerobic glycolysis in hiPSC-CMs. As a multi-target drug, Sorafenib inhibits multiple kinases and gene networks. Identifying targets relevant to cardiotoxicity is a key goal of my research. I will tackle this by establishing the sequential onset of molecular networks after drug treatment and their causal relation with the increased glycolysis phenotype. Single cell heterogeneous molecular responses will be analyzed to find non-genetic mechanisms that determine the differential sensitivity of cardiotoxicity to Sorafenib. I will build quantitative models to fit and explain data at population and single cell levels. Ultimately, to find means to increase therapeutic effects, I want to systematically compare target expression, phenotypic responses and molecular mechanisms induced by Sorafenib in both hiPSC-CMs and hepatocellular carcinoma cells (treated by Sorafenib clinically). My study will generate pilot methods in converting big data into mechanistic insights in cardiac biology, and facilitate development of new therapies to mitigate cardiotoxicity without compromising efficacy of cancer elimination. PROJECT NARRATIVE The use of many cancer drugs, including tyrosine kinase inhibitors, is complicated by cardiotoxicity, which can be debilitating and life-threating but is poorly understood. My research aims to understand the molecular changes associated with drug-induced cardiotoxicity as a means to screen for adverse effects in new drug, identify patients who are particularly susceptible to heart damage and develop strategies for mitigating such toxicity.",Single cell molecular network mechanisms of cardiotoxicity induced by tyrosine kinase inhibitors,9541584,F32HL142231,"['Address', 'Adverse effects', 'Aerobic', 'Age', 'Algorithms', 'Amino Acids', 'Antineoplastic Agents', 'BAY 54-9085', 'Big Data', 'Bioinformatics', 'Biological Markers', 'Biology', 'Breast Cancer survivor', 'Cancer Patient', 'Cancer cell line', 'Cardiac', 'Cardiac Myocytes', 'Cardiac development', 'Cardiology', 'Cardiotoxicity', 'Cardiovascular system', 'Cell Survival', 'Cells', 'Cellular biology', 'Chemicals', 'Clinical', 'Computer Simulation', 'Computing Methodologies', 'Cues', 'Data', 'Development', 'Dose', 'Drug Combinations', 'Drug Targeting', 'Electrocardiogram', 'Energy Metabolism', 'Genes', 'Glycolysis', 'Goals', 'HIF1A gene', 'Heart', 'Heart Hypertrophy', 'Heart failure', 'Human', 'Human body', 'Hydrogels', 'Hypertension', 'Image', 'Incidence', 'Ion Channel', 'Least-Squares Analysis', 'Life', 'Linear Models', 'MAP Kinase Gene', 'MAPK14 gene', 'Machine Learning', 'Malignant Epithelial Cell', 'Malignant Neoplasms', 'Mediating', 'Membrane Potentials', 'Metabolic', 'Metabolism', 'Methods', 'Mitochondria', 'Modeling', 'Molecular', 'Myocardial Infarction', 'Myocardial Ischemia', 'Network-based', 'Normal tissue morphology', 'Oncogenic', 'Organ', 'Oxidative Phosphorylation', 'Oxidative Stress', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Pharmacotherapy', 'Phenotype', 'Phosphotransferases', 'Physiology', 'Population', 'Potassium Channel', 'Primary carcinoma of the liver cells', 'Protein Tyrosine Kinase', 'Proteomics', 'Regression Analysis', 'Regulation', 'Renal Cell Carcinoma', 'Reproducibility', 'Research', 'Role', 'Sarcomeres', 'Signal Pathway', 'Signal Transduction', 'Stable Disease', 'Systems Biology', 'Testing', 'Therapeutic', 'Therapeutic Effect', 'Time', 'Tissues', 'Toxic effect', 'Transcript', 'Tyrosine Kinase Inhibitor', 'United States National Institutes of Health', 'Work', 'anaerobic glycolysis', 'antitumor effect', 'base', 'cancer care', 'cancer cell', 'cardioprotection', 'cellular imaging', 'chemical genetics', 'childhood cancer survivor', 'design', 'experimental study', 'fatty acid oxidation', 'glucose metabolism', 'heart damage', 'human model', 'improved', 'induced pluripotent stem cell', 'insight', 'interest', 'mitochondrial membrane', 'molecular phenotype', 'mortality', 'non-genetic', 'novel therapeutics', 'precision oncology', 'response', 'transcription factor', 'treatment effect']",NHLBI,HARVARD MEDICAL SCHOOL,F32,2018,12484,0.10378921357656036
"Novel mechanisms and treatment of arrhythmia during resuscitation Resuscitation from sudden cardiac arrest (SCA) is typically initiated in patients with ongoing ischemia and ventricular fibrillation (VF) or tachycardia (VT) that, even if successful, is commonly followed by repeated rearrest. Despite significant efforts to improve resuscitation from SCA, survival remains poor prompting NIH to identify resuscitation as a high priority for emergency care research. Beat-to-beat alternans of cellular repolarization in the myocardium (repolarization alternans) is a substrate for arrhythmias, is rampant during resuscitation, and is manifested on the ECG as T-wave oscillations that can alternate (2:1) or as more complex oscillations. In preliminary studies, we observed in resuscitation patients and in an in vivo translational model of resuscitation from SCA, that rearrest due to VT/VF is preceded by T-wave oscillations that are complex; whereas, rearrest due to pulseless electrical activity (PEA) is preceded by increased T-wave oscillations that alternate. Accordingly, we contend that when T-wave oscillations are complex, repolarization alternans in the myocardium is spatially discordant, which is repolarization alternans occurring out-of-phase in adjacent regions and is highly arrhythmogenic. In contrast, when T-wave oscillations alternate, repolarization alternans in the myocardium is spatially in-phase (concordant), which poses no known immediate arrhythmia risk but is associated with mechanical dysfunction and, thus, PEA. Finally, in the absence of any repolarization alternans, risk of rearrest due to PEA or VT/VF is low. We hypothesize that during resuscitation rearrest due to VT/VF or PEA is strongly linked to repolarization alternans in the myocardium that is spatially discordant or not, respectively, and that specifically targeting the underlying mechanisms can prevent rearrest due to VT/VF and, possibly, PEA. In addition, the full spectrum of ECG T-wave oscillations can be utilized to predict no rearrest and rearrest from VT/VF or PEA and, thus, be used in the future as a biomarker to guide therapy and significantly improve outcomes. Our hypotheses will be tested with the following aims. 1) Determine the mechanistic relationship between cellular repolarization alternans and rearrest due to VT/VF or PEA in an in vivo model of resuscitation. 2) Determine if targeting the mechanisms of repolarization alternans can prevent rearrest during resuscitation, thereby gaining additional mechanistic insight. 3) Develop and test an ECG biomarker for predicting risk of rearrest due to VT/VF and PEA in resuscitation patients. To achieve these aims, we will utilize sophisticated instrumentation and signal processing in an in vivo translational model of resuscitation as well as in pre-hospital and in- hospital resuscitation patients. We have also established a highly translational collaboration that combines expertise in emergency medicine, cardiac arrhythmia, and clinical electrophysiology. Our scientific environment provides a unique opportunity to develop a better understanding of arrhythmia mechanisms relevant to resuscitation in order to develop novel and effective therapies. Project Narrative Sudden cardiac arrest (SCA) due to arrhythmia is a major public health problem and despite significant efforts to improve resuscitation from SCA, rearrest and survival remain poor. Consequently, improved approaches are needed, and NIH has recently identified resuscitation as a high priority for emergency care research. We propose to investigate the mechanisms of rearrest during resuscitation to develop novel and effective therapeutic strategies that improve outcomes.",Novel mechanisms and treatment of arrhythmia during resuscitation,9886863,R01HL142754,"['Acute', 'Arrhythmia', 'Biological Markers', 'Blood Circulation', 'Cardiac', 'Clinical', 'Collaborations', 'Complex', 'Coupling', 'Data', 'Development', 'Distress', 'Electrocardiogram', 'Electrophysiology (science)', 'Emergency Medicine', 'Emergency research', 'Environment', 'Functional disorder', 'Future', 'Gap Junctions', 'Heart', 'Heart Arrest', 'Hospitals', 'Ischemia', 'Link', 'Machine Learning', 'Mechanics', 'Metabolic', 'Modeling', 'Myocardial Ischemia', 'Myocardium', 'Outcome', 'Patients', 'Pattern', 'Phase', 'Public Health', 'Reperfusion Therapy', 'Resuscitation', 'Risk', 'Sum', 'Techniques', 'Testing', 'Therapeutic', 'Translating', 'Treatment Efficacy', 'United States', 'United States National Institutes of Health', 'Ventricular Fibrillation', 'Ventricular Tachycardia', 'base', 'effective therapy', 'epicardial mapping', 'hemodynamics', 'improved', 'improved outcome', 'in vivo', 'in vivo Model', 'insight', 'instrument', 'instrumentation', 'mortality', 'novel', 'novel therapeutics', 'predictive marker', 'prevent', 'rearrest', 'signal processing', 'translational model']",NHLBI,CASE WESTERN RESERVE UNIVERSITY,R01,2020,668976,0.09395700686327287
"Scalable platform for optimizing human cardiac tissue engineering via optical pacing and on-demand oxygenation PROJECT SUMMARY Induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) are emerging as an invaluable in vitro human experimental platform for disease modeling, drug discovery, cardiotoxicity screening, gene editing and functional genomics. For the first time, cardiac electrophysiology has access to a scalable human experimental model, which, currently, offers the only path to personalized (cardiac) medicine as patient-derived iPS-CMs can be generated on a progressively faster time scale. The clear potential of this technology motivates efforts to address the main criticisms facing iPS-CMs, namely the need for further maturation and reduction of phenotype heterogeneity. As multiple approaches are being pursued to improve iPS-CM maturation and to approximate the functionality of the adult human myocardium, we argue that combinatorial optimizations necessitate new high-throughput (HT) technology and automation. The overall goal of this project is to develop and validate a scalable platform for optimizing cardiac tissue engineering via chronic reconfigurable optical pacing and on-demand oxygenation for gaining mechanistic insights into cardiac metabolism and electrophysiology, a platform we call ChROME. Chronic electrical stimulation is a viable lead to iPS-CM maturation, yet it has remained under-explored, specifically as related to the role of mass transport and oxygenation during such stimulation. Leveraging our expertise in the theoretical and experimental use of optogenetic tools for cardiac applications (Entcheva) and automation (Kostov, Li, Entcheva, Kay), we propose to design and validate the first-generation HT-ChROME platform, that will integrate continuous monitoring of key physiological parameters. Our teams expertise in optical oxygen sensing (Kostov), in-house manufacturing of on-demand oxygenation nanocarriers (perfluorocarbons, PFC) (Kay) and metabolic characterization (Kay, Beard) will be applied to address the increased metabolic demands during stimulation. The ability to quantify functional maturation by relevant measures (voltage, calcium, contraction) in a high-throughput manner (Entcheva) in 2D and 3D cardiac tissue constructs (Vunjak-Novakovic), using our automated platform OptoDyCE (all-optical dynamic cardiac electrophysiology) is critical in this undertaking. Employing these HT tools and other imaging and omics modalities (Popratiloff, Horvath), we will elucidate the spectrum of responses triggered by chronic stimulation of iPS-CMs: beneficial/maturation effects vs. pathological overload effects, depending on load and oxygenation conditions. The proposed HT-ChROME platform represents a critical step in resolving issues impeding progress with iPS-CMs to accelerate their wide-spread adoption in basic and translational applications. The obtained large-scale data will inform a new generation of biophysical models linking human cardiac metabolism and electrophysiology. PROJECT NARRATIVE Recent advances in stem-cell technology enable patient-derived cells to be turned into functional heart cells, and this is an exciting direction towards personalized medicine; yet, there are many challenges in optimizing these cardiomyocytes to better mimic the real heart  a problem that the proposed engineering tools will help resolve.",Scalable platform for optimizing human cardiac tissue engineering via optical pacing and on-demand oxygenation,9687111,R01HL144157,"['3-Dimensional', 'Address', 'Adoption', 'Adult', 'Affect', 'Automation', 'Biological', 'Calcium', 'Cardiac', 'Cardiac Electrophysiologic Techniques', 'Cardiac Myocytes', 'Cardiotoxicity', 'Cells', 'Chronic', 'Combinatorial Optimization', 'Data', 'Disease model', 'Electric Stimulation', 'Engineering', 'Event', 'Experimental Models', 'Fluorocarbons', 'Frequencies', 'Future', 'Generations', 'Genes', 'Goals', 'Heart', 'Heterogeneity', 'Hip region structure', 'Human', 'Human Engineering', 'Image', 'In Vitro', 'Incubators', 'Lead', 'Light', 'Link', 'Longitudinal Studies', 'Measures', 'Mechanics', 'Mediating', 'Medicine', 'Metabolic', 'Metabolism', 'Mitochondria', 'Modality', 'Modeling', 'Monitor', 'Myocardium', 'NADH', 'Optics', 'Oxygen', 'Oxygen Consumption', 'Pathologic', 'Patients', 'Phenotype', 'Physiologic pulse', 'Physiological', 'Regression Analysis', 'Role', 'Site', 'Technology', 'Testing', 'Time', 'Tissue Engineering', 'Tissues', 'Transcriptional Regulation', 'Viral', 'Work', 'biophysical model', 'cardiac tissue engineering', 'design', 'drug discovery', 'functional genomics', 'heart cell', 'heart metabolism', 'high throughput technology', 'improved', 'induced pluripotent stem cell', 'insight', 'machine learning algorithm', 'nanocarrier', 'optogenetics', 'personalized medicine', 'programs', 'response', 'screening', 'side effect', 'stem cell technology', 'tool', 'transcriptomics', 'voltage']",NHLBI,GEORGE WASHINGTON UNIVERSITY,R01,2019,728876,0.20319334094654026
"Scalable platform for optimizing human cardiac tissue engineering via optical pacing and on-demand oxygenation PROJECT SUMMARY Induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) are emerging as an invaluable in vitro human experimental platform for disease modeling, drug discovery, cardiotoxicity screening, gene editing and functional genomics. For the first time, cardiac electrophysiology has access to a scalable human experimental model, which, currently, offers the only path to personalized (cardiac) medicine as patient-derived iPS-CMs can be generated on a progressively faster time scale. The clear potential of this technology motivates efforts to address the main criticisms facing iPS-CMs, namely the need for further maturation and reduction of phenotype heterogeneity. As multiple approaches are being pursued to improve iPS-CM maturation and to approximate the functionality of the adult human myocardium, we argue that combinatorial optimizations necessitate new high-throughput (HT) technology and automation. The overall goal of this project is to develop and validate a scalable platform for optimizing cardiac tissue engineering via chronic reconfigurable optical pacing and on-demand oxygenation for gaining mechanistic insights into cardiac metabolism and electrophysiology, a platform we call ChROME. Chronic electrical stimulation is a viable lead to iPS-CM maturation, yet it has remained under-explored, specifically as related to the role of mass transport and oxygenation during such stimulation. Leveraging our expertise in the theoretical and experimental use of optogenetic tools for cardiac applications (Entcheva) and automation (Kostov, Li, Entcheva, Kay), we propose to design and validate the first-generation HT-ChROME platform, that will integrate continuous monitoring of key physiological parameters. Our teams expertise in optical oxygen sensing (Kostov), in-house manufacturing of on-demand oxygenation nanocarriers (perfluorocarbons, PFC) (Kay) and metabolic characterization (Kay, Beard) will be applied to address the increased metabolic demands during stimulation. The ability to quantify functional maturation by relevant measures (voltage, calcium, contraction) in a high-throughput manner (Entcheva) in 2D and 3D cardiac tissue constructs (Vunjak-Novakovic), using our automated platform OptoDyCE (all-optical dynamic cardiac electrophysiology) is critical in this undertaking. Employing these HT tools and other imaging and omics modalities (Popratiloff, Horvath), we will elucidate the spectrum of responses triggered by chronic stimulation of iPS-CMs: beneficial/maturation effects vs. pathological overload effects, depending on load and oxygenation conditions. The proposed HT-ChROME platform represents a critical step in resolving issues impeding progress with iPS-CMs to accelerate their wide-spread adoption in basic and translational applications. The obtained large-scale data will inform a new generation of biophysical models linking human cardiac metabolism and electrophysiology. PROJECT NARRATIVE Recent advances in stem-cell technology enable patient-derived cells to be turned into functional heart cells, and this is an exciting direction towards personalized medicine; yet, there are many challenges in optimizing these cardiomyocytes to better mimic the real heart  a problem that the proposed engineering tools will help resolve.",Scalable platform for optimizing human cardiac tissue engineering via optical pacing and on-demand oxygenation,9839658,R01HL144157,"['3-Dimensional', 'Address', 'Adoption', 'Adult', 'Affect', 'Automation', 'Biological', 'Calcium', 'Cardiac', 'Cardiac Electrophysiologic Techniques', 'Cardiac Myocytes', 'Cardiotoxicity', 'Cells', 'Chronic', 'Combinatorial Optimization', 'Data', 'Disease model', 'Electric Stimulation', 'Engineering', 'Event', 'Experimental Models', 'Fluorocarbons', 'Frequencies', 'Future', 'Generations', 'Genes', 'Goals', 'Heart', 'Heterogeneity', 'Hip region structure', 'Human', 'Human Engineering', 'Image', 'In Vitro', 'Incubators', 'Lead', 'Light', 'Link', 'Longitudinal Studies', 'Measures', 'Mechanics', 'Mediating', 'Medicine', 'Metabolic', 'Metabolism', 'Mitochondria', 'Modality', 'Modeling', 'Monitor', 'Myocardium', 'NADH', 'Optics', 'Oxygen', 'Oxygen Consumption', 'Pathologic', 'Patients', 'Phenotype', 'Physiologic pulse', 'Physiological', 'Regression Analysis', 'Role', 'Site', 'Technology', 'Testing', 'Time', 'Tissue Engineering', 'Tissues', 'Transcriptional Regulation', 'Viral', 'Work', 'biophysical model', 'cardiac tissue engineering', 'design', 'drug discovery', 'functional genomics', 'heart cell', 'heart metabolism', 'high throughput technology', 'improved', 'induced pluripotent stem cell', 'insight', 'large scale data', 'machine learning algorithm', 'nanocarrier', 'optogenetics', 'personalized medicine', 'programs', 'response', 'screening', 'side effect', 'stem cell technology', 'tool', 'transcriptomics', 'voltage']",NHLBI,GEORGE WASHINGTON UNIVERSITY,R01,2020,706471,0.20319334094654026
"Automatic quantification of myocardial motion in older adults Abstract  Heart failure (HF) is a common condition that represents the end stage of cardiovascular diseases (CVDs) subsequent to progressing myocardial damage or ischemia. In populations at ages 65 and older, coronary artery disease (CAD) serves as the leading cause of HF. Although low left ventricular (LV) ejection fraction (EF) is a major evidence for the diagnosis of HF in clinical practice, impaired regional myocardial dysfunction is expected to present the existence of CAD in its early stage.  Heart deformation analysis (HDA) is a cutting-edge myocardial motion analysis technique that is able to automatically track the myocardium borders on time frames and calculate global and regional cardiac functional and motional indices on existing cine images without extra scans. In the present study, we will use the HDA tool to analyze existing cine images of CHARISMA study. From 2009 to 2012, cardiac MRI exams (including coronary wall imaging and cine MRI at two-chamber, four-chamber and short-axis views) and concurrent tests for traditional cardiovascular risk factors were performed on 440 older participants (age: 65 - 84 years old at the time of MRI scans) without documented history of CVDs. During the present R03 project (2019-2021), CHARISMA participants would have been followed-up for 10 - 12 years. We plan to relate newly- acquired regional myocardial motion indices (displacement, velocity, strain and strain rate) to clinical outcomes, existing coronary wall measures and results of lab tests in CHARISMA datasets. We will test the overall hypothesis that regional myocardial motion indices have the potential to present cardiovascular risk in asymptomatic elderly. Three specific aims are: 1) Predict cardiovascular events using baseline regional myocardial motion indices; 2) Relate regional myocardial motion indices to MRI-derived features of coronary remodeling; and 3) Determine correlations between regional myocardial motion indices and traditional cardiovascular risk biomarkers/conditions collected in CHARISMA study.  No new MRI scans or lab tests are required in this project. Through a cost-effective approach, the immediate objective of the proposed project is to evaluate the clinical value of regional myocardial motion for cardiovascular risk stratification in asymptomatic older adults, a major target population of cardiovascular prevention. This study will also help us better understand the correlations between impaired myocardial function/motion and subclinical CAD burden. Furthermore, the results will facilitate the selection of quantitative imaging biomarkers and their optimal cut-off points for predicting cardiovascular events in future clinical studies. Project Narrative  In the present study, we will use heart deformation analysis (HDA) to reanalyze existing cardiac MRI data of CHARISMA study. The goal of the present study was to test the hypothesis that regional myocardial motion indices have the potential to predict cardiovascular risk in older adults.",Automatic quantification of myocardial motion in older adults,9647817,R03HL144891,"['Adopted', 'Age', 'Area', 'Artificial Intelligence', 'Biological Markers', 'Biomechanics', 'C-reactive protein', 'Cardiac', 'Cardiomyopathies', 'Cardiovascular Diseases', 'Cardiovascular system', 'Chicago', 'Cine Magnetic Resonance Imaging', 'Clinical', 'Clinical Research', 'Comorbidity', 'Coronary', 'Coronary Arteriosclerosis', 'Data', 'Data Set', 'Development', 'Diabetes Mellitus', 'Diagnosis', 'Disease', 'Echocardiography', 'Elderly', 'Event', 'Functional disorder', 'Funding', 'Future', 'Gelatinase B', 'Goals', 'Heart', 'Heart failure', 'Hypertension', 'Image', 'Impairment', 'Incidence', 'Individual', 'LDL Cholesterol Lipoproteins', 'Left', 'Left Ventricular Ejection Fraction', 'Left Ventricular Mass', 'Left ventricular structure', 'Longitudinal observational study', 'MRI Scans', 'Machine Learning', 'Magnetic Resonance Angiography', 'Magnetic Resonance Imaging', 'Manuals', 'Measures', 'Medicine', 'Methods', 'Motion', 'Myocardial', 'Myocardial Ischemia', 'Myocardial dysfunction', 'Myocardium', 'National Heart, Lung, and Blood Institute', 'Older Population', 'Outcome', 'Participant', 'Patients', 'Pattern', 'Peroxidases', 'Population', 'Prevention', 'Prospective Studies', 'Protocols documentation', 'Radial', 'Recording of previous events', 'Research Project Grants', 'Risk', 'Risk stratification', 'Scanning', 'Series', 'Smoking', 'Target Populations', 'Techniques', 'Testing', 'Thick', 'Time', 'Training', 'Ventricular', 'base', 'burden of illness', 'cardiovascular risk factor', 'clinical practice', 'coronary plaque', 'cost', 'cost effective', 'design', 'diabetic patient', 'follow-up', 'healthy aging', 'heart damage', 'human old age (65+)', 'human subject', 'imaging biomarker', 'improved', 'indexing', 'myocardial damage', 'quantitative imaging', 'tool']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R03,2018,79000,-0.023490025431745335
"Automatic quantification of myocardial motion in older adults Abstract  Heart failure (HF) is a common condition that represents the end stage of cardiovascular diseases (CVDs) subsequent to progressing myocardial damage or ischemia. In populations at ages 65 and older, coronary artery disease (CAD) serves as the leading cause of HF. Although low left ventricular (LV) ejection fraction (EF) is a major evidence for the diagnosis of HF in clinical practice, impaired regional myocardial dysfunction is expected to present the existence of CAD in its early stage.  Heart deformation analysis (HDA) is a cutting-edge myocardial motion analysis technique that is able to automatically track the myocardium borders on time frames and calculate global and regional cardiac functional and motional indices on existing cine images without extra scans. In the present study, we will use the HDA tool to analyze existing cine images of CHARISMA study. From 2009 to 2012, cardiac MRI exams (including coronary wall imaging and cine MRI at two-chamber, four-chamber and short-axis views) and concurrent tests for traditional cardiovascular risk factors were performed on 440 older participants (age: 65 - 84 years old at the time of MRI scans) without documented history of CVDs. During the present R03 project (2019-2021), CHARISMA participants would have been followed-up for 10 - 12 years. We plan to relate newly- acquired regional myocardial motion indices (displacement, velocity, strain and strain rate) to clinical outcomes, existing coronary wall measures and results of lab tests in CHARISMA datasets. We will test the overall hypothesis that regional myocardial motion indices have the potential to present cardiovascular risk in asymptomatic elderly. Three specific aims are: 1) Predict cardiovascular events using baseline regional myocardial motion indices; 2) Relate regional myocardial motion indices to MRI-derived features of coronary remodeling; and 3) Determine correlations between regional myocardial motion indices and traditional cardiovascular risk biomarkers/conditions collected in CHARISMA study.  No new MRI scans or lab tests are required in this project. Through a cost-effective approach, the immediate objective of the proposed project is to evaluate the clinical value of regional myocardial motion for cardiovascular risk stratification in asymptomatic older adults, a major target population of cardiovascular prevention. This study will also help us better understand the correlations between impaired myocardial function/motion and subclinical CAD burden. Furthermore, the results will facilitate the selection of quantitative imaging biomarkers and their optimal cut-off points for predicting cardiovascular events in future clinical studies. Project Narrative  In the present study, we will use heart deformation analysis (HDA) to reanalyze existing cardiac MRI data of CHARISMA study. The goal of the present study was to test the hypothesis that regional myocardial motion indices have the potential to predict cardiovascular risk in older adults.",Automatic quantification of myocardial motion in older adults,9789927,R03HL144891,"['Adopted', 'Age', 'Area', 'Artificial Intelligence', 'Biological Markers', 'Biomechanics', 'C-reactive protein', 'Cardiac', 'Cardiomyopathies', 'Cardiovascular Diseases', 'Cardiovascular system', 'Chicago', 'Cine Magnetic Resonance Imaging', 'Clinical', 'Clinical Research', 'Comorbidity', 'Coronary', 'Coronary Arteriosclerosis', 'Data', 'Data Set', 'Development', 'Diabetes Mellitus', 'Diagnosis', 'Disease', 'Echocardiography', 'Elderly', 'Event', 'Functional disorder', 'Funding', 'Future', 'Gelatinase B', 'Goals', 'Heart', 'Heart failure', 'Hypertension', 'Image', 'Impairment', 'Incidence', 'Individual', 'LDL Cholesterol Lipoproteins', 'Left', 'Left Ventricular Ejection Fraction', 'Left Ventricular Mass', 'Left ventricular structure', 'Longitudinal observational study', 'MRI Scans', 'Machine Learning', 'Magnetic Resonance Angiography', 'Magnetic Resonance Imaging', 'Manuals', 'Measures', 'Medicine', 'Methods', 'Motion', 'Myocardial', 'Myocardial Ischemia', 'Myocardial dysfunction', 'Myocardium', 'National Heart, Lung, and Blood Institute', 'Older Population', 'Outcome', 'Participant', 'Patients', 'Pattern', 'Peroxidases', 'Population', 'Prevention', 'Prospective Studies', 'Protocols documentation', 'Radial', 'Recording of previous events', 'Research Project Grants', 'Risk', 'Risk stratification', 'Scanning', 'Series', 'Smoking', 'Target Populations', 'Techniques', 'Testing', 'Thick', 'Time', 'Training', 'Ventricular', 'base', 'burden of illness', 'cardiovascular risk factor', 'clinical practice', 'coronary plaque', 'cost', 'cost effective', 'design', 'diabetic patient', 'follow-up', 'healthy aging', 'heart damage', 'human old age (65+)', 'human subject', 'imaging biomarker', 'improved', 'indexing', 'myocardial damage', 'quantitative imaging', 'tool']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R03,2019,79000,-0.023490025431745335
"Deep Neural Networks To Treat Atrial Fibrillation PROJECT SUMMARY Atrial fibrillation (AF) is a major health problem affecting over 5 million people in the US leading to significant morbidity and even mortality. Therapy for this epidemic is suboptimal, with success of 30-70% at 1 year for most therapies. Despite great advances in understanding potential AF mechanisms, these insights have not yet translated into better AF therapy. The scientific focus of the project centers on the issue of identifying novel phenotypes for the heterogeneous conditions that currently fall under the rubric of AF. Machine learning is an approach well-suited to identify novel classifications from large diverse data sets that are traditionally difficult to separate. I will use machine learning and computational methods to analyze detailed clinical, structural, cardiac electrophysiological and biochemical features in patients with AF, to better predict responders and non-responders to various therapies. This may enable prospective guidance to tailor personalized therapy. In performing this project, I will grow as a physician-scientist focused on patient-oriented research in atrial fibrillation. The specific aims of the scientific project are as follows: First, I will create a novel disease taxonomy for AF that classifies patients successfully treated by risk factor modification, antiarrhythmic drug therapy, or diverse approaches to ablation, using computational methods and supervised learning on large training data from my collaborators. I will assess the predictive efficacy of these disease partitions in a testing cohort of patients referred for treatment of AF. Second, I will use advanced techniques in machine learning and patient-level analyses to explain why a certain strategy may fail or succeed in an individual, paving the way for clinical use. Third, in a pilot prospective clinical study, I will assess the feasibility and accuracy of these machine learning models. The findings from these experiments may provide an immediate clinical impact by delivering AF therapy options in a patient-specific manner that optimizes benefit while reducing risk. In addition, under the balanced and expert mentorship provided by this award, I will gain the necessary computational modelling, clinical research design and biostatistical methodology experience to design comprehensive studies and be competitive for independent funding. PROJECT NARRATIVE Atrial fibrillation (AF) is the most prevalent heart rhythm disorder in adults, which may lead to significant morbidity, mortality and economic burden. The results of pharmacologic and non-pharmacologic therapy remain suboptimal, despite the fact that mechanistic data in patients are increasing on atrial structure, electrophysiology and clinical risk factors yet are rarely used to individualize AF therapy to each patient. In this project, computational methods and machine learning are proposed to harmonize large amounts of data, including clinical factors, imaging studies and cardiac signals, to provide tools to devise an individualized AF management strategy.",Deep Neural Networks To Treat Atrial Fibrillation,9995010,K23HL145017,"['Ablation', 'Address', 'Adult', 'Affect', 'Anti-Arrhythmia Agents', 'Arrhythmia', 'Atrial Fibrillation', 'Award', 'Biochemical', 'Biometry', 'Cardiac', 'Classification', 'Clinical', 'Clinical Research', 'Computer Models', 'Computing Methodologies', 'Data', 'Data Element', 'Data Set', 'Disease', 'Economic Burden', 'Electrophysiology (science)', 'Epidemic', 'Failure', 'Fatigue', 'Flecainide', 'Freedom', 'Funding', 'Health', 'Heart Atrium', 'Heart failure', 'Individual', 'Judgment', 'Lead', 'Life Style Modification', 'Machine Learning', 'Medicine', 'Mentored Patient-Oriented Research Career Development Award', 'Mentorship', 'Methodology', 'Modeling', 'Modification', 'Morbidity - disease rate', 'Nonpharmacologic Therapy', 'Outcome', 'Patients', 'Pharmaceutical Preparations', 'Pharmacology', 'Pharmacotherapy', 'Phenotype', 'Physicians', 'Positioning Attribute', 'Pulmonary veins', 'Registries', 'Research Design', 'Research Personnel', 'Risk', 'Risk Factors', 'Scientist', 'Signal Transduction', 'Stroke', 'Structure', 'Supervision', 'Syndrome', 'Taxonomy', 'Techniques', 'Testing', 'Therapeutic', 'Training', 'Translating', 'Triage', 'Work', 'clinical center', 'clinical phenotype', 'clinical predictors', 'clinical risk', 'cohort', 'cost', 'deep neural network', 'design', 'diverse data', 'dofetilide', 'economic implication', 'experience', 'experimental study', 'falls', 'functional outcomes', 'heart rhythm', 'imaging study', 'individualized medicine', 'insight', 'machine learning algorithm', 'machine learning method', 'mortality', 'neural network', 'novel', 'patient oriented research', 'personalized medicine', 'predictive modeling', 'predictive test', 'prevent', 'prospective', 'responders and non-responders', 'response', 'skills', 'success', 'supervised learning', 'tool', 'unsupervised learning']",NHLBI,STANFORD UNIVERSITY,K23,2020,193536,0.07931264315291336
"Deep Neural Networks To Treat Atrial Fibrillation PROJECT SUMMARY Atrial fibrillation (AF) is a major health problem affecting over 5 million people in the US leading to significant morbidity and even mortality. Therapy for this epidemic is suboptimal, with success of 30-70% at 1 year for most therapies. Despite great advances in understanding potential AF mechanisms, these insights have not yet translated into better AF therapy. The scientific focus of the project centers on the issue of identifying novel phenotypes for the heterogeneous conditions that currently fall under the rubric of AF. Machine learning is an approach well-suited to identify novel classifications from large diverse data sets that are traditionally difficult to separate. I will use machine learning and computational methods to analyze detailed clinical, structural, cardiac electrophysiological and biochemical features in patients with AF, to better predict responders and non-responders to various therapies. This may enable prospective guidance to tailor personalized therapy. In performing this project, I will grow as a physician-scientist focused on patient-oriented research in atrial fibrillation. The specific aims of the scientific project are as follows: First, I will create a novel disease taxonomy for AF that classifies patients successfully treated by risk factor modification, antiarrhythmic drug therapy, or diverse approaches to ablation, using computational methods and supervised learning on large training data from my collaborators. I will assess the predictive efficacy of these disease partitions in a testing cohort of patients referred for treatment of AF. Second, I will use advanced techniques in machine learning and patient-level analyses to explain why a certain strategy may fail or succeed in an individual, paving the way for clinical use. Third, in a pilot prospective clinical study, I will assess the feasibility and accuracy of these machine learning models. The findings from these experiments may provide an immediate clinical impact by delivering AF therapy options in a patient-specific manner that optimizes benefit while reducing risk. In addition, under the balanced and expert mentorship provided by this award, I will gain the necessary computational modelling, clinical research design and biostatistical methodology experience to design comprehensive studies and be competitive for independent funding. PROJECT NARRATIVE Atrial fibrillation (AF) is the most prevalent heart rhythm disorder in adults, which may lead to significant morbidity, mortality and economic burden. The results of pharmacologic and non-pharmacologic therapy remain suboptimal, despite the fact that mechanistic data in patients are increasing on atrial structure, electrophysiology and clinical risk factors yet are rarely used to individualize AF therapy to each patient. In this project, computational methods and machine learning are proposed to harmonize large amounts of data, including clinical factors, imaging studies and cardiac signals, to provide tools to devise an individualized AF management strategy.",Deep Neural Networks To Treat Atrial Fibrillation,9821943,K23HL145017,"['Ablation', 'Address', 'Adult', 'Affect', 'Anti-Arrhythmia Agents', 'Arrhythmia', 'Atrial Fibrillation', 'Award', 'Biochemical', 'Biometry', 'Cardiac', 'Classification', 'Clinical', 'Clinical Research', 'Computer Simulation', 'Computing Methodologies', 'Data', 'Data Element', 'Data Set', 'Disease', 'Economic Burden', 'Electrophysiology (science)', 'Epidemic', 'Failure', 'Fatigue', 'Flecainide', 'Freedom', 'Funding', 'Health', 'Heart Atrium', 'Heart failure', 'Individual', 'Lead', 'Life Style Modification', 'Machine Learning', 'Medicine', 'Mentored Patient-Oriented Research Career Development Award', 'Mentorship', 'Methodology', 'Modeling', 'Modification', 'Morbidity - disease rate', 'Nonpharmacologic Therapy', 'Outcome', 'Patients', 'Pharmaceutical Preparations', 'Pharmacology', 'Pharmacotherapy', 'Phenotype', 'Physicians', 'Positioning Attribute', 'Pulmonary veins', 'Registries', 'Research Design', 'Research Personnel', 'Risk', 'Risk Factors', 'Scientist', 'Signal Transduction', 'Stroke', 'Structure', 'Supervision', 'Syndrome', 'Taxonomy', 'Techniques', 'Testing', 'Therapeutic', 'Training', 'Translating', 'Triage', 'Work', 'clinical phenotype', 'clinical predictors', 'clinical risk', 'cohort', 'cost', 'deep neural network', 'design', 'dofetilide', 'economic implication', 'experience', 'experimental study', 'falls', 'functional outcomes', 'heart rhythm', 'imaging study', 'individualized medicine', 'insight', 'learning strategy', 'machine learning algorithm', 'mortality', 'neural network', 'novel', 'patient oriented research', 'personalized medicine', 'predictive modeling', 'predictive test', 'prevent', 'prospective', 'responders and non-responders', 'response', 'skills', 'success', 'supervised learning', 'tool', 'unsupervised learning']",NHLBI,STANFORD UNIVERSITY,K23,2019,193536,0.07931264315291336
"A Combinatorial Bioreactor for Electromechanical Conditioning of Differentiated Stem Cells PROJECT SUMMARY The failure of a drug during the development process is extraordinarily costly and dangerous. Indeed, it can take upwards of 10 years and $2-3 billion to develop just one drug, and much of that cost is derived from other candidates that fail. Most of these failures occur towards the end of the development process when the costs are highest and when the drug is exposed to the most patients. One of the most common reasons for failure is a compounds propensity for causing cardiac arrhythmias in patients. In some rare cases, these cardiotoxic effects arent even detected during clinical trials and are only discovered once the drug is exposed to the population at large, resulting in harm to patients and a costly withdrawal from the market place. Consequently, the FDA has mandated that all new drugs be tested for cardiotoxic effects, but they and the drug industry realize that current screening tools fall short. This has led to a growing market for screening tools that are more predictive than existing technologies. Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) represent a promising avenue towards building high-representative in vitro tissue models for preclinical drug screening. However, most iPSC-CM models do not develop into mature, adult-like tissue and fail to recapitulate some in vivo drug responses. NanoSurface Biomedical is applying for Phase 1 SBIR funding to develop a combinatorial bioreactor system to enhance the maturation of cardiac stem cells for improved drug-induced cardiotoxicity screening. The bioreactor will generate tissues that are more functionally mature and can be fed into various down-stream assays. We hypothesize that the combination of nanoscale structural cues, mechanical stretch, and electrical stimulation will improve cardiac structural and functional development to enable the collection of cardiotoxicity data with more predictive capacity. To test these hypotheses, this project will focus on the design and fabrication of a combinatorial bioreactor that can reproducibly and reliably apply the required stimuli (Aim 1). New methods of fabrication must be tested and implemented to ensure production of highly precise nanoscale architectures that promote cell development. Reliability and selection of actuators for mechanical stretch will also be undertaken. The company will develop hardware and software for in situ electrical stimulation that is applied in a spatiotemporally coordinated manner with the other external stimuli. Lastly, the company will develop protocols and validate the hypothesis that these combinatorial cues can enhance iPSC-CM maturation (Aim 2). This will be assessed via a suite of structural, electrophysiological, and functional metrics combined with statistical analysis. These data will be used to assess the validity of the approach for eventual scale up during Phase 2, and for commercial release and market delivery in Phase 3. Successful validation of the companys combinatorial bioreactor will produce an innovative new product aimed at relieving critical deficiencies in preclinical toxicity models and reduce cost and time in the drug development process. PROJECT NARRATIVE We will develop a combinatorial bioreactor capable of promoting the functional development of human-derived cardiac stem cells in a controlled laboratory setting by combining structural, mechanical, and electrical developmental cues. Cells and tissues developed in this device will enable more accurate and predictive screening of the toxicity and efficacy of candidate drugs on human heart tissue prior to their advancement to human trials. In turn, this will streamline drug development protocols, leading to shorter development times, and bringing new life-saving drugs to the market more quickly.",A Combinatorial Bioreactor for Electromechanical Conditioning of Differentiated Stem Cells,9778205,R43HL146043,"['Address', 'Adult', 'Adverse effects', 'Architecture', 'Arrhythmia', 'Benchmarking', 'Biochemical', 'Biological', 'Biological Assay', 'Bioreactors', 'Cardiac', 'Cardiac Myocytes', 'Cardiotoxicity', 'Cell Culture Techniques', 'Cell Line', 'Cell Maturation', 'Cell Size', 'Cells', 'Clinical Trials', 'Collection', 'Computer software', 'Cues', 'Dangerousness', 'Data', 'Detection', 'Development', 'Devices', 'Drug Industry', 'Drug Screening', 'Economics', 'Electric Stimulation', 'Electrophysiology (science)', 'Engineering', 'Ensure', 'Exhibits', 'Exposure to', 'Failure', 'Funding', 'Gap Junctions', 'Goals', 'Heart', 'Human', 'In Situ', 'In Vitro', 'Industry', 'Laboratories', 'Life', 'Measurable', 'Measurement', 'Mechanics', 'Metabolic', 'Methods', 'Mission', 'Modality', 'Modeling', 'Molds', 'Muscle Cells', 'Oxygen Consumption', 'Patients', 'Periodicity', 'Pharmaceutical Preparations', 'Phase', 'Phenotype', 'Physiological', 'Physiology', 'Population', 'Pre-Clinical Model', 'Price', 'Principal Component Analysis', 'Process', 'Production', 'Protein Isoforms', 'Protocols documentation', 'Resources', 'Risk', 'Sarcomeres', 'Savings', 'Screening procedure', 'Shapes', 'Small Business Innovation Research Grant', 'Source', 'Statistical Data Interpretation', 'Stem cells', 'Stimulus', 'Stress', 'Stretching', 'Structure', 'System', 'Techniques', 'Technology', 'Testing', 'Time', 'Tissue Model', 'Tissues', 'Toxic effect', 'Up-Regulation', 'Validation', 'Variant', 'Withdrawal', 'Work', 'base', 'biomaterial compatibility', 'combinatorial', 'conditioning', 'cost', 'cost effective', 'design', 'drug candidate', 'drug development', 'elastomeric', 'falls', 'flexibility', 'health care delivery', 'human pluripotent stem cell', 'human subject', 'improved', 'in vivo', 'induced pluripotent stem cell', 'innovation', 'nanopattern', 'nanoscale', 'novel', 'novel therapeutics', 'phenotypic biomarker', 'pre-clinical', 'preclinical toxicity', 'protocol development', 'prototype', 'response', 'scale up', 'screening', 'spatiotemporal', 'stem cell differentiation', 'tool', 'wasting']",NHLBI,"NANOSURFACE BIOMEDICAL, INC.",R43,2019,225000,0.02334126587186081
"International Consortium for Multimodality Phenotyping in Adults with Non-compaction Summary Non-compaction cardiomyopathy (NCCM) is a heterogeneous, poorly understood disorder characterized by a prominent inner layer of loose myocardial tissue. Patients with NCCM are at increased risk of heart failure, stroke, severe rhythm irregularities and death. Current imaging techniques cannot differentiate pathological from benign hypertrabeculation. In addition, current echo/MRI-based criteria of NCCM lead to over-diagnosis of NCCM, provide no prognostic value, and lead to implantation of defibrillators (ICD) and the use of anticoagulation without a positive benefit in many otherwise healthy individuals with non-compacted myocardium. For a growing population diagnosed with NCCM there is an urgent need for better risk stratification to appropriately allocate (or safely withhold) these impactful preventive measures. Our international consortium combines expertise in myocardial disease, cardiac imaging and advanced computer analytics from 5 centers dedicated to the care of patients with cardiomyopathies, and has the ultimate goal to improve care of patients with non-compaction cardiomyopathy. We hypothesize that comprehensive analysis of clinical, genetic, structural and functional information will improve risk stratification. In addition, we hypothesize that detailed structural analysis will allow for differentiation of pathological and benign patterns of non-compaction. In a large cohort of adult patients with suspected NCCM we will perform in-depth phenotyping, including clinical information, pedigree data, genetics, echocardiography and MRI, and follow patients for up to 3 years. We will apply machine-learning based analytics to develop predictive models and compare their performance to currently used models and treatment criteria. Secondly, in a subset of patients we will perform high-resolution cardiac CT for detailed structural characterization of the myocardial wall. Novel analytical methods will be developed to characterize the 3D architectural complexity based on pathophysiological hypothesis, but also using hypothesis-free analyses of raw images using deep learning techniques. In addition, we will investigate associations between myocardial structure and regional contractile function, as assessed by echo and MRI. The aim of this proposal is to identify a structural signature associated with pathological non-compaction and improve developed risk prediction models. This international consortium dedicated to NCCM will be the first to collect genetic and multi-modality imaging data. Discovery of pathological structural signatures through innovative imaging techniques, in relation to myocardial contractility, will advance our understanding of NCCM. There is an urgent clinical need for diagnostic techniques that detect pathological non-compaction and identify patients at risk of devastating complications. This study is clinically relevant because the developed predictive models may permit more effective, personalized preventive care in a growing number of individuals diagnosed with non-compaction cardiomyopathy. Project Narrative The proposed research is relevant to the public health because recognition of pathological myocardial non- compaction and identification of patients at risk for embolic stroke, ventricular arrhythmia and sudden cardiac death will allow for more effective use of life-saving measures, but also avoid unnecessary ICD implantations and anticoagulation in healthy individuals with benign hypertrabeculation. Thus, the proposed research is relevant to the NIH's mission that pertains to the discovery of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.",International Consortium for Multimodality Phenotyping in Adults with Non-compaction,9977674,R01HL146754,"['3-Dimensional', 'Adult', 'Adverse event', 'Anticoagulation', 'Architecture', 'Arrhythmia', 'Artificial Intelligence', 'Awareness', 'Behavior', 'Benign', 'Cardiac', 'Cardiomyopathies', 'Cessation of life', 'Clinic', 'Clinical', 'Complex', 'Computers', 'DNA Sequence Alteration', 'Data', 'Data Analyses', 'Defibrillators', 'Detection', 'Diagnosis', 'Diagnostic', 'Diagnostic Imaging', 'Diagnostic Procedure', 'Disease', 'Echocardiography', 'Event', 'Family member', 'Foundations', 'Fractals', 'Genetic', 'Genetic Structures', 'Goals', 'Guidelines', 'Health', 'Heart failure', 'Histologic', 'Image', 'Image Analysis', 'Imaging Techniques', 'Individual', 'International', 'Intervention', 'Joints', 'Knowledge', 'Lead', 'Left ventricular non-compaction', 'Life', 'Machine Learning', 'Magnetic Resonance Imaging', 'Measures', 'Medical Genetics', 'Mission', 'Modeling', 'Multimodal Imaging', 'Mutation', 'Myocardial', 'Myocardial tissue', 'Myocardium', 'Nature', 'Non-compaction cardiomyopathy', 'Organism', 'Outcome', 'Pathologic', 'Patient Care', 'Patients', 'Pattern', 'Pennsylvania', 'Performance', 'Phenotype', 'Physiological', 'Population', 'Predictive Value', 'Preventive Intervention', 'Preventive care', 'Preventive measure', 'Preventive therapy', 'Public Health', 'Research', 'Resolution', 'Risk', 'Risk Factors', 'Risk stratification', 'Savings', 'Stroke', 'Structure', 'Sudden Death', 'Techniques', 'United States National Institutes of Health', 'Universities', 'Ventricular Arrhythmia', 'accurate diagnosis', 'adjudicate', 'adjudication', 'adverse event risk', 'analytical method', 'base', 'clinically relevant', 'cohort', 'deep learning', 'density', 'disability', 'embolic stroke', 'genetic pedigree', 'heart imaging', 'high risk', 'imaging genetics', 'implantation', 'improved', 'improved outcome', 'innovation', 'multimodality', 'novel', 'outcome prediction', 'patient subsets', 'predictive modeling', 'prognostic value', 'prospective', 'radiomics', 'research clinical testing', 'risk prediction model', 'sudden cardiac death', 'thrombogenesis', 'young adult']",NHLBI,STANFORD UNIVERSITY,R01,2020,805761,0.032576850988551224
"Prediction of imminent sudden cardiac death based on warning signs Sudden cardiac arrest (SCA), a sudden catastrophic loss of the pulse, affects >350,000 in the US annually. Most will suffer sudden cardiac death (SCD) within 10 minutes of presentation, yielding a mortality rate >90%. Based on our recent work, we have proposed a novel paradigm for SCD called near-term prevention. SCA is often not as sudden as one might expect. At least 50% of individuals will have warning symptoms at some time in the 4 weeks prior to SCD, but these can be non-specific, so are often not acted upon. The overall goal of this proposal is to refine the identification of the symptomatic individual at high-risk of SCD, during this 4-week window of opportunity. We propose that a simultaneous examination of symptoms, clinical factors and biomarkers may identify individuals at highest risk of imminent SCD, which could enable prediction and pre-emptive management, thereby preventing SCD. We are proposing to develop a comprehensive risk score from two population-based studies founded by the PI. The Portland, Oregon Sudden Unexpected Death Study (Oregon-SUDS, catchment area  1 million) is now in its 17th year and the Ventura, California PRESTO study (Prediction of Sudden Death in Multi-Ethnic Communities, catchment area  850,000) is in its 5th year. The resulting combined databank contains information on >7500 SCD cases and controls, with detailed clinical phenotyping and a biobank of plasma samples. From Oregon-SUDS, we recently reported that 51% (n=430) of 839 individuals who suffered SCD presented with at least one symptom within the 4 weeks prior to their lethal event. The main symptom was chest pain, but dyspnea, fatigue, syncope and palpitations were also recorded. Warning signs could represent an opportunity for near-term prediction of SCD. While these symptoms are common and may be non-specific for SCD, we hypothesize that a combination of specific symptoms and clinical profile could facilitate the identification of patients at high risk of impending SCA. In addition, the discovery of novel plasma biomarkers for SCD could have additional utility for risk stratification. We therefore hypothesize that biomarkers, when combined with specific symptoms and clinical profile, will maximize the likelihood of identifying symptomatic subjects at highest risk of SCD, allowing for early intervention. SCD remains a major public health problem with a critical need for novel prediction and prevention. Development of this user-friendly risk score for imminent SCD in those with warning symptoms would represent a practical and clinically meaningful advance for triage of patients for optimal care. Sudden cardiac death (SCD) is a public health problem of substantial magnitude and at least fifty percent of affected individuals have warning signs in the four weeks preceding their event. The overall goal of this proposal is to develop a comprehensive risk prediction score for imminent SCD in those that have warning signs, in order to improve the effectiveness of SCD prevention.",Prediction of imminent sudden cardiac death based on warning signs,9916644,R01HL147358,"['911 call', 'Affect', 'Archives', 'Biological Markers', 'California', 'Caring', 'Catchment Area', 'Cessation of life', 'Chest Pain', 'Clinic', 'Clinical', 'Communities', 'Control Groups', 'DNA', 'Data', 'Development', 'Dyspnea', 'Early Intervention', 'Effectiveness', 'Electrocardiogram', 'Event', 'Family', 'Fatigue', 'Future', 'Goals', 'Heart Arrest', 'Hour', 'Individual', 'Investigation', 'Lead', 'Link', 'Lipids', 'Machine Learning', 'Medical', 'Methods', 'Minority', 'Modeling', 'Oregon', 'Palpitations', 'Patient Triage', 'Patients', 'Physiologic pulse', 'Plasma', 'Population', 'Population Study', 'Prevention', 'Proteomics', 'Public Health', 'Reporting', 'Risk', 'Risk stratification', 'Sampling', 'Subgroup', 'Sudden Death', 'Survivors', 'Symptoms', 'Syncope', 'Time', 'Tissue Sample', 'Wireless Technology', 'Woman', 'Work', 'base', 'biobank', 'case control', 'circulating biomarkers', 'clinical phenotype', 'clinical risk', 'common symptom', 'community living', 'data warehouse', 'design', 'high risk', 'improved', 'men', 'mortality', 'mortality risk', 'novel', 'prevent', 'prospective', 'response', 'sex', 'specific biomarkers', 'sudden cardiac death', 'user-friendly']",NHLBI,CEDARS-SINAI MEDICAL CENTER,R01,2020,816401,0.08207506440155866
"Improving cardiovascular image-based phenotyping using emerging methods in artificial intelligence Summary / Abstract Objective  The goal of this proposal is to develop and optimize novel deep learning (DL) assisted approaches to improve diagnosis and clinical decision-making for congenital heart disease (CHD). This will be achieved by using DL, machine learning (ML), and related methods to extract diagnosis, biometric characterizations, and other information from fetal ultrasound imaging. Notably, this work includes a clinical translational evaluation of these methods in a population-wide imaging collection spanning two decades, tens of thousands of patients, and several clinical centers. Background  Despite clear and numerous benefits to prenatal detection of CHD and an ability for fetal ultrasound to detect over 90% of CHD lesions in theory, in practice the fetal CHD detection rate is closer to 50%. Prior literature suggests a key cause of this startling diagnosis gap is suboptimal acquisition and interpretation of fetal heart images. DL is a novel data science technique that is proving excellent at pattern recognition in images. DL models are a function of the design and tuning of a neural network architecture, and the curation and processing of the image data used to train the network. Preliminary Studies  We have assembled a multidisciplinary team of experts in echocardiography and CHD (Drs. Grady, Levine, and Arnaout), DL and data science (Drs. Keiser, Butte and Arnaout), and statistics and clinical research (Drs. Arnaout and Grady) and secured access to tens of thousands of multicenter (UCSF and six other centers), multimodal fetal imaging studies. We have created a scalable image processing pipeline to transform clinical studies into image data ready for computing. We have designed and trained DL models to find key cardiac views in fetal ultrasound, calculate standard and advanced fetal cardiac biometrics from those views, and distinguish between normal hearts and certain CHD lesions. Hypothesis  While DL is powerful, much work is still needed to adapt it for clinical imaging and to translate it toward clinically relevant performance in patient populations. We hypothesize that an integrated ensemble DL/ML approach can lead to vast improvements in fetal CHD diagnosis. Aims  To this end, the main Aims of this proposal are (1) to develop and optimize neural network architectures and efficient data inputs to relieve key performance bottlenecks for DL in fetal CHD; and (2) to deploy DL models population-wide to evaluate their ability to improve diagnosis, biometric characterization, and precision phenotyping over the current standard of care. Our methods include DL/ML algorithms and retrospective imaging analysis. Environment and Impact  This work will be supported in an outstanding environment for research at the crossroads of data science, cardiovascular and fetal imaging, and translational informatics. The work proposed will provide valuable tools and insight into designing and evaluating both the data and the algorithms for DL on imaging for clinically relevant goals, and will lay important groundwork for DL-assisted phenotyping for both clinical use and precision medicine research. Project Narrative Medical imaging is critical to almost every type of diagnostic and management decision, but human interpretation of medical images can lack accuracy and reproducibility. By developing machine learning methods for analyzing medical images, the work in our proposal can improve diagnostic accuracy in medical imaging, for both clinical and research uses.",Improving cardiovascular image-based phenotyping using emerging methods in artificial intelligence,9867431,R01HL150394,"['Abdomen', 'Address', 'Adult', 'Age', 'Aging', 'Apical', 'Artificial Intelligence', 'Biometry', 'Birth', 'Cardiac', 'Cardiovascular Diseases', 'Cardiovascular system', 'Clinical', 'Clinical Research', 'Collection', 'Communities', 'Complex', 'Congenital Abnormality', 'Data', 'Data Science', 'Data Set', 'Detection', 'Diagnosis', 'Diagnostic', 'Early Diagnosis', 'Early treatment', 'Echocardiography', 'Environment', 'Evaluation', 'Face', 'Fetal Heart', 'Goals', 'Heart', 'Heart Abnormalities', 'Human', 'Image', 'Image Analysis', 'Informatics', 'Label', 'Lead', 'Lesion', 'Life', 'Literature', 'Machine Learning', 'Measurement', 'Medical Imaging', 'Methods', 'Modeling', 'Morbidity - disease rate', 'Outcome', 'Patients', 'Pattern', 'Pattern Recognition', 'Performance', 'Phenotype', 'Physicians', 'Population', 'Pregnant Women', 'Provider', 'Psyche structure', 'Quality Control', 'Rare Diseases', 'Reproducibility', 'Research', 'Secure', 'Structure', 'Supervision', 'Surveys', 'Techniques', 'Testing', 'Time', 'Trachea', 'Training', 'Translating', 'Ultrasonography', 'Variant', 'Work', 'base', 'cardiovascular imaging', 'clinical center', 'clinical decision-making', 'clinical imaging', 'clinically relevant', 'comorbidity', 'computerized data processing', 'congenital heart disorder', 'cost', 'data curation', 'data harmonization', 'deep learning', 'deep learning algorithm', 'design', 'diagnostic accuracy', 'disease diagnosis', 'fetal', 'fetal diagnosis', 'heart imaging', 'image guided', 'image processing', 'imaging study', 'improved', 'insight', 'learning network', 'machine learning algorithm', 'machine learning method', 'model design', 'mortality', 'multidisciplinary', 'multimodality', 'neural network', 'neural network architecture', 'novel', 'patient population', 'precision medicine', 'prenatal', 'prevent', 'programs', 'repaired', 'screening', 'standard of care', 'statistics', 'theories', 'tool']",NHLBI,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",R01,2020,806128,0.031086597726775005
"Computer-Assisted Histologic Evaluation of Cardiac Allograft Rejection Project Summary Though cardiac transplantation is a lifesaving intervention, cardiac allograft rejection (CAR) remains a relatively common and serious complication that confers an increased risk of acute graft failure and adverse patient outcomes. For three decades, endomyocardial biopsy (EMB) with histological grading, as recommended by the International Society of Heart and Lung Transplantation (ISHLT) has been the broadly applied standard for CAR diagnosis. However, it is widely appreciated that the ISHLT rejection grading standard lacks diagnostic accuracy and has limited ability to discern the mechanism of rejection. These limitations expose patients to risks of both over-treatment and under-treatment, and highlight the unmet need for more accurate and informative approaches to histopathologic analysis of EMB samples. Our team is a leader in computational pathology image analysis with over 200 papers and >30 issued patents in this area. We have already developed and evaluated a computer assisted histopathology grading evaluation (CACHE) scheme which (1) in N=205 patients, had an area under the receiver operating characteristic curve (AUC)=0.95 compared to two cardiac pathologists (mean AUC=0.74) in distinguishing normal from failing hearts and (2) could distinguish low and high ISHLT rejection grades in N=1109 patients with a performance that exceeds that of trained cardiac pathologists. Recognizing the frequent discordance between ISHLT rejection grade and the clinical trajectory of a rejection event, we will further develop and optimize CACHE to identify new grade agnostic morphologic biomarkers of clinically serious CAR. Our scientific premise is that morphologic biomarkers prioritized based on their correlation to patients clinical trajectories and underlying immunological disease mechanisms will generate an accurate, consistent and informative classifier for diagnosing allograft rejection. In service of this hypothesis, the proposed research will address three specific aims. In Aim 1, we will utilize computational image analysis to discover the morphologic biomarkers of rejection-related injury which are needed to develop a classifier capable of assessing the clinical trajectory of CAR. In Aim 2, we will provide mechanistic annotation of biomarkers identified in Aim 1 through correlation with in-situ immunologic markers using custom multi-parameter immunofluorescence panels. In Aim 3, we employ a multicenter, prospective cohort to validate the diagnostic and mechanistic accuracy of the new rejection classifier developed in Aims 1 and 2. Ultimately, development of a more accurate and mechanistically informative tool for morphologic diagnosis of CAR will improve patient outcomes by reducing over- and under- treatment and inspire applications in other organ transplants. Interestingly, development of a superior histologic diagnostic tool will empower development of alternative, biopsy-free diagnostic approaches that have been handicapped by the necessity of comparison with the flawed ISHLT rejection grade as a reference standard. Project Narrative For heart transplant recipients, allograft rejection remains a relatively common and serious complication associated with adverse patient outcomes. Shortcomings of the current rejection grading standard for heart biopsies leads to both over- and under-treatment, accordingly, this proposal will develop and validate a computer assisted rejection grading classifier that is more accurate, consistent and informative for diagnosing heart allograft rejection. Improved diagnostic accuracy will improve patient outcomes, inspire similar applications in other organ transplants and empower development of additional technologies that have been constrained by the current flawed rejection standard.",Computer-Assisted Histologic Evaluation of Cardiac Allograft Rejection,10070406,R01HL151277,"['Acute', 'Address', 'Allografting', 'Antibodies', 'Archives', 'Area', 'Benign', 'Biological Markers', 'Biopsy', 'Biopsy Specimen', 'Cardiac', 'Cells', 'Classification', 'Clinical', 'Clinical Trials Design', 'Complication', 'Computer Assisted', 'Computer Vision Systems', 'Custom', 'Data', 'Derivation procedure', 'Development', 'Diagnosis', 'Diagnostic', 'Disabled Persons', 'Disease', 'Evaluation', 'Event', 'Flow Cytometry', 'Functional disorder', 'Gene Expression Profiling', 'Graft Rejection', 'Guidelines', 'Heart', 'Heart Transplantation', 'Heart-Lung Transplantation', 'Histologic', 'Histopathologic Grade', 'Histopathology', 'Human', 'Image', 'Image Analysis', 'Immune', 'Immune System Diseases', 'Immunofluorescence Immunologic', 'Immunologic Markers', 'Immunologics', 'In Situ', 'Injury', 'International', 'Interobserver Variability', 'Intervention', 'Journals', 'Legal patent', 'Lymphocyte', 'Machine Learning', 'Malignant neoplasm of lung', 'Mediating', 'Medical', 'Methods', 'Molecular', 'Monitor', 'Morphology', 'Organ Transplantation', 'Outcome', 'Paper', 'Pathologist', 'Patient-Focused Outcomes', 'Patients', 'Pattern', 'Performance', 'Population', 'Prevention', 'Prospective cohort', 'Protocols documentation', 'ROC Curve', 'Recurrence', 'Reference Standards', 'Research', 'Retrospective cohort', 'Risk', 'Sampling', 'Scheme', 'Services', 'Severities', 'Slide', 'Societies', 'Stains', 'Syndrome', 'Technology', 'Testing', 'Therapeutic', 'Tissue imaging', 'Tissues', 'Training', 'Transplant Recipients', 'Transplantation', 'allograft rejection', 'base', 'biomarker discovery', 'biomarker validation', 'clinical predictors', 'clinically significant', 'cohort', 'diagnostic accuracy', 'feature detection', 'graft failure', 'heart allograft', 'heart imaging', 'improved', 'innovation', 'molecular marker', 'novel', 'outcome forecast', 'overtreatment', 'pathology imaging', 'phenotypic data', 'population based', 'post-transplant', 'prospective', 'screening', 'success', 'tool', 'transplant centers', 'treatment as usual', 'treatment choice']",NHLBI,UNIVERSITY OF PENNSYLVANIA,R01,2020,845590,0.10982234837439424
"Serial evaluation of cardioprotective effects of exercise training in heart failure using cardiac diffusion tensor MRI Project Summary / Abstract  Heart failure (HF) is accounts for 1 in 9 deaths in the United States and currently affects ~6 million with a prevalence of 250,00-400,000 and incidence of 70,000-120,000. Current therapy does not address the underlying loss of functional heart muscle and adverse structural remodeling. One novel potential treatment of HF is exercise (aerobic) therapy that has demonstrated various cardioprotective properties to halt and potentially reverse adverse structural remodeling. However, dosing of exercise therapy remains a challenge due to each individual's inherent differences and consequentially, serial non-invasive monitoring of the therapy would be necessary to evaluate the change on structural remodeling. Furthermore, current non-invasive technologies characterize structural remodeling with surrogate measures and thus, there is no consensus on a single clinical gold-standard. Without a tool to monitor and characterize the degree of structural remodeling, the evaluation of the therapeutic potential of exercise therapy in HF patients cannot be fully realized representing an unmet need in ultimately improving therapy. The proposed project aims to improve the therapy monitoring of exercise training to cardioprotect against HF by revealing its effect on microstructural remodeling with cardiac diffusion tensor MRI (DT-MRI). DT-MRI is a unique, non-invasive technology capable of characterizing myocardial fiber orientation and directly reflecting microstructural remodeling. However, despite major advances, there are fundamental challenges that limit the capability of current cardiac DT-MRI methods to be applied robustly in a clinical setting. In this project, an innovative 5-min push button DT-MRI method will be developed that overcomes such limitations. We also leverage institutional strengths to further quantify the accuracy of in vivo DT-MRI in revealing myocardial microstructure using novel tissue cleared 3D histology. The central hypothesis is that addressing these major technical challenges will allow for clinical translation of cardiac DT-MRI to serve as a tool to monitor the therapeutic effects of HF on microstructural remodeling. This is achieved by extending previously developed technologies used for myocardial fibrosis detection with diffusion-weighted MRI. The proposed project is designed to systematically develop an innovative and robust clinical DT-MRI methodology and rigorously validate in a pre-clinical setting the effects of exercise therapy on the microstructural remodeling of HF thereby laying the groundwork for potential optimization of dosing exercise therapy. Project Narrative This project ultimately aims at optimizing the non-invasive monitoring of exercise therapy in heart failure patients to potentially improve outcome. The research strategy is designed to systematically develop an innovative cardiac diffusion tensor MRI method that overcomes major shortcomings of the conventional methods and aims at immediate clinical translation. Successful completion of this project will result in a clinically robust cardiac diffusion tensor MRI method that can effectively monitor the efficacy of exercise therapy and potentially improve treatment of heart failure.",Serial evaluation of cardioprotective effects of exercise training in heart failure using cardiac diffusion tensor MRI,9946164,R01HL151704,"['3-Dimensional', 'Address', 'Aerobic', 'Affect', 'Agreement', 'Architecture', 'Biological Markers', 'Biopsy', 'Blood', 'Bone Marrow', 'Cardiac', 'Cardiac Myocytes', 'Cell Therapy', 'Cessation of life', 'Clinical', 'Consensus', 'Consequentialism', 'Data', 'Detection', 'Diffusion', 'Diffusion Magnetic Resonance Imaging', 'Dose', 'Echocardiography', 'Effectiveness', 'Electrocardiogram', 'Evaluation', 'Exercise', 'Exercise Therapy', 'Exhibits', 'Family suidae', 'Fiber', 'Financial compensation', 'Fluorescence Microscopy', 'Genetic Transcription', 'Gold', 'Heart failure', 'Histology', 'Imaging Techniques', 'Incidence', 'Individual', 'MRI Scans', 'Magnetic Resonance Imaging', 'Measures', 'Methodology', 'Methods', 'Monitor', 'Motion', 'Mus', 'Myocardial', 'Myocardial Infarction', 'Myocardium', 'Outcome', 'Pacemakers', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Prevalence', 'Prognostic Marker', 'Property', 'RNA marker', 'Reproducibility', 'Research', 'Sampling', 'Scanning', 'Signal Pathway', 'Slice', 'Structure', 'Tachycardia', 'Techniques', 'Technology', 'Testing', 'Therapeutic', 'Therapeutic Effect', 'Time', 'Tissues', 'Translating', 'Treatment outcome', 'United States', 'cardioprotection', 'clinical translation', 'clinically translatable', 'cohort', 'coronary fibrosis', 'denoising deep learning', 'design', 'effective therapy', 'exercise training', 'functional loss', 'heart function', 'imaging modality', 'improved', 'improved outcome', 'in vivo', 'innovation', 'insight', 'multitask', 'new technology', 'non-invasive imaging', 'non-invasive monitor', 'novel', 'pre-clinical', 'preclinical study', 'preservation', 'prognostic tool', 'prognostic value', 'reconstruction', 'sedentary', 'therapeutic evaluation', 'tomography', 'tool']",NHLBI,MASSACHUSETTS GENERAL HOSPITAL,R01,2020,673600,0.10201774295732619
"Multi-Omic Markers of Cardiac Function and Structure within the Pressure Overloaded Heart PROJECT SUMMARY/ABSTRACT This proposed study is motivated by the public health importance of aortic stenosis (AS), a common form of valvular heart disease that is associated with substantial morbidity and mortality. Once symptomatic, survival is a dismal 50% at 1-year if left untreated. Clinical symptoms develop once cardiac compensatory mechanisms fail, indicating the need for aortic valve replacement (AVR), but because AS primarily affects the elderly, symptoms are often incorrectly attributed to comorbid conditions, advanced age, or bothresulting in delayed treatment. While most patients that eventually undergo AVR experience improvements in symptoms and survival, nearly half of patients die within the first year after AVR or fail to reap the symptom and health status improvements for which they underwent AVR. Our research suggests that irreversible cardiac remodeling and injury related to delayed treatment contribute to these poor clinical outcomes, highlighting the unmet need for objective and sensitive measures to inform clinical decisions regarding the timing of AVR. Our long-term goal is to develop and implement an omics-based precision medicine approach for identifying patients with severe AS at-risk for irreversible cardiac remodeling and injury who would benefit from earlier AVR, and our central hypothesis is that multi-omic signatures reflective of dimensions of cardiac structure and function will identify irreversible cardiac remodeling and therefore predict the clinical response to AVR. Our prior work and preliminary studies provide strong support for our hypothesis and demonstrate that our experienced multidisciplinary team is uniquely qualified to complete the proposed study. We have identified metabolomic signatures that relate strongly to measures of cardiac function and structure and predict mortality after AVR, and also proteomic signatures relating to cardiac function that differentiate severe AS and associate with mortality. Within this proposal, we adopt a longitudinal systems biology approach that leverages the latest in proteomic and metabolomic (multi-omic) sciences to: discover, test, and cross-validate multi-omic signatures of cardiac function and structure in patients with severe AS (Aim 1); characterize longitudinal multi-omic signatures and associations with changes in cardiac structure and function after AVR (Aim 2); and evaluate the accuracy with which multi-omic signatures predict response to AVR (Aim 3). Our approach will enable us to identify multi-omic signatures of irreversible cardiac remodeling and injury in patients with severe AS. These data will support the development of new precision medicine-based strategies for identifying patients who would benefit from earlier clinical intervention in an effort to reduce mortality and maximize health after AVR. PROJECT NARRATIVE Aortic stenosis ultimately leads to heart failure and death, but valve replacement is curative. For many patients, valve replacement is performed too late, after damage to the heart muscle is no longer reversible, resulting in persistent symptoms and increased risk for death. The goal of my research is to identify compounds within the blood that can serve as an early warning that the heart is struggling to overcome aortic stenosis and can therefore help physicians plan the optimal timing of valve replacement surgery.",Multi-Omic Markers of Cardiac Function and Structure within the Pressure Overloaded Heart,9946858,R01HL151838,"['Adopted', 'Affect', 'Aortic Valve Stenosis', 'Biological Process', 'Blood', 'Cardiac', 'Cause of Death', 'Cessation of life', 'Clinical', 'Clinical Practice Guideline', 'Complex', 'Data', 'Development', 'Disease', 'Distress', 'EFRAC', 'Early Intervention', 'Elderly', 'Energy Metabolism', 'Functional disorder', 'Goals', 'Grant', 'Growth', 'Health', 'Health Status', 'Heart', 'Heart Injuries', 'Heart Valve Diseases', 'Heart failure', 'Impairment', 'Individual', 'Injury', 'Intervention', 'Left', 'Left Ventricular Ejection Fraction', 'Left Ventricular Remodeling', 'Machine Learning', 'Measures', 'Metabolic', 'Modeling', 'Morbidity - disease rate', 'Myocardial dysfunction', 'Myocardium', 'Operative Surgical Procedures', 'Outcome', 'Patients', 'Physicians', 'Prospective cohort', 'Proteomics', 'Public Health', 'Research', 'Risk', 'Sampling', 'Science', 'Structure', 'Symptoms', 'Systems Biology', 'Testing', 'Time', 'Ventricular', 'Work', 'aortic valve replacement', 'classification algorithm', 'clinical predictors', 'cohort', 'comorbidity', 'experience', 'heart dimension/size', 'heart function', 'metabolomics', 'mortality', 'mortality risk', 'multidisciplinary', 'multiple omics', 'patient registry', 'persistent symptom', 'precision medicine', 'predict clinical outcome', 'predicting response', 'predictive signature', 'pressure', 'protein metabolite', 'proteomic signature', 'response', 'valve replacement']",NHLBI,MASSACHUSETTS GENERAL HOSPITAL,R01,2020,696226,0.1591551978392187
"QT prolonging medications and sudden cardiac death among individuals on hemodialysis PROJECT SUMMARY/ ABSTRACT Individuals receiving maintenance hemodialysis (HD) have exceedingly high mortality, driven largely by cardiovascular events. The rate of sudden cardiac death (SCD) in the HD population exceeds that of the general population by more than 20-fold. Risk factors for SCD such as structural heart disease and conduction abnormalities are common among people with end-stage kidney disease, but traditional preventive strategies, such as antiarrhythmic medications and implantable cardioverter defibrillators, do not lower SCD risk in HD patients. However, medication-provoked SCD may be preventable, and, to-date, has been understudied in HD patients. Dialysis patients are often prescribed medications that have the undesirable, off-target effect of delayed ventricular repolarization, which manifests as QT-interval prolongation on an electrocardiogram, and can trigger fatal arrhythmias. Although more than 50% of dialysis patients are prescribed medications that can prolong the QT-interval (e.g. certain antidepressants, antibiotics, antiemetics), there are critical knowledge gaps about the cardiac safety of these medications. In fact, their safety profiles rest on data obtained from healthy volunteers and have not been explicitly evaluated in HD patients. By executing the proposed studies, we will provide a comprehensive understanding of the essential safety data relevant to the prescription of non- cardiac QT-prolonging medications to HD patients. In Aim 1, we will determine the relative SCD risk of the most commonly prescribed non-cardiac medications with higher QT-prolonging potential vs. clinically relevant comparator medications with lower QT-prolonging potential among HD patients. In Aim 2, we will identify modifiable clinical factors (e.g. dialysate composition and concurrent prescription medications) that may be targeted to mitigate SCD risk from QT-prolonging medications. In Aim 3, we will identify prescribers of higher risk QT-prolonging medications and associated encounters that should prompt medication reconciliation and decision support tool use. Then, in Aim 4, we will develop individualized decision support tools for QT- prolonging medication prescribing that integrate many comorbid conditions, HD treatment, and medication- related risk factors. This work will yield decision support tools that facilitate personalized SCD risk assessments and safer prescribing of QT-prolonging medications to reduce SCD risk among HD patients. Moreover, the decision support tools generated in this project will serve as the subject of future pragmatic trials testing the impact of tool implementation on cardiovascular outcomes. PROJECT NARRATIVE Hemodialysis patients experience a disproportionately high burden of sudden cardiac death. Medication- provoked sudden cardiac death (i.e. death triggered by QT-prolonging medications) may be preventable and has not been studied enough in this population. Our project aims to uncover medication-related risk factors for sudden cardiac death and develop clinical decision support tools that will promote safer medication prescribing.",QT prolonging medications and sudden cardiac death among individuals on hemodialysis,9943546,R01HL152034,"['Antibiotics', 'Antidepressive Agents', 'Antiemetics', 'Arrhythmia', 'Benefits and Risks', 'Biometry', 'Calcium', 'Cardiac', 'Cardiovascular system', 'Cessation of life', 'Clinical', 'Data', 'Data Analytics', 'Dialysis patients', 'Dialysis procedure', 'Drug Interactions', 'Electrocardiogram', 'Electrolytes', 'Electronic Health Record', 'Emergency Care', 'End stage renal failure', 'Epidemiology', 'Event', 'Future', 'General Population', 'Hemodialysis', 'Implantable Defibrillators', 'Individual', 'Investments', 'Knowledge', 'Laboratories', 'Life', 'Link', 'Location', 'Machine Learning', 'Maintenance', 'Medicare', 'Observational Study', 'Online Systems', 'Outcome', 'Patients', 'Persons', 'Pharmaceutical Preparations', 'Pharmacology', 'Polypharmacy', 'Population', 'Potassium', 'Prevention strategy', 'Publishing', 'Rest', 'Risk', 'Risk Assessment', 'Risk Factors', 'Risk-Benefit Assessment', 'Safety', 'Selective Serotonin Reuptake Inhibitor', 'Testing', 'Ventricular', 'Work', 'base', 'case control', 'clinical decision support', 'clinically relevant', 'comorbidity', 'experience', 'healthy volunteer', 'high risk', 'machine learning algorithm', 'medication safety', 'modifiable risk', 'mortality', 'mortality risk', 'personalized decision', 'point of care', 'pragmatic trial', 'structural heart disease', 'sudden cardiac death', 'support tools', 'tool']",NHLBI,UNIV OF NORTH CAROLINA CHAPEL HILL,R01,2020,606842,0.038114391377117814
"Rapid Comprehensive Cardiac MRI Exam for Diagnosis of Coronary Artery Disease PROJECT SUMMARY/ABSTRACT Coronary artery disease (CAD) is the leading cause of death in the United States. The clinical gold standards to diagnose and guide treatment of patients with CAD are based on invasive catheter-based procedures, such as x-ray coronary angiography (XCA) for anatomic assessment or fractional flow reserve (FFR) for physiologic assessment. However, there are costs and risks associated with such invasive procedures. Such concerns are further highlighted by the fact that large studies have shown nearly two-thirds of patients referred for their initial elective invasive XCA were found to have no significant stenoses. Thus, better non-invasive diagnostic tools are needed. Cardiac MRI (CMR) is the only non-invasive imaging modality that provides a comprehensive assessment of CAD in a single examination, including an assessment of myocardial perfusion, cardiac function and viability, as well as angiographic evaluation of stenoses, without requiring ionizing radiation. These properties also allow for repeat testing as may be clinically indicated. However, despite its great potential to serve as the non- invasive gatekeeper for costly invasive procedures, lengthy examination times have prevented CMR from clinical translation. Although several accelerated imaging techniques have been proposed, these still require trade-offs between coverage, resolution and signal-to-noise ratio. In this proposal, we will develop and validate novel acquisition and reconstruction strategies to enable a highly accelerated high-resolution whole heart CMR exam for comprehensive CAD assessment in under 10 minutes. We will develop fast and low specific absorption rate outer volume suppression modules to reduce the source of aliasing artifacts from the chest and the back. This will enable higher rates for simultaneous multi-slice imaging in perfusion and cine CMR, improving coverage substantially with minimal noise amplification. For coronary MRI and viability imaging, simultaneous multi-slab imaging will be introduced to CMR, facilitating high isotropic resolution acquisitions with fast coverage. These acquisitions will be supplemented with regularized leakage-blocking and patient- specific machine learning reconstructions for further artifact and noise removal. Finally, we will implement and validate the proposed rapid comprehensive CMR exam in a cohort of suspected CAD patients, comparing our approach with conventional clinical CMR for the assessment of function, perfusion, and viability, and with invasive XCA for the assessment of coronary stenosis. Successful completion of this project has the potential to transform CMR into a leading rapid non-invasive tool for safe and accurate diagnosis of CAD, improving the healthcare of several million patients with chest pain and other CAD symptoms annually. PROJECT NARRATIVE Coronary artery disease (CAD) is the leading cause of death in the United States, accounting for one in six deaths. Cardiac MRI is a non-invasive non-ionizing technique for comprehensive evaluation of CAD, but its clinical translation is hampered by lengthy exam times. In this work, we will develop and validate techniques for rapid cardiac MRI in a short exam time for comprehensive CAD assessment.",Rapid Comprehensive Cardiac MRI Exam for Diagnosis of Coronary Artery Disease,10030978,R01HL153146,"['3-Dimensional', 'Acceleration', 'Accounting', 'Anatomy', 'Award', 'Back', 'Breathing', 'Cardiac', 'Catheters', 'Cause of Death', 'Cessation of life', 'Chest', 'Chest Pain', 'Clinical', 'Coronary', 'Coronary Angiography', 'Coronary Arteriosclerosis', 'Coronary Stenosis', 'Data', 'Development', 'Diagnosis', 'Diagnostic', 'Evaluation', 'Excision', 'Extravasation', 'Gadolinium', 'Gatekeeping', 'Gold', 'Healthcare', 'Heart', 'Image', 'Imaging Techniques', 'Ionizing radiation', 'Machine Learning', 'Magnetic Resonance Imaging', 'Medical Care Costs', 'Methods', 'Morphologic artifacts', 'Myocardial perfusion', 'Noise', 'Patients', 'Perfusion', 'Physiological', 'Preparation', 'Procedures', 'Property', 'Resolution', 'Risk', 'Roentgen Rays', 'Sampling', 'Scanning', 'Scheme', 'Signal Transduction', 'Slice', 'Source', 'Symptoms', 'Techniques', 'Testing', 'Time', 'United States', 'Work', 'absorption', 'accurate diagnosis', 'artificial neural network', 'base', 'clinical translation', 'cohort', 'cost', 'diagnosis standard', 'disease diagnosis', 'heart function', 'high resolution imaging', 'imaging modality', 'improved', 'non-invasive imaging', 'noninvasive diagnosis', 'novel', 'prevent', 'rapid technique', 'reconstruction', 'temporal measurement', 'tool']",NHLBI,UNIVERSITY OF MINNESOTA,R01,2020,504903,0.14244366235120284
"Deviceless and Autonomous Prospective Cardiac CT Triggering PROJECT SUMMARY/ABSTRACT Coronary heart disease (CHD) is the leading cause of death worldwide. An estimated 3.8 million men and 3.4 million women die each year from CHD. Cardiac CT is a safe, accurate, non-invasive imaging modality used for diagnosing CHD and for planning therapeutic interventions. Cardiac CT exams are still challenging to perform due to the beating heart and the need to carefully time the scan based on cardiac phase and based on when the peak iodine contrast enhancement is reached. The overall exam duration and the complexity of performing these exams (contrasted with limited reimbursement levels) have limited patient access to cardiac CT to academic hospitals and specialized cardiac imaging centers. As compared to other CT exams, cardiac CT exams require additional patient preparation time, additional CT scans to track the bolus, and additional contrast agent to avoid missing the peak enhancement.  The goal of this project is to develop a smart cardiac CT scanner that autonomously determines the optimal scan time interval without ECG, traditional bolus tracking or timing bolus. Initial results show that it is possible to extract cardiac gating information from a few CT projection measurements prior to the diagnostic CT scan, without reconstruction. This is made possible by an innovative combination of fast X-ray tube pulsing and deep learning raw data analysis. This project builds on GE Research's experience with cardiac CT technologies, deep learning algorithms and X-ray tube physics, as well as the strong clinical cardiac CT expertise at the University of California San Diego.  The outcome of this project will be a clinical feasibility study of the autonomous triggering approach, which has the potential to simplify and increase patient access to cardiac CT, while reducing exam time, reducing con- trast agent volume, and ensuring robust image quality. PROJECT NARRATIVE The goal of this project is to develop a smart cardiac CT scanner that autonomously determines the optimal scan time interval without ECG, traditional bolus tracking or timing bolus. The result will be a patient-friendly and technologist-friendly cardiac CT exam with reduced exam time, minimal contrast agent volume and radia- tion dose, and robust image quality.",Deviceless and Autonomous Prospective Cardiac CT Triggering,10029731,R01HL153250,"['Algorithms', 'Anatomy', 'Angiography', 'Bolus Infusion', 'California', 'Cardiac', 'Cause of Death', 'Clinical', 'Contrast Media', 'Coronary', 'Coronary heart disease', 'Data', 'Data Analyses', 'Diagnosis', 'Diagnostic', 'Electrocardiogram', 'Ensure', 'Feasibility Studies', 'Financial compensation', 'Goals', 'Heart', 'Hospitals', 'Image', 'Institutional Review Boards', 'Iodine', 'Measurement', 'Morphology', 'Motion', 'Myocardial', 'Outcome', 'Patients', 'Performance', 'Perfusion', 'Phase', 'Physics', 'Physiologic pulse', 'Preparation', 'Prospective Studies', 'Protocols documentation', 'Radiation Dose Unit', 'Research', 'Roentgen Rays', 'Rotation', 'Scanning', 'System', 'Techniques', 'Technology', 'Therapeutic Intervention', 'Time', 'Training', 'Translating', 'Tube', 'Universities', 'Woman', 'X-Ray Computed Tomography', 'algorithm development', 'base', 'contrast enhanced', 'deep learning', 'deep learning algorithm', 'experience', 'heart imaging', 'image reconstruction', 'imaging modality', 'innovation', 'men', 'non-invasive imaging', 'prospective', 'reconstruction', 'standard of care', 'temporal measurement', 'time interval']",NHLBI,GENERAL ELECTRIC GLOBAL RESEARCH CTR,R01,2020,1060608,0.1564196973266058
"Prospective sudden cardiac death risk stratification using CMR and echocardiography machine learning in mitral valve prolapse PROJECT SUMMARY Mitral valve prolapse (MVP) is a common valvulopathy affecting over 170 million worldwide. Every year, 0.4- 1.9% of individuals with MVP will develop sudden cardiac arrest (SCA) or sudden cardiac death (SCD), and 7% of SCDs in the young are caused by MVP. However, predictors of this devastating outcome are not readily available, and indications for a primary prevention implantable cardioverter defibrillator (ICD) in MVP are lacking. Severe mitral regurgitation explains only 50% of SCA cases in MVP. SCD/SCA risk has also been linked to a bileaflet phenotype with mild MR, mitral annular disjunction (MAD), and left ventricular focal fibrosis on cardiac magnetic resonance (CMR)-late gadolinium enhancement (LGE) images. Such imaging parameters (including LGE) have not been evaluated prospectively. Moreover, they are not consistently found in SCA survivors, and diffuse fibrosis has been proposed as an alternative arrhythmic substrate by our group and others based on CMR/T1 mapping, strain echocardiography, and post-mortem data. Overall, it is challenging to pinpoint a unique imaging phenotype, and uncertainty exists about which MVP patients should undergo CMR. Regardless of arrhythmic phenotype, complex ventricular ectopy (ComVE - defined as frequent polymorphic PVCs, bigeminy or non-sustained ventricular tachycardia) is detected in 80-100% of MVP cases prior to SCA or SCD. ComVE, commonly associated with left ventricular fibrosis on CMR, is linked to higher all-cause mortality and SCA rates (20% versus 12% if no ComVE, p < 0.05) based on preliminary cross-sectional data. Our central hypothesis is that MVP patients with ComVE, because of the higher prevalence of either LGE or abnormal T1 mapping, represent ideal CMR candidates regardless of leaflet involvement or MAD, and can be rapidly identified by an automated surveillance tool within a large echocardiographic database. Moreover, we hypothesize that fibrosis is the strongest predictor of SCD/SCA in an unprecedented, multi-center effort to longitudinally assess clinical and CMR parameters of arrhythmic risk in MVP. Specifically, we aim to 1) Assess the role of CMR as a screening tool for fibrosis in MVP with ComVE incorporating T1 mapping in addition to LGE in an unselected MVP sample; 2) Develop an echo-based machine-learning algorithm to detect MVP with ComVE, test its association with myocardial fibrosis on CMR and longitudinal SCD/SCA risk; and 3) Build a novel prospective SCD/SCA risk prediction model in MVP. Better selection of CMR candidates and development of a SCD/SCA risk prediction tool inclusive of fibrosis by CMR are expected to dramatically improve risk stratification in MVP and establish future criteria for primary prevention ICD trials. PROJECT NARRATIVE Every year, 0.4-1.9% of individuals with mitral valve prolapse (MVP) will develop sudden cardiac death or arrest. In this application we propose to better identify those at risk by using cardiac magnetic resonance and echocardiography-based artificial intelligence, with the long-term goal of selecting those that may benefit most from a defibrillator. .",Prospective sudden cardiac death risk stratification using CMR and echocardiography machine learning in mitral valve prolapse,10034460,R01HL153447,"['Affect', 'Artificial Intelligence', 'Autopsy', 'California', 'Cardiac', 'Clinical', 'Clinical Markers', 'Complex', 'Data', 'Databases', 'Defibrillators', 'Development', 'Diffuse', 'Echocardiography', 'Fibrosis', 'Future', 'Gadolinium', 'Goals', 'Heart Arrest', 'High Prevalence', 'Holter Electrocardiography', 'Hybrids', 'Image', 'Image Enhancement', 'Implantable Defibrillators', 'Individual', 'Lead', 'Left', 'Link', 'Machine Learning', 'Magnetic Resonance', 'Mission', 'Mitral Valve Insufficiency', 'Mitral Valve Prolapse', 'Myocardial', 'Outcome', 'Patients', 'Phenotype', 'Population', 'Prevalence', 'Primary Prevention', 'Registries', 'Retrospective Studies', 'Risk', 'Risk stratification', 'Role', 'Sampling', 'San Francisco', 'Screening procedure', 'Survivors', 'Testing', 'Training', 'Uncertainty', 'United States National Institutes of Health', 'Universities', 'Validation', 'Ventricular', 'Ventricular Tachycardia', 'base', 'cardiovascular risk factor', 'coronary fibrosis', 'cost', 'extracellular', 'hemodynamics', 'high risk', 'improved', 'machine learning algorithm', 'mortality', 'neural network architecture', 'novel', 'prognostic significance', 'prospective', 'recurrent neural network', 'risk prediction model', 'secondary analysis', 'stem', 'sudden cardiac death', 'tool']",NHLBI,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",R01,2020,810751,0.17262416136557954
"Development of advanced cardiac SPECT imaging technologies Project Abstract Single Photon Emission Computed Tomography (SPECT) continues to play a critical role in the diagnosis and management of coronary artery disease (CAD). While conventional SPECT scanners using parallel-hole collimators are still the foundation of cardiac SPECT, recently our field observed an exciting growth of new developments of dedicated cardiac scanners. Such dedicated scanners, such as the GE Alcyone 530/570c systems and the D-SPECT systems both with CZT detectors, typically have multiple detectors collecting photons emitted from the heart simultaneously, leading to dramatically improved sensitivity (2-5 X). In addition, the GE systems use pinhole collimators and can achieve much higher resolution. These dedicated scanners opened doors to new applications with significant clinical impact, including ultra-low-dose imaging, absolute quantification of myocardial blood flow (MBF) and coronary flow reserve (CFR), high resolution molecular imaging, multi-isotope imaging, motion correction, and many more. Most of these new applications are uniquely achievable only using dedicated scanners. While the dedicated cardiac SPECT systems can improve clinical practice and lead to numerous new clinical applications, such systems are far from being optimized to fully realize their great potentials. In this grant, we propose to systematically develop and optimize innovative imaging technologies for the GE 530/570c systems to further improve its clinical efficacy in a variety of significant ways. In Aim 1, we will develop and optimize methods for static cardiac SPECT imaging. We will develop various deep learning methods and investigate approaches to increase angular sampling to reduce noise, and improve resolution and quantitative accuracy. In Aim 2, we will develop and validate methods for dynamic SPECT imaging, particularly involving direct parametric image reconstruction. In Aim 3, we will develop and validate methods for dual-isotope SPECT. Monte Carso simulation and deep learning based methods will be developed for tracers with different spatial distributions and fast kinetics. In all three aims, large animal studies and human subject data will be used for optimization and validation. Narrative The success of imaging technology developments proposed in this grant will substantially improve the image quality, reduce patient dose, expand the applications of cardiac SPECT from mainly static imaging to dynamic imaging, and establish multi-isotope clinical imaging.",Development of advanced cardiac SPECT imaging technologies,10064473,R01HL154345,"['Address', 'Advanced Development', 'Algorithms', 'Amyloidosis', 'Anatomy', 'Animals', 'Blood flow', 'Cardiac', 'Charge', 'Clinical', 'Collimator', 'Computed Tomography Scanners', 'Coronary', 'Coronary Arteriosclerosis', 'DCNU', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Dose', 'Event', 'Foundations', 'Gold', 'Grant', 'Heart', 'Human', 'Hybrids', 'Image', 'Imaging technology', 'Infarction', 'Isotopes', 'Kidney', 'Kinetics', 'Lead', 'Maps', 'Methods', 'Microspheres', 'Molecular Target', 'Monte Carlo Method', 'Motion', 'Myocardial', 'Myopathy', 'Noise', 'Patients', 'Perfusion', 'Photons', 'Play', 'Positioning Attribute', 'Positron-Emission Tomography', 'Radiation Dose Unit', 'Resolution', 'Role', 'Sampling', 'Spatial Distribution', 'Study Subject', 'System', 'Tail', 'Toxic effect', 'Tracer', 'Training', 'Validation', 'animal data', 'attenuation', 'base', 'cardiac single photon emission computed tomography', 'clinical application', 'clinical efficacy', 'clinical imaging', 'clinical practice', 'contrast enhanced', 'convolutional neural network', 'deep learning', 'detector', 'human subject', 'image reconstruction', 'imaging agent', 'imaging modality', 'improved', 'innovation', 'learning strategy', 'molecular imaging', 'new growth', 'parametric imaging', 'prospective', 'reconstruction', 'respiratory', 'simulation', 'single photon emission computed tomography', 'success', 'technology development']",NHLBI,YALE UNIVERSITY,R01,2020,806926,0.18220456364110688
"Predicting Drug Cardiotoxicity Targets Using iPSC-Derived Cardiomyocytes and Machine Learning PROJECT SUMMARY Drug development and approval is a costly process with nearly $2 billion spent for each drug that is approved. One of the most significant contributors to this high cost is the expense of developing drugs that fail to pass clinical trials  only 15% of drugs that begin clinical trials are approved for use on humans. A common reason for not reaching the FDAs criteria for approval is that the drug is classified as cardiotoxic, which cannot be detected during early stages of drug development. One way that drugs can lead to cardiotoxicity is by altering the electrical activity of ion channels that are responsible for the excitation of the heart tissue that pumps blood to the body. Understanding which ion channels, and the extent to which these ion channels are affected is central to determining the cardiotoxicity of a drug. Early-stage predictions of cardiotoxicity are based on animal studies that are poor models of human heart behavior or single-cell electrophysiological studies that falsely assume underlying pathophysiology based on action potential changes. The recent development of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offers an opportunity to study drug effects on human cells in a preclinical setting. In this study, we hypothesize that fitting a computational iPSC-CM model to voltage-clamp (VC) data acquired before and after drug application provides a means of quantifying unknown drug effects on specific cardiac ion channels. We will address this hypothesis through the following Specific Aims: 1) Use machine learning to design a novel VC protocol that improves the quality of data for hiPSC-CM model fitting. 2) Quantify the change in hiPSC-CM ion channel conductances before and after drug application. We will use machine learning to develop a novel voltage clamp protocol that improves the electrophysiology data acquired from our hiPSC-CMs. The data is optimized to improve predictions of the conductances for all ion channels activated during the cardiac action potential. We can apply this voltage clamp protocol in an in vitro setting before and after drug application, then fit our computational model to each dataset. The change in ion channel conductances, predicted by the model fit, serves as an estimate of the channel-specific effects of the drug. The contributions of this proposal will be significant because it will be the first study to use human cardiac cells to produce quantitative measurements of channel-specific drug targets that may lead to lethal cardiac arrhythmias. PROJECT NARRATIVE Many promising drugs developed to treat a variety of diseases have undesirable effects on the heart, including increased risk of sudden cardiac death. Often, these drugs are not found to have adverse effects until they reach clinical trials, and failure of drugs at this stage of development is very costly. We aim to develop a method that leverages machine learning and human stem cell-derived heart cells to predict drug cardiotoxicity in a pre-clinical setting to substantially reduce the cost of the drug development process.",Predicting Drug Cardiotoxicity Targets Using iPSC-Derived Cardiomyocytes and Machine Learning,10068266,F31HL154655,"['Action Potentials', 'Address', 'Adverse effects', 'Affect', 'Algorithms', 'Animals', 'Arrhythmia', 'Behavior', 'Benchmarking', 'Binding', 'Cardiac', 'Cardiac Myocytes', 'Cardiotoxicity', 'Cavia', 'Cells', 'Clinical Trials', 'Closure by clamp', 'Complex', 'Computer Models', 'Computing Methodologies', 'Data', 'Data Set', 'Detection', 'Development', 'Disease', 'Drug Approval', 'Drug Costs', 'Drug Targeting', 'Early Diagnosis', 'Electrophysiology (science)', 'Equation', 'Failure', 'Functional disorder', 'Goals', 'Heart', 'Human', 'In Vitro', 'Ion Channel', 'Kinetics', 'Knowledge', 'Lead', 'Learning', 'Machine Learning', 'Manuals', 'Measurement', 'Measures', 'Methods', 'Modeling', 'Morphology', 'Pharmaceutical Preparations', 'Population', 'Process', 'Protocols documentation', 'Publishing', 'Recovery', 'Research', 'Risk', 'Risk Assessment', 'Sensitivity and Specificity', 'Standard Model', 'Testing', 'Tissues', 'base', 'blood pump', 'cost', 'design', 'drug development', 'experimental study', 'heart cell', 'human data', 'human model', 'human stem cells', 'human subject', 'improved', 'induced pluripotent stem cell', 'insight', 'machine learning algorithm', 'novel', 'patch clamp', 'pre-clinical', 'predictive modeling', 'screening', 'sudden cardiac death', 'voltage', 'voltage clamp']",NHLBI,CORNELL UNIVERSITY,F31,2020,39120,0.12263445734638047
"Optimization of diagnostic accuracy, radiation dose, and patient throughput for cardiac SPECT via advanced and clinically practical cardiac-respiratory motion correction and deep learning Single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is widely used to detect and evaluate coronary artery disease. The goal of this project is to reduce the radiation dose and/or scan time of SPECT MPI by a combined factor of 16x, while maintaining or increasing diagnostic accuracy. This would enable SPECT MPI to be performed, e.g., with 4x reduced radiation dose and 4x shorter scan time (~2.5 minutes) than typical protocols. Radiation dose in SPECT MPI has been recognized as an important issue, accounting for ~25% of all radiation exposure to patients in medical imaging. Dose reduction particularly addresses the increased prevalence of obese patients (who receive higher dose) and younger cardiac patients (whose radiation risk is higher due to longer life expectancy). Reduction in scan time would improve comfort for elderly and infirm cardiac patients, while mitigating body-motion image artifacts and reducing healthcare costs by increasing clinical throughput. We will reduce dose and scan time through innovative image reconstruction methods that involve little or no cost and require no additional patient setup steps. We will employ new respiratory and cardiac motion compensation to reduce image artifacts, as well as new deep learning techniques, which will be used for both respiratory-signal estimation and high-performance denoising. We will methodically optimize these techniques and then validate our algorithms in multicenter clinical reader studies. SA1: Develop clinically practical respiratory motion surrogates for low-count studies. T1: Perfect data- driven respiratory surrogate estimation; T2: Optimize data-driven surrogate estimation at reduced counts; T3: Develop and clinically validate depth-sensing cameras for respiratory and body-motion surrogate estimation; T4: Generalization of data-driven surrogate estimation to SPECT systems not having a CT. SA2: Develop deep-learning reconstruction methods and optimize for diagnostic accuracy and dose/scan time. T1: Post-reconstruction DL denoising algorithms for 3D perfusion images for reduced-count and standard- count studies; T2: DL denoising algorithms for 4D cardiac-gated studies; T3: 4D reconstruction with embedded DL denoising, cardiac motion estimation and correction; and T4: DL reconstruction methods with both RMC and CMC, with projection data binned using respiratory surrogate signals derived in SA1. SA3: Perform multicenter clinical reader studies (6 clinicians, 3 institutions) to validate the new algorithms and compare to current clinically-available methods based on diagnostic performance and repeatability in assessing both perfusion and wall motion defects. T1: In comparison to baseline clinical reconstruction, evaluate added benefit of: a) including attenuation and scatter correction, and b) additionally including RMC; T2: Validate DL for improvement of perfusion and function (wall motion) task performance at full-count levels; and T3: Validate DL for improvement of task performance at reduced counts. PROJECT NARRATIVE In this project we will employ new methods of image reconstruction and processing to reduce radiation dose and scan time in cardiac SPECT imaging, which is used 15-20 million times per year to evaluate coronary artery disease. Dose reduction is important because cardiac SPECT accounts for ~25% of all radiation exposure to the public due to medical imaging; reducing scan time would make SPECT more comfortable for elderly and infirm cardiac patients, while mitigating image artifacts, as well as and reducing healthcare costs by allowing more patients to be scanned per day. Our goal will be to achieve a combined 16x reduction in dose and scan time while maintaining or improving diagnostic accuracy, thereby permitting a 4x reduction in dose while reducing scan time from ~10 minutes to ~2.5 minutes.","Optimization of diagnostic accuracy, radiation dose, and patient throughput for cardiac SPECT via advanced and clinically practical cardiac-respiratory motion correction and deep learning",10072432,R01HL154687,"['3-Dimensional', '4D Imaging', 'Accounting', 'Address', 'Advocate', 'Algorithms', 'American', 'Cardiac', 'Clinic', 'Clinical', 'Computer software', 'Coronary Arteriosclerosis', 'Data', 'Defect', 'Development', 'Diagnostic', 'Disease', 'Dose', 'Effectiveness', 'Elderly', 'Electromagnetic Energy', 'Exposure to', 'Financial compensation', 'Functional Imaging', 'Goals', 'Health Care Costs', 'Image', 'Imaging Techniques', 'Institution', 'Left Ventricular Function', 'Life Expectancy', 'Measures', 'Mechanics', 'Medical Imaging', 'Methods', 'Modality', 'Morphologic artifacts', 'Motion', 'Myocardial perfusion', 'Noise', 'Nuclear', 'Obesity', 'Patients', 'Performance', 'Perfusion', 'Photons', 'Play', 'Population', 'Prevalence', 'Protocols documentation', 'Radiation Dose Unit', 'Radiation exposure', 'Reader', 'Recommendation', 'Resolution', 'Risk', 'Role', 'Scanning', 'Signal Transduction', 'Societies', 'System', 'Task Performances', 'Techniques', 'Technology', 'Time', 'Translating', 'Validation', 'Work', 'X-Ray Computed Tomography', 'attenuation', 'base', 'cardiac single photon emission computed tomography', 'clinical care', 'cost', 'deep learning', 'denoising', 'denoising deep learning', 'diagnosis evaluation', 'diagnostic accuracy', 'heart motion', 'hemodynamics', 'image processing', 'image reconstruction', 'imaging modality', 'imaging system', 'improved', 'innovation', 'perfusion imaging', 'preservation', 'prognostic', 'quantum', 'radiation risk', 'radiologist', 'reconstruction', 'respiratory', 'single photon emission computed tomography', 'tool', 'visual tracking']",NHLBI,ILLINOIS INSTITUTE OF TECHNOLOGY,R01,2020,786840,0.14996081551583967
"Gadolinium Free Cardiac MR Imaging of Scar and Fibrosis Cardiovascular disease continues to be the leading cause of morbidity and mortality in the United States. Magnetic resonance imaging (MRI) of scarred or fibrotic heart tissue plays a major diagnostic and prognostic role in patients with coronary heart disease (CHD) or non-ischemic cardiomyopathy (NICM). Cardiac MRI is a non-invasive, multifaceted imaging modality and is the clinical gold standard for scar and fibrotic cardiac tissue imaging with use of gadolinium-based contrast injection. However, administration of such gadolinium-based contrast agents (GBCA) prolongs the scan time, increases scan cost, and is contra-indicated in patients with impaired kidney function? a highly prevalent comorbidity in CHD patients. Until recently, GBCA was presumed to be safe in patients with normal kidney function; however, there are emerging data on long-term GBCA retention in the body. We aim to develop two complimentary approaches to reduce GBCA use in myocardial, or cardiac muscle, scar imaging. Initially, we will develop a quantitative risk-benefit model to identify NICM patients with a low chance of having scarred myocardium. Concurrently, we will develop a GBCA-free cardiac MR myocardial tissue probe platform based on AI (MyoProbe.ai) to quantify scarred regions of the heart. To accomplish this, we will develop and evaluate an individualized, patient-specific scar prediction model to reduce GBCA use in NICM patients with different etiologies by training the model to learn to identify whether the patient is likely to have scarring based on non-contrast images. If it is unlikely that a patient has scarring, contrast administration can be avoided. To develop and evaluate MyoProbe.ai for GBCA-free quantification of myocardial scar in CHD patients, we will use AI to integrate signal intensity and heart motion data from MRI images to accurately locate and quantify scar tissue. This information can then be used by cardiologists to diagnose and treat the patient. We will rigorously validate our risk-benefit model and AI myocardial probe platform using retrospectively and prospectively collected cardiac MRI images from multiple healthcare centers, MRI vendors, and magnetic field strengths. Our dataset will include different types of NICM and CHD patient populations to ensure that our work is applicable to patients with many different types of NICM and CHD. Cardiac magnetic resonance imaging (MRI) of scarred/fibrotic heart tissue with gadolinium- based contrast agents (GBCA) plays a major diagnostic and prognostic role in patients with coronary heart disease (CHD) or non-ischemic cardiomyopathy (NICM). However, administration of GBCAs prolongs the scan time, increases scan cost, contaminates surface and drinking water, is retained in the body long-term, and is contra-indicated in patients with impaired renal function a highly prevalent comorbidity in CHD patients. The goal of our study is to reduce or eliminate GBCA use in cardiac MR scar imaging using artificial intelligence (AI) by concurrently developing a quantitative model to identify NICM patients with a low likelihood of scarring and a GBCA-free cardiac MR AI platform to quantify scar tissue.",Gadolinium Free Cardiac MR Imaging of Scar and Fibrosis,10072898,R01HL154744,"['Adopted', 'Algorithms', 'Artificial Intelligence', 'Benefits and Risks', 'Blood Vessels', 'Cardiac', 'Cardiovascular Diseases', 'Chronic Kidney Failure', 'Cicatrix', 'Clinical', 'Contrast Media', 'Coronary heart disease', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Diagnostic', 'Diffuse', 'Ensure', 'Etiology', 'Fibrosis', 'Fostering', 'Gadolinium', 'General Population', 'Goals', 'Gold', 'Growth', 'Healthcare', 'Heart', 'Heterogeneity', 'Hypertrophic Cardiomyopathy', 'Image', 'Imaging Techniques', 'Impaired Renal Function', 'Impairment', 'Injections', 'Ischemia', 'Kidney', 'Learning', 'Location', 'Magnetic Resonance Imaging', 'Maps', 'Modeling', 'Morbidity - disease rate', 'Motion', 'Myocardial', 'Myocardial Infarction', 'Myocardial tissue', 'Myocardium', 'Noise', 'Patients', 'Pattern', 'Performance', 'Phenotype', 'Pilot Projects', 'Play', 'Protocols documentation', 'Reference Standards', 'Relaxation', 'Renal function', 'Research', 'Risk', 'Role', 'Scanning', 'Signal Transduction', 'Surface', 'Technical Expertise', 'Techniques', 'Testing', 'Time', 'Tissue imaging', 'Tissues', 'Training', 'United States', 'Validation', 'Vendor', 'Work', 'base', 'clinical application', 'clinical practice', 'comorbidity', 'coronary fibrosis', 'cost', 'deep learning', 'drinking water', 'heart imaging', 'heart motion', 'imaging modality', 'improved', 'individual patient', 'magnetic field', 'mortality', 'non-invasive imaging', 'novel', 'patient population', 'patient safety', 'predictive modeling', 'prognostic', 'prospective', 'radiomics']",NHLBI,BETH ISRAEL DEACONESS MEDICAL CENTER,R01,2020,946194,0.18142167577552856
"Machine learning driven transthoracic echocardiographic analysis and screening for cardiac amyloidosis Machine learning driven transthoracic echocardiographic analysis and screening for cardiac amyloidosis Cardiac amyloidosis (CA) is a serious but increasingly treatable cause of heart failure. Autopsy studies have estimated the prevalence of CA at approximately 25% of all octogenarians, and 15 to 20% of patients with aortic stenosis. Despite the increasing prevalence of CA within the general population and specific subpopulations, its diagnosis as a cause of heart failure is hampered by under recognition and subsequent underdiagnosis in clinical practice. Data suggest that the average time from onset of symptoms to diagnosis is 2 years and that patients report seeing an average of 5 physicians prior to establishing a definitive diagnosis. Transthoracic echocardiography (TTE) testing is the most common initial evaluation because of its wide availability. A recent utilization review in the Medicare population indicated over 7 Million echocardiographic tests are performed each year accounting for $1.2 Billion in healthcare costs. TTEs provide comprehensive information about cardiac structure and function, yet complexity of interpretation has limited its screening performance in patients with CA, and diagnosis can be challenging. Thus, our group seeks to offer a computer vision and machine learning based TTE analysis and screening solution for CA. We are uniquely positioned for accelerated development with a cohort of 359 patients with confirmed CA and 4,862 controls. In Phase I, we will build a deep learning neural network-based image processing pipeline. It maps the TTE sequence into a 2-dimensional space that allows for the identification of the 4-chamber peak diastolic and peak systolic images within the cardiac heartbeat cycle. This will enable our screening model to recognize regional myocardial wall motion changes and hypertrophic patterns that characterize amyloidosis in comparison to controls with normal cardiac function. The operational point defining the performance characteristics of our screening-oriented model (including sensitivity, specificity, and negative predictive value) will be optimized using an average weighted accuracy (AWA) approach which accounts for CA disease prevalence along with a desired false positive and false negative tradeoff. If we are successful, we envision a Phase II proposal to build and deploy an automated TTE analysis tool, and to evaluate it in a multi- center clinical study. This sets the stage for our long-term goal to implement a computer assisted TTE screening solution to improve identification and by extension care of patients with cardiac amyloidosis. PROJECT NARRATIVE While non-invasive echocardiography is a first line tool for diagnosis for many cardiovascular symptoms, it is underutilized for less common diseases such as cardiac amyloidosis which recently has been shown to be increasingly prevalent in general and specific subpopulations. In this project, we will develop and validate a novel computer-assistive echocardiographic analysis tool to recognize the presence of cardiac amyloidosis. It is our hope that this technology will enhance the screening and subsequent diagnosis of cardiac amyloidosis, ultimately, leading to improved patient outcomes.",Machine learning driven transthoracic echocardiographic analysis and screening for cardiac amyloidosis,10081836,R43HL154896,"['Accounting', 'Adult', 'Age-Years', 'Amyloid', 'Amyloidosis', 'Aortic Valve Stenosis', 'Area', 'Autopsy', 'Awareness', 'Biopsy', 'Cardiac', 'Cardiovascular system', 'Characteristics', 'Classification', 'Clinical', 'Collection', 'Computer Assisted', 'Computer Vision Systems', 'Computers', 'Data', 'Data Set', 'Databases', 'Deposition', 'Development', 'Diagnosis', 'Disease', 'Disease Progression', 'Echocardiography', 'Evaluation', 'Future', 'General Population', 'Goals', 'Health Care Costs', 'Heart failure', 'Image', 'Institutional Review Boards', 'Laboratories', 'Left Ventricular Hypertrophy', 'Left ventricular structure', 'Machine Learning', 'Maps', 'Medicare', 'Modeling', 'Motion', 'Multi-site clinical study', 'Multicenter Studies', 'Myocardial', 'Octogenarian', 'Patient Care', 'Patient-Focused Outcomes', 'Patients', 'Pattern', 'Pattern Recognition', 'Performance', 'Phase', 'Physicians', 'Population', 'Positioning Attribute', 'Predictive Value', 'Prevalence', 'Process', 'Reporting', 'Research', 'Review Literature', 'Screening procedure', 'Sensitivity and Specificity', 'Structure', 'Surveys', 'Symptoms', 'Target Populations', 'Technology', 'Testing', 'Time', 'Tissues', 'Training', 'Ultrasonography', 'Utilization Review', 'Validation', 'Ventricular', 'Work', 'autoencoder', 'base', 'case control', 'classification algorithm', 'clinical application', 'clinical practice', 'cohort', 'convolutional neural network', 'deep learning', 'deep neural network', 'genetic analysis', 'heart function', 'image processing', 'imaging genetics', 'improved', 'neural network', 'neural network classifier', 'novel', 'point of care', 'screening', 'tool', 'two-dimensional']",NHLBI,"VIGILANT MEDICAL, INC.",R43,2020,249373,0.14962155205810235
"Genetic determinants of 4D genome folding in human cardiac development PROJECT SUMMARY A major unanswered question is how chromatin topology coordinates human development and cellular differentiation, and how genome folding is differentially regulated in human disease. It is thought that three- dimensional (3D) chromatin organization is driven by transcriptional regulators, but fundamental mechanisms of this regulation as it relates to disease-relevant human cells have not been well explored. We propose to elucidate the temporally dynamic 3D nucleome (4DN) that underlies human cardiac differentiation, its molecular underpinnings, and the impact of mutations that underly defective 4DN organization in human congenital heart disease (CHD). CHDs are the most common birth defect and arise from abnormal heart development. The genetic basis of CHD is largely mutations in genes encoding chromatin modifiers (e.g. WDR5, KMT2D) and transcription factors (TFs, e.g. TBX5, GATA4), many of which also cause adult-onset arrhythmias. The impact of CHD mutations on the 4DN has not been explored. We hypothesize that 3D genome folding is highly regulated during cardiac differentiation and is impacted by disease-causing mutations in transcriptional regulators and non-coding elements. We will use iPS cell models and machine learning to elucidate dynamic 3D chromatin organization in human cardiomyocytes and endothelial cells during normal and diseased cardiac differentiation. We propose 3 specific aims: Aim 1: Establish a kilobase-scale 4D map of genome folding in human cardiomyocytes (CM) and endothelial cell (EC) differentiation. We will use directed differentiation of human iPS cells towards the two major cell types of the developing heart: CMs and ECs, and using microC across a fine time course of differentiation we will define at kilobase scale the 3D organization of the genome, capturing the states of developmental intermediates and the final differentiated cells. This aim will generate an essential integrated 4DN template for discovery in cardiac differentiation. In Aim 2: we will Determine the regulatory and disease-related basis for cardiac 3D chromatin organization. We will perform microC in iPS cell lines with CHD-associated mutations in transcriptional regulators, differentiated into CMs and ECs. These findings will establish the degree to which CHD is caused by abnormal genome folding and chromatin states, with important relevance to other human cardiovascular diseases. Finally, Aim 3 will address High-throughput screening of millions of CHD and synthetic non- coding mutations with a deep-learning model of dynamic genome folding. We will build a deep-learning model predicting 3D chromatin contact frequencies across cardiac differentiation at kilobase-resolution. By introducing thousands of CHD patient deletions and other non-coding mutations in silico, we will prioritize variants likely to interact with transcriptional regulators to cause disease through disrupted genome folding. Several candidates will be validated in engineered iPS cells differentiated into CMs and ECs. These results will provide a novel platform for computational discovery of disease variant impact across diverse human diseases PROJECT NARRATIVE Congenital heart defects are present in 1-2 out of 100 births, and are caused by mutations in genes that may control the 3-dimensional organization of chromosomes. We will use human cellular models and Artificial Intelligence to understand how chromosome organization is controlled during heart development and altered by disease processes. This will reveal fundamental concepts of gene regulation and may lead to a better understanding congenital heart defects towards improving diagnosis and treatment.",Genetic determinants of 4D genome folding in human cardiac development,10118056,U01HL157989,"['3-Dimensional', 'ATAC-seq', 'Address', 'Adult', 'Architecture', 'Arrhythmia', 'Artificial Intelligence', 'Birth', 'CCCTC-binding factor', 'Cardiac', 'Cardiac Myocytes', 'Cardiac development', 'Cardiovascular Diseases', 'Cell Differentiation process', 'Cell Line', 'Cell model', 'Cells', 'ChIP-seq', 'Child', 'Chromatin', 'Chromatin Remodeling Factor', 'Chromosome Structures', 'Code', 'Complement', 'Complex', 'Congenital Abnormality', 'Congenital Heart Defects', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Disease', 'Elements', 'Endothelial Cells', 'Engineering', 'Enhancers', 'Family', 'Frequencies', 'GATA4 gene', 'Gene Expression', 'Gene Expression Regulation', 'Genes', 'Genetic', 'Genetic Determinism', 'Genetic Transcription', 'Genome', 'Genomics', 'Heart', 'Heart Abnormalities', 'Heart Diseases', 'Histones', 'Human', 'Human Biology', 'Human Development', 'Lead', 'Machine Learning', 'Maps', 'Measures', 'Modeling', 'Molecular', 'Mutate', 'Mutation', 'Patients', 'Phenotype', 'Process', 'Proteins', 'Regulation', 'Regulator Genes', 'Regulatory Element', 'Resolution', 'SMARCA2 gene', 'Structure', 'Time', 'Untranslated RNA', 'Variant', 'Work', 'cardiogenesis', 'cell type', 'cohesin', 'computational platform', 'congenital heart disorder', 'deep learning', 'disease-causing mutation', 'high throughput screening', 'histone modification', 'human disease', 'human model', 'human pluripotent stem cell', 'improved', 'in silico', 'machine learning method', 'novel', 'predictive modeling', 'promoter', 'stem cell differentiation', 'stem cell model', 'transcription factor']",NHLBI,J. DAVID GLADSTONE INSTITUTES,U01,2020,742240,-0.01391993890396997
"Personalized dynamic risk-stratification model for childhood cancer survivors PROJECT SUMMARY/ABSTRACT This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-20-038. Cardiovascular complications have emerged as the leading cause of death among long-term childhood cancer survivors. It has been well-studied that these survivors have 15- and 7-fold of increased risk of developing congestive heart failure and premature death due to cardiac events compared to the general population. Since a long latency period often occurs before the clinically evident disease, the ability to predict is critical to expand the impact of survivor-based research to inform the future design and treatment regimes. To provide proper follow-up care for survivors, it is imperative to conduct patient-centered risk predictions that incorporate patient heterogeneity in a personalized and dynamic manner. While there is a growing body of literature on risk-stratification methods, most models only utilize baseline factors associated with the disease outcome. Cardiovascular burden is well-documented among childhood cancer survivor with cardiac risk factors increasing over time. In addition, a range of neighborhood and socioeconomic factors can affect risk for specific outcomes such as obesity. Leveraging the resources of the St. Jude Lifetime Cohort study (SJLIFE), we aim to develop a novel statistical model for personalized dynamic cancer risk prediction to improve the current cancer risk classification paradigm. Given that longitudinal information is routinely measured and documented for SJLIFE survivors, it is optimal to make full use of available longitudinal data to improve risk classification and guide timely risk-based prevention interventions to reduce the burden of cardiac diseases. The proposed method is appealing for its conceptual simplicity and efficiency for conducting dynamic prediction incorporating comprehensive longitudinal information, where risk prediction/ stratification can be updated as new observations are gathered to reflect the patient's latest health and behavior status. The proposed solutions will be accessible through open-source R software that we will make publicly available, and will be applied to data from childhood cancer survivors participating in SJLIFE. PROJECT NARRATIVE The goal of this project is to develop a novel statistical model for personalized dynamic cancer risk prediction integrating comprehensive longitudinal information. Successful completion of the proposed study will serve as a promising tool to improve risk stratification among cancer survivors to guide cancer survivorship care.",Personalized dynamic risk-stratification model for childhood cancer survivors,10166232,U01CA195547,"['Address', 'Administrative Supplement', 'Affect', 'Algorithmic Analysis', 'Algorithms', 'Cancer Survivor', 'Cancer Survivorship', 'Cardiac', 'Cardiovascular system', 'Caring', 'Cause of Death', 'Cessation of life', 'Characteristics', 'Classification', 'Clinical', 'Code', 'Cohort Studies', 'Computer software', 'Congestive Heart Failure', 'Data', 'Development', 'Disease', 'Disease Outcome', 'Dose', 'Evaluation', 'Event', 'Future', 'General Population', 'Genetic Markers', 'Genomics', 'Goals', 'Health behavior', 'Heart Diseases', 'Heterogeneity', 'Intervention', 'Investigation', 'Length', 'Life Style', 'Literature', 'Malignant Childhood Neoplasm', 'Measurement', 'Measures', 'Methodology', 'Methods', 'Modeling', 'Nature', 'Neighborhoods', 'Obesity', 'Outcome', 'Patients', 'Pattern', 'Performance', 'Positioning Attribute', 'Preventive Intervention', 'Principal Component Analysis', 'Research', 'Resources', 'Risk', 'Risk Factors', 'Risk stratification', 'Saint Jude Children&apos', 's Research Hospital', 'Scheme', 'Socioeconomic Factors', 'Statistical Models', 'Stratification', 'Structure', 'Survivors', 'System', 'Time', 'Treatment Protocols', 'Update', 'Validation', 'Work', 'base', 'cancer risk', 'cardiovascular risk factor', 'childhood cancer survivor', 'cohort', 'comorbidity', 'design', 'follow-up', 'genetic profiling', 'high dimensionality', 'improved', 'insight', 'interest', 'novel', 'open source', 'patient oriented', 'personalized risk prediction', 'predictive modeling', 'premature', 'response', 'risk prediction model', 'simulation', 'socioeconomics', 'survivorship', 'tool', 'trend']",NCI,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,U01,2020,137876,0.07552202258553352
